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A Maitane,
porque la espera forma parte de la alegría.
¿Conoces esa enfermedad febril que se apodera de nosotros en las miserias frías,
esa nostalgia de un país ignorado, esa angustia de la curiosidad?
Charles Baudelaire.
Invitación al viaje.
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• cfp10: culture filtrate protein of 10 kDa.
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• ER: Erdos-Renyi (network).
• ESAT-6: early secreted antigenic target of 6 kDa.
• FBL: feedback loop.
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• FFL: feed-forward loop.
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• LMA: Levemberg-Marquardt algorithm.
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• MF: mean field.
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• MMC: mitomycin C.
• mRNA: messenger ribonucleic acid.
• MTB : Mycobacterium tuberculosis.
• NAM: nicotinamide.
• NFV: newborn focused vaccine.
• PCL: poorly characterized link.
• PDIM phthiocerol dimycocerosates.
• PPIN: protein-protein interaction network.
• PZA: pyrazinamide.
• qRT-PCR: quantitative real time polymerase chain reaction.
• SBM: stochastic block model.
• SDS: sodium dodecyl sulfate (a detergent).
• SEAR south East Asia Region.
• SEIR: susceptible-exposed-infected-recovered (model).
• SF: scale-free (network).
• SIG: sigma factor.
• SIM: single input module.
• SIR: susceptible-infected-recovered.
• SIS: susceptible-infected-susceptible.
• SL: suspicious link.
• SOM: single output module.
• TB: tuberculosis.
• TELC: target expression levels comparison.
• TF: transcription factor.
• TRN: transcriptional regulatory network.
• TSP: triad significance profile.
• TST tuberculin skin test.
• WCL: well characterized link.
• WPR west Pacific Region.
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Resumen
La tuberculosis (TB), –pese a ser comúnmente considerada como una enfermedad en
vías de erradicación, propia de tiempos peores– es, junto a malaria y SIDA, una de las
tres mayores causas de mortandad a nivel mundial, con devastadoras cifras en países
subdesarrollados de África y Asia. Según estimaciones de la Organización Mundial
de la Salud (OMS), en 2012 casi 9 millones de personas desarrollaron la enfermedad
en todo el mundo, y 1.3 millones murieron por su causa. Su agente etiológico -el
bacilo Mycobacterium tuberculosis (MTB)– es un parásito humano cuyo sofisticado
ciclo de vida involucra mecanismos que tienen lugar a muy variadas escalas temporales
y espaciales, convirtiéndolo en un interesante objeto de estudio desde el punto de vista
de la Física y la Biología de sistemas complejos, tanto por los retos conceptuales que
su estudio plantea como por el potencial impacto científico y social que éste implica
[2].
En este contexto se enmarca la presente Tesis Doctoral, a través de la cual se pro-
pone el estudio de diferentes aspectos relacionados con el proceso de infección tubercu-
losa que tienen lugar a diferentes escalas, sirviéndonos para ello de métodos analíticos
y computacionales tomados de la Física de Sistemas y Redes Complejas. Dichos as-
pectos abarcan desde el estudio de la adaptación al medio de células individuales del
patógeno, hasta el estudio de la propagación de la enfermedad sobre poblaciones dis-
tribuidas en continentes enteros. En lo que respecta a la Biología del bacilo, hemos
usado herramientas de análisis de Teoría de Redes Complejas para caracterizar redes de
interacciones bio-moleculares, tanto redes de transcripción génetica como redes de in-
teracciones entre proteínas. En lo que respecta al nivel de poblaciones humanas hemos
trabajado en la incorporación de determinadas propiedades de las poblaciones humanas
sobre modelos clásicos de propagación de la TB, con el propósito de avanzar hacia un
conocimiento más detallado de los factores que afectan la propagación de la enfermedad
a escala global. Nuestro objetivo aquí es el desarrollo de herramientas cada vez más
fiables para la evaluación de nuevas intervenciones epidemiológicas; particularmente
vacunas preventivas contra la TB.
Esta tesis se estructura en seis partes: una introducción (parte I); dos partes
dedicadas al estudio de redes de interacciones bio-moleculares (partes II y III); dos
partes más dedicadas al desarrollo de modelos epidemiológicos de propagación de en-
fermedades (partes IV y V) y una parte final para las conclusiones VI.
En la introducción expondremos los principales conceptos utilizados, o simplemente
mencionados, durante el resto de capítulos. Por una parte, esto incluye un breve repaso
de los principales métodos, modelos y conceptos de la Teoría de Redes Complejos y sus
aplicaciones en Biología y Medicina (capítulo 1), los cuales constituyen los fundamen-
tos metodológicos utilizados en este texto. Por otra parte, una vez que los métodos
que utilizaremos han sido contextualizados, discutiremos las principales característi-
cas biológicas del principal objeto de estudio de esta Tesis: el patógeno MTB y la

enfermedad de la que es responsable (capítulo 2).
En las secciones siguientes, los contenidos de cada parte del texto son desglosados.
Partes II y III: Interactomas celulares como redes
complejas
A buen seguro, entre todas las escalas biológicas implicadas en el proceso de infección
de la TB, el nivel celular es aquel sobre el cual una cantidad más grande de datos
experimentales ha sido recopilada durante la última década. La generalización y el
abaratamiento de las técnicas de secuenciación genómica; junto al florecimiento de
diversas técnicas experimentales en transcriptómica y proteómica, ha generado una
proliferación masiva de datos experimentales que ha sido explotada sólo parcialmente.
En este sentido, la investigación en TB ha asistido durante los últimos años a la com-
pilación de los primeros datasets relativos a interactomas celulares con ánimo de com-
pletitud, desde redes de regulación transcripcional hasta redes de interacciones entre
proteínas y mapas metabólicos [89, 4]. Las técnicas experimentales siguen avanzando
en precisión, precio, flexibilidad y alcance, y una fracción cada vez mayor de los datos
generados se dispone libremente en bases de datos on line [5]. El procesamiento e in-
tegración de dichos datos de origen diverso alrededor nuevos modelos basados en redes
ofrece múltiples posibilidades, y sin duda contribuirá a mejorar nuestro conocimiento
de la enfermedad desde una perspectiva sistémica.
En este contexto, en la parte II de esta Tesis, caracterizamos y estudiamos diversas
redes bio-moleculares en MTB. El punto de partida de esta parte del trabajo (capítulo
3), consiste en la compilación de la red de regulación transcripcional del bacilo [3].
Reuniendo toda la información disponible en la literatura sobre regulación transcrip-
cional en MTB alrededor de un único dataset, construimos una red de regulación que,
además de constituir un recurso útil por sí mismo, nos permite analizar la maquinaria
de control genético en la bacteria desde una perspectiva de red.
Además, en el capítulo 4, estudiamos cómo la respuesta a los diversos estímulos
ambientales que MTB debe afrontar durante su ciclo de vida se refleja en la estructura
de su red de interacciones entre proteínas. Para completar esta tarea, hemos estudiado
cómo dicha red se transforma a consecuencia de los diferentes perfiles de expresión
genética que la bacteria reproduce en respuesta a diferentes condiciones experimentales.
En este punto hemos sido capaces de descubrir un elevado grado de coherencia en la
estructura topológica de la red en respuesta a algunos de los principales stresses que la
bacteria afronta al entrar en la célula huésped, así cómo el rol privilegiado que algunos
de los principales antígenos de la bacteria juegan en este contexto.
Por otro lado, en la parte III de esta Tesis, nuestro principal objetivo es el de
utilizar la red de regulación genética del bacilo, junto a otros sistemas similares, para
estudiar la topología de este tipo de redes desde una perspectiva más genérica, revisando
ciertos resultados clásicos en el campo y extendiendo el rango de utilidad de otros. En
esta parte hemos prestado especial atención al papel jugado por la incertidumbre e
incompletitud que acompañan, de manera inherente, a la información a partir de la
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cual se construyen estas redes. Específicamente, en el capítulo 5 nos dedicamos a
caracterizar el efecto que la incompletitud de los datos puede llegar a ejercer sobre
el resultado de ciertos análisis topológicos en redes genéticas [6]; mientras que, en el
capítulo 6, proponemos nuevos métodos para la medida de la fiabilidad de los enlaces
en redes complejas dirigidas [7].
Partes IV y V: modelos epidemiológicos
En los últimos años, la Teoría de Redes ha realizado una serie de relevantes aporta-
ciones metodológicas a la epidemiología matemática que han permitido describir la
relación existente entre ciertas características de las poblaciones humanas y la facili-
dad con la que las enfermedades infecciosas se transmiten a través de ellas. Aspectos
como las estructuras de las redes de contactos, los patrones de movilidad e incluso los
cambios en el comportamiento causados por la irrupción de una enfermedad, han sido
profundamente estudiados, y su sorprendente influencia sobre la propagación de en-
fermedades, caracterizada [8, 9, 10]. Adicionalmente, importantes datasets en relación
a estas cuestiones han sido compilados y utilizados por la comunidad científica en la
implementación de modelos de propagación de enfermedades cada vez más sofisticados
[11, 12, 13], lo que ha producido relevantes avances en el campo [14]. Esta confluencia
entre avances teóricos y disponibilidad de datos ha hecho posible la aparición de nuevos
modelos guiados por datos con elevadas capacidades predictivas [15, 16]; permitiendo
su uso por las autoridades, en foros relacionados con la salud pública y la vigilancia y
control de enfermedades infecciosas.
No obstante, todos estos avances no han tenido lugar del mismo modo para todas las
enfermedades; sino que la gran mayoría de ellos han sido aplicados hasta el momento al
estudio de enfermedades de ciclo corto como la gripe [15], caracterizadas por periodos
infecciosos mucho menores que la esperanza de vida de los individuos afectados. Pese a
la relevancia de este tipo de enfermedades; existen otro tipo de agentes infecciosos cuya
propagación no puede ser descrita utilizando las mismas herramientas de modelización.
Específicamente, las descripciones de ciertas enfermedades persistentes como la TB
suelen basarse en descripciones menos sofisticadas.
Mi principal propósito en este punto ha consistido en extender el marco conceptual
de la epidemiología matemática sobre poblaciones estructuradas hacia determinados
escenarios epidemiológicos estrechamente relacionados con la TB que han recibido una
menor atención hasta la fecha. Esto incluye el desarrollo de modelos epidemiológicos
genéricos, de clara inspiración teórica, así como la implementación de modelos guiados
por datos útiles para propósitos cuantitativos. Los resultados de mi investigación en
este campo se presentan en esta Tesis en las partes IV y V; correspondientes a los
capítulos 7, 8, 9, 10 y 11.
De este modo, en una primera fase correspondiente a la parte IV, nos centramos
en el desarrollo de modelos matemáticos de propagación de enfermedades desde un
punto de vista teórico; a través de los cuales estudiamos la influencia de ciertos as-
pectos característicos de la propagación de la TB, como son sus largos periodos de
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latencia (persistencia) así como sus fuertes interacciones con otros agentes infecciosos:
(principalmente, el VIH); cuando las redes de contactos sobre las cuales el patógeno
se propaga son heterogéneas. En esta linea, comenzamos derivando, en el capítulo
7, un modelo general para la descripción de enfermedades persistentes sobre pobla-
ciones estructuradas [17, 18]. Los largos periodos de latencia que caracterizan este
tipo de enfermedades nos obligan a considerar, de manera explícita, las variaciones de
población que, por razones ajenas a la enfermedad, ocurren en las poblaciones bajo
estudio mientras se propaga la infección. En el contexto de nuestro modelo, com-
probamos como la consideración de dichas variaciones de población introduce nuevas
propiedades y plantea nuevos problemas que somos capaces de resolver. Algo similar
ocurre, de hecho, cuando consideramos interacciones entre enfermedades que se pro-
pagan sobre topologías complejas. En el capítulo 8 exploramos este escenario, en el
cual caracterizamos los umbrales epidémicos de parejas de enfermedades propagándose
bajo dichas circunstancias.
En una fase ulterior de la investigación, correspondiente a la parte V, nos centramos
en la implementación de modelos específicos para TB, guiados por datos, y cuyo ob-
jetivo es la evaluación cuantitativa de vacunas preventivas; un tema de actualidad
científica, dada la cantidad de proyectos de nuevas vacunas que hoy en día se encuen-
tran siendo testados en diferentes fases de desarrollo clínico [20]. En este sentido, en
el capítulo 9, se presenta un nuevo modelo de propagación de la TB, que, tomando
como base una serie de trabajos previos de C. Dye y colaboradores [21, 22], incluye
una descripción detallada de todos los proceso de infección, reactivación, re-infección,
tratamiento y recuperación relevantes en este caso, sobre un esquema de modelización
estructurado por edades. A partir de este punto, incorporamos una serie de nuevos in-
gredientes a nuestro modelo, como patrones de contactos heterogéneos entre distintos
grupos de edad, así como un acoplamiento explícito con la evolución demográfica esper-
ada para las próximas décadas en las diferentes regiones del mundo [23]. Confrontando
nuestro modelo con datos públicamente disponibles sobre demografía e incidencia de
la TB [23, 24] somos capaces de demostrar como esta serie de aspectos, ignorados
hasta ahora en los modelos de propagación de TB son capaces de ejercer una influencia
poderosa sobre las predicciones de los modelos de propagación. Esto hace evidente
la necesidad de mejorar los modelos actualmente disponibles; especialmente si se pre-
tende realizar estimaciones de impacto fiables para las nuevas vacunas actualmente en
desarrollo.
Aprovechando el modelo desarrollado en el capítulo 9, en los capítulos 10 y 11
exploramos determinadas cuestiones abiertas en el campo del desarrollo de nuevas va-
cunas contra la TB, entre las cuales destaca a qué edad debería aplicarse una vacuna
antituberculosa para maximizar su impacto. En estos capítulos exploramos cómo la
respuesta a dicha pregunta permanece sujeta a determinados factores como la capaci-
dad de los modelos de reproducir las tasas de incidencia de la enfermedad en cada
grupo de edad por separado, los distintos niveles de persistencia en el tiempo que las
nuevas vacunas puedan ofrecer o, notablemente, la exposición previa de los individuos
vacunados a antígenos mycobacterianos.
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Summary
Tuberculosis -even if commonly conceived as an old-fashioned disease, proper of past,
worse times-, is, along HIV and malaria, one of the three single leading causes of
death worldwide; specially in underdeveloped african and asian countries. According
WHO estimations, in 2012, almost 9 million people developed the disease all around
the world, and 1.3 million died for its cause [1]. Its causative agent, –the bacillus My-
cobacterium tuberculosis– is a human obligate parasite whose elusive life cycle involves
many different spatial and temporal scales, which ultimately make it an optimal tar-
get of a research program based on complex systems science, both with respect to the
conceptual challenges it poses and to the potential impact that such a project might
offer [2].
In this context, the principal purpose of this Thesis is the use of certain methods and
tools taken from Physics of complex systems and networks to the study and modeling
of tuberculosis disease (TB) at different biological levels, spanning from the study of
cellular interactomes within single bacterial cells to the study of the spreading dynamics
of TB on top of human societies. From the pathogen side, complex networks analysis
(both transcriptional regulatory networks and networks of protein-protein interactions)
is used to define systems of bio-molecular interactions within a single pathogen. At
hosts’ population level, I focus on the incorporation of certain complex features of
human societies on top of classical spreading models of TB epidemiology, with the pur-
pose of increasing current understanding of the factors affecting TB burden at a global
scale, and deepening in the impact forecasting of novel epidemiological interventions
such as preventive vaccines.
This thesis is structured in six parts: an introduction (part I); two parts devoted
to the study of bio-molecular networks (parts II and III); two additional parts focused
on the development of mathematical models of disease spreading (parts IV and V) and
a section for the final conclusions (part VI).
In the introduction, for the sake of completeness, I review the main concepts used,
or just mentioned, in the rest of the chapters. On the one hand, this includes a brief
review of the most important concepts of complex networks theory and its applications
on Biology and disease spreading modeling (chapter 1), which constitute the method-
ological foundations of the research conducted in this Thesis. On the other hand,
once the methods used are put into context, the focus is shifted on the system under
study: the pathogen MTB and the disease it causes: its life-cycle and epidemiological
implications (chapter 2.
In the following paragraphs, the contents of the different parts of the text are
summarized.
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Parts II and III: Network-based analysis of cell inter-
actomes
Probably, among all biological levels involved in TB infection, the cellular is the one
for which a more overwhelming amount of experimental data has been achieved during
the past decade. Generalization –or cheapening– of genome sequencing tools, tran-
scriptomics and proteomic techniques have resulted in a particular big-bang of data
that has been only partially exploited so far, specially from a systemic perspective. In
this context, the first genome wide interactome datasets of the bacterium [3, 4] are
being collected, and the amount and quality of the data available is continuously in-
creasing because of both the use of better and more accurate experimental techniques
and the generalization of the use of on-line databases [5], which allow repurposing of
experimental information. The gathering of these data of disparate origin (and initial
purposes) around new network-based models offers many possibilities, and undoubt-
edly will contribute to the improvement of our current understanding of the pathogen
from a systemic perspective.
In this context, in part II, we present a study of diverse bio-molecular networks of
MTB. The starting point of this part of the Thesis is the compilation of the TRN of
the bacillus, in chapter 3. By gathering all the information processed in this chapter
around a unique, coherent dataset, we constructed a network that, beyond constituting
a useful resource by itself, allowed us to analyze the transcriptional machinery of the
bacterium from a networked perspective.
In chapter 4, we study of how the response to the disparate environmental stimuli
that MTB has to face during its life cycle reflects into the structure of the PPIN of
the bacterium. In order to do so, we have characterized how the PPIN of MTB, as
compiled in a genome-wide two-hybrid assay [4], is transformed as a consequence of
the different expression profiles that follow the exposure to different stimuli. By doing
so, we have discovered a high coherence in the topological structure of the bacterial
PPIN in response to the main stresses associated to the pathogen’s environment when
invading host’s immune cells, and a central role reserved for ESAT-6 family of antigens
in the network.
In the part III of this Thesis, our first scope consisted in using the compiled TRN
of MTB, along with other related networks, to study the topology of TRNs from a
general perspective, revising certain classical results on the field and expanding the
applicability of others. In this part, we have payed a central attention to the role of
data uncertainty and incompleteness on the structure of TRNs. More precisely, in
chapter 5 we have come to isolate some of the most relevant caveats of topological
analysis on TRNs inherited from the lack of data reliability [6]. Similarly, in chapter 6,
we propose some network-based methods to overcome these issues in a general context
[7], by studying the performance of different algorithms for the measurement of links
reliabilities in complex directed networks.

Parts IV and V: epidemiological models
In the last years, network theory has provided mathematical epidemiologists with new
theoretical tools to understand certain features of human populations and how these
influence the spreading of infectious diseases. Aspects such as contact networks struc-
tures, mobility patterns or behavioral responses against disease have been studied, and
their striking influences on the overall disease spreading addressed [8, 9, 10]. Further-
more, relevant datasets regarding all these questions have been rendered available to
the research community [11, 12, 13], which has constituted an optimum complement
responsible of much progress in the field [14]. This confluence between theory and data
availability has allowed the appearance of data-driven epidemic models with mean-
ingful predictive skills [15, 16], so bringing all those scientific developments closer to
epidemiological and public health policy grounds.
However, most of these advances have been used so far to describe short-cycle dis-
eases like influenza [15], for which the typical infectious periods are much shorter than
individuals’ lifetime. Despite of that, many relevant real diseases or epidemiological
situations cannot be described under such narratives, which makes their description to
lie a step behind. More specifically, current descriptions of persistent diseases, like TB,
are grounded on simpler modeling schemes.
Our main purpose in this context has been to extend the conceptual framework of
disease spreading on structured populations to some relevant epidemiological scenarios
tightly related to TB which have been neglected so far. This includes the development
of generic models according to a general, theoretical perspective and the implemen-
tation of data-driven, complex models useful for quantitative purposes. The results
obtained are presented in this Thesis in parts IV and V; chapters 7, 8, 9, 10 and 11.
Thus, in a first phase, corresponding to part IV, we focus on the development
of general epidemic models whereby we studied the influence of aspects relevant to
TB spreading, such as long persistence times or disease-disease interactions, when the
epidemics being modeled spread through complex, structured populations. In this
line, we start by developing, in chapter 7, a general model of persistent infections
on structured populations [17, 18]. Long latency periods that characterize persistent
diseases like TB are typically longer than single individuals’ life expectance, which
forces us to consider open populations subject to variation due to natural causes, not
related to TB (i.e. births or natural death fluxes). In the context of these models, we see
how considering such open populations on models with contact heterogeneities results
into new features and challenges -both from the analytical and the numerical points
of view- which we are able to successfully address. Something similar occurs in what
regards the effects of disease-disease interactions on the spreading dynamics, studied
in chapter 8, where we address how this kind of phenomenology influences epidemic
phenomena when the heterogeneous nature of human populations is considered [19].
In a second phase, corresponding to part V, we focused on the development of
specific data-driven models of TB spreading for the evaluation of novel epidemic in-
terventions, principally age-focused preventive vaccines, motivated by the numerous
candidates that are currently under development, being tested in clinical trials [20].

To accomplish that goal we present, in chapter 9, a novel TB spreading model that
takes as a basis previous works developed by C.Dye et al. [21, 22] for the description of
the disease, which include a detailed description of all relevant processes of infection,
re-infection and endogenous or exogenous reactivation, and an age-structured descrip-
tion of the spreading dynamics. From that starting point, we have incorporated some
new ingredients, like non-homogeneous population mixing patterns [12] and disparate
data driven scenarios of demographic evolution for the populations under study, ad-
dressing the influence of these relevant aspects on model outcomes. By confronting our
model to publicly available data on trans-national demography and TB burden levels
[23, 24], we show how these so-far neglected model ingredients strongly influence model
predictions; which makes evident the need of refining current state-of-the-art tools for
TB spreading modeling, specially if a reliable estimation of novel vaccines impacts is
intended.
Taking advantage of the model developed in chapter 9, we explore, in chapters 10
and 11, different effects of TB spreading dynamics that may exert relevance influences
on vaccine impact evaluations. In the context of the vaccine development pipeline, a
number of open questions remain, as for example the age segments on which successful
candidates should be applied. In this context, in chapters 10 and 11, we evaluate how
the answer to this question is subject to factors like models’ ability to offer proper
age-distributed descriptions of TB burden, the different possible patterns of vaccine
persistence or, very relevantly, the presence of prior sensitization to environmental
mycobacteria in the populations under study.
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Part I
Introduction
To begin with, the art of jigsaw puzzles seems of little substance, easily exhausted,
wholly dealt with by a basic introduction to Gestalt: the perceived object – we may be
dealing with a perceptual act, the acquisition of a skill, a physiological system, or, as
in the present case, a wooden jigsaw puzzle – is not a sum of elements to be
distinguished from each other and analysed discretely, but a pattern, that is to say a
form, a structure: the element’s existence does not precede the existence of the whole,
it comes neither before nor after it, for the parts do not determine the pattern, but the
pattern determines the parts: knowledge of the pattern and of its laws, of the set and
its structure, could not possibly be derived from discrete knowledge of the elements
that compose it. That means that you can look at a piece of a puzzle for three whole
days, you can believe that you know all there is to know about its colouring and shape,
and be no further on than when you started. The only thing that counts is the ability
to link this piece to other pieces, and in that sense the art of the jigsaw puzzle has
something in common with the art of go. The pieces are readable, take on a sense,
only when assembled; in isolation, a puzzle piece means nothing – just an impossible
question, an opaque challenge. But as soon as you have succeeded, after minutes of
trial and error, or after a prodigious half-second flash of inspiration, in fitting it into
one of its neighbours, the piece disappears, ceases to exist as a piece. The intense
difficulty preceding this link-up – which the English word puzzle indicates so well – not
only loses its raison d’ être, it seems never to have had any reason, so obvious does
the solution appear. The two pieces so miraculously conjoined are henceforth one,
which in its turn will be a source of error, hesitation, dismay, and expectation.
George Perec
Life, a User’ s manual, 1978
(translation by D. Bellos in 1987)

 Applications of networks theory in Medicine and Biology
Chapter 1
Applications of networks theory in Medicine
and Biology
Complexity is the most genuine fingerprint of life. Its manifestations can be recurrently
identified at virtually all scales, ranging from simple biomolecules, organelles, cells and
tissues to organisms, populations and, finally, the entire Biosphere. In all these levels,
biological systems are usually described as large ensembles of agents hatching complex
networks of interactions among them, whose structure and dynamics are in turn coupled
to other systems, often belonging to different scales. In that sense, as George Perec
wrote [25], Biology has much to do with the art of solving jigsaw puzzles: each piece by
itself is hardly informative of the truly nature of the whole picture. Infectious diseases
are not an exception to this rule. From pathogens’ biochemistry to host-pathogen cross
talk processes and, finally, the transmission mechanisms that take place over hosts’
populations, bio-molecular, medical and epidemiological research adapts its focus on a
large range of scales, both spatial and temporal, where complexity is pervasively found.
In the last decades, complexity sciences have emerged as a precious tool that
promises to allow the study of entire biological entities and processes as a whole, over-
coming classical reductionist approaches according to which one was forced to split
systems into isolated sub-elements of smaller entity, as the only way to gain meaning-
ful insight of their biological functions. The circumstances that have allowed scientific
community to start dreaming at this new way of studying Biology have to do with the
confluence of different critical advances in experimental, theoretical and computational
grounds. On the one hand, the advent of high throughput techniques to cell Biology has
rendered available to the scientific community an unprecedented and massive amount
of valuable data about genomics, transcriptomics and proteomics, on top of which re-
construct a faithful portrait of cellular Biology at a global scale. Complementarily, the
very availability of this new source of information has motivated the development of
new theoretical and computational tools, and their applications on a field whose de-
nomination -(Complex) Systems Biology, computational Biology, theoretical Biology-
is yet subject to certain contingency.
The birth of complex networks’ theory, in the last years of XXth century, and the
development of its applications program in Biology have arguably constituted one of
the theoretical advances of deeper implications in the field. In the precise context of
the study of infectious diseases, complex networks have brought with them relevant
breakthroughs, from epidemiology –by providing the conceptual background for the
characterization of contact networks relevant for disease transmission– to cell Biol-
ogy, where gene regulatory systems, protein interactome datasets and metabolic maps
are systematically studied as complex networks with relevant results that find direct
1.1 — About complex networks 
translation on Medicine, Pharmacology and Agriculture.
In this chapter, we will introduce the principal concepts of complex networks the-
ory, which has constituted one of the main theoretical basis for the research conducted
around this thesis, as well as its principal applications on the study of biological sys-
tems.
1.1 About complex networks
In a first approximation, networks science can be defined as the scientific discipline
devoted to the study and modeling of whatever system composed by a multitude of
agents interacting trough channels which share some set of topological, non trivial prop-
erties which are assimilable neither to random connection patterns nor to regular ones.
These properties may include heterogeneous connectivity distributions, short average
path lengths between nodes, specific local (and intermediate) aggregation patterns, ex-
otic scaling features etc; as we will review in the following lines. These properties have
been shown to recurrently appear when real systems are modeled as networks, in fields
as disparate as Biology, computer science, Sociology and engineering, making pointless
their description using classical models borrowed to Graph Theory, as regular lattices
and random graphs. Furthermore, the emergence of these topological footprints of
complexity exerts a crucial influence on the dynamical processes that take place over
the systems themselves.
1.1.1 Concepts and elementary definitions
A complex network is nothing else but a particular type of graph, i.e. a mathematical
object G = {N ,L} defined as a set of N > 0 elements or nodes, connected through L
links among them. We can denote the i-th node as ni (i ∈ [1, N ]) and the j-th link,
connecting nodes nα and nβ as lj = (nα, nβ) (j ∈ [1, L] and both {α, β} ∈ [1, N ]).
Probably, the most elementary object codifying all the information within a network is
the adjacency matrix ; a NxN matrix whose entry Ai,j = 1 if the link between ni and
nj exists, and 0 otherwise:
Ai,j =
{
1 if ∃ lk = (ni, nj)
0 if 6 ∃ lk = (ni, nj) (1.1)
As it is obvious, in different grounds, nodes and links represent different concepts.
For example, in a protein-protein interactions network (PPIN), nodes will be proteins,
and links will connect pairs of nodes that are able of physically interact to form –even
transitorily– a protein complex. Instead, if we think about a social network, nodes will
represent persons and links social interactions among them. The strong resemblance
that appear among systems as disparate as these, once described as complex networks,
is probably the most striking fact in the discipline, and allow us to use a similar toolbox
to study a disparate range of systems that traditionally belonged to diverse disciplines.
In the most simple case, links constitute un-ordered couples of nodes, so representing
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Figure 1.1: Types of networks according to links directionality and weights. Left: undi-
rected, unweighted network . Center: directed, unweighted network. Right: weighted directed
network. Below the graphs, we represent the corresponding adjacency matrices Ai,j or, for
the case of the weighted network, the weights matrix wi,j
symmetric interactions between them. In such cases, the adjacency matrix is symmetric
(Ai,j = Aj,i) and the sum over both indexes of the adjacency matrix entries is twice
the number of links:
∑
i,j Ai,j = 2L. In that case, the maximum number of links
that a network with N nodes can admit is, in principle N(N − 1)/2. This is true for
networks in which 1) self-interactions are not allowed (i.e. links of type l = (nα, nα)
are forbidden, and so Aii = 0∀i) and 2) there cannot be multiple links between a given
pair of nodes.
In case self-interactions, but no multiple links are allowed, the maximum number
of links is trivially equal to N(N + 1)/2. That is the case, for example, of the PPIN, in
which a protein can interact with itself to form a homo-dimeric complex, but, almost by
definition, multiple links are not allowed. In case multiple links are allowed, the upper
bound for the number of links in lost. An example of such network could be recovered
from a list of interaction events stablished between a set of individuals. These could be
radio calls among a set of radio operators [26] or e-mails interchanged among a set of
employees of an University [27]. In these cases, each interaction (radio call or e-mail)
can be listed as a link, and so, limitless links might appear both in the whole network
and between two given nodes of it.
From the idea of networks allowing multiple links, the transition to weighted graphs
naturally emerges. In the networks mentioned before, the number of links between
a given pair of nodes can be conceived as the intensity of the interaction between
them. This conceptual step is naturally described by allowing the adjacency matrix to
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adopt any natural value: Ai,j ∈ [0,∞). The situation naturally suggest to perform a
normalization process, for example, dividing Ai,j by L, to recover a rational number
-instead of a natural one- for representing the intensity, or weight of the interaction
between ni and nj. The kind of networks in which interactions are labeled with rational
numbers, instead boolean (or integer) variables, are known as weighted networks. In
that case, the adjacency matrix is substituted by a weight matrix wi,j of the same
dimension, containing the intensity of the interaction –normalized or not–, between
nodes ni and nj. It is worth noticing that weighted networks can be reconstructed from
disparate types of data beyond the normalization process mentioned before for systems
containing multiple links. Many natural and engineered systems can spontaneously be
described as weighted networks of real weights, as the intensity of the interactions
can be explicitly measured as a continuous variable. In these systems, the notion
of number of links in the network loses importance, as typically the whole weight
matrix (or a large part of it) may contain non-zero values, representing some degree
of residual interaction among most nodes in the system: different thresholds levels
imposed on interaction weights will give different numbers of relevant (or discarded)
interactions. Furthermore, networks contemplating negative wights (or values of the
adjacency matrix) are commonly denoted as signed networks, and in these, interactions
can be attractive or repulsive, represent correlation or anti-correlation etc.
In some occasions, the systems being modeled consist of nodes that establish asym-
metric interactions among them. An example is constituted by gene regulatory net-
works, in which nodes are genes and links are regulatory interactions that point from
the regulatory gene to the gene whose activity is regulated. As a matter of fact, the
examples introduced two paragraphs before (i.e. radio calls or e-mail networks) can
also be considered (should, if the information is available) as an example of this, as in
these cases, the communication is asymmetric as there is an information sender and
an information receiver. Networks of asymmetric interactions are noted as directed
networks, and within them links are ordered nodes’ pairs and the adjacency matrix (or
the weight matrix, if applies) is not symmetric any more: Ai,j 6= Aj,i, or wi,j 6= wj,i,
generally speaking. In directed networks not containing multiple links, the maximum
number of links possible are N(N − 1), if self-loops are forbidden, and N2 otherwise.
Finally, as a last, particularly relevant type of systems, bipartite networks consists
of two different sets of nodes N andM belonging to two distinct categories and a set of
links connecting pairs of element, one of each group: GB = {N ,M,L}. Such a system
will have N nodes of the first class, M nodes of the second class and L link connecting
pairs of nodes of different sets. The i-th mode in N is ni (i ∈ [1, N ]), the j-th node
inM is mj (j ∈ [1,M ]), and an eventual link connecting them could be lk = (ni,mj)
with k ∈ [1, L]. Relevant systems described as bipartite networks are metabolic maps.
Accordingly, metabolites taking part in diverse chemical reactions occuring within a
cell are associated to first-class nodes, while nodes of the second class represent the
chemical reactions. Generally speaking, a metabolic network is both bi-partite and
directed, as the participation of a metabolite in a reaction as a reactive is represented
as a link from the metabolite to the reaction and viceversa: links from reaction to
metabolites represent the formation of products. Furthermore, this representation of
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metabolic systems as networks spontaneously offers and adequate framework for the
description of chemical equilibria, as in these case, a metabolite is both reactive and
product of the same reaction, and so, it both sends and receives a link from the reaction
representing the equilibrium. Adjacency (or weight) matrices of bipartite networks are
not squared, but of NxM dimension. Maximum number of links of a bipartite network
is NM , if they are not directed and 2NM otherwise. Very often, bipartite networks
are “bypassed”, which means that one of the node’s categories is disregarded and two
nodes of the other set become connected if they contacted some node of the eliminated
category.
In the following sections, unless the contrary is stated, we will refer to undirected
networks.
1.1.2 A brief history of networks theory: from systems to mod-
els.
From the foundations of Graph Theory –commonly dated in 1736, with the popular
problem of Köninsberg bridges solved by L.Euler [28]–, more than 250 years passed
until the notion of complex network was firstly used, at the end of the XXth century.
The reason for this dormancy period for the discipline, which for the rest can be
considered as a particular branch of Graph Theory, is related simply to the impossibility
of observing any system assimilable to a complex network until very recently. Whenever
system size does not guarantee the emergence of complex features of any type in any
system, for a footprint of complexity to be identified in a networked system, a minimum
number of interacting agents is necessary. For example, a network of four nodes can
never be considered complex, as no statistically relevant connection pattern, modular
structure, clustering, or correlation of any type could be confidently addressed by an
elementary problem of lack of resolution. Thus, the identification of these topological
traits, which are privative of complex networks would not be possible until systems
of multiple interacting agents of enough size (probably more than 1000, although for
some purposes this is yet too small) could be characterized and analyzed in a systematic
way. These tasks require computational resources that, even if nowadays are trivially
affordable by a laptop or even a phone, have resulted privative until the advent of
computers and modern telecommunications, which have allowed massive generation
and gathering of data and their further analysis.
Indeed, the first systems characterized as complex networks were assembled and
analyzed in the last decade of the XXth century [29, 30]. These first examples included
collaboration networks (in Science and cinema) built up upon on-line databases, the
US power grid, the synaptic wiring of the netamatode C.elegans, Internet itself and the
world wide web [29, 31]. Strikingly, these systems were found to share a common set
of exotic properties, that have attracted massive attention since then. Some of these
topological treats that were identified first are the small-world property, high clustering
levels and scale freedom. We will review in the following lines the definition of these
unequivocal characteristics of complex networks and the way researchers have tried
since then to build up relevant network models capturing them.
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Small path-lengths: the Erdös Renyi random graph model.
A cardinal property of networks is the distance that separate a typical couple of nodes
in the system. More formally speaking, in any network we can define the average path
length as follows:
〈d〉 = 1
N(N − 1)
∑
i,j 6=i
di,j (1.2)
where di,j is the distance between nodes ni and nj. if the network is disconnected,
some nodes are isolated from others, and, in that cases di,j is not always defined. A
possibility for recovering a meaningful average path length is to average di,j just among
the nodes’ couples for which di,j is defined or, instead, to average the inverse: d−1i,j , for
all node pairs, which is called network efficiency.
Strikingly, all the networks analyzed in those first amazing years of networks science
presented strikingly low average path lengths, when compared with systems sizes. As
an example, a network of N = 209293 co-authors of scientific papers in neurosciences
had an average path length of just 〈d〉 = 6 . This observation made the experiments
of the famous psychologist S.Milgram regain popularity, through which the scientist
found that the average number of steps for a package to get from randomly selected
people in Omaha, Nebraska to reach one target person in Boston (an stranger person,
for the package initial senders) were less than six [32]. These experiments, conducted
in 1967, were not the only vintage scientific contribution rescued from the analysis
of these novel complex networks, but the random graph model of Erdös and Renyi,
developed at the end of the fifties [33, 34], also was.
According to the Erdös-Renyi (ER) random graph model, a network is built just
by assigning, to each possible link in the system, a probability p to occur. The most
relevant feature of this model is that, in the point pc = 1/N , it presents a phase transi-
tion: ER networks with p > pc present a giant component whose size is a macroscopic
fraction of the entire system within which each node is reachable from any other node
(i.e. di,j distances are defined); instead, for p < pc, the system splits up into a myriad
of small, disconnected clusters none of which reach a macroscopic size.
For ER graphs above the critical threshold pc, average path lengths scales at a
logarithmic pace with system’s size: 〈d〉 ' log(N). For example, a network of the same
number of nodes and links of the network of neuroscientists collaborations mentioned
before, built following ER model, presents even a lower average path length: 〈d〉 = 5.01
[31]. This means that classical ER model is able to essentially explain low path lengths
found in real systems.
High clustering: random graphs
Another relevant feature of real systems is the notion of transitivity, i.e. the tendency
for nodes that share common neighbors in the network to form links among them. This
property, that finds its more immediate interpretation in social grounds (my friends’
friends are my friends), implies the appearance of triangles in the network, and its
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mathematical definition is indeed the quotient between the number of triangles in a
network and the number of connected triplets:
T =
# triangles
# connected triplets
(1.3)
Closely related to this idea, we define clustering coefficient of a node in an undirected
network as the number of links existing Ei among neighbors of node i, divided by the
maximum number possible of that number, defined by ki(ki − 1), where ki is the
connectivity, or degree of ni, that is, its number of neighbors.
c(i) =
Ei
ki(ki − 1)/2 (1.4)
From there, network clustering is obtained by averaging local clustering on the
whole system: C = 〈c(i)〉.
The problem with clustering was that real networks showed high levels of clustering
systematically higher than those produced by ER model. For example, the network of
neuroscience collaborations presents a clustering equal to C = 0.76, while the associated
ER network of same number of links and nodes presents only C = 5.5 ·10−5, four orders
of magnitude less.
This does not mean, though, that there is no classical graph model able to produce
networks with high clustering. Indeed, maybe the most elementary network model:
regular lattices, resent high levels of clustering. For example, let us think on a ring of
size N (with 4 << N), in which each node is connected to its 4 closets neighbors (2 on
each side). In this regular network, it is straightforward to show that all nodes have
the same clustering: C = 1/2.
But the picture is not complete yet. Regular models are able to produce high
clustered networks, but, when regular models of the same sizes of real systems were
built (i.e. same numbers of nodes and links), average path lengths were too high
to reproduce those of real systems. The order of regular systems seemed to favor
clustering, but not reduced path lengths, and the randomness of ER networks worked
in the opposite way. The question, at this point, seem obvious: is there a way to
produce a network with reduced path lengths and high clustering at the same time?
That kind of systems were named small-world networks.
The small-world network model by Watts and Strogatz
The answer is obviously affirmative. In 1998 [29] Watts and Strogatz described a model
able to produce small-world networks following a rather simple approach: if you know
where to find red objects and you also know where to find big stuff, when looking for
big, red things you shall probably look at the middle of those spots.
Somehow following this idea, they conceived a model in which, starting from a ring
regular lattice as the one described in the previous section (N nodes on a ring and
K neighbors per node, K/2 on each side),one fraction p ∈ [0, 1] of links is randomly
rewired. By proceeding this way, authors elegantly build a mono-parametric family
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of models that spans from a regular network, when p = 0, to a random-regular graph
(RRG) in which although all nodes retain the same number of links, their neighbors are
randomly chosen among the nodes set. The difference from WS model with p = 1 to
ER network consists on that, in WS, the total number of links, as well as the number
of links per node are fixed, which is not true for ER graphs.
The most relevant feature of this model is that, even for small values of p (i.e. after
the rewiring of a reduced amount of links), average path lengths are drastically reduced
from the case of p = 0 (i.e. the regular lattice), because of that rewired links acts as
shortcuts that allow one to navigate through the system in a much more efficient way.
In that regime, however, the local surroundings of most nodes yet resembles that of
the regular network, and so, network clustering is substantially high.
By this way, Watts-Strogatz (WS) method constitutes the first model able to gener-
ate networks both clustered and of small average path lengths, something privative of
previous models taken from Graph Theory, as regular lattices or random graphs. For
that reason, it is commonly considered as the first model of complex networks theory.
The importance of the degree distribution: scale free networks and prefer-
ential attachment
A relevant question, though, remained unnoticed in the first works by Watts and
Strogatz that, as time passed by, turned into a crucial property of complex networks
able to exert strong influences on their behavior, dynamics and robustness: the degree
distribution.
As we have already say, we denote the number of neighbors of a node (the number
of links) as its connectivity or degree ki. From there, we can average over all nodes in a
network and define its average degree 〈k〉 = 2L/N . Analogously, we can define in and
out degrees of a node (kini and kouti ) in a directed system, as the number of incoming
and out-going links it has, and, in the most basic case, the average in and out degrees
of the network will verify: 〈kin〉 = 〈kout〉 = L/N = 〈k〉/2. In certain occasions (see
chapter 3), when the set of nodes that acts as links senders or link receivers in a network
is a reduced subset of the entire system, it can be convenient to re-define these averages
restricting them to the nodes with kin > 0 or kiout > 0 (i.e. to calculate the average
out degree of links senders only or the average in degree of sole link receivers).
The hidden property of complex networks that passed unnoticed in the first analysis
by Watts and Strogatz was the high heterogeneous patterns that are found in real
systems in what regards the way in which connectivities are distributed among the
nodes of a network, that is represented mathematically by the degree distribution P (k).
A regular graph (as well as a WS network) has a degree distribution which is equal to
a δ function:
P (k) =
{
1 if k = K
0 if k 6= K (1.5)
while an ER graph has a degree distribution defined by a binomial:
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Figure 1.2: Left: Erdös Renyi graph. Right: scale free network. The main topological
difference between both models is its degree distribution (low).
P (k) =
(
n
k
)
pk(1− p)n−k (1.6)
where n must be substituted by n− 1 if self-loops are not allowed.
The behavior of the degree distribution in real networks was found to be radically
different from these functions. In the year 1999, Barabasi and Albert found that real
systems use to present a connectivity distribution that obeys a power law of negative
exponent: P (k) ' k−γ, with γ ∈ [2, 3]. This finding implied that the real networks
analyzed so far had a microscopical structure radically different to those of WS model,
random graphs or regular lattices. The key concept is the idea of average degree and
the typical deviations of node’s degrees around that average: while in network models,
degree fluctuations around the average 〈k〉 are absent (WS and regular graphs) or
strongly bound (ER graphs), degree fluctuations in power-law distributed networks
may be huge 8see figure 1.2.
For this reason, this kind of systems were named scale free networks, as there is no
characteristic scale for nodes’ degrees (i.e. a typical number of links one random node
is expected to have). Remarkably, in this kind of systems, small fractions of nodes -the
so called hubs– present a very high amount of links when compared with the average,
which make them play a central role in many of the different dynamical processes that
take place over these systems.
In their seminal work, Barabasi and Albert proposed a model for generating scale
free networks based on the mechanism of preferential attachment, according to which,
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in a growing system, more connected nodes tend to gain new connections faster than
less connected ones. The preferential attachment model (or Barabasi-Albert (BA)) for
network generation consists of the following steps: 1) We start with an small network
of (n << N nodes in which all are connected to all (which is defined as a clique).
Then, at each step, we add a new node, which will send l << L links to the already
existing network. The probability of sending a link to any of the existing nodes in the
network will be proportional to its degree. By proceeding this way, scale free networks
of exponent γ = 3 are produced. Other exponents are possible, if the probabilities
scale, instead of with k, with increasing functions of k (typically powers ka of afine
functions k + A).
From the works by Watts, Strogatz, Barabasi and Albert, many other network
models have been proposed so as to take account of each time more detailed topological
features of real networks. However, the works mentioned in this section, the models
proposed and the network properties they succeed at describe are probably the most
essential in networks theory, both for their future influence on the development of the
discipline and the intrinsic importance of the concepts that they develop.
Network motifs in directed systems
Clustering coefficient tells us about the local surroundings of a node in an undirected
network. Its definition can be re-formulated by using a terminology based on trian-
gles and connected triplets, as made with transitivity in equation 1.3: the clustering
coefficient of a node in an undirected network is the number of triangles it takes part
in divided by the maximum number of triangles it could join, given its number of
connections.
When moving to directed networks, the general question of studying the local sur-
roundings of nodes becomes subtler, as many different types of triangles are found,
as well as an enhanced diversity of connected triplets. Leaving apart the task of re-
defining clustering on directed networks (something that has attained proper attention
in the field [35]), the question of studying the different types of connection patterns
among reduced groups of nodes (the so called network motifs), and their respective
abundances in real networks has constituted a prolific research topic in the field.
A motif is a subgraph formed by a low number of nodes -typically 3 or 4- which are
connected according to a defined topological pattern. For example, with three nodes
we have thirteen possible motifs (or triads) in a directed network.
About motifs, a key question that has been systematically posed during the last
years has been: how anormally high –or low– is the number of motifs of each type
within a network? Admittedly, the question, as posed, could be reasonably answered by
another question: when compared to what? A situation that highlights the importance
of having adequate null-models in networks theory to use as meaningful comparison
terms in order to test whatever hypothesis.
The more usual null model in networks theory is the configuration model (CM). The
configuration model is a model that is built upon an existing network, by preserving
the whole degree sequence of it, and randomizing everything else. This means that
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any node will have the same connectivity of the original system, but its neighbors will
be chosen at random. In the practice, this can be achieved by rewiring links of the
existing network, although a CM can also be built from the degree sequence itself,
without need of accessing to all the information of the original network (typically
encoded in its adjacency matrix). CM’s are also widely used for generating scale-free
graphs, as these overcome certain “pathological” topological treats of BA networks (e.g.
the emergence of degree-degree correlations)
In order to test motifs abundances in real, directed networks, a particular configu-
rational model was used by Alon and co-workers in 2004, which consists in generating
CM-versions of the network to study in which, not just the in, and out degrees of each
node are preserved, but also the number of feedback loops (bi-directional links) each
node has. This can be achieved easily by rewiring separately single-directional links
and feedback loops.
In a series of works by Alon and co-workers, they aimed at studying how the number
of appearances of each possible triad in different real networks compare with the same
measures performed on the corresponding CM-derived null network models. To do
that, given a real network, they re-construct a set of CM random versions of the real
systems and compare the number of appearances of a triad T on the real system nT , to
the average number of appearances of it within the CM networks of the null ensemble
〈nrandT 〉, through the following Z score:
ZT =
nT − 〈nrandT 〉
σrandT
(1.7)
where σrandT represents the typical deviation of the appearances of triad T in the
networks of the null ensemble, in such a way that positive Z-scores stand for motifs
appearing in the real network more than expected by random and viceversa. If one
calculates the 13 scores associated to each triad, and normalizes them as if they were the
components of a 13-dimensional vector of norm 1, we get the so called triad significance
profiles (TSPs), which constitute a way to visualize relative trends of a particular
network to choose certain motifs and to discard others.
Technical nuances apart (which will be further discussed in chapters 3 and 5),
through these analysis, Alon and co-workers found an striking result: the TSP of
different real networks tend to group around four neatly different profiles o super-
families. This includes social systems, semantyc networks, and two families of biological
networks for information processing: one formed by transcriptional regulatory networks
(TRNs) of unicellular organisms and other one by developmental regulatory networks
of pluricellular organisms and synaptic systems.
Community structure in complex networks
Between local metrics (i.e. node degrees or clustering coefficients) and global traits of
complex networks (average path lengths, average degrees and clusterings or transitivity)
there is a vast range of relevant levels storing meaningful information about the ultimate
structure of complex networks. The study of the patterns of aggregation within groups
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Figure 1.3: Community structure and network motifs. A: The thirteen possible connected
network motifs in directed networks. B. (Adapted from [37]) Community structure of the
social network of Zachary karate club [38]. Nodes shapes and colors represent the community
structure of the network at two different scales. Squares and circles represent the community
structure resembling the process of social division that took place among the members of
Zacchary club. The color-based partition is one particular outcome of the parametric method
for modularity optimization proposed in [37].
of nodes (typically, of n nodes, with 1 << n << N) has attained much attention in
the last ten years.
The key question about mesoscale in a complex network can be expressed around
two questions: can be identified within a given network subsets of nodes more intensely
connected among them than expected (taking into account the overall properties of the
network)? Can the network be splitted in groups –or communities– each one of them
presenting more intense internal coherence than external connections with the rest?
Generally speaking, we say that a network is modular (or presents a high modularity,
or a relevant community structure) if the answers to these questions are affirmative.
Admittedly, the question is complex and subject to ambigüity, as there is no an
unique way to define modularity. Notwithstanding that, the first and probably most
relevant definition of network modularity is due to Newman [36]. According to Newman
definition, we start by defining a partition of the nodes set in groups, assigning each
node to one cluster. Let us denote the cluster which node i belong as Ci. Then, we
can calculate the modularity associated to that partition as follows:
Q =
1
2L
∑
i,j
(Ai,j − kikj
2E
)δ(Ci, Cj) (1.8)
where δ stands for the Kronecker Delta function. Newman’s modularity is a measure
of the fraction that links connecting nodes within the same cluster represent, minus
what one would expect, for the same fraction, if links were randomly distributed across
the network. So, identifying the relevant mesoscale structure of a network means find
a partition in clusters maximizing Q.
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The problem of modularity maximization has turned into a hot-topic in the field,
since modular structure in complex networks have been recurrently found to be related
to functional aspects. Since an exhaustive search of all possible partitions is absolutely
prohibitive, even for small-size networks, many different computational approaches
have been proposed to solve the problem [39, 40, 41, 42], each of which presents advan-
tages and caveats that usually corresponds to an inverse correlation between method’s
performance and computational requirements and scaling properties. The modularity
landscape is usually complex, and characterized by multiple maxima yielding similar
values of Q, yet constituting very different partitions. Additionally, modularity max-
imization is hampered by an intrinsic resolution problem, that impose constraints to
the size of partitions accessible to many of the methods of mesoscale analysis. This
issue, however, has been treated in a number of works, in which methods for optimizing
modularity at different scales are proposed.
1.1.3 Theoretical developments of networks theory
There is yet a long way to walk in networks theory of which the end can hardly be
imagined yet. The theoretical development of the discipline goes in parallel to an expo-
nential increase in the quantity and resolution of the data we count with to reconstruct
new complex systems as networks. In the so called big-data era, our knowledge of the
networked systems that are around us –from human societies to cell interactomes– is
each time more thorough and precise.
This explosion of information has allowed researchers to transcend the technical
limitations that constrained them to the classical representation of complex systems
as static, “simple” complex networks in which nodes and links are frozen objects, im-
mutable in time and intrinsically (i.e. without considering its network properties) iden-
tical to each other. In this sense, the study of time evolving networks have emerged
as a relevant new branch in the topic, as it allows to study, in a natural way, not only
the way in which network’s topology influences dynamics of processes taking part over
it, but also the way the function of the network modifies the structure of the network
itself.
Another relevant emerging thread that can be circumscribed to this context is the
development of multi-layer (ormultiplex ) networks theory. In a multiplex network, a set
of nodes can interact through different kind of links, typically associated to different
layers. Examples of real systems that are naturally modeled as multiplex networks
are on-line social networks: although networks like twitter, facebook, Instagram, or
even e-mail networks, the blogosphere, etc, can be initially understood as independent
systems, actual nodes of these networks are people, and no user accounts: the same
individual can appear simultaneously in more than one layer if, for example she has a
facebook account, an e-mail address and a blog.
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1.2 Networks theory applications in epidemiology
Epidemic spreading processes constitute a vast field of intense research since nearly a
century [43, 44, 45]. The mathematical models developed in this period to describe
disease dynamics have become invaluable tools for health authorities. These theoretical
tools have been at the root of many of their decisions about strategies of vaccination,
prevention and profilaxis [43, 44, 45, 46].
As time goes by, these models have suffered a gradual process of sophistication, very
specially during the XXIth century, thanks to the development of networks science and
its applications in the field. In this context, one single discovery has supposed a greater
impact than any other: contact trees relevant for disease spreading often present the
properties of a complex network. From that point on, the influence of these complex
properties of contact networks were addressed [47, 13, 14], and, each time, more subtle
and precise dynamics [48, 49] considered.
Admittedly, the improvement of computational modeling platforms aimed at pro-
viding an increasing accuracy and predictive power necessary implies the gathering of
information regarding both population structure and disease specificities. The task of
improving the quality and accessibility of the actual information required for an optimal
description of epidemic processes is challenging, but in the last few years, the topo-
logical characterization of contact networks on top of which epidemics take place has
actually stirred up the discipline [50, 51, 52, 49, 53, 54]. This has been feasible thanks
to the use of new computational methods, and the incorporation of data coming from
such diverse sources as simple statistical surveys [11], mobile phone calls registers [55],
bank note mobility patterns [10], global transport networks [53] and geo-demographical
distributions of population [56].
Despite of all the progresses made, epidemic modeling has not gained in accu-
racy for all types of diseases the same way. In fact, as a consequence of its greater
-and grateful- mathematical simplicity, SIR (susceptible-infected-recovered) and SIS
(susceptible-infected-susceptible) models are the frameworks for which highest levels
of accuracy and sophistication have been achieved, both at a theoretical, general level
[8, 57, 58, 59] or within more precise, applied scenarios [54, 49, 56]. Moreover, the
current degree of modeling sophistication corresponds to short-cycle diseases, whose
main feature consists in that individuals become infectious suddenly after becoming
infected [45]. These are the cases of diseases that typically transmit from one person to
another like respiratory virus and influenzas, two highly topical examples being SARS
and H1N1 (influenza A). The fact that the cycle of infection is short-lived allows a
most efficient reconstruction of the contact maps between infectious and susceptible
individuals and a key theoretical and computational approximation, common to most
of current models: the total population size can be assumed to be constant during the
outbreak.
Persistent diseases −for which infected individuals can enter into asymptomatic,
latent states for not negligible periods before developing clinical symptoms− are the
paradigmatic, opposite scheme to short cycle diseases, both regarding the mathematical
and computational challenges that their modeling represents, and the relative less
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sophisticated models currently available for their description [48, 60, 18]. However, the
global impact of persistent diseases -mostly in underdeveloped countries- is everything
but a small problem, evidencing the need for a global research effort.
In this Thesis, one of the central objectives is to explore, in the context of persistent
diseases like tuberculosis (TB), the influences on the disease spreading process exerted
by certain properties of the populations studied, assimilable to cardinal treats of com-
plex networks. In the following lines we will review the models that constitute the
basis of our work, as well as the kind of network properties and dynamical behaviors
which we aim to study and particularize for the case of TB.
1.2.1 Compartmental models in mathematical epidemiology
Most common theoretical approaches for the spreading of epidemics are based on com-
partmental models, which offer a description of disease spreading that is based on
dividing a population into different subgroups, according to the state of individuals
with respect to the disease. Most simple compartmental models are the susceptible-
infected-recovered (SIR), firstly introduced by Kermack and McKendrick in the decade
of 1920 [61], and, as a variation of it, the susceptible-infected-susceptible (SIS) case.
As a first example, SIR model describes diseases in which susceptible individuals
(in class S) can only be infected once (passing to class I), gaining immunity to further
re-infection after the first infection (i.e. entering class R). The model, in its classical
description, takes into account no more than two parameters: the infectiousness λ, and
the recovery rate µ. Each contact between a susceptible individual and an infected one
result in a contagion process with a probability λ, i.e.:
λ
S + I → I + I (1.9)
On the other hand, for each time stage, the infected individuals have a probability
µ to reover:
µ
I → R (1.10)
At this point, all the individuals in the system are considered to be dynamically
equivalent, which is usually designed as the mean field approximation (MF), and sup-
poses that the probability of getting infected is the same for all susceptible individuals,
and proportional to I. Furthermore, all individuals are considered to be in contact
(well-mixed populations), and the number of contagions per unit time that take place
in the system is approximated by the product λSI (where S and I are the number of
susceptible and infected individuals, respectively). Under these circumstances, model
dynamics is described by the following ordinary differential equations system:
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S˙(t) = −λS(t)I(t) (1.11)
I˙(t) = λS(t)I(t)− µI(t) (1.12)
R˙(t) = µI(t) (1.13)
Nevertheless, for many diseases, an initial episode of disease does not prevent further
re-infection. In these cases, spreading dynamics is better described by the SIS model,
whereby recovered individuals after infection simply return to the susceptible class:
I → S, also with probability µ. Again, in the approaching of well-mixed populations,
the model is described by the following system:
S˙(t) = −λS(t)I(t) + µI(t) (1.14)
I˙(t) = λS(t)I(t)− µI(t) (1.15)
Both models reproduce different dynamics after the introduction of a little seed
of infected individuals in a fully susceptible population. In particular, due to the
continuous decreasing of the type S, the long term survival of the pathogen within the
population is impossible in accordance with classical SIR model. Both formulations
are suitable to describe the time course of short cycle diseases, for which an epidemic
outbreak is fast enough to justify considering the total volume of the population N as
a constant. The modification of the model by allowing new individuals associated with
births (or migrations) join the system (and others to leave it) can revert the extinction
of susceptible individuals in the SIR case, enabling more naturally the survival of the
pathogen within a population even if immunity after infection is attained.
SIS model, though, does not need demographic dynamics to allow asymptotical,
stable endemic levels of infection in a population 8see figure 1.4). In this case, the
equilibrium between contagion and recovery defines a dynamical equilibrium charac-
terized by the presence of an endemic infection prevalence in the population, that is
stable under certain circumstances.
Taking that into account, the metrics reflecting the severity of an epidemic episode
according to each model are different. In the case of SIR model, this is the fraction of
individuals that have been affected by the disease before the natural extinction of the
outbreak (i.e. the number of individuals in class R at time t =∞: R∞); while, for the
SIS case, this is the endemic level of infection prevalence I∗.
So, if, as we say, the above mentioned magnitudes –R∞ for SIR and I∗ for SIS–,
constitute the more elementary measures of the severity of a finished epidemic event,
one obvious question arises: what will be their values as a function of the model
parameters? Or, relatedly, what are the conditions after which, the appearance of an
infectious agents will spread yielding the occurrence of epidemic events with R∞, or
I∗ greater than zero? In the context of these simple models, the last question can be
answered by studying the response of a fully susceptible system (S(t = 0) = N), in
which we introduce an infinitesimal amount of infected individuals I → 0.
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Figure 1.4: SIR and SIS compartmental models. Transition schemes (up) and temporal
courses of epidemic episodes beyond the thresholds (low).
The question is more easy for the SIS case, because system 1.15 can be rewritten
as a one-dimensional system just by substituting S = N − I to get:
I˙(t) = (λ(N − I(t))− µ) I(t) (1.16)
Which has two solutions: I = 0 which correspond to the trivial disease-free fixed
point and another, non trivial solution for the endemic equilibrium given by:
I∗ = N − µ
λ
(1.17)
which is only physically meaningful (i.e. greater than zero) if:
λ > λc =
µ
N
(1.18)
The critical value λc is called the epidemic threshold, and stands for the minimum
value for the infectiousness needed for the endemic equilibrium to exist. It is easily
demonstrable that the condition λ > λc not only yields the existence of the endemic
fixed point, but also its stability, as well as the instability of the disease free equilibrium
I = 0. In other words, when λ > λc, the introduction of a perturbation from the disease
free state, as a small infection seed in the system, yields the installation of the disease,
and the arrival of an endemic equilibrium. In the case of SIR, it can be similarly shown
that an equivalent critical infectivity λc = µ/N defining an epidemic threshold can
be found, and that, in this case λ > λc yields the emergence of transient epidemic
outbreaks that, once finished, have affected a macroscopical fraction of the population,
represented by R∞ > 0, whereas, in the opposite case (λ < λc) R∞ will remain of the
order of the infection seed (i.e. Rinfty ' I(0) ' 0).
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More complex compartmental models are essentially based in SIS and SIR. These
contemplate the incorporation of latency periods [48], fluxes associated to births and
deaths, different kinds of disease and other more sophisticated phenomenologies. How-
ever, existence of epidemic thresholds is a common feature of all of them, and their
characterization a central matter in the discipline.
1.2.2 Complex networks and mathematical epidemiology
Compartmental models used during the past century, like the basic formulations of SIR
and SIS models presented in the previous section, relied on the well-mixed approxi-
mation to describe disease spreading dynamics. Even if it could seem adventured to
assume that all the individual within a city are equivalent, and equally able to interact
all-to-all at each time step, the approximation had remarkable success at providing a
theoretical framework for the description of the time-course of real epidemic events,
like the plague outbreak occurred in Bombay in 1906-1907 [61, 62, 63].
The advent of complex networks at the last years of XXth century allowed scientists
revisit the works by Kermack and McKendrick with renewed eyes. Key questions for the
further development of the discipline were firstly formulated at that time. What can we
expect from compartmental models once we abandon the well-mixed scenario? What
are the topological properties of actual contact networks through infectious disease
spread? Around the answers of these, and other related questions, the foundations of
modern mathematical and computational epidemiology have been settled during the
last fifteen years.
sexual mating is a complex issue
More than seventy years later the works by Kermack and McKendrick, in 2001, Liljeros
and collaborators analized data from a series of social surveys conducted in Sweden [11].
The participants of these surveys were asked for the number of sexual partners they
had had in the last year and during their entire lives. Results were crystal clear: the
distributions of the number of sexual contacts -both recent and accumulated during the
whole life- were strikingly reproduced by power-laws, with slight differences in what
regard exponents between men and women. This result means that the network of
sexual contacts is also a complex network; more precisely an scale free one.
The relevance of this finding transcended anthropological grounds, causing a big
impact in mathematical epidemiology. Sexually transmitted diseases, like the acquired
immune deficiency syndrome (AIDS), spread precisely on top of networks of sexual
contacts: if its topology can not be reasonably assimilated to a regular graph, classical
models of mathematical epidemiology might be substantially wrong. So, the question
is obvious: how do degree heterogeneities affect the dynamical predictions of classical
compartmental models?
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Compartmental models beyond well-mixing hypothesis: the heterogeneous
mean field
As we say, using well mixed compartmental models means allowing nodes to interact
all-to-all in each time step. The first way to abandon this hypothesis is to restrict the
interaction range of each individuals to β neighbors, as in a random regular graph. By
this way, we have, βS I
N
contacts between susceptible and infected individuals per unit
time instead of the simple product SI that we had for the well mixed case. In this
case, βS I
N
contacts yield circa λβS I
N
contagions, the system of equations remains as
follows:
S˙(t) = −λβS(t)I(t)
N
(1.19)
I˙(t) = λβS(t)
I(t)
N
− µI(t) (1.20)
R˙(t) = µI(t) (1.21)
and it is easy to show that, (both for SIS and SIR), the epidemic threshold reads
as:
λc =
µ
β
(1.22)
as now, instead well-mixing, we have just β, and, as it is logical, the less connected
is the network the larger the value of the epidemic threshold. Nevertheless, the works
of Liljeros and co-workers had demonstrated that connectivity patterns of real contact
networks were not assimilable to those of a regular graph, which pointed to the need
of abandoning classical mean field approaches in epidemic modeling [11].
As a matter of fact, things are less intuitive when the mean field approximation is
discarded. In this context, heterogeneous mean field (HMF) constituted one of the first
theoretical approaches to abandon classical mean field in order to consider dynamical
differences between individuals [8, 58].
According HMF, individuals are distributed among different classes, each of which
associated to a different connectivity. This way, all the individuals within a single
degree class not just have the same number of neighbors but also are dynamically
equivalent. For this reason, HMF does not fully eliminate mean field, but simply
constraint it to the internal domain of each connectivity class.
under the HMF approximation, the SIR model –for example– has no longer three
equations, but three times the number of degree classes considered in the system. If
we consider a single degree class within which individuals have k neighbors, we call the
number of susceptible, infected and recovery individuals in that group as (Sk, Ik, Rk),
which will evolve in time according to the following equations:
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S˙k(t) = −λβSk(t)θ(t) (1.23)
I˙k(t) = λβS(t)θ(t)− µIk(t) (1.24)
R˙k(t) = µIk(t) (1.25)
where θ(t) –that plays the same role of the fraction I(t)/N in the case of regular
networks (eq. 1.21)–, is the probability per link of pointing to an infected node, which
is responsible of coupling the dynamical state of all connectivity classes:
θ(t) =
∑
k P (k)kIk
〈k〉 (1.26)
In 1.26 P (k) is the degree distribution of the system, that defines how individuals
are divided in the different connectivity classes, and 〈k〉 the average degree of the
network.
The relevance of considering network topology in compartmental models can be
easily understood after deriving the epidemic threshold expression in a HMF model,
which was done in a series of works by Vespignani and collaborators [8, 58] more
than ten years ago. Straightforward calculations allowed the authors to find that the
epidemic threshold –both for SIR or SIS models– results to be proportional to the
quotient 〈k〉/〈k2〉:
λc = µ
〈k〉
〈k2〉 (1.27)
On the other hand, as Liljeros and collaborators found, networks of sexual contacts
presented highly heterogeneous degree distributions, best fitted by power laws of the
form P (k) ' k−γ with γ ranging between 2 and 3 (2.54 ± 0.2 in the range k > 4 for
females, and 2.31±0.2 for males in the range k>5 [11]). Strikingly, the denominator of
the epidemic threshold, 〈k2〉, when P (k) obeys a a power law distribution with γ < 3
diverges as the system size increases. This means that, the bigger an scale free like that
of sexual contacts is, the closer to zero is the epidemic threshold of a disease spreading
over it. The message is really disturbing: the novelly observed network heterogeneity
promotes the spreading of diseases, and even the most weak pathogen will be able to
cause macroscopic outbreaks if the networks on top of which it transmit are big and
heterogeneous enough.
Contact patterns relevant for the spreading of airborne diseases
Strong heterogeneities observed in networks of sexual contacts motivated the appear-
ance of a whole new family of epidemic models on heterogeneous populations which
is still growing nowadays. However, other types of diseases, like airborne or zoonotic
infections, do not transmit over sexual routes, and so, it would seem that considering
complex networks as the most adequate substrate to use for their spreading description
may not be a reasonable hypothesis. The key question is whether the contact networks
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relevant for the spreading of these kind of diseases are heterogeneous, or if, instead,
classical descriptions based on random graphs may account for the contact structures
observed.
In what regards airborne transmitted diseases, it is commonly assumed that ca-
sual close contact among individuals can result in disease transmission, including, for
example, face to face conversations, co-occurrence in confined environments (e.g. pub-
lic transportation means) or, for some diseases like influenza, physical contact with
surfaces previously touched by an infected individual.
The distribution of the number of this kind of social, casual contacts is not as clear
as that of sexual encounters. Many aspects exerts an strong influence on the number of
social contacts a person is expected to present per unit time: her culture and country,
the size of her city and its population density, the number of members living in her
household, her occupation etc. This makes the task of estimating degree distributions
of social contacts a subtle matter, subject to a multitude of different factors whose
multi-variate structure has only been partly characterized in the literature.
Although characterization of such contact distributions is unarguably an open prob-
lem, the dependence of numbers of contacts with age has emerged as a central factor
exerting a robust influence on the number of contacts of individuals, at least in some
countries (see figure 1.5. In 2010, John Edmunds and co-workers conducted a series
of surveys in eight different european countries on this matter: the so-called Poly-
mod project [12]. Their findings resulted in the emergence of a robust pattern of age
dependence for the number of social contacts per unit time reported by individuals
surveyed, essentially preserved across the different countries studied. According to this
pattern, individuals tend to interact more strongly with people of the same age, ex-
cept for the case of strong interactions observed between parents and sons (and, less
intensely, grandparents and grandchildren). Additionally, people interacts much more
intensely during their first years (i.e. until circa 20 years old), and from that point on,
interactions lose frequency and intensity.
Polymod project is not the only work completed so far for characterizing contact
patterns relevant for disease spreading. Until a systematic characterization of this
kind of systems is available in the different countries (or at least, in the different con-
tinents), these systems provide an adequate initial basis for evaluating how emerging
heterogeneity in the contact networks affects the spreading dynamics of diseases whose
main transmission routes are not sexual; like influenza and, more relevant for us, tu-
berculosis.
1.2.3 Models for the description of coupled epidemics
In this context, an emergent field of research is the modeling of coupled spreading
phenomena, as for example two pathogens or multiple strains of the same disease that
propagate concurrently on the same population [64, 65, 66, 67, 68]. Focusing on the two-
pathogen scenario, the complexity of the problem increases because now the natural
history of one of the diseases is affected by the presence of the second one, typically as
a consequence of the modification of the host’s immune response after infection − with
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Figure 1.5: Heterogeneous patterns in contact networks. Left: Smoothed age-dependent
patterns of physical contacts for Deutchland, as reported by Polymod project [12]. Right:
distribution of the number of sexual contacts per year corresponding to the surveys performed
in Sweden and analyzed by Liljeros et al. [11]. Center: epidemic thresholds in homogeneous
(blue) and scale free networks at the thermodynamic limit. As network size increase, the
degree fluctuations that characterize SF networks make epidemic thresholds lower.
a plethora of possibilities as given by different interaction schemes −. In addition, the
networks of contacts through which the pathogens spread can vary from one disease to
the other. Typical examples of these coupled spreading phenomena are given by the
interaction between HIV infection and the spreading of certain opportunist pathogens
[69, 70], or the strain-strain interactions of a viral pathogen like the flu virus [71].
From a theoretical point of view, one of the first works that considered the above
problem from a networked point of view is due to Funk and Jensen in 2010 [66]. In this
work, authors address the issue of epidemic thresholds in a SIR (Susceptible-Infected-
Removed) model. However, this first work did not consider a framework in which
the temporal evolution of the epidemics can be studied. Following a similar approach
Mills et al. [72], motivated by the interaction between AIDS and Tuberculosis, stud-
ied two coupled SIR models where the diseases can spread in both layers at different
rates. Also in this case, due to the static nature of the theoretical approach used,
the temporal evolution of the diseases can neither be addressed. Recently, Marceau et
al. presented a new model [68] aimed at studying the latter aspect, also for the SIR
scheme, using “on-the-fly graphs”, a network generation model previously introduced
by the authors [73]. In this work, although the temporal evolution of the system can
be monitored, the modeling approach does not provide information about epidemic
thresholds. In addition, the model can not be trivially generalized so as to cover other
classical models like SIS (Susceptible-Infected-Susceptible). Other works have consid-
ered the problem by studying the spreading of the diseases as a Markovian process. In
[74] the authors, using two coupled Markov processes, studied the competition of two
epidemics and found different regions of the parameters space where the two diseases
can coexist. However, the model in [74] only represents the specific scenario of two
mutually excluding diseases. It is also worth mentioning that using a similar approach,
the so-called microscopic Markov-Chain [75], the specific case in which a disease and
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an "awareness" diffusion process coexist has been studied in [76].
In conclusion, the problem of how the interaction two or more diseases affects their
spreading processes has only been partly addressed in the literature. Two diseases
can interact through very assorted different mechanisms, like modifying each other’s
transmission parameters, infectiousness times, mortality, latency periods etc.; and it is
not clear yet what differences can be expected in the spreading processes as a function
of what are the specific driving interaction mechanisms. Furthermore, the interplay
between the interaction mechanisms, the particular details of the natural history of
the diseases (e.g. if immunity is gained after infection or not), and the topology of
the networks of contacts through which they spread (and their eventual correlations)
constitute a vast landscape of possibilities that definitely deserves thorough exploration.
1.2.4 Spatial patterns of disease spreading
Compartmental models, as well as mean field approaches (homogeneous or heteroge-
neous) constitute useful tools for the description of the epidemic spreading on localized
populations within which geographical distribution of nodes is neglected.
However, in many occasions, it is important to understand how an epidemic is
expected to geographically propagate across an extended area. For answering this kind
of questions, many different modeling approaches are available, from reactive-diffusive
models to agent based and meta-populations approaches [77, 78].
According reactive-diffusive models, punctual amounts (or densities) of suscepti-
ble, infected and recovered individuals are substituted by fields whereby each point
in space ~x is assigned with a density of individuals within each class, for example:
(S(~x, t), I(~x, t), R(~x, t)) in a SIR. Temporal evolution of these densities in a point is
subjected to similar terms to those associated to disease dynamics in equations 1.21–
(reactive terms), but geographical diffusion of individuals within all classes is also al-
lowed. This kind of models are able to describe the formation of epidemic fronts and
waves, and they are suitable to describe epidemic processes taking place on top of popu-
lations distributed across extended areas, in which the mobility patterns of individuals
are mainly local (i.e. their movement ranges are lower than geographical distances).
That is the case of many zoonotic diseases affecting wild life animals [79], but it is
also the case of human populations previous to the industrial revolution. For example,
reaction-diffusion models incorporating estimations about geo-demographical distribu-
tions at the time have been able to reproduce the complex epidemic front of the black
death outbreak that devastated Europe from 1347 to 1351 A.C [45, 80, 81, 82, 83].
Admittedly, human mobility patterns are not any more those of the medieval Eu-
rope. The advent of mechanical transportation means after the Industrial revolution
first, and after that, the globalization of the air transportation network, have exerted
a deep transformation in the way we move, commerce, migrate and live. This trans-
formation has rendered obsolete reaction-diffusion approaches to describe the way in
which diseases spread through extended areas, as long-range movements, even at inter-
continental scales have become routine. This has motivated the use of novel approaches
to describe geographical spreading patterns in epidemic process. Among these, meta-
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population models are based on networks in which nodes represent entire populations
(i.e. countries, cities, or small geographical areas), and links movements of people from
one population to another. The integration of air-transportation networks, census data
on the geographical distribution of the populations and compartmental models within
each node has allowed researchers to build up detailed meta-population models, accu-
rate enough to reproduce and predict the time course of real epidemic episodes like the
influenza A−H1N1, from its emergence in 2009 to its worldwide pandemic spreading
a few weeks later [15, 16].
The different times needed for the black death and A − H1N1 influenza to get a
global (or continental) reach highlights the effect of the globalization of human mobility
in enhancing the spreading of diseases, and, ultimately, the need of developing accurate
models and theoretical tools able to help us to understand epidemic phenomena, with
the final objective of achieving preparedness and control of current infectious diseases
and future possible threats [47].
1.3 Networks theory applications in cell and systems
Biology
During recent years, simulations of biological systems have been spurred by the mas-
sive acquisition and availability of data in molecular and cell Biology. It is increasingly
becoming evident that simulations can be paired with experiments, and in fact, they
are customarily used by computational scientists to understand the quantitative be-
havior of many complex biological systems. Additionally, in silico simulations are also
successfully employed in the design of new biomolecular experiments thus driving ex-
perimentalists research. Although the gap between in vivo and in silico biology has
been remarkably reduced, there are still many limitations hindering the adoption of
computational approaches in everyday bio-molecular research. Filling in this gap will
help for a better understanding of mechanisms and operation of cellular processes.
Achieving such a goal is not easy. Experimental data for large biological systems are
often incomplete and of non-uniform quality, so that their modeling is often hampered
by the lack of complete knowledge of the cellular circuitry of interactions. However,
our still limited capability to produce accurate computational models of living systems
is however producing simulation tools useful in drawing new principles and laws, both
from the topology and the dynamics of the system under consideration, that comple-
ment the huge body of experimental work.
In particular, once again, the analysis of cellular interactomes at the light of net-
works theory has resulted into relevant advances in the field. Systems like metabolic
networks of reactions, protein-protein interactomes and gene regulatory systems have
been successfully described as networks sharing the same set of ubiquitous complexity
footprints: small-world property, high degree heterogeneity, high modularity and exotic
motifs profiles, among others. Viewing these systems as complex networks has revealed
as a powerful approach that allows elucidating the roles of its components and their
dynamical interplay, in order to understand the functioning of the system as a whole.
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1.3.1 A classification of biological networks
As it is commonly noticed in the literature, gene regulation is a complex process in-
volving different phases and biochemical phenomenologies [84, 85] that allow the cell
to adapt her composition and performance to the characteristics of a changing envi-
ronment.
Genetic information stored in DNA is first copied into messenger-RNA molecules
through a process named transcription. During this process, an enzyme called RNA-
polymerase recognize the starting point of a given gene and reads it, gliding over it and
generating during the process a transcribed copy of the gene. Then, mRNA diffuses to
ribosomes (crossing the nuclear membrane in an eukaryotic cell, or just through simple
diffusion, if we talk about prokaryotes) where they are translated into proteins, which
are the conceptual effectors of the information stored in DNA.
This process is regulated at different stages. First, the affinity of RNAp enzyme
for the transcription initiation sites can be altered in the cell, by the presence of
transcriptional factors (TFs): regulatory proteins which bind on specific DNA regions,
next to the transcription initiation sites of regulated genes, augmenting or diminishing
their affinity to RNAp, which makes these target genes be activated or repressed,
respectively. In bacteria, another family of transcriptional regulators called sigma
factors bind to the RNAp instead -sigma factor itself are considered RNAp subunits–,
equally affecting its affinity for different genes. Each sigma factor makes RNAp more
prune to transcribe a family of genes, and less prune to transcribe others, being the
number of genes regulated, in this case, typically higher than those affected by a a
single TF.
Admittedly transcription is not the only phase of biological information processing
that admit regulatory mechanisms. Non coding RNA are molecules that are transcribed
but not translated into proteins, some of which, like micro-RNA have regulatory func-
tion. miRNA are small molecules that bind to the mRNAs of the genes that they
regulate. By binding a mRNA, the regulator can inhibit its translation, favoring its
degradation [86].
Additionally to these transcriptional and translational regulatory mechanisms, en-
zymatic proteins are activated and deactivated as a function of the specific needs of
the cell. This is typically achieved through a series of post-translational modifications
through which the cell is able to perceive an external signal and modify her behav-
ior accordingly. Typically, a sensor protein interacts with a particular environmental
signal (i.e. the presence of an small molecule -or ligand-, a nutrient substrate, or a
physical condition), which modifies its conformation. Subsequently, the modification
in the sensor protein is transmitted over a signalling cascade to the particular proteins
that are intended to receive the signal (i.e. the effector proteins), whose differential
performance will drive the cellular response to the initial stimulus. Signalling cascades
are deeper in eukaryotic systems, while consisting in a few steps in prokaryotic cells.
Finally, a crucial part of the total amount of proteins present in the cell are de-
voted to enzimatic purpose designed to control the global pipeline of matter and energy
constituted by cellular metabolism. The control, homeostasis and environmental adap-
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tation of the metabolic networks of chemical reactions in the cell is the final target of
its regulatory machinery, and so, it will not be surprising that the anomalous presence
or absence of certain key metabolites constitute common signals to which the cells
responds.
In the left panel of figure 1.6 the whole process is schematized through a simple
example. In this figure, the metabolic network is as simple as a set of three reactions
and three metabolites: A,B and C. A would represent, for example, a substrate that
can be processed through two different pathways: depending of whether B is more
abundant to C or viceversa. A chemical equilibrium between B and C is observed.
In the figure, an active regulatory mechanism is represented through which the
cell controls the route for processing of substrate A. On the one hand, in presence
of metabolite B, the cell expresses the genes activating the processing of substrate A
through the pathway A + B → AB, and represses the genes needed for the comple-
mentary pathway, associated to the reaction A + C → AC. This is achieved by the
activation of the transcriptional factor I through its interaction with metabolite A,
that works as a ligand. Once activated, this transcription factor activates the genes
needed for final production of proteins V and V I, which forms the protein complex
able to catalyze the reaction A + B → AB, making it feasible. Simultaneously, tran-
scription factor I, once activated, stimulates the transcription of mi-RNA 4, on charge
of impairing the translation of protein V II. This ultimately avoid the association of
protein V with V II which has two effects: first, the complex V − V II is not formed,
and so, the reaction A + C → AC does not take place, and second, repressing V II
eliminates a competitor of V I for interacting with V , which facilitates the formation
of complex V − V I, needed for the catalysis of the desired reaction A+B → AB.
On the other hand, when the cell perceives an excess of metabolite C with respect
to B, it becomes desirable to activate the route A + C → AC and to inhibit the
complementary pathway associated to A + B → AB. To do so ligand C activates the
transcriptional regulator II, which has a role virtually opposite to that of I: it activates
the expression of genes 5 and 7, and represses the expression of 6. The final objective
is to promote formation of protein complex V −V II instead of complex V −V I, so as
to favor the kinetics of A+ C → AC in detriment of that of A+B → AB.
The example, obviously, is a highly simplified model of a much more complex reality.
However, it is illustrative because, besides exemplifying the overall rationale of signal-
ing and regulatory processes in the cell, it includes the principal regulatory mechanisms
through which homeostasis and environmental adaptation are achieved. This includes
transcriptional regulation, translational silencing mediated by mi-RNA, protein-protein
interactions, ligand-protein interactions driving signaling, and metabolism. Remark-
ably, many of these different mechanisms are customarily represented as networks, as
we can see in the right part of figure 1.6, in which the main types of biological networks
typically used to describe the cell as an entire system are represented.
First, we have the description of cellular metabolism through bipartite metabolic
networks. Under such representation, there exist two different types of nodes: metabo-
lites and reactions: a link connecting a metabolite to a reaction means the participation
of the former in the latter. In this sense, link directionallity, as it has been commented
 Applications of networks theory in Medicine and Biology
Figure 1.6: Left: Regulatory mechanisms involved in gene expression control. The figure
represents the main biological mechanisms that are involved in the control of gene expression
and protein activity. This includes transcriptional regulation (orange arrows), ncRNAs reg-
ulations (grey), protein protein interactions (blue) and enzimatic metabolic control (violet).
Magenta arrows from gene space to RNA space represent transcription, and garnet arrows
from RNAs to proteins; translation. Right: schematic representations of the different layers
coupled in the process.
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before, indicates whether the metabolite is being eliminated through a particular reac-
tion or produced (i.e. whether it is a reactive or a product), with bi-directional links
representing chemical equilibria.
Other relevant representation of cell system’s Biology is the network of protein-
protein interactions (PPIN), in which nodes are represented by proteins and links are
physical interactions among them. Arguably the most widely experimental technique
used to infer interactions between proteins are the so-called two hybrid screen systems.
The idea behind the technique is very easy: we start by identifying, for example, a
dimeric protein that, once dimerized, presents a particular behavior that allows us to
know that it is actually dimerized. This can be a fluorescent protein that only emits
light once dimerized, or a dimeric transcription factor that activates the transcription
of a reporter gene whose mRNA we are able to detect. Then, we scrutinize the struc-
ture of both monomers that form the dimer, and identify the binding domains that
allow them to attach and form the dimer. Finally, the DNA sequences corresponding to
those domains are deleted in each monomer and substituted by the sequence codifying
the two proteins whose interaction we want to address. The result is a couple of mod-
ified genes, each of which codifies monomeric “hybrids”, that we introduce in a model
organism (typically yeast, or easily growing bacteria) in such a way that guarantees
that both genes are going to be strongly expressed. In case the proteins we are test-
ing interact, the complex between both hybrids will form, and, as a consequence, the
signal that the original protein complex formation caused (i.e. fluorescence or reporter
gene transcription) will be observed; otherwise, the dimer doesn’t form and no signal
is registered.
PPIN topologies have been demonstrated to store useful information about the
biological function of the different proteins in a cell. As it is well known, proteins
that participate in common processes and interactions tend to be related to similar
biological functions. This is of particular usefulness for the development of methods
of protein function prediction, especially in organisms for which, as it is the case of
Mycobacterium tuberculosis (MTB), the function of a big fraction of proteins remains
unknown.
Finally, in the right, bottom diagram of figure 1.6, the gene regulatory network
that would be inferred from the system represented at the left panel of the figure is
sketched. Such a gene regulatory network represent the causal flux of events that
mediates between regulators activation and gene expression profile shifts in regulated
genes. Taking into account that these networks are commonly inferred on the basis
of identifying genes causing expression levels modifications at the level of mRNA in
other genes, they may contain links that represent different kinds of interactions (e.g.
the link 4− 7 represents the action of a miRNA, responsible of degradation of mRNA
of gene 7, while the link 1 − 5 represents a transcriptional activation), or even links
representing spurious interactions related to second order indirect effects (marked with
dashed lines in the figure). When only transcriptional links are contemplated in the
network (i.e. links from a transcription, or sigma factor to any target gene), we talk
about a transcriptional regulatory network.
Gene regulatory networks constitute a comprehensive representation of cell dynam-
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ics at a systemic level. For that reason, their systematic characterization, and coupling
with signaling processes has turned into a subject of high scientific interest [87]. Ad-
mittedly, as we see in the figure, none of the types of biological networks considered is
more than a partial representation of the whole dynamical function of the entire cell.
For the achievement of reliable in-silico simulations of the whole cell to be possible,
all the pieces of the puzzle will have to be fitted; a scientific goal that researchers of
systems and synthetic Biology have just started dreaming at.
1.3.2 Gene regulatory networks inference
Focusing on transcriptional regulatory networks, classical approaches to the problem
of network inference have consisted in making single perturbations to a network ele-
ment (for example, a transcription factor knockout [88]) and registering the differential
effects associated to such perturbation. By combining many of these perturbations a
network can be reconstructed, [89] whose degree of completeness will depend on the
number of perturbations that were performed. Beside the problem of completeness, the
experimental challenges underlying the systemic characterization of the TRNs are far
from being solved. The quantity and quality of available data on genome-wide tran-
scriptional regulation are significant only for a small set of model organisms. Besides
scarcity, the usual problem is related to the heterogeneous quality of the experimental
evidences of the regulatory interactions, the building blocks of TRNs, to the difficulty
associated to distinguish between correlation and causality to discriminate actual from
indirect interactions, and finally, to the fact that the existence of many of these inter-
actions is subject to particular environmental conditions whose characterization is yet
very partial.
Despite these problems, the amount of high-quality experimental information about
transcriptional regulation at systemic level is growing each day, not only within the
context of model prokaryotes
1.3.3 Topological analysis of biological networks
Topological features of TRNs are customarily characterized at all scales using different
metrics. At the large scale, genome-wide TRNs are signed and directed networks
which present the following features: (i) regulatory proteins –origin of the regulatory
interactions of the whole system– represent a small fraction of the total number of
nodes; (ii) out-going connectivity patterns are very heterogeneous –a small percentage
of global regulators (hubs) send most of the links; and (iii) in-coming link distributions
are quite compact: there is a characteristic scale that defines the typical number of
regulations each protein receives [90].
Turning to the mesoscale, modularity appears also in TRNs as a key feature to un-
derstand the dynamical function of the system. In genome-wide TRNs, each regulator
defines its own regulon as the set of nodes directly or indirectly regulated by it. Reg-
ulons are then subnetworks, that can be sometimes hierarchically organized; in other
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Figure 1.7: Experimental techniques used in biological networks inference. A) Micro-array
experiment scheme for measuring gene expression profiles. A micro-array consists on a physical
matrix formed by spots in each of which single-stranded nucleic acid segments corresponding
to a specific gene of an organism is attached (typically, to each spot corresponds one gene).
Once the array is available, an amount of cells whose gene expression is going to be measured
is lysed, along with an equivalent amount of control cells. Then, the mRNA corresponding to
each type of cells is marked with a fluorescent label of a different color and dropped on the
array, where mRNA hybridizes with the array’s strands. From the color adopted by each spot,
the ratio between the expression levels in the experimental and control cells is estimated. For
example, by comparing in a microarray wild type cells (control) to mutants in which a specific
transcription factor has been deleted (experimental), genes regulated by the deleted TF can
be inferred in a first approximation. B) Two hybrid assay. In this kind of experiment, the
starting point is a dimeric protein that -for example- is able to activate the transcription of a
reporter gene. Then, the binding domains that the monomers used to conjoin are substituted
by the sequences of the two proteins whose interaction is going to be tested (in red and blue
in the figure). In case the tested proteins interact, the reporter is transcribed.
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occasions, regulons partially overlap in non-trivial ways. Thus, the identification of
groups of regulons –or parts of them– interconnected through atypical, dense patterns
is expected to store information about the biological role of the proteins within them
[91]. The underlying idea is that community structure in biological networks might
contribute to unveil functional modularity, as it has been recurrently demonstrated in
metabolic and protein-protein interaction networks.
Chapter 2
Biological portrait of tuberculosis infection
Tuberculosis is an ancient disease whose presence in human populations is documented
from the Neolithic period, although its actual origin is thought to have happened
much earlier, circa 70.000 years ago [92]. Across the History of mankind, its principal
causative agent –the bacillus Mycobacterium tuberculosis, discovered by Robert Koch
in 1882– has constituted one of the deadliest pathogenic agents ever. However, in the
last decades, the increasing availability of antibiotics and the development of global
strategies for diagnosis and treatment optimization have made the disease burden to
decay worldwide [93]; even allowing the public health community to dream at the
disease eradication within the present century [94].
Nevertheless, many tragical problems remain open in tuberculosis epidemiology.
That is the case of the increasing emergence of multi drug and extreme drug resistant
strains [95], or the enhancement of the disease burden that appears in certain areas as
a consequence of the syndemics between tuberculosis and VIH [412, 96, 19]. For these
and other reasons, for tuberculosis eradication to be possible, novel epidemiological
interventions will have to be implemented, and relevant decisions about how to do it
will have to be made in the following years [94].
Surely, the most relevant tool the public health authorities count with to fight
tuberculosis in the next decades is the development of a new vaccine [97] aimed either
at substituting current BCG vaccine, or at least at enhancing its immunogenic action,
almost null in adult individuals [93].
In fact, nowadays more than fifteen novel vaccine candidates are being developed
by different research teams, and it is expected that, at least some of them will have
finished the complex process of development of the new drugs within the next decade.
By the end of this period, clinical trials will be finished and evaluated, the immuno-
genic efficacy of the new vaccines will be finally known and their respective impacts
will be forecasted and compared [429, 430]. Unraveling the biochemical mechanisms
behind M.tb infection is crucial for the development of new drugs and vaccines aimed
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at eradicating the disease.
2.1 Mycobacterium tuberculosis: the captain of all
these men of death
Human tuberculosis is caused by the bacillus Mycobacterium tuberculosis (MTB), a
human parasite unable to infect animals or to survive for prolonged periods outside its
host. MTB is characterized by a slow growth in vitro, airborne transmission between
humans and a life cycle characterized by causing long, asymptomatic latency periods of
infection in its host followed by eventual reactivation of bacterial proliferation causing
disease; alternated with cases of prompt disease progression after exposure. Such a
sophisticated life cycle is the product of a complex host-pathogen interaction process.
In the following lines, we will review the principal characteristics of the pathogen and
its parasitic life-style.
2.1.1 The life cycle of Mycobacterium tuberculosis
As we say, the infection cycle of tuberculosis is remarkably complex, and its final
outcome depends on a series of events and interactions between pathogen and host’s
immune system that take place over a vast range of temporal scales.
MTB infection starts when bacilli are inhaled as droplet nuclei. After inhala-
tion, viable bacteria reach the lungs, and they are phagocytosed by dendritic cells and
macrophages in lung alveoli [100, 101]. Through phagocytosis, immune cells engulf
pathogenic bacteria in a closed compartment called phagosome, which is separated
from the cytoplasm by a lipid bi-layer, where the immune cell will try to isolate and
kill the intruder.
The role of DCs is crucial at these initial stages of the infection process, and consists
of two phases: first, as we say, DCs work as phagocytic units that engulf and kill small
amounts of bacteria. Then, after phagocytosis, take the main antigens from the remains
of the bacterium killed and place them into their membranes, so becoming antigen-
presenting cells. At this point, they migrate from the lungs to the draining lymph
nodes, where they present antigens to awaiting lymphocytes, mainly T helper 1 cells
(THC1), and activate them by the production of signaling interleukin (IL)-12 and IL-18;
which yield TH1 activation after which they will accumulate in lungs and orchestrate
the acquired immune response against MTB. This process has been demonstrated to
last several weeks, much more time than for other diseases like influenza.
The performance of DC as TH1 activators and the ultimate role of these as pri-
mary drivers of the acquired immune response at the infection site is crucial for the
containment of infection. During the first weeks after infection, before acquired im-
mune response is deployed, naive phagocytic cells, like macrophages, monocytes, and
neutrophils constitute the main shock troops against the pathogen [102, 101], although
their sole performance is hardly able to contain bacterial growth. At this phase, bacilli
reproduce quickly, serially infecting and killing more and more macrophages. After en-
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Figure 2.1: Infection cycle of MTB. Viable bacteria are inhaled, and then, phagocyted by
macrophages and dendritic cells, which activate T-cells as a fundamental step of the acquired
immune response. Depending the adequacy of the immune response to the infection, bacteria
can be totally cleared, contained within granuloma (latency) or proliferate causing active dis-
ease. In turn, from latency, even decades after infection, bacterial growth can be reactivated,
generating endogenous re-activation of disease. When the focus of infection in active disease
is located in the lungs, bacteria reach the sputum and make the host infectious, so restarting
the cycle. Adapted from [2].
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counter with bacteria, alveolar macrophages invade the subtending epithelial layer and
secrete chemokines and cytokines that, in turn, yield the recruitment and activation of
inflammatory cells from neighbouring blood vessels. As more cells of these and another
types are recruited, they progressively become infected by an increasing population of
bacteria that tends to expand.
This process of bacterial containment around primary infection foci has different
consequences at disparate levels. At the organismic level, the patient may suffer tran-
sient disease symptoms caused by the local inflammatory process, including fever and
an atypical skin rash termed erytrhema nodosum. At a tissular level, the successive
recruitment of phagocytic and inflammatory cells results in the formation of granu-
loma, which are a particular type of lung lesions characteristic of the disease consisting
of concentric layers of different types of immune cells trying to contain MTB growth;
primarily infected macrophages, epitheliod cells, foamy Mfs, and multinucleated giant
cells surrounded by a mantle of activated T lymphocytes [103, 104, 105, 106].
Granulomatous containment of bacterial proliferation results in different outcomes,
mostly depending on the delay and adequacy of the acquired immune response, de-
ployed by T-lymphocytes activated by DCs. In case this acquired immune response is
strong, T-cells will have success in totally clearing the infectious bacteria. This will
be achieved through the reproduction of interferon gamma (IFNγ) and other relevant
cytokines like tumor necrosis factor alpha (TNFα). The presence of these cytokines
promotes a process of macrophage activation, according to which the phagosomal en-
vironment of activated macrophages becomes much more hostile to MTB, eventually
making impossible its survival and further reproduction [107, 108].
In case the acquired immune response is not the adequate, bacterial containment
within granuloma become unlikely. This cause bacilli to grow, and to cause extended
cavities in host’s lungs where bacilli proliferate extra-cellularly causing pulmonary tu-
berculosis ; a medical condition that causes death in a high fraction of individuals if
not treated with antibiotics. In certain cases, bacteria can invade further host organs,
like his nervous system, digestive tract, bones or kidneys, where it will grow instead
in lungs; which is termed extra-pulmonary tuberculosis [109]. In some cases, it can
even invade simultaneously a number of different organs, where it proliferates under
no control, causing a rapid damage in host’s tissues. This last medical condition is
termed milliar tuberculosis, and, even under antibiotic treatment, presents a highly
uncertain medical prognostic. Individuals not fully immunocompetent (like newborns
or immuno-depressed people) are more prune to develop this form of the disease upon
infection, which is, paradoxically, associated to much lower transmission rates, as in
this case, bacteria is not dispersed in the air. Whatever the type of disease developed,
if this takes place right after infection (i.e. within a period lower than a year), we talk
about TB primo-infection.
Last, but not least, the most common infection outcome is neither fully bacterial
clearance nor prompt progression to disease. In circa 90% of cases, granuloma get closed
by the successive recruitment of immune cells, and bacteria get contained within it, but
not totally killed, entering in a dormant state (or a regime of limited growth) about
whose specific nature much has been discussed [110]. In this state, pathogenic load is
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low and sustained, as the granuloma interior is highly hypoxic and poor in nutrients
needed for the bacteria to grow. Additionally, antibiotics show a reduced efficacy to
kill dormant MTB.
Dormant state of bacteria within granuloma translates into an asymptomatic state
in the host, who neither experiment any clinical symptom, nor is infectious. Then,
a certain time after infection, spanning from a few months to several decades, the
equilibrium between host and pathogen can be broken, sometimes after an episode of
immuno-supression, (for example due to infection with HIV or cancer), and sometimes
without an apparent reason, in individuals fully immunocompetent. If infection re-
activation happens, the bacteria may break its confinement and reproduce outside
granuloma causing disease; if bacterial growth take place in the lungs, bacteria will
ultimately reach the upper respiratory tract and will appear in the sputum, making its
host infectious and restarting the cycle.
Probably the most striking feature of the life cycle of MTB is the extremely long
average latency period, which has been estimated to be longer than five centuries
(inverse of latency times ranging from circa 0.7·10−3 years [22] to 2·10−3) [60]. This huge
time scale means that, once granuloma are sealed, most infected individuals will not
have any relapse episode in their entire lives, but will have success in containing bacteria
within them for the rest of their lives. It is worth remarking that granuloma structure
is very heterogeneous at distinct phases of its evolution. Strikingly, different types
of granuloma can be identified simultaneously in a single host, evidencing a complex
interplay between organismic mechanisms of immune response and local differences in
the process of host-pathogen interactions (or cross talk) at the level of single granuloma,
or even at lower scales.
2.1.2 Phagosomal environment
As we say, MTB is an intracellular parasite which finds in the phagosomal environment,
under certain circumstances, an adequate medium to reproduce. For phagosomal sur-
vival and reproduction to be achieved, the pathogen must avoid the disparate means
by which macrophages modifies phagosomal environment with the purpose of killing
bacteria. This process is termed phagosome maturation, and mainly includes three
different mechanisms: acidification, release of oxygen-reactive species and fusion with
the lysosome. MTB has the ability of, at least in a first instance, inhibit it.
On the one hand, MTB, Ph levels in inmature containing phagosomes have been
estimated to be 6.4 [111]. Although this is more acidic than extracellular media, ma-
ture phagosomes reach much lower Ph levels between 4.5 and 5.0 [112], which have
highly deleterious effects for pathogen survival. Additionally, through phagosome mat-
uration, the inducible nitric oxide synthase (iNOS) enzyme generates NO, which is a
strong source of oxydative stress that, associated to acid Ph, has a strong bacterici-
dal activity [113]. Finally, the process of phagosome maturation is complete by the
phagosome-lysosome fusion, which releases lysosome contents into phagosome medium:
that consists of several enzymes with strong hydrolase activities, causing degradation of
MTB proteins, lipids and nucleic acids. Both iNOS activity and phagolysosome fusion
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are inhibited by MTB in naive macrophages, a situation that is reversed (or mitigated)
upon macrophage activation. IFNγ mediated active macrophages are more hostile to
mycobacteria, and phagosomes of active macrophages have been found to be more
acidic and to present stronger iNOS and hydrolitic activities [114, 115, 116].
Beside phagosome maturation arrest, one of the most relevant tasks that MTB
accomplishes upon its entrance on human macrophages is a global metabolic adaptation
to the phagosome medium. This includes a global shift from a carbo-hidrates based
metabolism to an state in which the pathogen takes advantage of host’s lipids, and
uses them as a main source of carbon and energy. This includes utilization of fatty
acids and host’s cholesterol [117], both for obtaining energy and for synthesizing the
complex lipids of the bacterial cell wall as well as other storage lipids.
This observation has been revealed by the different composition of the lipid frac-
tion of the cell wall that is observed after intracellular infection with respect to in
vitro cultures [118, 119]. Additionally, mutants lacking certain genes needed for lipid
metabolism show reduced virulence [120, 121, 122].
In this context, the role of the mycobacterial protein isocitrate lyase (icl1) has
been revealed to be necessary for bacterial viability in activated macrophages. Icl1
is the key enzyme of the glyoxilate cycle, which is needed for MTB to retain carbon
when growing relying on fatty acids as a carbon source. But beyond that question,
probably the most relevant issue that MTB is committed to solve when adapting
to a lipid-based metabolism is the accumulation in its cytoplasm of propionil-coA, a
subproduct of the metabolism of certain host’s lipids (like methyl-branched or odd-
chain-length fatty acids as well as cholesterol) which is highly toxic for the bacterium
unless it is metabolized [123]. Remarkably, icl1 plays also a relevant role in propionil-
coA detoxification, through its participation in 2-methylcitrate acid cycle, that yields
propionil-coA elimination [124].
Another relevant metabolic pathways used by the bacterium to reduce the pool of
cytoplasmic propionil-coA is its usage in anabolic routes to build up complex polikety-
des and methyl-branched fatty acids related to virulence. According to this mechanism,
proposed by Singh [119], the bacterium is able to respond to two concurrent challenges
by one single coupled mechanism, i.e. the need of synthesizing virulence lipids that
allow it to arrest phagosomal maturation and evade immune response and the need to
restore redox unbalance by the accumulation of propionil-coA, which is a consequence
of the usage of host’s lipids as energy source. Some of the best characterized cell wall
complex lipids whose synthesis is coupled to propionil-coA homeostasis are phthiocerol
dimycocerosates (PDIM) [125], sulfolipids (SL), and acyltrehalose-derived lipids.
Besides re-directing cell metabolism from carbohydrates to lipids, and solve the
redox homeostatic complications (e.g. propionil-coA homeostasis) that are derived
from that,and from direct host’s attacks; MTB is also able to orchestrate pathogenic
counter-attack mechanisms whereby phagocytic host cells are damaged, and granuloma
are modified by the pathogen to favor bacterial growth and transmission.
Secreted proteins constitute a relevant pathogenic resource for the bacteria. The
genome ofMTB contains diverse secretion systems formed by sets of membrane proteins
whose biological function consists of recognizing specific proteins and secreting them
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Figure 2.2: Propionyl-coA detoxification in MTB. Metabolism of certain host lipids, like
methyl-branched fatty acids or cholesterol, generate propionyl-coA, which is highly toxic for
the bacterium, and it is detoxified through two different routes: the 2-methylcitrate cycle,
and the methylmalonyl pathway. Furthermore, the bacterium is able to re-cycle the products
of methylmalonyl pathway and incorporate them into virulence lipids, such as sulfolipids or
phthiocerol dimycocerosates (PDIM). The bacterial proteins icl,PhoP and fadD26 regulate
these processes at different stages, as well as other relevant pathways, like the glyoxilate cycle,
needed for retaining carbon when lipids are its main source.
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to the extracellular medium (e.g., the host’s phagosome), allowing their traffic through
the highly hydrophobic cell wall which is a cardinal property of all mycobacteria. One
of the most relevant secretory systems in MTB is ESX-1; a type VII secretory system
[126] that presents as its principal function the secretion of the dimeric complex formed
by two small proteins: the early secreted antigenic target of 6kDa (ESAT6) and the
culture filtrate proten of 10 kDa (cfp10) [245]. These two small proteins form dimers
in the bacterial cytoplasm, which allows their correct secretion through the ESX1
secretory system [245]. Once secreted, cfp10 –whose principal role is thought to be
related to ESAT-6 stabilization– splits, and ESAT-6 develops a strong cytolitic activity,
opening pores in host’s lipidic membranes [246]. As an example of its central role in
immunogenicity, one of the principal features of the vaccine candidate MTBVAC is
that, through disruption of the global regulator PhoP, the proteins of the secretion
system of ESAT-6 become insufficiently expressed, which turns into a MTB strain
that, yet expressing ESAT-6 (which provides immunogenicity), is not able to secrete it
into the medium (with reduces its pathogenicity) [129].
Secretion of extra-cellular compounds is a double-edged weapon for pathogens
though. While secreted proteins, like ESAT6, can be indispensable for deploying cer-
tain pathogenic mechanisms, these are often recognized as major antigens by immune
cells, enhancing host’s immunogenicity capabilities. Remarkably, ESAT6 itself is not
only involved in pathogenesis, but also constitutes one of the most relevant antigens
used by the host to recognize MTB and deploy adequate acquired immune response to
the infection [244]. That is also the case, for example, of the major antigen complex
Ag85, formed by three small proteins (30-32 kDa) whose introduction in mice have
been demonstrated to engage a strong T-cell specific immune response in mice [131], a
result that has motivated the development of several new candidates for novel anti-TB
vaccines that are based in these effects. Ag85 antigens, as other proteins like Rv2525
are secreted through the twin-arginine-translocation (TAT) secretory system [132]
2.1.3 Gene diversity inMycobacterium tuberculosis and its host
Beyond MTB, M.africanum is a closely related species that (to a lower extent) can
cause human tuberculosis as well. Both are human obligate parasites with no zoonotic
reservoir and very reduced survival outside their host. Along with other bacteria caus-
ing disease in animals (and occasionally in humans), like M.bovis (responsible of bovine
TB) and M.microti, the so called vole bacillus, they form the Mycobacterium tubercu-
losis complex (MTBC ). In turn, MTBC belongs to Mycobacteria genus, that, beyond
these pathogenic species contains different non-pathogenic sole saprophytes with very
different lifestyles from that of an intracellular parasite like MTB.
Notwithstanding that, most mycobacteria share a number of characteristic features,
such as complex, lipid-rich cell walls and highly conserved families of genes [134, 135].
Noteworthy enough, some of the major immunodominant antigens are conserved among
mycobacteria, which causes cross reactivity [136, 137, 138], a phenomenon with crucial
implications for tuberculosis vaccine development, as we will discuss later. For example,
the antigenic complex Ag85 is one of most widely conserved antigens within the genus
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[139], and even ESAT-6 have found to be present in some subtypes of M. kansasii, M.
szulgai, M. marinum, and M. riyadhense [140].
In what regards genetic diversity within MTBC, it is very reduced, with a 99.9% of
identity at nucleotides level and identical 16S rRNA sequences [141]. Similarly, there
is a very constant gene content and no sign of ongoing recombination among strains
[142, 143]. Among the genes more conserved within MTBC genomes noteworthy lie
epitopes related to T-cell recognition [144], genes which precisely are those that show
greater variation in populations of pathogenic organisms which base their pathogenic
fitness in passing unnoticed to the human immune system [145], suggesting that tu-
berculosis has exactly an opposite behavior. Indeed, this finding has been related to
other experimental evidences pointing to T-cell specific responses having benefits for
the pathogen. Mainly, it has been observed that the existence of strong T-cell mediated
responses is a requisite for the formation of the characteristic cavitary lesions in host’s
lungs, which are the main requisite for efficient airborne transmission [146]. Relatedly,
individuals with reduced immunological competence, like HIV patients and infants,
present, at populations levels, more tendency to develop extra-pulmonary forms of dis-
ease, that, even if commonly associated to increased morbidity and mortality, generate
more reduced numbers of secondary cases [146].
The origin of parasitic association betweenMTBC and humans is dated circa 70.000
years ago, when a common ancestor would have jumped –more likely from a saprophytic
lifestyle [92]– to become one of the first documented parasites of mankind, along its
close relative M.leprae, causing lepra [147]. From that moment on, coevolution be-
tween MTB and humans is the story of a cheek to cheek dancing. Recent phylogenetic
studies conducted on large samples of MTBC representative strains and humans of all
ethnic profiles have stablished that the evolutionary history of MTBC have tightly fol-
lowed the demographical evolution of mankind and its geographical distribution; from
its african origins to its worldwide expansion followed by the neolithic demographic
transition [175]. This result has been complemented with the observation of that MTb
strains belonging to different evolutionary clades tend to associate with hosts of ethnic
profiles associated to the same region, when epidemiological studies of multi-cultural
communities are performed [174].
As a relevant conclusion of these studies, the Neolithic demographical transition,
circa 10.000 years ago, caused a major expansion event in MTBC global population.
The reason, rather than greater exposure to zoonotic reservoires, or even net augments
in human population –which, in other phases of History did not influence the overall
MTBC population–, is related to the emergence, for the first time in History, of large
human crowds around the first agricultural settlements, much more densely populated
than previous hunter-gatherers groups; with a subsequent impact in favoring MTBC
transmission.
This is unarguably a disturbing conclusion to reach for us, inhabitants of a hyper
populated world in which the fraction of people living in urban settings outnumbered
that of rural ares in the last decade for the first time in History, and continues growing.
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Figure 2.3: Host-pathogen coevolution and geographical distribution of TB. TB origin is
dated circa 70.000 years ago. Indeed, from that beginning, members of MTBC have evolved
into six main phylogenetic clades (panel a), whose geographical distribution (panel b) follows
human migration patterns (panel c), from their ancient african exodus to the rest of continents
(tick arrows) to the migration of europeans to America and Africa during colonialism and the
industrial era (red thin arrows). (figure adapted from [175]).
2.2 Tuberculosis epidemiology: stories of the white
plague
Mycobacterium tuberculosis is an extraordinarily successful pathogen that is usually
considered as on the deadliest killers of the History of mankind. Indeed, TB is the
disease responsible for a greater number of deaths in the past 200 centuries, with as
many as one billion casualties estimated to be attributable to the so-called white plague.
If we carry counts back two centuries more, we find that, between the seventeenth and
nineteenth centuries, TB was the responsible of 1 over each 5 deaths in Europe and
North America [148].
But even if historical records tell us that it has been one of the deadliest diseases
ever, the popular thought extended in western countries according to which TB is a
virtually eradicated disease, could hardly be more wrong. Indeed, TB is -with HIV and
malaria- one of the three deadliest diseases nowadays; specially in the underdeveloped
world. In the Global Tuberculosis report 2013, WHO estimates that in the precedent
year there were 8.6 new million TB cases all around the world; and 1.3 million deaths
caused by TB [1]. Current estimations tell us that 1 over 3 people in the world is
infected with MTB ; and the association between TB and HIV, as well as the emergence
of antibiotic resistant strains constitute critical concerns for Health Authorities.
In the following lines we review the principal characteristics of TB epidemiology:
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Figure 2.4: Geographic distribution of TB burden in 2011 (image extracted from [149].
According to Paulson, in 2011 there was 1.4 million deaths because of TB, and almost 9
million new TB cases (the 84% of which in Africa and Asia).
the issues related to its surveillance, the natural History of the disease and the state
of the art of TB spreading mathematical modeling.
2.2.1 Latent TB infection: a huge hidden variable
As we have discussed, tuberculosis infection cycle is characterized by the pathogen’s
ability of infecting huge amounts of hosts, causing in them an asymptomatic state of
latency that is frequently unnoticed. In this sense, probably the main hindrance in the
study of tuberculosis epidemiology is the difficulty of addressing chronic infection with
sufficient reliability.
Tuberculin skin test (TST) has been until recent the only tool at hand for assessing
TB infection; and it remains so in the clinical practice in many countries in the world.
TST consists in the intra-dermal injection of TB antigens, that cause a local inflam-
mation whose size serves as a proxy of previous infection with MTB. However, several
drawbacks make the outcome of TST not always perfectly interpretable. On the one
hand the purified-protein derivative (PPD) that is injected contains several antigens,
some of which are also present in other mycobacteria different from MTB ; which makes
TST prune to generate false positives. On the other hand, false negatives often take
place, mainly in immunocompromised individuals and young children. Last, but not
least, previous vaccination with BCG often yields a positive TST response, and, if the
test is repeated more than once in the same person, the results are less reliable, as the
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PPD exposure of the first test (eve if its result was negative) is able to cause a positive
response if the test is repeated.
These drawbacks has been solved, at least in research grounds, by the introduction
of Interferon-gamma-release assays (IGRA), which are performed on blood samples
extracted from the patients. In this test, the blood sampled is exposed to ESAT-6 (or
other antigens specific to MTB), and the release of IFNγ by T-cells in the sample is
then registered. IFNγ production after exposure to MTB antigens is a highly specific
sign of the existence of an acquired immune response to MTB, something only possible
after previous exposure to the bacillus. The specificity of the antigens used guarantees
a much lower rates of false positives, both caused by sensitization to environmental
mycobacteria foreign to MTB and by BCG vaccination.
Admittedly, IGRA tests are not available in the everyday clinics in most countries
with highest TB burden, when TST is yet the main tool used to assessing TB infection,
a diagnosis tool that was firstly proposed as many as 124 years ago, by Robert Koch
himself [150]. In addition, as we said before, MTB infection is strikingly general in
human populations, with an estimated prevalence of circa 1/3, huge numbers which
illustrate up to what point MTB infection is able to pass unnoticed at the level of
human populations. This ultimately compromise the accuracy of the estimations about
the global volume of MTB reservoir, and our knowledge about the Biology of latent
infection [110].
Notwithstanding that, tuberculosis is nowadays a notifiable disease (i.e. one of
compulsory declaration and surveillance) in most countries, which has allowed inter-
national authorities to build up an ever-increasing and more precise system for global
TB surveillance that is allowing epidemiologists to identify geographical trends and
caveats related to TB burden distributions worldwide. Additionally, the generalization
of molecular epidemiological tools have allowed the genetic foot-printing of clinical
isolates, which has supposed a great advance for backtracking epidemic outbreaks,
distinguising recent transmission from relapses from latency and, definitely, allowing
deeper understanding of the circulating strains and the main risk factors associated to
the disease.
These and other advances have allowed nowadays epidemiologists to reach an overall
knowledge of TB natural history and epidemiological characteristics of the disease more
complete than ever in the History of Medicine.
2.2.2 Types of tuberculous disease
Typically, different types of TB are distinguised depending on the organs where the
infection locates: pulmonary and extra-pulmonary TB. As we say, the main target of
TB infection is host’s lungs. Pulmonary tuberculosis is usually detected through X-ray
imaging of tuberculous cavities and/or molecular culturing of sputum. Patients with
positive results in sputum cultures (termed smear positive) are more infectious; though
smear negative tuberculosis is associated to lower, still non negligible infectiousness.
In turn, extra-pulmonary and miliar TB are different from pulmonary TB in many
aspects, being the main divergence the virtually null infectivity of TB when the infec-
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tion proliferates in organ foreign the lungs, as airborne transmission is the principal
contagion route for TB.
Beyond lungs, MTB is known to be able to colonize virtually all human organs
[151], and, as a function of the infection site, disease manifestations and diagnosis
proofs can be very assorted, and often requires invasive procedures [152]. This results
in much higher drawbacks for reliable diagnosis of extra-pulmonary TB, even in high
burden areas [153, 154, 155]. This situation often cases delay in the treatment start,
which, along with the fact that depending on the infection focus much more damage
can be achieved by lower pathogenic loads, make extra-pulmonary TB cause higher
morbidity and mortality rates than the pulmonary forms of the disease.
2.2.3 TB burden: global trends and prospects
Since the discoveries by Robert Koch at the end of XIXth century, burden levels asso-
ciated to TB have been consistently decreasing during decades in Europe and America.
The reasons for this situation have been the introduction of the first anti-tuberculosis
vaccine (Bacillus Celmette-Guerin, or BCG) in the decade of 1920, and, even more
important, the advent of anti tuberculous antibiotics in the fifties. Additionally, the
deployment of specific public health plans against the disease and the intense socio-
economic improvements that western societies have progressively enjoyed during the
last century contributed to sustain the decline of a disease typically associated to
poverty, malnutrition and insalubrity. Nowadays, the main risk factors associated to
TB consists of poor living conditions that favors disease transmission and factors asso-
ciated to the inability of deploying an adequate immune response against disease, like
malnutrition, diabetes, drug abuse, alcoholism and HIV infection [156]. Furthermore,
young adults constitute the age segments typically more affected by the disease, mostly
in what regards pulmonary TB.
The decline of the disease during the last century had the effect of generating relax-
ation in all grounds related to anti TB fight, ranging from public health authorities to
researchers and clinicians. However, this situation reversed in the decade of 1980 due
to the emergence of the new human immunodeficiency virus (HIV), after whose irrup-
tion TB burden rates turned to scale worldwide. TB re-emergence associated to HIV
[157] constitute one of most worrying phenomena in current TB epidemiology, and it
has motivated renewed research efforts in anti tuberculosis fight; from the development
of new drugs and vaccines to the general awareness of the need to improve diagnosis
protocols and techniques for reducing infectious periods and disease misreporting.
This global relapse of tuberculosis burden has not hit uniformly all countries in the
world. As Lauzardo and Ashkin write [160]: “HIV, the scourge of the late 20th century,
has conspired with poor distribution of resources and poverty to fuel the fire of the TB
epidemic. More people have died during the last decade from TB than perhaps any
other decade in history.” As a matter of fact, under-developed countries, now much
more populated than the western world in the XIXth century, bear similar incidence
rates to those that devastated Europe at that time, which constitute a dramatic pub-
lic health situation that made the WHO declare tuberculosis a global emergency in
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Figure 2.5: TB burden by ages. A: number of deaths caused by TB per 1000 inhabitants of
the same age in the spanish province of Soria, from 1900 to 1907, as reported by M. Íñiguez
and M. Hercilla in 1909 [158]. B: Number of TB cases notified in Cape Town, Republic of
South Africa during 2009, according to [159], stratified by age and HIV status. Even if the
measurements of the two graphs are not fully comparable, they constitute graphical examples
of how TB burden is distributed among the different age groups: with higher affection in
infants younger than five years old and young adults from 20 to 50 years old. Remarkably,
the first dataset corresponds to a period in which antibiotics or vaccines were not available,
and HIV did not constitute a thread for human health yet. Even if that is not the case of
panel B, the age distribution of both burden measures is highly similar.
1993. Nowadays, South and east Asia constitute the main geographical focus of TB in
number of cases, followed by sub-saharian Africa, where HIV-TB syndemic association
constitutes the main driving effect of TB epidemics.
Eradication of TB within 2050 was settled as the initial objective of the “STOP-
TB” global strategy conceived by the world health organization in 2000. This global
campaign was based on the creation of an international partnership including interna-
tional, nongovernmental and governmental organizations and patient groups all over
the world. Their principal activities and objectives consist of the promotion of social
awareness and funding for TB prophylaxis and prevention and the development of new
treatments, enhanced diagnosis tools and vaccines. 14 years later the partnership was
conceived, the final goal of eradicating TB at the equator of the XXIthe century seems
unlikely; very specially unless new vaccines are not urgently deployed [94].
2.2.4 TB spreading models
Tuberculosis has attracted the attention of mathematical epidemiology, at least, from
1962 [161, 162, 163, 164]. The dynamics of its natural history has been the matter of
an extensive and thorough bibliographical corpus within the discipline [165]. Ordinary
differential equations, partial differential equations, finite difference equations, integro-
differential equations and Markov chain models are mathematical methods that have
been recurrently used to model TB dynamics in the literature [166].
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The particularities and complexity of TB infection cycle are usually taken into ac-
count in the models mentioned, to the extent of the degree of detail of the models them-
selves. This way, aspects like long latency periods and primo-infection, age-dependence
of the susceptibility to disease, different types of diseases, effects of treatment and vac-
cination and other phenomenologies are usually taken into account.
Beyond the mathematical implementation of these modeling tools, and the specific
details of the natural History of the diseases being described, an important feature of
all spreading models is their range of application and their data feedback. This way,
on the one hand, some spreading models are built up and studied from an eminent the-
oretical viewpoint, with the main objective of exploring the dynamical features of the
system in generic regions of the parameter spaces, like epidemic thresholds or predicted
endemic levels. The development of epidemic models of this kind, from the works by
Kermack and McKendrick to our days, has allowed mathematical epidemiologists to
develop increasing insight of the dynamics of the spreading processes under different
conditions, which has constituted an essential step towards the development of mod-
eling tools of greater usability. Admittedly, the task of epidemic modeling does not
(and must not) stop at this point, and, upon the basis of a general knowledge of the
spreading processes along with the estimation of dynamical parameters through epi-
demiological studies, mathematical epidemiology have moved forward by substituting
parameters by numbers, as a first step towards the development of operative platforms
for epidemiological surveillance, forecast and control. In that phase, a thorough assess-
ment of outcome’s uncertainties and sensitivities to modeling hypothesis constitute a
fundamental issue that is not always easy to accomplish. Finally, a relevant character-
istic of this family of data-driven models is their generality and range of application,
that can range to specific epidemic settings (based, for example, on high-resolution
data extracted from exhaustive field studies on reduced areas during reduced periods)
to the entire world over decades.
In this context, diverse models for the quantitative description of worldwide TB
burden levels have been developed during the last two decades [422, 167, 22, 21],
which incorporate data from the transnational TB database curated by the WHO,
and nowadays publicly available [24], with the aim of providing suitable platforms
for quantitative evaluation of TB burden levels worldwide. These models explicitly
consider a detailed description of the Natural History of the disease, including age-
dependencies of different dynamical parameters, as well as regional variations for some
of these, in some cases in which homogeneous country specific information relevant for
parameter estimation is available [22]. However, different conceptual issues, mostly
–but not exclusively– related to the lack of appropriate data to feed them, impose
limitations to these models.
First, TB spreading dynamics is usually presented uncoupled from demographical
evolution, through different algorithmic procedures [422, 22] in an attempt of isolating
TB intrinsic dynamics from the influence of demographic variations. The suitability of
this classical hypothesis in epidemic modeling may be argued in the context of a disease
whose dynamics is strongly age-dependent, like TB, due to the fact that, in such a case,
disregarding demographical variations might result in the introduction of systematic
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bias in the forecasts, as it has been recently suggested [168]. Additionally, contact
patterns are classically disregarded in these kinds of models, in which homogeneous
mixing for all the individuals within all age groups is considered. Instead, the influence
of the contact patterns is known to be crucial for disease spreading, as it has also been
shown in TB, where the impact of preventive and therapeutical measures foreseen by
spreading models is known to strongly depend on the structure of the contact networks
considered [169]. Even if these dynamical aspects have been predicted to play a relevant
role in TB spreading dynamics, [168, 169], it remains pendent the quantification of their
effects on overall burden rates at a global scale.
Additionally, the integration of “fine grain” phenomenologies on data-driven TB
spreading models constitute a major challenge for mathematical epidemiologists. Ad-
mittedly, the dynamical description of the emergence of antibiotic resistences [170],
the explicit consideration of HIV-TB co-occurring epidemics [171, 172, 169], the ad-
dressing of the influence of human mobility patterns on the spreading of the disease
[173] and even the consideration of genetic heterogeneities, both of pathogens and hosts
[60, 174, 175, 176, 177] have been all considered, and, for some cases, thoroughly ana-
lyzed under the light of specificly devised spreading models. Nevertheless, the context
of these studies is always subject to the particular phenomenology being analyzed,
the degree of detail of the spreading dynamics is lower (e.g. without age-structure)
and not even a tentative of quantifying the influences of these effects on global TB
burden levels is provided by most of these works. Once again, integration of all these
phenomenologies around global data-driven models able to offer simultaneous forecasts
about all the relevant aspects of TB epidemiology suppose the assembling of a huge
scientific puzzle, which, though, could hardly be better motivated.
2.3 The fight against tuberculosis
Upon the global re-emergence of TB promoted by HIV irruption, huge investment ef-
forts have been made in TB pharmacology, focused at the development of new drugs
and vaccines against TB aimed at substituting those currently on use. The discov-
ery and commercialization of improved, novel pharmacological tools, both for disease
prevention and treatment is nowadays considered an urgent need if TB wants to be
eradicated in the following decades [94]. In the following lines, we contextualize the
state of current TB pharmacology and the perspectives in the field.
2.3.1 Current anti-TB antibiotics: the story of an obsolete war-
fare
Along with the dramatic consequences of HIV-TB interactions, the emergence of drug
resistances constitutes a global concern for public health authorities [178]. TB is a
particularly stubborn microorganism, against which regular treatments consists of the
administration of a series of different antibiotics (typically rifampizin, isoniazid, pyrazi-
namide and ethambutol) during several months. Other anti-TB drugs complementarily
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used are fluoroquinolones and several injectable drugs like kanamycin. Multi-drug re-
sistent (MDR) [179, 180] and extensively drug resistant (XDR) [181]strains [182] are
also emerging, and their spreading threatens to carry back a dramatic epidemiological
situation in which TB would constitute again a hardly remediable condition. For a
strain to be considered MDR, it must present resistance at least to rifampizin and iso-
niazide, while XDR strains show additional resistances to any fluoroquinolone, and one
of the three injectable drugs, capreomycin, kanamycin, and amikacin [178]. Recently,
there have been detected strains that show no susceptibility to any anti-tuberculous
drug known [183].
The reason for the emergence of these resistance strains is two-fold. On the one
hand, long periods of current antibiotic treatment protocols, –that typically last 6
months [184]–, make treatment adhesion highly challenging, mostly in underdeveloped
areas with fragile health care systems. Treatment default is indeed a major correlate
for further relapse and emergence of drug resistances, and for this reason, WHO comes
developing DOTS strategy (directly observed treatment, short course), which consists
in a treatment follow-up protocol for physicians that has allowed a relevant increase
in both treatment adherence and curation rates worlwide [185]. Beyond the problems
associated to long treatment duration and therapeutic default, the emergence of an-
tibiotic resistances is favored by the fact that first-line treatments against the disease
have remained essentially unaltered during the last 50 years; being the youngest among
the four first-line antibiotics most widely used (rifampicin) discovered in 1963. This
highlights the need of developing new anti-TB antibiotics to be administrated during
shorter time courses to reduce the threaten of drug resistant strains.
2.3.2 Anti-TB vaccines: past, present and future
These are exciting days in tuberculosis research. As we talk, more than fifteen inde-
pendent teams all over the world are developing as many different vaccine candidates
aimed either at substituting current, deficient BCG vaccine or at enhancing its effects
[186]. This situation has motivated the creation of two independent agencies for the
promotion and development of new TB vaccines: Aeras TB vaccine foundation, in the
US, and the european TB vaccine initiative (TBVI) [187, 188]. Similarly, a precise
development protocol have been defined, according to which each vaccine candidate
needs to go through a six-phases pathway of testing, from its discovery (1) to final
market licensure (6), including, as intermediate steps, preclinical development (2) ,
Phase I (3) and Phase II/IIb (4) o proof-of concept trials and Phase III large clinical
trials (5), before commercialization. In each of these phases, each vaccine candidate
must fulfill a series of stringent requirements so as to pass to the next step, according to
a stage-gating approach designed for optimizing limited resources [187]. Among these
new candidates, there are novel vaccines of different profiles that base their action on
disparate immunological principles and mechanisms; all of which holding the promise
of offering better levels of protection than BCG, whose global administration for almost
a century has not been enough for eradicating the disease. As Hellen McShane wrote in
a recent editorial comment, our understanding of current BCG impact on reducing TB
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burden levels wordwide is still limited; and a better understanding on the performance
of the old vaccine constitute the key to improve it [189].
BCG: the willful vaccine against TB
The current TB vaccine was developed in the decade of 1920 by Albert León Charles
Calmette and Camile Guérin, based on a series of repeated sub-cultures of a strain
of Mycobacterium bovis isolated from a cow, that resulted on a live attenuated strain
named BCG (bacillus Calmette-Guérin). The new strain, because of reasons that
would not be fully understood until decades later, presented an avirulent phenotype
when inoculated on humans, yet generating an immune response in the host that offers
partial protection against further infection with MTB. The principal genetic treats
responsible of such phenotype are the deletion of a genetic region –called RD1: region
of difference 1– during the process of culturing [190], containing the genes Rv3874
and Rv3875, which codify the major MTB antigens ESAT-6 and cfp10, central for
mycobacterial virulence [191]; combined with the production of other relevant antigens,
like the Ag85 complex, which is considered the main cause for its immunogenic effect.
BCG offers consistently protection against the disease in children, specially to the
worst types of tuberculous meningitis and miliar TB. Despite constituting a great
advance in the fight against TB, BCG’s importance for the overall trend of TB decay
observed worldwide during the XXth century has been largely argued [192, 193], as it
fails at providing consistent protection to the pulmonary forms of the disease, specially
in adults, with relevant variances among the studies performed to test it. Currently,
BCG induced protection is estimated to last between 10 and 20 years after newborn
vaccination [214, 203, 215].
Epidemiological assays aimed at determining BCG efficacy started in the decade of
1930, but it was not until the decade of 1950 that the scientific community was conscious
of the high disparities found among the different studies [197]. The causes underlying
the observed variability of BCG efficacy in different settings still constitute a matter
of open debate [194, 195], and they include strain variation in BCG preparations [196],
genetic, epi-genetic or socio-economical differences between populations, study quality,
parasitic co-infections, etc [186].
However, multi-variate meta-analysis of BCG efficacy determination studies consis-
tently determine that latitude is a variable showing a great –direct– correlation with
BCG performance [197, 198, 199, 194], pointing to the existence of latitude-driven
mechanisms influencing BCG performance. Among these possible mechanisms, differ-
ent levels of exposure to UV light, due to its mycobacterial killing effect is commonly
mentioned, although the hypothesis that arouses greater consensus points to exposure
to environmental non-tuberculous mycobacteria (NTM), whose presence is greater in
tropical and sub-tropical areas [200, 201, 202], as the most likely cause underlying
BCG efficacy variability. According this hypothesis, greater levels of exposition to
these sources of immunological sensitization prior to the moment of vaccination would
cause reduced protection by the vaccine, which would explain BCG’s reduced perfor-
mance as trials get closer to the equator. NTM share many relevant antigens with
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MTB, which causes cross-reactivity [136, 137] able to generate cell mediated immune
responses that have been measured in-vitro [200, 202]
It is worth mentioning that, beyond NTM, BCG vaccine itself, as well as the very
reservoir of latent MTB infection constitute relevant relevant sources of exposition to
mycobacterial antigens at populations level. Although individuals infected with MTB
or vaccinated with BCG use to be discriminated in clinical trials (at least, in some of
them, with enough reliability) their implications as environmental sources of antigenic
sensitization should be also considered, as we will discuss later.
Diverse epidemiological observations backup the hypothesis of sensitization with
environmental mycobacteria being the source of BCG efficacy variability. First, it has
been observed that BCG is effective in trials from which tuberculin-skin-test-positive
individuals have been stringently excluded [194, 203]. Second, neonatal vaccination
-and therefore applied on individuals that have not been exposed to mycobacteria- is
successful against TB [204, 205], and BCG efficacy is lower the older the individuals
are at the moment of vaccination [195]. This last observation is coherent with the
fact that older individuals have been exposed during more time to the mycobacterial
agents, and so, are more strongly sensitized.
Two different mechanisms have been theorized on how this exposition to mycobac-
teria would affect the behavior of the host to a vaccine like BCG [139]. The masking
hypothesis postulates that environmental sensitization confers a significant protection
against TB in such a way that a vaccine can barely offer an additional level of protec-
tion [206]. Another possible effect is that the exposition to mycobacteria may trigger
a immune response capable to block the assimilation of the vaccine by the host. This
is known as the blocking hypothesis [207].
These two effects have the potential to explain a considerable fraction of the vari-
ability observed in the trials performed, which explains both the dependence of BCG
efficacy with age at the time of vaccination -as an individual gets older its exposition
to mycobacteria increases- and its geographical variations. The crucial implications of
these effects in TB vaccine development are twofold. On the one hand, understanding
the range and causes behind the variations of BCG efficacy is essential [189], as the
efficacy of any novel vaccine will be measured on counterposition to BCG. On the other
hand, depending the type of vaccine, where it is applied and how old are the target
populations, new vaccines could also be affected by masking or blocking effects.
Types of preventive vaccines
As we say, several research teams are currently developing new candidates for novel
anti-TB vaccines aimed at substituting or complementing current BCG. Depending
on the specific objective of the novel candidates, we can distinguish two main groups
of vaccines, preventive vaccines –aimed at reducing risk of infection–, and therapeutic
vaccines, whose objective is to reinforce antibiotic therapy during active disease, shorten
the time needed for therapy completion and, in general, augment the proportion of
treatment success. Along this thesis, we will primarily focus on preventive vaccines,
which, in turn, are divided in two groups.
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Figure 2.6: TB vaccine candidates in clinical development. The pipeline is organized in
three main phases: phase I trials are devoted to assess safety and immunogenicity in reference
populations, usually healthy adults. Instead, Phase II trials consist on similar tests, now
conducted in the age target populations. Phase III constitute a final step in which trials
previous to marketing authorization are conducted at a greater scale. Image adapted from
[186].
The first of these groups is that of BCG booster vaccines, designed to be applied
on individuals previously immunized with BCG, and more advanced, in general, across
the development pipeline. The immunogenic principles of these vaccines are based on
providing an additional exposure to one or several relevant antigens from BCG itself or
from MTB, in their standard molecular form or, instead, as protein hybrids of two or
more antigens. The delivery of these antigens in host’s organisms is achieved through
the usage of viral vectors or synthetic adjuvants.
The second group of vaccines is constituted by prime, vaccines consist of attenuated
live strains of M.bovis or MTB, genetically modified so as to guarantee safe, avirulent
but yet immunogenic phenotypes. Primer vaccines, instead of boosters, are intended
to substitute BCG, although, in principle, they could be used on individuals previously
vaccinated with BCG. The most advanced of these vaccines is the BCG-recombinant
VPM1002, currently into PhaseII clinical trials [208, 209].
Caveats in the process of vaccine development
Current knowledge of tuberculosis immunology is only partial. The complexity of
the infection cycle of the disease, and the disparity of the immunological processes
that articulate host’s response make difficult to find robust immunological correlates
of infection or protection, something that constitutes a fundamental drawback for the
development of novel vaccines [186]. For example, IFNγ production by T-cells, even
 Biological portrait of tuberculosis infection
if it has been found to be significantly associated to the onset of TB disease, may not
be so clearly correlated to vaccine-induced protection [210]. In this line, the adequacy
of using the presence of multifunctional T cells as a principal readout for predicting
vaccine efficacy is currently being questioned, after a trial conducted on South African
infants in which no correlation was found between BCG induced protection and mul-
tifunctional T-cells ten weeks after vaccination [211]. Furthermore, other readouts for
vaccine protection, like lung histopathology and replication reduction, offer also highly
arguable outcomes [212], that very often result to be poorly correlated to actual vaccine
protection.
In this context, the lack of an adequate protection correlate shifts the focus to
clinical trials of efficacy determination as the main tool we count with to reliably
evaluate different vaccine candidates. However, these kind of trials must be conducted
in high burden areas, and need the recruitment of numerous cohorts of individuals and
observe them during long periods of time in order to generate statistically relevant
results; which makes them extremely costly, slow and hard to design. For example,
the most advanced vaccine in the development pipeline is the booster MVA85A, who
presented in January 2014 the results of a phase IIb trials conducted in Worcester,
South Africa, for the testing of safety and efficacy of the novel vaccine [213]. This trial,
designed by the South Africa Tuberculosis Vaccine Initiative –SATVI–, constituted
the first Phase IIb clinical trial conducted since the approval of BCG; and needed the
recruitment of almost 3000 BCG-vaccinated infants (6 months old).
Although the safety assessment of MVA85A in the trial of Worcester was posi-
tive, the disappointing results regarding vaccine efficacy have made the whole research
community enter in a state of alarm. The failure of MVA85A at providing consistent
protection, either to infection or to disease progression, has made evident the need
of improving the procedures to compare and discriminate possible candidates at their
early stages of development. According to both funders and researchers, a cardinal
priority in the field is to limit, as much as possible, the risks of that any other vaccine
candidate comes to reach reach advanced phases of the pipeline to finally get there a
negative result.
That is arguably a fundamental goal, but it is obviously pointless unless any vaccine
able to offer adequate protection levels when properly tested and administered can
confidently rely on not being prematurely discarded during the development process.
In this context, the development of new, better protection correlates for TB is an urgent
necessity.
Whom do vaccinate first?
Until immunology advances allow the identification of general protection correlates of
usefulness on all the vaccine candidates, it is indeed the refinement of the design of
clinical trials the only tools available for the community to ensure that, if not positive,
at least meaningful outcomes are obtained from the trials themselves. Among the
aspects that have been more strongly questioned after the publications of the results of
the trials of MVA85A; a central place is reserved for the age group of the populations
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on which the efficacy of the vaccines must be tested, and eventually, applied.
On the one hand, the results of ref. [213] suggest that MVA85A is not able to
offer a better performance than BCG on infants. However, when talking about adults,
its immunogenic role could be different because that –recalling that the waning of
BCG induced immunity is thought to take place after 10-20 years of vaccination [214,
203, 215]–, at that age, the baseline BCG reduced performance could be much easier
to overcome –or repair– by the administration of a booster vaccine. Additionally,
temporal patterns of efficacy waning found in BCG could also be observed again in
novel vaccines –no matter if these are boosters or primes– , which would advise to
apply them on adolescents or young adults, so as to take advantage of the first, fresh
years of the new vaccine to cover these age groups, which are those bearing more intense
incidence and prevalence levels, as it has been discussed before.
This situation has made emerge a general consensus towards the idea of that new
vaccines should be targeted on adolescents, in order to provide a rapid and more intense
protection to these age groups more affected by the disease [216, 217].
Notwithstanding that, the application of tuberculosis vaccines on individuals of
that age may not be equally suitable for all new vaccine candidates. In the case of live
attenuated vaccines, waiting until adolescence make target populations be consistently
sensitized to NTM at the moment of vaccination in many parts of the world. That might
impair proper reproduction of any novel live vaccine, preventing adequate vaccine “take”
the same way it is thought to impair that of BCG when applied on individuals of this age
[194, 195] (blocking hypothesis), or, alternatively, vaccine mediated protection could
be impossible to observe above protection levels induced by individuals’s exposition
to mycobacterial antigens (masking hypothesis). Noteworthy, not only live vaccines
might suffer efficacy loss due to these effects, but also boosters [139]. For example,
for booster vaccines based on viral vectors, the existence of viral-antibodies in the
vaccinated populations (for instance, from the smallpox vaccination campaign) could
equally block viral booster vaccines [139], and protection by environmental sources of
mycobacterial antigens could mask their effect too.
Furthermore, it is worth noting that, in case the vaccine is intended to have any
additional effect beyond diminishing the infection probability of immunized individuals
(paradigmatically, reducing the progression rates from latency to disease), the differ-
ence between vaccinating people before or after they could have been infected withMTB
has to be considered, as MTB itself may act, in these cases, as a source of antigenic
sensitization that could affect vaccine performance in what regards these additional
effects, in the large population fractions latently infected. For this type of vaccines, no
matter the vaccine type, depending on whether a vaccine applied on already infected
individuals with MTB retains its properties or not, the optimal vaccination strategies
could differ.
In conclusion, defining the precise age group on which new vaccines should be ad-
ministrated (and previously tested) to achieve greater impacts is a crucial task affected
by different effects. The quantification of the the effects of prior sensitization to my-
cobacterial antigens, and their variation with age is, indeed, one of the main objectives
of this Thesis.
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MTBVAC: learning to tame bacteria
After VPM1002, the only alternative live attenuated vaccine currently on clinical trials
is MTBVAC, developed by the group of mycobacterium genetics of the University of
Zaragoza [129]. Furthermore, MTBVAC is the only candidate that instead on being
based on BCG modification or boosting, consists in the attenuation of a virulent strain
of MTB, something that, once it has been demonstrated as safe as BCG in humans,
constitutes a promising, conceptual advantage with respect to other candidates. The
reason is that its similarity with the causative agent of the disease is, by definition,
greater than that of any other vaccine, and, particularly, it shares a more complete
antigen collection with wild type MTB, overcoming this way the principal limitation of
boosters, which base their activity on the presence of a very limited number of antigens
[186], or recombinant-BCG candidates, which are genetically further to MTB [218].
MTBVAC is built upon the deletion of two key genes that regulate different viru-
lence related mechanisms: PhoP and fad26. The vaccine represents a second version
of a previous vaccine, called SO2, based in the sole deletion of PhoP. Although SO2
passed through successive phases of security and stability testing [219, 220, 221, 222], it
did not fulfill the Geneva consensus, that stablished –among other stringent requisites–
that novel MTB based vaccine candidates must present, at least, two stable gene dele-
tions within the genome to be considered safe enough to enter clinical trials [223, 224],
which rendered SO2 unsuitable for further development. The incorporation to the sec-
ond gene deletion of fadD26 solved the problem, generating a vaccine fulfilling all the
required safety requisites, yet functionally similar to SO2.
PhoP is the sensor protein of a two component signaling system that acts as a
global regulator [88]. Among the genes controlled by PhoP there are several key pieces
for MTB virulence. First, it activates transcription of proteins of the ESX1 secretion
system, that allow proper secretion of the key antigens ESAT6-cfp10 [88]. Second,
it activates a novel non-coding RNA recently discovered, named mcr7, responsible of
repressing tatC, a protein of TAT secretion system, in charge of secretion of Ag85 com-
plex antigens [132, 225]. Thus, deletion of PhoP translates on a phenotype whereby
ESAT-6/cfp10 are expressed but not secreted, and secretion levels of Ag85 antigens
are, in turn, augmented with respect to wild-type strains. This ultimately translates
into reduced pathogenicity (because of MTBVAC inability to secrete ESAT6) concur-
rent with immunogenicity levels improved (due to augmented exposure to Ag85 and
intracellular presence of ESAT6, which BCG lacks)[129].
On the other hand, fadD26 gene is needed for the synthesis of phthiocerol dimyco-
cerosates (PDIM), complex virulence lipids of the cell wall [226], and so, its knockout
also contributes to reduce virulence inMTBVAC. Remarkably, if we recall section 2.1.2,
we have that synthesis of PDIMs is a resource of MTB to detoxify the pool of cytoplas-
mic propionyl-coA, through the methylmalonyl pathway, a metabolic route that can
not be completed after the knockout of fadD26 (see figure2.2). As a consequence, the
bacterium is still able to transform propionyl-coA into methylmalonyl-coA; but fur-
ther synthesis of PDIM from that point is impaired because of the deletion of fadD26
[227, 228]. This situation could ultimately compromise the ability of MTBVAC to per-
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sist with a lipid based metabolism, because of a deficient detoxification of propionyl-coA
products from the methylmalonyl cycle. Fortunately, it is not the case, as MTBVAC
is able to persist within the host. Indeed, the reason for this is thought to be related
to the isocitrate-lyase (icl) which indeed constitutes one of the few genes repressed
by PhoP. In this way, PhoP deletion in MTBVAC causes an enhanced expression for
icl, which offers a robust alternative pathway to detoxify propionyl-coA through the
2-methylcitrate acid cycle, and maintain an adequate REDOX balance when lipids con-
stitute the principal metabolic substrate, even if MTBVAC is not able to synthesize
PDIMs. In conclussion, simultaneous deletion of PhoP and fadD26 reduces MTBVAC
virulence without compromising its in vivo survival [88, 129].
The combination of these three features –i.e. low pathogenicity, enhanced immuno-
genicity and persistence– makes MTBVAC a conceptually optimal vaccine candidate.
Nowadays, the novel vaccine is finishing Phase I clinical trials, the performance of the
novel vaccine, as well as the level of protection it is able to offer will be eventually
measured in the following years, if MTBVAC progresses to the final phases of the
production pipeline satisfactorily.
 Biological portrait of tuberculosis infection
Part II
Networks of bio-molecular interactions
in M.tuberculosis
–Pray of what disease did Mr. Badman die, for now I perceive we are come up to his
death?
–I cannot so properly say that he died of one disease, for there were many that had
consented, and laid their heads together to bring him to his end. He was dropsical, he
was consumptive, he was surfeited, was gouty, and, as some say, he had a tang of the
Pox in his bowels. Yet the Captain of all these men of death that came against him to
take him away, was the Consumption, for ’twas that that brought him down to the
grave.
John Bunyan
Life and Death of Mr. Badman, 1680.
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Chapter 3
The transcriptional regulatory network of M.tb
3.1 Introduction.
A thorough understanding of the biochemical mechanisms behind MTB infection is an
unavoidable step for the development of new drugs and vaccines aimed at eradicating
TB. Such a challenging goal would imply to comprehend both the transcriptional con-
trol of the signaling system and the interaction of the bacillus with the immune system
of the host. As a first step, it is necessary to study the backbone of this complex system,
i.e., the circuitry behind the biochemical processes operating at the gene expression
and signaling levels. In this chapter, we report the most complete transcriptional reg-
ulatory network (TRN) of MTB to the date this work [3] was published, in July 2011.
Capitalizing on previous attempts to build up the TRN of MTB, we have been able to
assemble a network that links together the many isolated interactions reported in the
literature.
Thinking on a wider perspective than the strictly biomedical interest of this work,
our study also addresses important open questions in the field of network science. To
the best of our knowledge, the network here assembled is the first intracellular pathogen
whose TRN is characterized to a reasonable level of accuracy and completeness. In this
paper, we calculate the main macro-scale features of the MTB TRN: connectivity dis-
tributions and mean values and clustering coefficients as well as average path lengths
[50]. Of further interest is the analysis of small scale features as given by the abun-
dances and significances of network motifs. As it has been thoroughly discussed in
the introduction to this thesis, motif abundance profiles can be interpreted as topo-
logical markers carrying relevant information about the effective tasks for which the
network under study is designed or evolved [261, 262]. To illustrate this point in this
context, we also present a comparative topological analysis between the TRN of an
intracellular parasite like MTB and other already available analogous system, E.coli,
with diametrically opposite life styles.
3.2 Results.
3.2.1 Construction of the TRN of MTB
Our starting point is the TRN proposed by Balázsi and colleagues a few years ago [89],
which is the largest MTB transcriptional network to date (783 nodes, 50 regulators
and 936 links). Based on this TRN, we have performed a considerable expansion by
using publicly available sources, most of which appeared after Balazsi’s compilation,
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expanding the network up to 1624 nodes (which supposses, roughly, a 40% of the
genome) and 3212 interactions sent from 83 transcription and sigma factors.
For such an expansion, the links we are reporting have been reported upon the out-
comes of experiments belonging to two different groups of methodologies. Within the
first family of experimental procedures, we have considered techniques that are based
on detecting significant changes of target-gene expression levels caused by disrupting,
over-expressing, or inducing a certain regulator, compared with wild type reference
expression levels. These techniques include microarray (MA) analysis (genome-wide,
poorly specific), or quantitative real time PCR analysis (qRT-PCR , that provides
higher accuracy and reliability), as well as fusion in target promoters of sequences
coding reporters like green fluorescent protein (GFP) or lacZ. On the other hand, the
second family of methodologies covers procedures that are based on the identification
of the binding sites of DNA and transcription factors (TFs), and, eventually, the char-
acterization of the physical protein-DNA interaction. Electrophoretic mobility shift
assays, one hybrid reporter systems and ChiP-on-chip assays are examples of these
methodologies. Moreover, once the new information coming from experimental sources
and computational inference is compiled, we have further enlarged the network by
operon-based expansion as done in [89], using the operon map predicted in [263]. See
Materials and Methods for more details. Figure 3.1 shows the resulting TRN of MTB.
We next analyze its main topological properties at different resolution levels.
3.2.2 Global topological properties of the network.
We have measured several topological properties of the assembled network. It consists
of N = 1624 nodes and E = 3212 edges, with a giant connected component of order
N . As the network is directed, one can compute the total degree of a node, k, as
the sum of the incoming links (meaning that the node is a target of a regulation)
and the outgoing links (meaning that the node regulates another node), i.e., k =
kin + kout. Figure 3.2 represents the cumulative degree distributions for the TRN of
MTB, either for total, in and out connectivities. As can be seen from the figure, the
cumulative degree distribution reasonably follows a power law P (k〉k∗) ∼ k−γ, (best fit
γ = 0.99± 0.07 with R2 = 0.974). In other words, the TRN of MTB shows the same
highly heterogeneous degree distribution found for other biological networks not only
at the cellular level, but also at larger scales [50]. This means that the vast majority
of genes only interact with a few other genes, while there is a small but statistically
significant number of genes that interact with hundreds of genes.
Concerning the directionality of the regulations we find, as usual for these kind of
system that links senders constitute a small fraction of all the genes in the network:
83 over 1624. This is coherent with the fact that the larger contribution to degree
heterogeneity is caused by out-coming links, sent by this reduced set of 83 regulators
formed by transcription and sigma factors. In-degree heterogeneities are much more
reduced, as, even is most of genes in the network receive some regulation (1598 over
1624), the gene receiving more links gets just 12 regulations.
This can be appreciated already in table 3.1, where we have summarized several
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Figure 3.1: TRN of MTB. Blue nodes represent regulatory genes that are not regulated by
other nodes, while green ones are transit nodes, both regulating the activity of other targets
and receiving regulation from other TFs. Self-regulations are represented by black arcs, while
feedback loops (FBL) of mutual regulations are represented in green, thick lines.
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Figure 3.2: Total, in and out degree distributions of the TRN of MTB. The figure shows
the cumulative degree distributions, i.e., the probability to find a node whose connectivity is
larger than or equal to k∗. For the in and out distributions –in the insets– only genes that
receives (1598) or send (83) links has been considered in each case so as to normalize the
distribution. Hence, the lower inset represent the probability P (kin > k∗in) for any of the 1598
regulated genes to receive more than kin∗ links; while, for the upper inset, we represent the
probability P (kout > k∗out) for each of the 83 regulators found to send more than kout∗ links.
Property MTB TRN
genes 1624
Regulators 83
Links 3212
Self-loops 43
2 nodes FBLs 6
Mean connectivity 3.96
Mean in-connectivity 2.01
Mean out-connectivity 38.70
Directed average path length (Giant Component) 2.07
Table 3.1: Topological properties of TRN of MTB. We report some global metrics of the
network such as its mean connectivity and directed average path length. For the definition of
this quantities, see [50]. Note that the mean in and out degrees are calculated with respect
to the number of target genes and regulators, so they are not normalized in the same way.
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Figure 3.3: Most connected regulatory hubs in the MTB TRN.
topological properties. As a matter of fact, the average out-degree of TFs is much
larger than the average in-degree of genes that have at least one regulator, indicating
that the networks retains this typical characteristics of this kind of networks (i.e. a
reduced set of links senders distribute all the links across the system, and so, when
summing up incoming and outcoming degrees, most hubs are link senders). At this
point it worths mentioning that average in and out degrees (as well as the degree
distributions represented in the insets of figure 3.2) are not calculated in the usual
way, -i.e. averaging over N -, otherwise 〈kin〉 = 〈kout〉 = 〈k〉/2), but averaging only
over the number of link senders and over the number of link receivers for 〈kout〉 and
〈kin〉, respectively. Concerning other topological features, we see that they are within
the typical range of values for other biological (and, in general, real complex) networks
[50].
We have also inspected what are the most connected TFs, see figure 3.3. As one can
see, phoP, whose deletion –aside to that of fadD26– is at the root of the new live vaccine
MTBVAC [129], appears as the third most connected hub of the network, only following
to mosR and sigmaE regulators. Indeed, it is known that PhoP regulates key functions
required for the intracellular survival and persistence of MTB. Remarkably, as it has
discussed in the introduction, inactivation of phoP results in down-regulation of genes
needed to successfully grow within macrophages and consequently in MTB virulence
attenuation. Summarizing, TFs and SigFs highlighted in the degree rank as principal
network hubs in our system are those for which a role of global regulators -i.e. a large
number of regulations targeting a relevant fraction of the bacterial genome– has been
already characterized in the literature analyzed to build the network. Admittedly, taken
that into account, it is not surprising that key roles in cell cycle regulation, metabolic
control and virulence, similar to those mentioned for PhoP, had been reported precisely
for these genes, provided that the very existence of such studies is the ultimate reason
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for the privileged topological situation that these nodes have in our network.
However, even that the analysis summarized in figure 3.3 is in that sense quite
straightforward once the network is built up, integration of transcriptomic data around
a single dataset is a meaningful way to compare the role and relevance of network
regulators that have been similarly studied in literature.
The situation is somehow different when checking what are the genes receiving a
higher number of regulations in the system, as their identification among all the genes
of the network is a genuine result derived from the assembling of the network. The
reason is that, unless what happens with global regulators (i.e. one can understand
the their global action by obtaining a knockout mutant and conducting a genome wide
transcriptomic comparison WT-mutant, with no particular necessity of a network based
context), the task of identifying genes receiving more transcriptional inputs than others
is not so clear.
Although the heterogeneity in the number of links received per gene is much more
reduced than for the case of link senders, genes receiving a higher number of regulatory
inputs are reasonably expected to be related to relevant biological functions that must
can be controlled either by a different set of inputs (or particular combinations of them).
Remarkably, among the only 12 genes that receive more than 10 links in our network
we have the gene cluster Rv2930-Rv2939 (receiving 12 links each) and the genes icl
and fadB2 (receiving 10 links each). The gene group that spans from fadD26 (Rv2930)
to Rv2939 is known to be involved, as it has been discussed in the Introduction, in
the biosynthesis of the complex lipids phthiocerol dimycocerosates (PDIM), some of
the more relevant mycobacterial virulence factors. In what regards to icl and fadB2;
they are both part of the same operon, and they are related to the metabolic shift
from carbo-hidrates to lipids that follows intracellular infection [88, 264], as it was
also issued in the introduction to this thesis. Very remarkable is the role of icl, whose
expression has been related to the pahogen’s ability to persist within macrophage.
Relevantly, the final genetic profile of the MTB based, live attenuated vaccine
MTBVAC modifies the expression profiles of all these highly regulated genes. On
the one hand, fadD26 (Rv2930) is directly deleted in MTBVAC, which prevents the
bacterium to synthesize PDIMs [129]. On the other hand, the couple icl-fadB2 has been
identified as one of the few genes negatively regulated by PhoP, which has been related
to the more accused tendency of MTBVAC to show a dormant, persistent phenotype
[88], a definitely desired property for a live vaccine to present.
All these results, taken together, suppose an examplo of how trying to establish
links between genes biological relevance and their position and importance within a
regulatory network often is a meaningful way to give clues about their potential as
putative drug targets.
3.2.3 Small-scale properties of the network: motifs.
Beyond the topological characterization of the macroscopic traits of the network sum-
marized in table 3.1, mesoscopic or small scale topological features are key to under-
stand the dynamics and function of biological networks like the one we are studying
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Figure 3.4: The figure represents the set of allowed and forbidden rewiring steps for the
randomization of the TRN. The left panel corresponds to the situation in which simple links
are being rewired whereas the right panel represent the cases considered when mutual links
are being rewired. More details are provided in 3.5.
in this chapter. For instance, as we have discussed in the introduction to this the-
sis, communities are often identified with functional modules, and motifs statistics are
thought to store much relevant information about the structural design principles of
the complex systems in which appear.
Using an approach similar to that introduced by Alon and coworkers [261, 262],
we have registered the number of appearances for each of the subgraphs of size 3 and
4 in the TRN of MTB and compared them to what is found in a null ensemble of
networks built up from the original system after an adequate random rewiring proce-
dure schematized in figure 3.4. In this case, the null ensemble essentially consists in
a collection of randomized networks, in each of which every node preserves its in and
out degree -and, remarkably, its number of –bi-directional links–, but its neighbors are
randomized.
The way in which the null ensemble can be constructed for extracting meaningful
conclussions from NMs analysis has been the subject of intense research in the last
years, and besides the method used in this paper, there are other alternative random-
ization schemes [262, 265, 266].
Once the ensemble of randomized networks is generated, we calculate the mean
values and the typical deviations of the number of appearances of each of the possible
motifs of a given size in all the randomized networks. The significance of each motif h
is determined by the following Z-Score:
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Figure 3.5: Triads significance profile of the MTB TRN. We represent the values of the
Z-scores as defined in Eq. (3.1) for each of the 13 possible 3-nodes directed motifs, which are
depicted in the x-axis. Only one of them cannot be defined in the MTB network. See the
main text for further details as well as the section 3.5.
Z − Scoreh = nh − 〈nrand,h〉
σrand,h
(3.1)
At this point, it is worth noticing that, if a given motif h, is absent in any of
the randomized networks of the null model, then σrand,h is not defined and so is Z −
Scoreh. Moreover, all the defined Z-scores are normalized considering each of them
to be a component of a unitary vector. This normalization allows to compare motifs
significance profiles of networks of very different sizes.
We have calculated the significance profiles for the newly assembled TRN of MTB
focusing on 3 and 4 nodes’ motifs. Figure 3.5 shows the Z-scores obtained for triads.
Note that as our network is directed, so are the triads. Out of 13 possible motifs of
size 3, only triad 13 is not present in the Z-scores representation. Additionally, the
first six motifs, all of which correspond to open structures (i.e., loopless motifs) are
underrepresented in the MTB TRN, while those that are found more frequently than
in the random version of the TRN are closed motifs.
3.3 Tetrads statistics of MTB and E.coli.
The kind of statistics of motifs as represented in figure 3.5 for our case, have been
commonly used as a way to deepen our understanding of the relation between the
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structure and function the biological networks analyzed. Specifically, as we have dis-
cussed in the introduction to this thesis, previous works have focussed on directed triads
as a means to categorize networks around superfamilies which, roughly, share the same
functionality even when the networks belong to very different fields [267]. Two dis-
tinct superfamilies were identified for informational-processing networks [267]. In one
of these superfamilies, we can find networks for which the response of the whole system
to an stimulus cannot last much more than the response time of one of its interactions.
These so-called rate-limited networks include TRNs of unicellular microorganisms, cov-
ering both prokaryotic and eukaryotic organisms. The second informational processing
superfamily groups networks that work in a less immediate way, being able to perform
slower responses with characteristic times that can be even several orders of magnitude
greater than the response times of its single interactions. Synaptic and developmental
networks in multicellular organisms are typical cases of this kind of not rate-limited
behaviors.
The question is then how the TRN of an intracellular parasite like the MTB inte-
grates into the above framework, i.e., which of the two informational processing super-
families the MTB TRN belongs to. It is worth mentioning that a priori the question is
not trivial. All unicellular microorganisms have presented up to now the characteristic
profiles of rate-limited networks [267], so that one may be tempted to ascribe to this
family the network of MTB. However, the bacillus spent most of its vital cycle within
the macrophage, so that the characteristic response times of its TRN should be slower.
Several findings support this hypothesis. For instance, it has been reported [89] that
after hypoxia stimulus, the dynamics stabilizes in a time as long as eighty days, sug-
gesting that the TRN of MTB could better adjust to the not rate-limited superfamily.
As a matter of fact, after a direct comparison of the triads profile of MTB with those
reported in [267] would seem that this is indeed the case. The interpretation of this
result is beyond the scope of this section, and will be addressed in chapter 5.
Beyond the question of network superfamilies, it is also of interest to compare the
TRNs of E.coli and MTB as two examples of prokaryotic, unicellular bacteria. The
aim is to identify whether there are relevant divergences in their motifs profiles that
could be related to their different vital cycles: that of an intracellular parasite in the
case of MTB and that of an extracellular bacterium in the case of E.coli.
Taking into account the above remarks, we have compared the Z-scores significance
profiles for the networks of E.coli and MTB looking for common (i.e., present in both
organisms) structures that exhibit the larger differences in their Z-scores. In our anal-
ysis, we only consider FBL-free tetrads that appear in both TRNs at least a thousand
times. This pruning is made so as to restrict our analysis on motifs for which we are
sure that the analysis is robust enough- This excludes scarce structures and motifs
that, even being relatively numerous, only appear grouped around punctual structures
in the system: i.e. FBLs, which are really scarce in our systems (only 10 in the TRN of
E.coli and 5 in the TRN of MTB). Within this subset, of confidently well represented
motifs, we have selected the structures with a differential behavior in both systems (i.e.
tetrads being over-represented (Zscore > 0) in one system and under-represented in the
other (Zscore < 0). The reason for choosing tetrads instead of triads for this analysis is
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Figure 3.6: Differentially significant motifs present in MTB and E.coli TRNs. Feedback-
free tetrads present more than 1000 times in both networks were divided into three groups
according to their Z-scores: we consider as overrepresented those tetrads with Z-Score> 1 and
as underrepresented those with Z-Score< 1, being the third group joined by tetrads for which
|Z-score| < 1. We have only looked for motifs that belong to different groups in E.coli and
in MTB, and we have sorted them according to the absolute difference ∆Z=Z-ScoreE.Coli-Z-
ScoreM.tb. After this filtering process, the tetrads in the figure are those with |∆Z| > 1. The
resulting tetrads with highest |∆Z| are the same when one takes the normalized Z-score.
that, the more numerous statistics associated to them allows us to find some examples
of such divergent motifs between the networks being analyzed: indeed, Z-scores of tri-
ads have always the same sign in both TRNs, so, the kind of differential behaviors we
want to look at are not present at the –more coarse grained– level of triads.
The results are depicted in figure 3.6, where we have plotted the cases, within
this group, for which the differences in Z-scores between tetrads of both networks
are greater than unity. As one can see in the figure, E.coli presents stronger trends
for two of the simplest parallel combinations of feedforward loops (FFLs) with single
regulations (tetrads 4 and 5). On the other hand, the three structures with highest
differences in favor of MTB are single output modules (SOM, tetrad 1), cascades,
(tetrad 3) and the combination of them (tetrad 2). The preference for different motifs
in E.coli and MTB TRNs supports the evolutionary pressure hypothesis put forward
in [261, 262, 267]. At a glance, given the homology between the two networks −
both organisms are bacteria −, one might think that their TRNs come from common
underlying mechanisms that regulate the way they grow and are assembled. However,
the TRNs should have been shaped in relation to the vital needs of both bacteria, which
are known to be radically different. Therefore, over and under represented subgraphs
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with different significances in these two organisms would be, under this perspective, a
consequence of an evolutionary process related to the adaptation of both bacteria to
their respective life-styles.
From a dynamical point of view, the previous results also make sense. The dy-
namics associated to most of the motifs that appear to be under or over represented
in the TRNs of MTB or E.coli have been well characterized previously [261, 268, 269,
270, 271, 272, 273, 274]. For instance, FFLs have been described as a discriminator
between persistent and transient signals [261, 268] or as a pulse-generator to accelerate
signal responses [269]. The performance of the motif as persistence discriminator or
accelerator depends, essentially, on the signs of the regulations and the logical scheme
[275], but nevertheless, both functions are useful for the organism when it is subjected
to a highly dynamic or unpredictable environment. This is the case of E.coli whose
environment offers a very rich amount of nutrients to the bacterium, but also a con-
siderable concentration of harmful substances and other threats. This highly variable
environment requires a valuable mechanism to filter the very noisy signals that are be-
ing sensed continuously. Therefore, it is to be expected that FFLs and closely related
structures be over represented in the E.coli TRN, as they are.
On the other hand, as noted before, the MTB bacillus expends, on average, more
than 90% of its vital cycle in a dormant state, surviving under a latency regime within
the human immune system macrophages, which principal function is, essentially to kill
the pathogen. In this sense, it is difficult to conceive a bacterial environment more
hostile than that of MTB. However, hostility does not mean variability, so that the
environment of any bacterium could be hardly less volatile or more predictable than the
intracellular environment to which MTB has specifically evolved to live within. These
considerations are in qualitative agreement with our observations of a less marked bent
for FFLs in MTB.
3.4 Conclusion
In this chapter, we have assembled the more complete TRN of MTB. to the date
this work was published. The network has been built up by exhaustively including
publicly available bibliographical information relative to MA essays, protein-promoter
binding sites determination experiments and synthetic biology techniques coming from
as many as 31 different works. The importance of gathering all this information into
a common frame with tractable format is twofold. First, it is a valuable database that
can be directly used for research purposes. And second, the new network constitutes an
important tool for the application and development of computationally inspired models
and methods that may be able to guide future in-vitro and in-vivo experiments. The
latter includes using the network to develop new tools for tasks such as the identification
of spurious links and missing interactions [276], prediction of unknown functions of
the proteins, the generation of more accurate operon maps predictions [263] or the
dynamical modeling of network operations as a sensory system [277]. Concerning the
role of phoP, our analysis shows that it appears as the third-most connected hub of
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the network (see figure 3.3), thus, the relevance of altering its functionality is easily
understandable and expected from a network viewpoint. Analyzing the most regulated
genes in our network remarkably we recover genes like icl or fadD26, whose expression
profiles are altered in the new vaccine MTBVAC, resulting in improved persistence
and reduced virulence, in part because of the altered performance of the very genes
mentioned [88, 129].
Additionally, we have performed a detailed analysis of the topology of the TRN.
The results show that our system shares the main macro-scale features of other similar
systems such as the small-world property or a fat-tailed degree distribution [278]. The
statistical characterization of the relative abundance of different motifs has also shown
interesting results.
First, our new system could initially be incorporated into the differentiation scheme
firstly proposed in [267], apparently joining the family of not rate-limited family pro-
posed by Alon et al. [267]. This preliminary result is intriguing, as, if confirmed, would
suppose the first example of an unicellular organism resembling, at the level of NMs
statistics, the structure of pluricellular networks of biological information processing.
Secondly, we have performed a comparative analysis between the significance levels
of the most relevant tetrads in the TRNs of E.coli and MTB. The reason for choosing
tetrads instead triads is due to the fact that, given the more reduced combinations that
we have for triads, there exist no triad of different Zscore sign of size 3. Our results
show that the relative abundance of the different subgraphs is reasonably related to
the dynamical response of each subgraph [261, 268, 269, 270, 271, 272, 273, 274] and to
the life styles (in relation to their environments) of both bacteria. Besides, given that
the TRNs correspond to two bacteria, the differences between subgraph significances
of E.coli and MTB can only be a consequence of divergent evolutive pathways.
In summary, the expanded TRN will be useful to provide an overview of multiple
functional aspects of MTB, and to suggest new experiments. It is also important to
note (especially for future studies) that the network obtained neither distinguish the
relative strength of the different interactions reported (i.e. link weights) nor the specific
environmental conditions or signals needed for a given regulation to actually take place
under in-vivo conditions.
About interaction signs, although they were not reported in the original article
in which we published this research [3], these were collected whenever possible and
reported in a second release firstly referenced in [6].
Besides, the methodology used to expand the network and the different kinds of
resources used in the process, which have been treated case by case, individually for
each TF, allow for a quick and easy review and extension of the network. Finally, the
development of a functional sense upon the extended TRN of MTB that encompasses
the whole network and the integrative action of the signaling system, would be one of
the essential objectives to achieve in the future.
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3.5 Materials and methods
3.5.1 Bibliographical revision and datasets of the TRN ofMTB
We have updated the network presented in [89], using new and copious experimental
information available from as many as 31 different works dated in the last ten years,
(see table 3.2). To assemble and expand the network, we have also used the predicted
operon map proposed in [263] assuming that if a TF A regulates a gene B belonging
to an operon BCD, then, also the interactions A-C and A-D are present.
All the information extracted is available in the supplementary information of [3],
including all the links, works in which they had been reported (also including those
already present in Balázsi’s compilation) and experimental methodologies used to infer
them.
Finally, we filtered all repeated information to build our network. The final system
contains more than two times the number of genes or links than the previously available
dataset [89]. The expanded network is freely available on-line [279], also with all the
interaction signs, whenever available.
3.5.2 E.coli TRN
We have used the TRN of E.coli [314] updated as of August 2010 (release 6.8), which
contains experimental information until the ultimate large-scale revision published in
2008 [311]. Dimeric TFs and toxin/antitoxin systems are taken as single nodes of the
network. The network can be found in the supplementary material of [3].
Chapter 4
Context-specific networks of protein-protein in-
teractions in M.tb.

Reference Strain Methodologies Regulator(s) Links
[118] H37Rv MA phoP 78
[280] H37Rv MA, qRT-PCR phoP 114
[281] H37Rv MA RegX3 98
[282] H37Rv MA, EMSA, CS dosR 49*
[283] H37Rv LacZ,EMSA mce2R 14
[284] H37Rv MA, qRT-PCR, EMSA mosR 173
[285] H37Rv MA, qRT-PCR, CS, EMSA FurB 32
[286] H37Rv OH ** 325
[287] H37Rv MA, qRT-PCR, EMSA MprA 135
[288] H37Rv MA, qRT-PCR sigE 16
[289] H37Rv MA, CS sigE 116***
[290] CD1551 MA, qRT-PCR, CS, IVTA sigF 74
[291] H37Rv MA, CS sigM 43
[292] CD1551 MA, qRT-PCR, CS, IVTA sigG 43
[293] CD1551 MA, qRT-PCR, CS, IVTA sigB, sigF 78
[294] H37Rv CS crp 44
[295] H37Rv MA, qRT-PCR, EMSA RamB 4
[296] Erdman MA, qRT-PCR, EMSA EspR 12
[297] H37Rv EMSA, CS LrpA 15
[298] BCG,H37Rv MA, qRT-PCR, PS, EMSA cmr 5
[299] CD1551 MA, qRT-PCR, CS sigM 25
[300] H37Rv MA Rv0576 2
[301] H37Rv MA IdeR 71
[302] H37Rv qRT-PCR, EMSA CsoR 4****
[303] H37Rv PSBI pyrR 6
[304] H37Rv qRT-PCR, EMSA, CS mprA 3
[305] Erdman LacZ, GFP VirS 8
[306] H37Rv MA, qRT-PCR, PS, CS Mce3R 27
[307] H37Rv ORT, EMSA, PS, CS KstR 77
[308] H37Rv MA, qRT-PCR Rv0485 13
[309] H37Rv qRT-PCR, EMSA, ChiP-on-chip, CS BlaI 16
Table 3.2: The table contains the references used to build up the TRN reported in the
main text as well as the TFs studied. ∗, ∗∗∗ and ∗∗∗∗: These are works already cited in
[89], nevertheless, not all the regulations included in these works was considered in the com-
pilation of Balazsi et al. ∗∗ reports regulations coming from the following 31 TFs: oxyS,
Rv0260c, sigK, regX3, Rv0818, Rv0823c, mprA, sigE, Rv1359, Rv1931c, higB1, Rv1990c,
Rv2017, Rv2021c, Rv2034, Rv2175c, Rv2669, sigB, Rv2745c, dosR, moxR3, sigJ, Rv3334,
sigD, whiB3, Rv3557c, Rv3678c, whiB4, moxR2, nmtR, Rv3833. Abreviations used: MA: mi-
croarrays. qRT-PCR: quantitative real time polimerase chain reaction. EMSA: electrophoretic
mobility shift assay. CS: identification of consensus sequences. LacZ: LacZ-promoter fusion.
OH: one hybrid reporter system. IVTA: in-vitro transcription assay. PS: proteomic studies.
PSBI: protein structure based inference. GFP: green fluorescent protein promoter fusion.
ORT: orthologies with M.smegmatis.
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4.1 Introduction
The general purpose of this chapter is the study of the protein-protein interaction
network (PPIN) of MTB. To do so, we capitalize on a previous dataset described by
Wang et. al. [4], in which all the physical interactions between couples of proteins
observable in a two-hybrid in-vitro assay are listed.
More specifically, we aim to characterize which of these interactions are strength-
ened under disparate environmental conditions, as a consequence of gene expression
variation of the genes codifying the respective proteins involved in the interactions. In
the end, at a systemic level, this means to characterize the topological transformations
that the PPIN suffers as a consequence of the gene expression shifts that follow expo-
sure to different environments, either in vivo or in vitro. To achieve that goal, we have
analyzed all the information available in the on-line database gene-expression omnibus
(GEO) about microarray (MA) experiments conducted in MTB [5].
The analysis of how the PPIN of the pathogen adapts to disparate conditions will
help us to discuss some open questions regarding the life cycle of the pathogen. For
example, by comparing the overall topologies of the PPIN corresponding to different
in-vitro models of phagosomal infection based on exposure to different stresses may
help us to address which of these models more closely resemble pathogen’s response
within the phagosome.
Moreover, the kind of analysis proposed in this chapter could be applied in other
organisms to uncover general tendencies that could help to understand transcriptional
responses to similar stresses, as well as the relationships between these responses and
the organisms’ life styles, among other relevant biological questions.
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Figure 4.1: PPIN of MTB compiled in [4]. In this network each node represents a protein,
and a link between two proteins is registered if they physically interact, according to the
bacterial two hybrid screen performed by Wang et al. The network has no weights, and
nodes’ sizes indicate proteins connectivity in the system. Nodes’ colors are the outcome
of a simple community structure analysis (performed using the software Gephi for network
representation and analysis [229]). The network has 2907 nodes and 8042 links
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4.2 Methods
4.2.1 Multi-layer network construction
In order to evaluate the changes of the PPIN of MTB followed by exposure to different
environmental conditions, we have followed a procedure whereby we reconstruct a
different version of the original PPIN [4] for each environment analyzed. By proceeding
that way, we obtain a multi-layer system [230] in which each layer corresponds to each of
these versions, and contains only the genes and interactions that, in the correspondent
environmental contexts, are over-expressed with respect to a basal, stress-free state.
The idea behind this rationale is certainly simple. Wang et al. dataset describes all
the possible physical interactions between couples of proteins that might be observed
in vivo provided that the proteins involved in one of these interactions are present in
the cell at minimum concentrations. So, under a given environment, some interac-
tions are expected to gain relevance -as a consequence of that the proteins involved
are over-expressed- and some others will directly vanish, as a consequence of gene re-
pression. Therefore, we aim to reconstruct a layer for each environmental condition
studied, containing only genes and interactions which are over-expressed with respect
to a common basal state. The topological characterization of the multi-layer system
[230, 231] resulting from that process constitutes our principal scope.
In order to perform that analysis, microarray data were extracted form Gene Ex-
pression Omnibus [5] on March, 2014. GEO data is structured in GEO-series, each of
them containing a set of GEO-samples. Each GEO-sample contains the information of
a single microarray experiment in which, typically, two conditions are compared, and-
folding rates (FR) associated to expression variation between both conditions for each
gene are reported. The first of these conditions (channel 1 of the MA) typically corre-
sponds to an untreated MTB culture exponentially growing in vitro under no stress,
while the second channel corresponds to the experimental setup being studied. The FR
of a gene is the relation between its expression in the two channels of the microarray,
typically channel 2 divided by channel 1 (when the sample description indicated the
contrary; FR’s were inverted). By this way, if FR=1 for a particular gene, it means
that that gene is expressed at the same level both in the environment studied and basal
conditions. By contrast, a FR > 1 corresponds to an over expression of that gene in
this situation and FR < 1 is shown by repressed genes.
A GEO-series contains samples of related experiments (for example, samples corre-
sponding to exposure to a particular stimulus), with minor differences among samples
regarding, for example, to exposure times or stress agents concentration levels. In ad-
dition, two different GEO samples often correspond to technical or biological replicates
of the same experiment, and, similarly, in a single GEO sample, more than one repli-
cate can be reported (for example, if more than one copy of the same gene has been
seeded in a single microarray) or, for some genes, no report may be available.
As an example of GEO-sample we can mention the sample GSM886273, contained
within the GEO-series GSE8839, in which the results of a genome-wide microarray ex-
pression profiling experiment are reported, for an experiment consisting on comparing
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gene expression profile of a sample of MTB ’s strain 1254 after exposure to hypoxia
during two hours (channel 2) to the gene expression profile corresponding to the sit-
uation of exponential growth prior to exposure of the same strain to stress (channel
1). The series within which this sample is reported is GSE8839, that contains 131
samples corresponding to as many different experiments, all of them related to hypoxic
conditions and/or exposure to oxidative stress.
Taken that into account, let us denote FR(i, j, l) the FR corresponding to the
lth lecture associated to gene i in sample j. In the most common case, the only
possible value for l is 1, although, in some cases, l will take more values (or none,
in which case, we have gene i not being reported in sample j). So, we will name
N(i, j) the number of times that expression of gene i is reported in sample j (and
therefore l ∈ [1, N(i, j)]↔ N(i, j) > 0) The first task to accomplish is to group samples
corresponding to repetitions (either technical or biological) of the same experiment, so
as to define the average FR of a gene i in a experiment k 〈FR〉k(i) as follows:
〈FR〉k(i) =
∑
j∈{exp(k)}
∑N(i,j)
l FR(i, j, l)
Nk(i)
(4.1)
where {exp(k)} represents the set of samples associated to experiment k (ie. repe-
titions of the same experiment) and Nk(i) is the total number of reports of gene i FR
within such set:
Nk(i) =
∑
j∈{exp(k)}
N(i, j) (4.2)
Besides the average expression level of gene i in experiment k, we can also calculate
its standard deviation:
σk(i) =
√∑
j∈{exp(k)}
∑N(i,j)
l (FR(i, j, l)− 〈FR〉k(i))2
Nk(i)
(4.3)
Now, let us focus on a couple of proteins a and b between which an interaction
is reported in the PPIN [4]. Making use of the average expression level of the genes
codifying proteins a and b in experiment k we can define the “expression level” of the
interaction a↔ b in that experiment, as follows:
〈FR〉k(a↔ b) = 〈FR〉k(a) · 〈FR〉k(b) (4.4)
The biochemical meaning of that magnitude is related to the kinetic rate ρ at which
the chemical reaction A+B → AB takes place:
ρa−b ' [a][b] (4.5)
where we assume that the reaction between a and b to form the complex ab takes
place at a stoichoimetry 1 : 1, and that it occurs in a unique step, which is a reasonable
assumption, provided that two-hybrid screens’ positive results are primarily constituted
by this kind of interactions [4].
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It is straightforward to show that 〈FR〉k(a ↔ b) represents the FR associated to
ρa−b, and so 〈FR〉k(a↔ b) > 1 means that the interaction a↔ b is taking place in the
studied condition faster than in the basal state (and viceversa, for the opposite case).
Similarly, we can also define the associated typical deviation for these interaction
expression levels as follows:
σk(a↔ b) =
√
(〈FR〉k(a) · σk(b))2 + (σk(a) · 〈FR〉k(b))2 (4.6)
And we can use equations 4.4 and 4.6 to define a criterion of statistical significance
useful for discriminating whether a given link is present in a layer or not. This criterion
is that the average FR of each interaction must lie at least one sigma over unity; i.e.,
the Z-score of the link FR:
Zk(a↔ b) = 〈FR〉k(a↔ b)− 1
σk(a↔ b) (4.7)
must be greater than one for the interaction to be considered within the layer
corresponding to experiment k: Zk(a ↔ b) > 1. in other words, and since that what
we pursue is a weighted representation of the system, we assimilate the weight of a
given link a ↔ b within layer k to the interaction expression level 〈FR〉k(a ↔ b),
provided that the interaction has passed the significance test Zk(a ↔ b) > 1. More
formally, we have:
wk(a, b) =
{ 〈FR〉k(a↔ b) if Zk(a↔ b) > 1
0 if Zk(a↔ b) ≤ 1 (4.8)
The final result of this simple thresholding procedure is a multilayer network of
147 layers each of them containing data from an independent experiment. These
experimental conditions can be grouped around 8 major groups: respiration arrest,
cell wall damage, ion deprivation, oxidative stresses, DNA damage, dormancy models,
macrophage (Mφ) infections and exposure to cholesterol) each of them, in turn, con-
taining experiments grouped into sub-types. The original size of the network compiled
by Wang et al. is 2907 nodes and 8042 interactions. Among the 147 layers of our sys-
tem, we have, over the same nodes’ set, as many as 388464 interactions, which makes
an average of 2643 over-expressed links per layer.
Data necessary for that reconstruction come from 22 series and 609 samples within
them. In addition to these sources, data from 27 additional series reporting MA exper-
iments for MTB were analyzed, but no profitable information could be extracted from
these. The reasons for that were two. On the one hand, we are only interested on the
analysis of MA experiments reporting gene expression response of any experimental
condition in relation to a basal, stress-free state consisting in bacterial cultures grow-
ing exponentially at the initial phases of a culturing procedure performed on standard
culture media. Taken that into account, we must discard experiments reporting varia-
tions between two conditions none of which is assimilable to basal exponential growth.
For similar reasons, as we aim to address stress response of circulating and reference
strains of MTB, we discard samples corresponding to mutant strains (i.e. knockout
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mutants). Finally, experiments related with exposure to antibiotics were also excluded
from the analysis, as our aim is that of studying stimuli that MTB faces (or may face)
in a natural way during its lifecycle.
Additionally, data stored in 6 additional series lacked the sufficient statistics so
as to allow any interaction to pass the significance criterium. This occurs when all
the samples in the series report un-repeated experiments, and so, there is, at most,
one expression report per gene and experiment. This prevents us to define typical
deviations and z-scores. Remarkably, this kind of problem prevented us to build any
layer corresponding to acid Ph experiments, one of the major traits of phagosomal
environment [232]. The reason for this problem is arguably related to the difficulties
associated to make cultures grow under acid Ph [234].
Detailed information about the identity of the specific samples and series used in
this study, types of stresses corresponding to each sample and experiment, etc. is
available in the appendix (section 4.5).
4.2.2 Consensus multi-layer of stress response
Among the 147 layers of our original multi-layer system, very assorted experiments are
represented. This includes in vivo infection assays and in vitro experiments, addressing
response to single or multiple stresses or to the presence of certain signaling molecules
thought to generate consistent and relevant transcriptional responses in vivo.
In this section, we will focus on addressing MTB defense to individual environ-
mental stresses in vitro, more specifically, to those that have been associated to the
principal characteristics of phagosomal environment. This includes oxidative stresses,
nutrient deprivation, hypoxia and cell wall damage, beside others that we will not be
able to analyze because of lack of relevant data (i.e. acid Ph). With this purpose
in mind, we have first discarded layers corresponding to in vivo experiments, in vitro
multi-stress dormancy models (as we aim to address the isolated response to single,
not combined, stimuli), and in vitro exposure to signaling intermediates not causing
cell-stress (e.g. cholesterol).
Once isolated the layers corresponding to in vitro exposure to environmental stresses,
we have grouped them around six biologically meaningful categories:
• Hypoxia. This contains layers originally grouped under the label of “respiration
arrest” in which the reason for such arrest is oxygen deprivation. It contains layers
associated to different hypoxia models (“regular” hypoxia and Wayne’s model of
hypoxic growth), reareation experiments (channel 2 corresponds to initial hypoxia
and channel 1 to final re-aireated sample).
• General oxidative stress. This corresponds to exposure to agents generating ox-
idative stress, like diamide and hydrogen peroxide H2O2.
• Exposure to NO. Nitric oxide is the principal damaging agent causing oxidative
stress that MTB faces in the phagosomal environment. Nevertheless, it is known
to interfere in the respiration pathways, behaving like an intermediate signal that
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shares certain pathways with hypoxic conditions [233]. For these reasons, it is of
high interest to consider NO exposure as an independent layer.
• Exposure cell wall damaging environments. These environments consist of expo-
sure to surfactants that attack the integrity of lipids in the outer layers of the
cell envelope, and exposure to extreme conditions of osmotic pressure.
• Ion deprivation. Corresponding to experimental setups in which MTB access to
key nutrients (oligo-element ions) is impaired. This can be achieved through cul-
turing MTB in ion deprived media (iron or phosphate, for example), or through
introducing, for the case of iron, “iron scavengers”, which are siderophores that
sequestrate iron ions which can not be up-taken by MTB.
• Starvation: here we group layers corresponding to respiration arrest in which res-
piration is disrupted by nutrient deprivation. This can be achieved after culturing
MTB in minimal, or deprived media or by leaving cultures reach the stationary
phase, in which it is the very growth of the culture the ultimate reason for nutrient
deprivation.
Once we have defined our main stress types, we aim at grouping all the layers of
our previous dataset that correspond to each of these categories into single consensus
layers. The resulting consensus multilayer system will thus contain just six layers, one
for each of these major groups. Our purpose is to represent in any of these layers,
only those interactions significantly represented in most of the experiments associated
to that stress category. Taken that into account, we denote the consensus expression
level of the interaction a↔ b in the category c as 〈F¯R〉c(a↔ b), and we have:
〈F¯R〉c(a↔ b) =
∑
k∈{cat(c)} 〈FR〉k(a↔ b)
N¯c
(4.9)
where {cat(c)} represents the sets of layers of the original multi-layer system asso-
ciated to the stress category c, and N¯c is precisely the number of such layers. For now
on, we will use bars to denote magnitudes referring to the reduced consensus multi-
layer. Additionally, it is worth noticing that, when an interaction has been discarded
in a certain layer k of the original system we have that it does not contribute to the
average, as we consider 〈FR〉k(a↔ b) = 0 for that case.
Additionally, we perform a similar average for the typical deviations:
σ¯c(a↔ b) =
∑
k∈{cat(c)} σk(a↔ b)
N¯c
(4.10)
and finally we define the corresponding Z-score for each interaction within each of
the layers of the consensus multi-layer system as follows:
Z¯c(a↔ b) = 〈F¯R〉c(a↔ b)− 1
σ¯c(a↔ b) (4.11)
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It is worth mentioning that it is not the only way to perform such filtering procedure,
but there exist other alternatives, like averaging Z-scores or only admitting links which
are present in a fraction of layers of the original system greater than a certain threshold.
We decided to use this one for two reasons. On the one hand, it favors a moderate
enrichment of consensus genes and interactions, (i.e. those genes whose presence is
recurrent in most the experiments within a category). Another interesting feature is
that it provides with the same statistical relevance to each of the experiments within
a category, regardless the number of samples corresponding to each experiment.
Once again, we will associate interaction expression levels to link weights only when
surpassing the overexpression threshold (〈F¯R〉c(a ↔ b) > 1) with a significance of at
least one sigma (Z¯c(a ↔ b) > 1). So we have that the interaction weight of the
interaction a↔ b within layer c in the consensus network w¯c(a, b) is defined as follows:
w¯c(a, b) =
{ 〈F¯R〉c(a↔ b) if Z¯c(a↔ b) > 1
0 if Z¯c(a↔ b) ≤ 1 (4.12)
The result was a reduced six-layer system containing 1593 interactions, which is
represented in figure 4.3.
4.2.3 Layer similarities in the complete multi-layer system
As we said before, among the 147 layers that constitute our original multi-layer system,
some correspond to in-vitro experiments, while others are associated to in-vivo MTB
infection trials performed on different types of Mφs (human or animal). In addition,
there are experiments performed using different MTB strains, and, of course, layers
can be also grouped according to the general type of environmental stimuli, as it has
been discussed previously.
A first question to address around this system is up to what extent the topologies of
each of the layers are similar to each other, and, more relevantly, how these similarities
correlate with the principal attributes of the correspondent experiments listed before.
So as to elucidate this question, we have selected two measurements of similarity
among couples of layers: the coherence between the nodes’ strength ranks of the layers,
and the conditioned probability for a random link to exist in one layer provided it
does exist in the other. Then, we linearly transform these similarity measurements
so as to get normalized distances, i.e. measures within the interval [0, 1], in which 0
means maximum similarity and 1 maximum dissimilarity. After transforming them
we perform a hierarchical clustering analysis in order to get from there an overview
of how topological similitude among layers is related to the different attributes of the
associated experiments.
Strength rank coherences
In order to compute the first of these measures, we recall the definition of node strength
in a given layer α as the sum of the weights of all the interactions it is involved in within
that precise layer:
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sα(i) =
∑
j
wα(i, j) (4.13)
From that definition, we can build a ranking for each layer, by decreasingly ordering
the nodes according to their strengths, and placing absent nodes (i.e. those for which
the strength is zero) at the end of the rank. Once done so, we are able to compare any
couple of layers according the coherence of their strengths ranks, using the Kendall
coefficient r(α, β):
r(α, β) =
2(c(α, β)− d(α, β))
n(n− 1) (4.14)
where c(α, β) is the number of pairs of nodes which are concordant between the
strength ranks of layers α and β and d(α, β) the number of discordant pairs. Couples
of nodes are concordant if they share the same hierarchy in the ranks of both layers
(i.e., if we talk about nodes i and j, they constitute a concordant pair if sα(i) > sα(j)
and sβ(i) > sβ(j) or if sα(i) < sα(j) and sβ(i) < sβ(j)), and they are discordant in
the strictly opposite case (i.e., i and j constitute a discordant pair if sα(i) > sα(j) and
sβ(i) < sβ(j) or if sα(i) < sα(j) and sβ(i) > sβ(j)). In case two nodes are equally
ranked in some of the layers (sα(i) = sα(j) or sβ(i) = sβ(j)) they are nor concordant
neither discordant. This metrics takes values in the interval [−1, 1], corresponding -1
to perfectly inverted ranks and 1 to identical ranks. The case r(α, β) = 0 indicates that
strength ranks of layers α and β are statistically independent. In order to transform
Kendall coefficients in a distance-like metrics whose image interval is [0, 1], we perform
he following transformation:
R(α, β) =
(1− r(α, β))
2
(4.15)
which is equal to zero when r(α, β) = 1 (identical layers, minimum distance) and
one when r(α, β) = −1 (opposite layers, maximum distance).
Conditioned probabilities
Let L(α) be the number of links with weight greater than zero in layer α. Furthermore,
let us denote α ∩ β as the intersection between layers α and β (i.e. the network that
we recover by considering links and nodes present only in both layers, disregarding link
weights). Then, the conditioned probability for a random link a ↔ b to exist in layer
β provided that it exists in layer α is defined as follows:
P (wβ(a, b) > 0|wα(a, b) > 0) = L(α ∩ β)
L(α)
(4.16)
So as to recover a distance-like symmetric measure from that conditioned probabil-
ity, we define:
Π(α, β) =
{
1− P (wβ(a, b) > 0|wα(a, b) > 0) if L(α) ≤ L(β)
1− P (wα(a, b) > 0|wβ(a, b) > 0) if L(α) > L(β) (4.17)
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which i) guarantees that Π(α, β) = Π(β, α) for all (α, β) and ii) verifies Π(α, β) = 0
when the smaller layer is totally included in the bigger one (minimum distance) and
Π(α, β) = 1 when α ∩ β = 0 (maximum distance).
Hierarchical clustering analysis
From the pairwise metrics defined in equations 4.14 and 4.16, we get two distance
matrixes of inter-layer topological dissimilarity in 4.15 and 4.17, what we analyze using
hierarchical clustering. The essential objective of clustering analysis algorithms is to
identify groups of elements (in our case, layers) that are at lower distances than from
elements belonging to other groups. In order to do so, and based on the distance
matrix, we start by identifying the couple of elements being at lowest distance among
all pairwise distances in the matrix. These two elements are then associated to a single
one (i.e. a cluster), after which the process is iterated until all elements have been
analyzed.
From the second iteration on, the algorithm must calculate distances between a
cluster and a node (or directly, between two clusters). As a cluster is an “extended”,
not punctual object, there exist different meaningful ways to compute distance among
clusters, which yield different algorithms for clustering analysis. In this Thesis we have
used average linkage algorithm (also called weighted pair-group method). According
to this algorithm, we define the distance between two clusters as the average distance
between each of the members. This method does not provide very large or very small
clusters and it is largely used for this type of representations [235].
4.2.4 Genes’ roles in stress-response
Once the methods used to disentangle relations among layers have been presented, we
aim to analyze the role of single nodes (genes) on our system. In order to do so, we
will follow the methodology proposed by Battiston et al. [231], directly inspired by
the previous work by Guimerá and Amaral [236]. This implies the characterization, in
the stress-response consensus multi-layer network, of two topological metrics for each
node, the node overlap, and, for example, the participation coefficient.
The overlap of a gene in the reduced multi-layer network is defined as the sum of
the node’s strengths in all the layers:
o¯(i) =
∑
c
s¯c(i) (4.18)
This quantity measures the total sum of all the weights of every interaction the
node take part in within any of the layers of the consensus system. Keeping in mind
that in that system each layer illustrates the PPIN after exposure to a different type
of stress condition, all of which are thought to be cardinal characteristics of the phago-
somal environment, the overlap of a gene can be interpreted as a measure of its global
relevance in mediating generic stress responses in MTB.
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Admittedly, this general measure of node’s importance can be complemented with
the participation coefficient p(i), defined as follows:
p¯(i) =
L
L − 1
(
1−
L∑
c=1
(
s¯c(i)
o¯(i)
)2)
(4.19)
where L = 6 is the number of layers of the consensus system. It is easy to show
that p(i) = 0 implies that the node is only present in one of the layers, while a value
of p(i) = 1 means that the presence of a gene –no matter how weak or strong– is
homogeneously distributed among all the layers in the system.
In our context, the participation coefficient can be interpreted as a measure of how
“specialist” a gene is in what regards the type of stresses that it primarily responds to:
high values of p will correspond to generic-stress response genes, and low values of p
will correspond to genes responding only after a particular type of stress.
4.3 Results
4.3.1 Layer clustering analysis: insights on TB infection models
The outcome of the hierarchical clustering analysis of the original multi-layer system
is captured in dendrograms depicted in figures 4.1 and 4.2. These dendrograms con-
stitute a valuable graphical resource to analyze the clustered structure of the datasets,
and to distinguish layers which share common topological profiles from those that
present more divergent topologies. Figure 4.1 represent the dendrogram correspond-
ing to nodes’ strength ranks coherences and figure 4.2 represents the outcome of the
clustering analysis based upon conditioned probabilities of links co-existence.
Below the dendrograms, four color bars are plotted, which represents experiments
classifications according to different criteria. By comparing the color bars with the
structure of the dendrograms, we can get a global understanding of what aspects of
the experiments exert deeper influences on PPIN topologies.
First of all, it worths noticing that both figures show strong similarities in what
regards the overall structure. On the one hand, layers corresponding to in-vivo assays
of murine derived Mφs infection appear consistently grouped in both figures. At the
same time, most in-vitro experiments tend also to form coherent clusters. Finally,
both dendrograms present an outlier region corresponding to control and low stress
exposure in vitro experiments (second color-bar, in black). Average distances among
these control-like experiments are highest, as well as the distances from them to the
rest of the layers. This is not surprising, as these layers correspond to experiments in
which the stress condition is absent, or too mild to generate substantial transcriptional
responses, which translates into high levels of noise and randomness. Remarkably,
most experiments associated to low availability of some key ions (i.e. phosphate and
Fe2+, GEO series GSE14840, GSE1642 and GSE8732) lie in this area in both figures
(yellow stripes, fourth color bar), suggesting that, at least at the doses applied in these
experiments, reduced ion availability generates a modest transcriptional response at
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Figure 4.2: Multilayer PPIN: layers’ clustering dendrogram according to strength ranks.
Each branch in the dendrogram represents a version of the original PPIN [4], transformed
using the transcriptional response associated to a different experiment obtained from GEO
database [5]. Different experiment attributes are indicated through different color codes.
Dendrograms contructed using software R (packet dendextend)
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Figure 4.3: Multilayer PPIN: layers’ clustering dendrogram according to conditional prob-
abilities of links coexistence between layers. Each branch in the dendrogram represents a
version of the original PPIN [4], transformed using the transcriptional response associated to
a different experiment obtained from GEO database [5]. Different experiment attributes are
indicated through different color codes.
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genome wide level.
However, additional nuances to the above general outline arise after a deeper analy-
sis of the dendrograms. On the one hand, it is important to note that, if murine-derive
Mφ infection experiments tend to group together, infection assays performed on hu-
manMφs (only two) split from them. Indeed, for some layers corresponding to in-vitro
experiments (“intermediate clusters” on green background), phylogenetic distances to
either murine-derived or –more remarkably– humanMφs infection layers are lower than
the distance between the clusters corresponding to both types of in-vivo infection mod-
els. In this line, we have that most in-vitro layers are at least as similar to humanMφs
layers as murineMφs infection layers, and, in addition, the closest layer to humanMφs
infection experiments is, in both dendrograms, an in-vitro experiment corresponding to
24 hours of exposure to cholesterol (taken from GSE13978). Similarly, several in-vitro
layers appear in the figures as the closest parents of murine Mφs infection assays, of
which, re-aireation after hypoxia experiments appears in both dendrograms.
The relevance of these results, from a biological perspective, is twofold. First, this
indicates that, for what respects the reach of our observations, murine infection assays
does not offer a particularly better proxy of human Mφ infection than certain in-vitro
setups. Furthermore, among all the layers corresponding to in-vitro experiments, those
corresponding to re-aireation experiments and exposure to cholesterol emerge from our
analysis as the most promising candidates to constitute more adequate in-vitro models
of intracellular MTB infection. This is of particular relevance in our case, as in-vitro
modeling of phagosomal environment has constituted an intense subject of debate
during the last decade [232]. Remarkably, the appearance of cholesterol as a putative
key signal mediator able to generate a global transcriptional response highly similar
to that followed by MTB infection in human Mφs results particularly suggestive at
the light of some recent works that have proposed a relevant role for this molecule
and its metabolic pathways in the adaptation of MTB to the intracellular environment
[117, 227, 119].
Beyond these principal results, further analysis of how the layers regarding in-vitro
and in vivo experiments organize deserve attention.
In-vitro layers tend to group according the type of stress (color bar 4), with two (or
three) major clusters of experiments standing out, corresponding to the two stress types
more represented in GEO database: respiration arrest experiments (in green in color
bar 4) and oxidative stress (in red). Associated to these stresses, multi-stress dormancy
models primarily based on oxidative stress (dark green) or hypoxia (dark blue) group
together to each of the two main stresses mentioned. Other less represented kinds of
stress tend to consistently group too, as cell wall damage (pink) and DNA damage
(violet). However, the structure of the data does not allow us to assure that the reason
of the emergence of this structure was the type of stress. Indeed, if we focus on the two
more represented types of stresses in the dendrogram we can see how almost all the
layers corresponding to respiration arrest experiments (green, fourth color bar) have
been conducted using H37RV strain (yellow in the third bar), while, for the case of
oxidative stress experiments (red in the fourth bar) we have an overwhelming majority
of experiments conducted on MTB strain 1254 (pink in the third bar). This means
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that the differentiation between the mentioned two clusters can be either a consequence
of the stresses associated to each group of experiments or to the strains on which the
experiments were performed.
Regarding the inner structure of the cluster of in vivo experiments performed on
murine-derived Mφs, the situation is much clearer. First, experiments on activated
Mφs (from GEO series GEO21113) and experiments on resting Mφ (from GEO series
GSE35362 and GEO21112) split almost perfectly, suggesting that phage activation is
a more relevant trait of the systemic response of MTB after infection than the specific
clinical isolate (MTB strain) within this group of layers. Additionally, the experiments
on resting Mφs also split in two major clusters in each graph: one for experiments
coming from GSE35362 (8 first layers of the orange cluster of murine Mφ infections,
not marked in the dendrograms), and other for experiments from GSE21113. This is
likely caused by different experimental protocols followed in both series (for example,
infection times are different in both the series mentioned). Finally, within the division
according to Mφ activation, the evolutionary clades which the strains used in each of
the infection experiments belong to can be distinguished, suggesting that our approach
is also sensitive to differences in gene expression attributable to a genetic origin as a
second (or third) order effect.
4.3.2 MTB genes roles in response to environmental stress
The consensus multi-layer system representing PPINs after different environmental
stresses contains 1593 interactions distributed among six layers, which corresponds to
265 interactions per layer. In this consensus system only 606 genes of the 2907 from
Wang’s original network take part. The six layers of this system are represented in
figure 4.4, where nodes are colored according to functional ontologies extracted from
tuberculist database [237], and node sizes correspond to genes’ strengths.
Looking at figure 4.4 two relevant features of the system are evident at a glance.
First, if we compare it to the original network by Wang et al., we have that hubs in that
network (i.e. nodes with more connections in the not-weighted network represented in
4.1) does not correspond with principal hubs in any of the layers of our stress-response
consensus system. The interpretation for this is simple: the activity of proteins with
the ability of interacting with large amounts of different proteins is not favored under
stress conditions. Instead of that, proteins showing greatest strengths in our stress-
related layers (i.e. those whose activity is most enhanced because of stress exposure)
present intermedium and low degrees in the original dataset. Additionally, we see how
the overall structure is highly similar in all the layers, with a reduced set of 6-8 hubs
belonging to the category of cell wall related proteins standing out among all the rest.
Remarkably, we also observe the presence of nodes that are hubs only in specific layers.
The most evident example is, in the layer of NO exposure, formed by a couple of genes:
Rv1738, of unknown function and Rv2925c, involved in information pathways.
In order to obtain a more rigorous picture in what concerns the role of these hubs
and all the other proteins, we have represented, in figure 4.5 the overlap of each gene
versus its participation index. The plot has been divided in three regions so as to
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Figure 4.4: Stress response consensus multi-layer system. In each layer, only those genes
and interactions systematically overexpressed in a majority of the experiments associated to
a single type of stress will appear.
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Figure 4.5: Overlap vs. participation coefficient for genes present in the stress-response
multi-layer system. Two regions are highlighted: that of specialist hubs (dark grey) and that
of generic hubs (light grey). All the genes classified in the second group (plus Rv1037c) form
six pairs of adjacent genes analogous to ESAT-6 and cfp10.
identify atypical genes that may have important roles in this context. This classification
distinguishes three types of nodes: regular nodes (white background in Figure 4.5),
specialist hubs (dark-grey background) and generic hubs that respond equally to every
stress studied (light grey). All the nodes appearing in the light grey or dark-grey
regions were identified.
Furthermore, nodes are colored according to the number of layers they appear in,
which defines the position of each node within the graph. Nodes that are absent in
some layers cannot reach high values of p. In accordance with the definition of the
participation coefficient, it is easy to show that nodes that appear in 1 to 5 layers can,
at most, have values of equal to 0, 3/5, 4/5, 9/10 and 24/25 respectively, if the overlap
of a node is homogeneously distributed among all the layers where it is present. On
the other hand, “peaked” patterns emerge for each group, so it implies the emergence
of “forbidden regions” for each one in the region of low p and low overlap. This is a
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Figure 4.6: Overlap vs. participation coefficient analysis. A. For nodes appearing only in
two layers, we represent the specific couple of layers in which they appear. Layers numbers:
Hypoxia (1), nutrient starvation (2), cell wall damage (3), ions deprivation (4), NO exposure
(5) and generic oxidative stress (6). B. Frequencies of association of each couple of layers.
Hypoxia-NO exposure (layers 1 and 5) appears as the most frequent association. C. Overlap
of genes appearing in only one layer. genes with maximum overlap in each layer are identified.
4. Cell wall related proteins highlighted in the graph. ESAT-6 protein family belongs to this
functional cathegory.
straightforward consequence of the definition of these parameters. Let us consider a
node preliminarily present in three layers (blue in the figure), as an example to illustrate
this. A low p means that the overlap of the node is heterogeneously distributed among
layers, and as a consequence, it is expected to have little strength in one of the layers,
much lower than in the rest. If, besides, the overall overlap is reduced, the strength of
the node in the weakest layer will not surpass the over-expression threshold, so it will
disappear from the layer “jumping” from the group of nodes present in the three layers
(light blue group) to the group present in only two (dark blue group). The graphical
display of the network in figure 4.3 shows that more relevant nodes in the network are
homogeneously distributed among all the layers. Surprisingly, all these genes, labelled
as cell-wall related, belong to to the Early Secreted Antigen Target of 6kDa (ESAT-6)
family, one of the most relevant antigens secreted by the bacterium (see Figure 4.5).
For those nodes that appear only in two layers, it would be interesting to know
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whether there is any combination of two layers with more nodes in common than
others, as this could indicate that some pair of stresses shares tighter common tran-
scriptional response mechanisms than others. As Figure 4.6 (panels (a) and (b)) show,
a high proportion of the nodes which are present only in two layers are in hypoxia
and NO-exposure stress layers. This is not surprising, as the association between the
bacterial responses to these stimuli is well known [238]. However, the different amount
of genes that appear in each layer should be taken into account in a deeper analysis
of these associations. Notwithstanding that, the six layers present a rather homoge-
neous number of nodes (267 in hypoxia, 402 in nutrient starvation, 297 in cell wall
damage, 250 in ions deprivation, 262 in NO exposure and 192 in oxidative stress) and
hypoxia (267) and NO layers (262) present modest number of nodes, which backs up
the biological implications of the outcome displayed in figures 4.6, panels (a) and (b).
Likewise, proteins that appear only in one layer have been divided in accordance
with the layer they belong to in figure 4.6 (c). Proteins with the greater overlap value
of each layer were identified.
4.4 Discussion
In this chapter, we have analyzed the transformations suffered by the PPIN of MTB
when dealing on different MTB strains facing different environmental conditions, both
in vitro or in vivo.
From the analysis of our original multi-layer system, a first conclusion is that it
is precisely the type of experiment performed -in vitro and in vivo– the factor more
strongly affecting PPIN topologies. This has, however, the crucial exception repre-
sented by the existence of relevant differences between human and animal infection
models, which are bigger than the differences between some of these in vivo models of
MTB infection and certain in vitro experiments. This observation can be interpreted
as a sign of the otherwise well known limitations of animal models in certain contexts
of TB research, something that has constituted a frequent matter of discussion [239].
In vitro experimental setups that produced more similar PPINs to in vivo infection
models include re-aireation and exposure to cholesterol.
In what regards re-aireation (GEO series GSE21590), experiments compare gene
expression profiles of dormant bacteria (7 days under hypoxia) to those obtained after
further ventilation during different times [240], which makes MTB cultures return to
exponential growth. Folding rates are calculated dividing the dormant expression levels
by subsequent exponential growth profiles obtained at the end of the experiment. Thus,
it is not surprising that these reareation assays are able to mimick, at the level of the
PPIN, in vivo infection models, as hypoxia-induced dormancy is known as one of best
stablished models for in vivo infection [89]. Nevertheless, it is remarkable the fact
that, among all experiments related to respiration arrest (green, in the fourth color
bar of figures 4.2 and 4.3), reareation experiments appear systematicly closer to Mφs
infection assays. This seems to suggest that the process of entrance and ulterior exit
from hypoxia-induced dormancy may not be totally (or instantaneously) simmetric, as
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thoroughly studied precisely in [240].
Furthermore, the emergence of cholesterol as the in vitro stimulus closest to in-
fection assays on human Mφs is suggestive. Cholesterol metabolism pathways have
been identified as a central piece of MTB adaptation to phagosomal environment. As
we discussed in the introduction, host’s cholesterol is used by MTB both as an en-
ergy source and as a precursor of more complex lipids that are essential for bacterial
survival and virulence [117, 119]. These are essential ingredients of a global shift in
MTB metabolism that substitutes carbo-hidrates to lipids as major carbon and en-
ergy sources [227]. The results of our analysis suggest that cholesterol exposure may
constitute a relevant signaling mediator for the adaptation of MTB to intracellular con-
ditions, able to generate a global transcriptional response that causes PPIN to closely
resemble those corresponding to in vivo infection assays performed in human Mφs to
a superior extent than any other in vitro setup.
In what regards genes’ roles analysis, our method has identified a group of 11 genes
as generic hubs, appearing in all the layers and having both the greatest overlaps and
high values of the participation coefficients. These eleven genes –along with Rv1037c,
that appears in three layers–, conform six gene pairs of the family of ESAT-6 secreted
antigens. This family of genes, as it has been discussed in the introduction to this
thesis, encode small proteins (molecular weights of the order of 5-10 kDa) that are
found in adjacent co-transcribed pairs across the mycobacterial genome. These pairs of
proteins form hetero-dimers that are secreted byMTB to the intracellular environment.
That is the case of the 12 genes (11 generic hubs plus Rv1037c) found in figure 4.6:
Rv1037c-Rv1038c, Rv1792-Rv1793, Rv1197-Rv1198, Rv3619c-Rv3620c and Rv2346c-
Rv2347c and Rv3874-Rv3875. Among these gene pairs, the last one –Rv3874-Rv3875,
commonly denoted as ESAT-6 and cfp10 (culture filtrate protein of 10kDa)–, have
received most of the attention during the last years [241, 242, 191, 243] for his strong
immunogenicity and pathogenic activity as major MTB antigens, which has motivated
its use for the development of novel vaccines [244]. ESAT-6 and cfp10 form hetero-
dimers in vivo, which allows their correct secretion through a secretion system that is
specific to this family of proteins [245]. Once secreted, cfp10 –whose principal role is
thought to be related to ESAT-6 stabilization– splits, and ESAT-6 develops a strong
cytolitic activity, opening pores in host’s lipidic membranes [246]. In addition, BCG
vaccine does not produce ESAT-6, [247, 248], which has indeed allowed the advent
of new diagnostic tools based on ESAT-6 that, in principle, are able to discriminate
between infected individuals and people vaccinated with BCG [249]. As an example of
its central role in immunogenicity, one of the principal features of the vaccine candidate
MTBVAC is that, through disruption of the global regulator PhoP, the proteins of the
secretion system of ESAT-6 become insufficiently expressed, which turns into a MTB
strain that, yet expressing ESAT-6 (which provides immunogenicity), is not able to
secrete it into the medium (with reduces its pathogenicity) [129].
The fact that our method is able to capture the central importance of the gene pair
ESAT-6/cfp10 constitutes an encouraging argument evidencing the need of systemic
analysis of global cellular adaptation beyond standard transcriptional characterization.
Nevertheless, our method also predicts a comparable role for five additional gene pairs
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parents to ESAT-6/cfp10. These proteins have not received a comparable attention,
and their biological role is assumed to be analogous to that of the pair ESAT-6/cfp10,
being their essential purpose that of providing a source for antigenic diversity to the
pathogen that could help it to evade host’ immune response [435, 436]. Summariz-
ing, our results suggest that the proteins mentioned could play a role comparable to
their most relevant member ESAT-6 and cfp10; an hypothesis that deserves further
exploration.
All these results, taken together, indicate that the methodology proposed in this
chapter constitutes a promising approach to the observation of cellular adaptive re-
sponses to different conditions at a systemic scale. The observation of the transfor-
mations suffered by the PPIN of MTB under different environments, specially under
different stresses, provides relevant biological insights of the underlying adaptation
mechanisms experienced by the pathogen and helps to discriminate most relevant in-
gredients in such processes by proposing putative key genes and signaling routes that
will need further experimental validation. Admittedly, our methodology relies on the
correspondence of gene expression levels measured in micro arrays and protein con-
centration, and for this reason further de-correlations between mRNA and protein
concentration due to post-transcriptional regulatory mechanisms can not be addressed
from the data we manage.
Further work in this line is currently under progress, whereby we aim to elucidate,
among other relevant aspects of our methodology, the following questions
• which part of the topological transformations suffered by PPIN as a consequence
of environmental shifts is imputable to transcriptional changes and which part to
the underlying topology of the PPIN?
• Is the convergent response of all the stresses listed a feature showed by other
bacteria with similar (or different) life-styles?
• Are the topologies associated to other stimuli not associated to stress (e.g. choles-
terol) similar to those of the stress consensus multi-layer system?
• Does the biological role of ESAT-6-like proteins present a comparable relevance
in pathogenicity and immunogenicity to that of the couple ESAT-6/cfp10?
4.5 Appendix
4.5.1 Discarded data
We accessed GEO in March 2014 and collected all the series corresponding to microar-
ray experiments conducted in MTB. We discarded the following 21 entire series for
the reasons adduced in the main text (i.e. inadequate basal reference channels, mu-
tants and/or antibiotics experiments): GSE7963, GSE17640, GSE29160, GSE31732,
GSE32076, GSE32157, GSE32178, GSE42151, GSE54289, GSE40917, GSE45811, GSE24035,
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GSE24045, GSE46212, GSE43466, GSE9776, GSE10897, GSE12364, GSE16626, GSE42293,
GSE26166.
On the contrary, we recovered useful information from the following 22 series:
GSE14840, GSE8732, GSE1642, GSE365, GSE16146, GSE8839 GSE8689, GSE15976,
GSE6750, GSE8664, GSE50159, GSE10391 GSE5977, GSE21590, GSE8786, GSE9331,
GSE8829, GSE13978 GSE6209, GSE35362, GSE21112, GSE21113.
Notwithstanding that, not all the samples within these series were useful for our
analysis. In the following table, we enlist the samples discarded from each of the series
used:
GEO-sample Description
GSM5277 0.2 µg/mL MMC (8h) vs control
GSM5281 0.2 µg/mL MMC (12h) vs control
GSM5285 0.2 µg/mL MMC (4h) vs control
GSM5286 0.2 µg/mL MMC (6h) vs control
GSM5295 0.2 µg/mL MMC (8h) vs control
GSM5299 0.2 µg/mL MMC (4h) vs control
GSM155430 Rv-Control(1) vs. Rv-∆981[mpr]-control(1)
GSM155431 Rv-Control(2) vs. Rv-∆981[mpr]-control(2)
GSM155432 Rv-Control(3) vs. Rv-∆981[mpr]-control(3)
GSM155433 Rv-Control(4) vs. Rv-∆981[mpr]-control(4)
GSM155434 Rv-Control(5) vs. Rv-∆981[mpr]-control(5)
GSM155435 Rv-Control(6) vs. Rv-∆981[mpr]-control(6)
GSM155436 Rv-∆981[mpr]-control(1) vs Rv-∆981[mpr]-SDS(1)
GSM155437 Rv-∆981[mpr]-control(2) vs Rv-∆981[mpr]-SDS(2)
GSM155438 Rv-∆981[mpr]-control(3) vs Rv-∆981[mpr]-SDS(3)
GSM155439 Rv-∆981[mpr]-control(4) vs Rv-∆981[mpr]-SDS(4)
GSM155440 Rv-∆981[mpr]-control(5) vs Rv-∆981[mpr]-SDS(5)
GSM155441 Rv-∆981[mpr]-control(6) vs Rv-∆981[mpr]-SDS(6)
GSM155442 Rv-SDS(1) vs Rv-∆981[mpr]-SDS(1)
GSM155443 Rv-SDS(2) vs Rv-∆981[mpr]-SDS(2)
GSM155444 Rv-SDS(3) vs Rv-∆981[mpr]-SDS(3)
GSM155445 Rv-SDS(4) vs Rv-∆981[mpr]-SDS(4)
GSM155446 Rv-SDS(5) vs Rv-∆981[mpr]-SDS(5)
GSM155447 Rv-SDS(6) vs Rv-∆981[mpr]-SDS(6)
GSM214900 H37Rv wild type vs. sigE mutant
GSM214901 H37Rv wild type vs. sigE mutant
GSM214902 H37Rv wild type vs. sigE mutant
GSM214909 Exposed to 0.05% SDS sigE mutant
GSM214910 Exposed to 0.05% SDS sigE mutant
GSM214911 Exposed to 0.05% SDS sigE mutant
GSM214912 Exposed to 0.05% SDS sigE mutant
GSM214913 Exposed to 0.05% SDS sigE mutant
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GEO-sample Description
GSM214914 Exposed to 0.05% SDS sigE mutant
GSM215378 H37Rv wild type vs. sigH mutant
GSM215379 H37Rv wild type vs. sigH mutant
GSM215380 H37Rv wild type vs. sigH mutant
GSM215387 Exposed to Diamide 5 mM sigH mutant
GSM215388 Exposed to Diamide 5 mM sigH mutant
GSM215389 Exposed to Diamide 5 mM sigH mutant
GSM215390 Exposed to Diamide 5 mM sigH mutant
GSM215391 Exposed to Diamide 5 mM sigH mutant
GSM215392 Exposed to Diamide 5 mM sigH mutant
GSM216629 ST22 mutant vs. H37Rv (iron sufficient : 50 µM FeCl3)
GSM216630 ST22 mutant vs. H37Rv (iron sufficient : 50 µM FeCl3)
GSM216631 ST22 mutant vs. H37Rv (iron sufficient : 50 µM FeCl3)
GSM216632 ST22 mutant vs. H37Rv (iron sufficient : 50 µM FeCl3)
GSM216633 ST22 mutant vs. H37Rv (iron sufficient : 50 µM FeCl3)
GSM216634 ST22 mutant vs. H37Rv (iron sufficient : 50 µM FeCl3)
GSM216635 ST52 mutant vs. ST22 mutant (iron sufficient : 50 µM
FeCl3)
GSM216636 ST52 mutant vs. ST22 mutant (iron sufficient : 50 µM
FeCl3)
GSM216637 ST52 mutant vs. ST22 mutant (iron sufficient : 50 µM
FeCl3)
GSM216638 ST52 mutant vs. ST22 mutant (iron sufficient : 50 µM
FeCl3)
GSM216639 ST52 mutant vs. ST22 mutant (iron sufficient : 50 µM
FeCl3)
GSM216640 ST52 mutant vs. ST22 mutant (iron sufficient : 50 µM
FeCl3)
GSM218911 Concanamycin A inhibition of phagosome acidification
GSM218912 phagocytosis inhibited with cytochalasin D
GSM219337 Hypoxia experiment with MTB dosR mutant
GSM219338 Hypoxia experiment with MTB dosR mutant
GSM219339 Hypoxia experiment with MTB dosR mutant
GSM219340 Hypoxia experiment with MTB dosR mutant
GSM219341 Hypoxia experiment with MTB dosR mutant
GSM219342 Hypoxia experiment with MTB dosR mutant
GSM886249 H37Rv 0 day ctrl vs Rv3132-34 KO hypoxia 4 day
GSM886251 H37Rv ctrl vs Rv3132-3134 KO 0,05 mM DETA-NO 40min
GSM886260 MTB strain 1254 Ctrl vs 0,5 mM KCN + 2hr hypoxia
GSM886265 H37Rv ctrl vs Rv3132-34 KO (complemented) 0,05 mM
DETA-NO 40min
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GEO-sample Description
GSM886275 H37Rv 0 day ctrl vs Rv3132-34 KO hypoxia 4 day
GSM886277 MTB strain 1254 Ctrl vs 0,5 mM KCN 20min + 0,05 mM
DETA-NO 40min
GSM886279 H37 Rv3132-34 KO 0 days vs Rv3132-34 KO (complemented)
hypoxia 4 day
GSM886285 MTB strain 1254 Ctrl vs 0,5 mM KCN 1hr
GSM886287 H37Rv ctrl vs Rv3132-34 KO (complemented) 0,05 mM
DETA-NO 40min
GSM886290 H37Rv 0 day ctrl vs Rv3132-34 KO hypoxia 4 day
GSM886292 H37Rv ctrl vs Rv3132-3134 KO 0,05 mM DETA-NO 40min
GSM886302 H37Rv ctrl vs Rv3132-3134 KO 0,05 mM DETA-NO 40min
GSM886318 H37Rv ctrl vs Rv3132-3134 KO 0,05 mM DETA-NO 40min
GSM886324 H37Rv ctrl vs Rv3132-34 KO (complemented) 0,05 mM
DETA-NO 40min
GSM886329 H37 Rv3132-34 KO 0 days vs Rv3132-34 KO (complemented)
hypoxia 4 day
GSM886336 H37Rv ctrl vs Rv3132-34 KO (complemented) 0,05 mM
DETA-NO 40min
GSM886342 H37Rv 0 day ctrl vs Rv3132-34 KO hypoxia 4 day
GSM886368 H37 Rv3132-34 KO 0 days vs Rv3132-34 KO (complemented)
hypoxia 4 day
GSM886370 H37 Rv3132-34 KO 0 days vs Rv3132-34 KO (complemented)
hypoxia 4 day
GSM886304 MTB strain 1254 Ctrl vs 0,5 mM KCN 1hr
GSM886321 MTB strain 1254 Ctrl vs 0,5 mM KCN + 2hr hypoxia
GSM886346 MTB strain 1254 Ctrl vs 0,5 mM KCN + 2hr hypoxia
GSM886361 MTB strain 1254 Ctrl vs 0,5 mM KCN 20min + 0,05 mM
DETA-NO 40min
GSM886363 MTB strain 1254 Ctrl vs 0,5 mM KCN 1hr
GSM886378 MTB strain 1254 Ctrl vs 0,5 mM KCN 20min + 0,05 mM
DETA-NO 40min
GSM237655 H37dosR mutant hypoxia 4hr
GSM237656 H37dosR mutant hypoxia 4hr
GSM237657 H37dosR mutant hypoxia 4hr
GSM237658 H37dosR mutant hypoxia 4hr
GSM237659 H37dosR mutant hypoxia 8hr
GSM237660 H37dosR mutant hypoxia 12hr
GSM237661 H37dosR mutant hypoxia 12hr
GSM237662 H37dosR mutant hypoxia 1day
GSM237663 H37dosR mutant hypoxia 1day
GSM237664 H37dosR mutant hypoxia 1day
GSM237665 H37dosR mutant hypoxia 1day
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GEO-sample Description
GSM237666 H37dosR mutant hypoxia 1day
GSM237667 H37dosR mutant hypoxia 4day
GSM237668 H37dosR mutant hypoxia 7day
GSM237672 H37dosR mutant hypoxia 8hr
GSM237673 H37dosR mutant hypoxia 12hr
GSM237674 H37dosR mutant hypoxia 1day
GSM351193 CDC1551 (146) vs CDC1551 kstR mutant (162) 24 hrs
GSM351195 CDC1551 (146) vs CDC1551 kstR mutant (162) 24 hrs
GSM351202 CDC1551 (146) vs CDC1551 kstR mutant (162) 24 hrs
GSM351208 CDC1551 (146) vs CDC1551 kstR mutant (162) 24 hrs plus
cholesterol
GSM351277 CDC1551 (146) vs CDC1551 kstR mutant (162) 24 hrs plus
cholesterol
GSM351278 CDC1551 (146) vs CDC1551 kstR mutant (162) 24 hrs plus
cholesterol
GSM400324 H37Rv wild type vs H37Rv sigB null mutant
GSM400326 H37Rv sigB null mutant control vs 0.05% SDS for 60 min
GSM400327 H37Rv sigB null mutant control vs 5mM Diamide for 60 min
GSM400329 H37Rv wild type vs H37Rv sigB null mutant
GSM400330 H37Rv wild type vs H37Rv sigB null mutant
GSM400332 H37Rv sigB null mutant control vs 0.05% SDS for 60 min
GSM400337 H37Rv sigB null mutant control vs 5mM Diamide for 60 min
GSM400338 H37Rv sigB null mutant control vs 5mM Diamide for 60 min
GSM400342 H37Rv wild type vs H37Rv sigB null mutant
GSM400343 H37Rv sigB null mutant control vs 0.05% SDS for 60 min
GSM400344 H37Rv sigB null mutant control vs 5mM Diamide for 60 min
GSM400345 H37Rv wild type vs H37Rv sigB null mutant
GSM400346 H37Rv sigB null mutant control vs 5mM Diamide for 60 min
GSM400347 H37Rv wild type vs H37Rv sigB null mutant
GSM400349 H37Rv sigB null mutant control vs 5mM Diamide for 60 min
GSM400352 H37Rv sigB null mutant control vs 0.05% SDS for 60 min
GSM400353 H37Rv sigB null mutant control vs 0.05% SDS for 60 min
GSM400355 H37Rv sigB null mutant control vs 0.05% SDS for 60 min
GSM27855 0.1 µg/mL MMC ctrl (0.33h)
GSM27856 0.2 µg/mL MMC ctrl (0.33h)
GSM27857 0.1 µg/mL MMC ctrl (0.75h)
GSM27858 0.2 µg/mL MMC ctrl (0.75h)
GSM27859 0.2 µg/mL MMC ctrl (1.5h)
GSM27860 0.2 µg/mL MMC ctrl (2h)
GSM27861 0.2 µg/mL MMC ctrl (2h)
GSM27862 0.2 µg/mL MMC ctrl (2h)
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GSM27863 0.2 µg/mL MMC ctrl (2h)
GSM27864 0.2 µg/mL MMC ctrl (4h)
GSM27865 0.2 µg/mL MMC ctrl (4h)
GSM27866 0.2 µg/mL MMC ctrl (4h)
GSM27867 0.2 µg/mL MMC ctrl (4h)
GSM27868 0.2 µg/mL MMC ctrl (4h)
GSM27869 0.2 µg/mL MMC ctrl (6h)
GSM27883 0.12mg mL PZA pH5.6 (2h)
GSM27884 1.2mg mL PZA pH5.6 (2h)
GSM27885 0.12mg mL PZA pH5.6 (2.5h)
GSM27886 0.12mg mL PZA pH5.6 (4h)
GSM27887 1.2mg mL PZA pH5.6 (4h)
GSM27888 0.12mg mL PZA pH5.6 (4h)
GSM27889 1.2mg mL PZA pH5.6 (4h)
GSM27890 0.12mg mL PZA pH5.6 (4h)
GSM27891 0.12mg mL PZA pH5.6 (4h)
GSM27892 1.2mg mL PZA pH5.6 (4h)
GSM27893 1.2mg mL PZA pH5.6 (5h)
GSM27894 0.12mg mL PZA pH5.6 (5h)
GSM27895 0.12mg mL PZA pH5.6 (5.5h)
GSM27896 1.2mg mL PZA pH5.6 (6h)
GSM27897 1.2mg mL PZA pH5.6 (6h)
GSM27898 0.12mg mL PZA pH5.6 (6h)
GSM27899 0.12mg mL PZA pH5.6 (6h)
GSM27900 1.2mg mL PZA pH5.6 (7h)
GSM27901 1.2mg mL PZA pH5.6 (7h)
GSM27902 1.2mg mL PZA pH5.6 (10.5h)
GSM27903 0.12mg mL PZA pH5.6 (10.5h)
GSM27904 0.12mg mL PZA pH5.6 (11h)
GSM27905 1.2mg mL PZA pH5.6 (16h)
GSM27906 0.12mg mL NAM pH5.6 (2h)
GSM27907 0.12mg mL NAM pH5.6 (2h)
GSM27908 0.12mg mL NAM pH5.6 (4h)
GSM27909 0.12mg mL NAM pH5.6 (4h)
GSM27910 0.12mg mL NAM pH5.6 (4h)
GSM27911 1.2mg mL NAM pH5.6 (5h)
GSM27912 0.12mg mL NAM pH5.6 (5.5h)
GSM27913 0.12mg mL NAM pH5.6 (7h)
GSM27914 1.2mg mL NAM pH5.6 (10.5h)
GSM27980 0.12mg mL BZA pH5.6 (2h)
GSM27981 0.12mg mL BZA pH5.6 (4h)
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GSM27982 0.12mg mL BZA pH5.6 (4h)
GSM27983 0.12mg mL BZA pH5.6 (5h)
GSM27984 0.12mg mL BZA pH5.6 (7h)
GSM27985 0.12mg mL BZA pH5.6 (11h)
GSM27986 40 µg/mL 5-CL-PZA pH5.6 (2h)
GSM27987 80 µg/mL 5-CL-PZA pH5.6 (2h)
GSM27988 40 µg/mL 5-CL-PZA pH5.6 (2h)
GSM27989 40 µg/mL 5-CL-PZA pH5.6 (4h)
GSM27990 40 µg/mL 5-CL-PZA pH5.6 (4h)
GSM27991 40 µg/mL 5-CL-PZA pH5.6 (4h)
GSM27992 pH4.8 pH6.8 (2h)
GSM27993 pH4.8 pH6.8 (2h)
GSM27994 pH4.8 pH6.8 (2h)
GSM27995 pH4.8 pH6.8 (4h)
GSM27996 pH4.8 pH6.8 (4h)
GSM27997 pH4.8 pH6.8 (4h)
GSM27998 pH4.8 pH6.8 (5h)
GSM27999 pH4.8 pH6.8 (5.5h)
GSM28000 pH4.8 pH6.8 (6h)
GSM28001 pH4.8 pH6.8 (7h)
GSM28002 pH4.8 pH6.8 (11h)
GSM28003 pH5.2 pH6.8 (2h)
GSM28004 pH5.2 pH6.8 (5h)
GSM28005 pH5.2 pH6.8 (5.5h)
GSM28006 pH5.2 pH6.8 (10.5h)
GSM28007 pH5.2 pH6.8 (11h)
GSM28008 pH5.2 pH6.8 (16h)
GSM28009 pH5.6 pH6.8 (2h)
GSM28010 pH5.6 pH6.8 (2h)
GSM28011 pH5.6 pH6.8 (4h)
GSM28012 pH5.6 pH6.8 (4h)
GSM28013 pH5.6 pH6.8 (4h)
GSM28014 pH5.6 pH6.8 (7h)
GSM28015 pH5.6 pH6.8 (5h)
GSM28016 pH5.6 pH6.8 (11h)
GSM28017 pH5.6 pH6.8 (16h)
GSM28018 0.1 µg/mL MMC ctrl (1.5h)
GSM28021 0.2 µg/mL MMC ctrl (8h) H37Rv
GSM28022 0.2 µg/mL MMC ctrl (8h) H37Rv
GSM28027 0.2 µg/mL MMC ctrl (12h) H37Rv
GSM28031 10 µg/mL EMB DMSO (12h)
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GSM28032 DIPED 5 µg/mL vs DMSO 12h
GSM28033 ethambutol (10 µg/mL) vs DMSO 12h
GSM28034 5 µg/mL DIPED vs DMSO 12h
GSM28035 DIPED (10 µg/mL) vs DMSO 12h
GSM28036 DIPED (10 µg/mL) vs DMSO 12h
GSM28037 EMB (10 µg/mL) vs DMSO 12h
GSM28038 EMB (10 µg/mL) vs DMSO 12h
GSM28039 DIPED (50 µg/mL) vs DMSO 12h
GSM28040 DIPED (50 µg/mL) vs DMSO 12h
GSM28041 DIPED (50 µg/mL) vs DMSO 12h
GSM28042 DIPED (100 µg/mL) vs DMSO 12h
GSM28043 DIPED (100 µg/mL) vs DMSO 12h
GSM28044 DIPED (100 µg/mL) vs DMSO 12h
GSM28045 EMB (10 µg/mL) vs DMSO 12h
GSM28046 241 (0.1 µg/mL) vs DMSO 12h
GSM28047 241 (1 µg/mL) vs DMSO 12h
GSM28048 241 (10 µg/mL) vs DMSO 12h
GSM28049 241 (10 µg/mL) vs DMSO 12h
GSM28050 109 (0.1 µg/mL) vs DMSO 12h
GSM28051 109 (1 µg/mL) vs DMSO 12h
GSM28052 109 (1 µg/mL) vs DMSO 12h
GSM28053 109 (10 µg/mL) vs DMSO 12h
GSM28054 109 (10 µg/mL) vs DMSO 12h
GSM28055 Rif (5 µg/mL) vs DMSO 2.5h
GSM28056 Rif (5 µg/mL) vs DMSO 2.5h
GSM28057 Rif (0.5 µg/mL) vs DMSO 2.5h
GSM28058 Rif (0.5 µg/mL) vs DMSO 2.5h
GSM28059 10 µg/mL Amikacin EtOH 6h
GSM28060 5 µg/mL Streptomycin EtOH 6h
GSM28061 5 µg/mL Streptomycin EtOH 6h
GSM28062 0.2 µg/mL INH EtOH 6h
GSM28063 0.2mg mL Amp EtOH 6h
GSM28064 0.2mg mL Amp EtOH 6h
GSM28065 12 µg/mL Ethionamide EtOH 6h
GSM28066 12 µg/mL Ethionamide EtOH 6h
GSM28067 0.13mg mL TLM DMSO 6h
GSM28068 0.13mg mL TLM DMSO 6h
GSM28069 0.1 mg mL Triclosan EtOH 6h
GSM28070 0.1 mg mL Triclosan EtOH 6h
GSM28071 10 µg/mL Ofloxacin DMSO 6h
GSM28072 10 µg/mL Ofloxacin DMSO 6h
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GSM28073 5 µg/mL Amikacin EtOH 6h
GSM28074 5 µg/mL Amikacin EtOH 6h
GSM28075 40 µg/mL Ethionamide EtOH 6h
GSM28076 40 µg/mL Ethionamide EtOH 6h
GSM28077 0.4 µg/mL INH EtOH 6h
GSM28078 0.4 µg/mL INH EtOH 6h
GSM28079 5 µg/mL Ofloxacin EtOH 6h
GSM28080 5 µg/mL Ofloxacin EtOH 6h
GSM28081 0.2 µg/mL Rif DMSO 6h
GSM28082 0.2 µg/mL Rif DMSO 6h
GSM28083 2 µg/mL Streptomycin EtOH 6h
GSM28084 2 µg/mL Streptomycin EtOH 6h
GSM28085 10 µg/mL Tetracycline EtOH 6h
GSM28086 10 µg/mL Tetracycline EtOH 6h
GSM28087 130 µg/mL TLM DMSO 6h
GSM28088 130 µg/mL TLM DMSO 6h
GSM28089 0.2mg mL Amp EtOH 6h
GSM28090 0.2mg mL Amp EtOH 6h
GSM28091 5 µg/mL Tetracycline EtOH 6h
GSM28092 0.2mg mL TLM EtOH 6h
GSM28093 0.2mg mL TLM EtOH 6h
GSM28094 0.15mg mL Triclosan EtOH 6h
GSM28095 0.15mg mL Triclosan EtOH 6h
GSM28096 10 µg/mL capreomycin EtOH 6h
GSM28097 10 µg/mL Capreomycin EtOH 6h
GSM28098 10 µg/mL Levofloxacin EtOH 6h
GSM28099 10 µg/mL Levofloxacin EtOH 6h
GSM28100 0.5 µg/mL Rifapentine EtOH 6h
GSM28101 0.5 µg/mL Rifapentine EtOH 6h
GSM28102 50 µg/mL Roxithromycin EtOH 6h
GSM28103 50 µg/mL Roxithromycin EtOH 6h
GSM28104 0.1mg mL Triclosan EtOH 6h
GSM28105 0.1mg mL Triclosan EtOH 6h
GSM28106 5 µg/mL Capreomycin EtOH 6h
GSM28107 5 µg/mL Capreomycin EtOH 6h
GSM28108 0.32 µg/mL Cerulenin EtOH 6h
GSM28109 0.32 µg/mL Cerulenin EtOH 6h
GSM28110 30 µg/mL Roxithromycin EtOH 6h
GSM28111 30 µg/mL Roxithromycin EtOH 6h
GSM28112 0.5 µg/mL Cerulenin EtOH 6h
GSM28113 0.5 µg/mL Cerulenin EtOH 6h
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GSM28114 10 µg/mL Chlorpromazine EtOH
GSM28115 10 µg/mL Chlorpromazine EtOH 6h
GSM28116 60 µg/mL Chlorpromazine EtOH 6h
GSM28117 10 µg/mL clotrimazole EtOH 6h
GSM28118 10 µg/mL Clotrimazole EtOH 6h
GSM28119 10 µg/mL Econazole EtOH 6h
GSM28120 10 µg/mL Econazole EtOH 6h
GSM28121 0.1 µg/mL Rifapentine EtOH 6h
GSM28122 0.1 µg/mL Rifapentine; EtOH 6h
GSM28123 10 µg/mL Roxithromycin EtOH 6h
GSM28124 10 µg/mL Roxithromycin EtOH 6h
GSM28125 20 µg/mL Cephalexin Control 6h
GSM28126 20 µg/mL Cephalexin Control 6h
GSM28127 100 µg/mL Cephalexin EtOH 6h
GSM28128 100 µg/mL Cephalexin EtOH 6h
GSM28129 50 µg/mL Triclosan EtOH 6h
GSM28130 50 µg/mL Triclosan EtOH 6h
GSM28131 100 µg/mL Triclosan EtOH 6h
GSM28132 100 µg/mL Triclosan EtOH 6h
GSM28133 10 µg/mL chlorpromazine ctrl 6h
GSM28134 10 µg/mL chlorpromazine ctrl 6h
GSM28135 20 µg/mL Procept 6776 DMSO 6h
GSM28136 0.5 µg/mL 121940 DMSO 6h
GSM28137 0.5 µg/mL 121940 DMSO 6h
GSM28138 0.5 µg/mL 111891 DMSO 6h
GSM28139 0.5 µg/mL 111891 DMSO 6h
GSM28140 0.5 µg/mL 111895 DMSO 6h
GSM28141 30 µg/mL Procept 6776 DMSO 6h
GSM28142 30 µg/mL Procept 6776 DMSO 6h
GSM28143 5 µg/mL Procept 6778 DMSO 6h
GSM28144 5 µg/mL Procept 6778 DMSO 6h
GSM28145 20 µg/mL Procept 6778 DMSO 6h
GSM28146 0.5 µg/mL 111895 DMSO 6h
GSM28147 0.5 µg/mL 124196 DMSO 6h
GSM28148 0.5 µg/mL 124196 DMSO 6h
GSM28149 2 µg/mL 121940 DMSO 6h
GSM28150 200µM Dipyridyl ctrl 6h
GSM28151 12.5 µg/mL Antimycin DMSO 6h
GSM28152 25 µg/mL Antimycin DMSO 6h
GSM28153 20 µg/mL Procept 6776 DMSO 6h
GSM28154 20 µg/mL Procept 6778 DMSO 6h
 Context-specific networks of protein-protein interactions in M.tb.
GEO-sample Description
GSM28155 20 µg/mL Procept 6778 DMSO 6h
GSM28156 40 µg/mL Procept 6778 DMSO 6h
GSM28157 40 µg/mL Procept 6778 DMSO 6h
GSM28158 2 µg/mL 111895 DMSO 6h
GSM28159 2 µg/mL 111895 DMSO 6h
GSM28160 9 µg/mL Ascididemin Natural product DMSO 6h
GSM28161 50 µg/mL Antimycin A DMSO 6h
GSM28162 50 µg/mL Antimycin A DMSO 6h
GSM28163 10 µg/mL PA-1 DMSO 6h
GSM28164 10 µg/mL PA-1 DMSO 6h
GSM28165 10 µg/mL PA-21 DMSO 6h
GSM28166 10 µg/mL PA-21 DMSO 6h
GSM28167 10 µg/mL Triclosan DMSO 6h
GSM28168 10 µg/mL Triclosan DMSO 6h
GSM28173 10 µg/mL PA-1 DMSO 6h
GSM28174 50 µg/mL PA-21 DMSO 6h
GSM28175 50 µg/mL PA-1 DMSO 6h
GSM28176 10 µg/mL Triclosan DMSO 6h
GSM28177 50 µg/mL PA-21 DMSO 6h
GSM28178 10 µg/mL Triclosan DMSO 6h
GSM28179 0.5 µg/mL Cerulenin DMSO 6h
GSM28180 0.5 µg/mL Cerulenin DMSO 6h
GSM28181 0.5 µg/mL Cerulenin DMSO 6h
GSM28182 150µM Deferoxamine ctrl 6h
GSM28183 150µM Deferoxamine ctrl 6h
GSM28184 150µM Deferoxamine ctrl 6h
GSM28185 100µM Dipyridyl ctrl 6h
GSM28186 100µM Dipyridyl Ctrl 6h
GSM28187 1 µg/mL 111891 DMSO 6h
GSM28188 1 µg/mL 111891 DMSO 6h
GSM28189 1 µg/mL 111895 DMSO 6h
GSM28190 1 µg/mL 111895 DMSO 6h
GSM28191 1 µg/mL 124196 DMSO 6h
GSM28192 1 µg/mL 124196 DMSO 6h
GSM28193 9 µg/mL Ascididemin Natural Product DMSO 6h
GSM28194 9 µg/mL Ascididemin natural product DMSO 6h
GSM28195 2 µg/mL 121940 DMSO 6h
GSM28196 2 µg/mL 111891 DMSO 6h
GSM28197 2 µg/mL 111895 DMSO 6h
GSM28198 50 µg/mL Antimycin DMSO 6h
GSM28199 0.5 µg/mL Cerulenin DMSO 6h
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GSM28200 250µM Deferoxamine DMSO 6h
GSM28201 200µM Dipyridyl DMSO 6h
GSM28202 9 µg/mL Natural product DMSO 6h
GSM28203 4 µg/mL Natural compound DMSO 6h
GSM28204 1 µg/mL 109 DMSO 6h
GSM28205 10 µg/mL 109 DMSO 6h
GSM28206 1 µg/mL 109 DMSO 6h
GSM28207 10 µg/mL 109 DMSO 6h
GSM28208 1 µg/mL 241 DMSO 6h
GSM28209 1 µg/mL 241 DMSO 6h
GSM28210 10 µg/mL 241 DMSO 6h
GSM28211 1 µg/mL 59 DMSO 6h
GSM28212 1 µg/mL 59 DMSO 6h
GSM28213 10 µg/mL 59 DMSO 6h
GSM28214 10 µg/mL 59 DMSO 6h
GSM28215 10 µg/mL EMB DMSO 6h
GSM28216 10 µg/mL EMB DMSO 6h
GSM28217 1 µg/mL 121940 DMSO 12h
GSM28218 1 µg/mL 111891 DMSO 12h
GSM28219 1 µg/mL 111895 DMSO 12h
GSM28220 10 µg/mL clofazimine DMSO 6h
GSM28221 24 µg/mL clotrimazole DMSO 6h
GSM28222 20 µg/mL chlorpromazine DMSO 6h
GSM28223 2.5mM Dinitrophenol DMSO 6h
GSM28224 50 µg/mL Thioridazine DMSO 6h
GSM28225 50 µg/mL Triclosan DMSO 6h
GSM28226 20 µg/mL Procept 6776 DMSO 6h
GSM28227 20 µg/mL Procept 6778 DMSO 6h
GSM28228 100 µg/mL Cephalexin Ctrl 6h
GSM28229 50 µg/mL Triclosan EtOH
GSM28230 10 µg/mL 109 DMSO 6h
GSM28231 10 µg/mL 59 DMSO 6h
GSM28232 20 µg/mL ethambutol DMSO
GSM28233 10 µg/mL 241 DMSO 6h
GSM28234 24 µg/mL Econazole DMSO 6h
GSM28235 24 µg/mL Econazole DMSO 6h
GSM28236 20 µg/mL Procept 6778 DMSO 6h
GSM28239 13 µg/mL clofazimine DMSO 6h
GSM28240 13 µg/mL clofazimine DMSO 6h
GSM28241 24 µg/mL clotrimazole DMS 6h
GSM28242 24 µg/mL Clotrimazole DMSO 6h
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GSM28243 20 µg/mL chlorpromazine DMSO 6h
GSM28244 0.4 µg/mL PA824 DMSO 6h
GSM28245 0.4 µg/mL PA824 DMSO 6h
GSM28246 2 µg/mL PA824 DMSO 6h
GSM28247 2 µg/mL PA824 DMSO 6h
GSM28248 0.2 µg/mL PA824 DMSO 6h
GSM28249 0.4 µg/mL PA824 DMSO 6h
GSM28250 0.2 µg/mL PA824 DMSO 6h
GSM28251 0.4 µg/mL PA824 DMSO 6h
GSM28252 10µM CCCP DMSO 6h
GSM28253 100 µg/mL Cephalexin DMSO 6h
GSM28254 100µM DCCD DMSO 6h
GSM28255 1mM DNP DMSO 6h
GSM28256 20 µg/mL KCN DMSO 6h
GSM28257 100 µg/mL Cephalexin DMSO 6h
GSM28258 10 µg/mL Thioridazine DMSO 6h
GSM28259 10 µg/mL Novobiocin DMSO 6h
GSM28260 5 µg/mL KCN DMSO 6h
GSM28261 0.5mM DNP DMSO 6h
GSM28262 20µM DCCD DMSO 6h
GSM28263 50µM CCCP DMSO 6h
GSM28264 Min med -Palmitate Min med - Glucose
GSM28265 Min med - Succinate Min med glucose
GSM28266 50µM CCCP DMSO 6h
GSM28267 20µM DCCD DMSO 6h
GSM28268 5 µg/mL KCN DMSO 6h
GSM28269 10 µg/mL Novobiocin DMSO 6h
GSM28270 10 µg/mL Thioridazine DMSO 6h
GSM28271 10mM Succinate (min med) 10mM Glucose (min med)
GSM28272 0.05mM Palmitate (min med) 10mM Glucose (min med)
GSM28273 1mM DNP DMSO 6h
GSM28274 25 µg/mL Thioridazine DMSO 6h
GSM28275 10 µg/mL Novobiocin DMSO 6h
GSM28276 10mM Succinate (min med) 10mM Glucose (min med)
GSM28277 0.05mM Palmitate (min med) 10mM Glucose (min med)
GSM28278 1 µg/mL ARP4 DMSO 6h
GSM28279 4 µg/mL ARP4 DMSO 6h
GSM28280 1 µg/mL ARP2 DMSO 6h
GSM28281 4 µg/mL ARP2 DMSO 6h
GSM28282 10mM Succinate (min med) 10mM Glucose (min med)
GSM28283 0.05mM Palmitate (min med) 10mM Glucose (min med)
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GSM28284 10 µg/mL Methoxatin DMSO 6h
GSM28285 0.1mM GSNO 5 µg/mL KCN DMSO 6h
GSM28286 0.1mM GSNO DMSO 6h
GSM28287 7d Dubos NRP-1 Dubos log phase
GSM28288 7d Dubos NRP-1 Dubos log phase
GSM28289 20 µg/mL methoxatin DMSO 6h
GSM28290 10 µg/mL methoxatin DMSO 6h
GSM28291 0.1mM GSNO DMSO 6h
GSM28292 0.1mM GSNO 5 µg/mL KCN DMSO 6h
GSM28293 Dubos NRP-1 Dubos log-phase
GSM28294 1mM DTNB DMSO 6h
GSM28295 2mM DTT DMSO 6h
GSM28296 1µM Valinomycin DMSO 6h
GSM28297 10µM Valinomycin DMSO 6h
GSM28298 2mM b-mercaptoethanol DMSO 6h
GSM28299 2mM DTNB DMSO
GSM28300 2mM DTT DMSO 6h
GSM28301 50µM Nigericin DMSO 6h
GSM28302 1µM Valinomycin DMSO 6h
GSM28303 50 µg/mL Verapamil DMSO 6h
GSM28304 1µM Valinomycin DMSO 6h
GSM28305 20 µg/mL CPZ DMSO 6h
GSM28306 PBS Tw DMSO 7H9 6h
GSM28307 10 µg/mL menadione DMSO 6h
GSM28308 0.1mM GSNO 20 µg/mL CPZ DMSO 6h
GSM28309 0.1mM GSNO 10 µg/mL menadione DMSO 6h
GSM28310 50µM CCCP DMSO 6h
GSM28311 50µM Nigericin DMSO 6h
GSM28312 0.5µM Valinomycin DMSO 6h
GSM28313 0.5µM Valinomycin 70mM KCl DMSO 6h
GSM28314 0.1mM GSNO 20 µg/mL CPZ DMSO 6h
GSM28315 0.1mM GSNO 10 µg/mL menadione DMSO 6h
GSM28316 20 µg/mL CPZ DMSO 6h
GSM28317 10 µg/mL menadione (Dubos) DMSO 6h
GSM28318 4d Dubos NRP-1 Dubos aerobic log phase
GSM28319 4d 20mM nitrate in Dubos NRP-1 aerobic Dubos
GSM28320 25 µg/mL CPZ DMSO ctrl 6h
GSM28321 0.02mM GSNO DMSO 6h
GSM28322 25 µg/mL CPZ + 0.1mM GSNO DMSO ctrl
GSM28323 5 µg/mL Clofazimine + 0.1mM GSNO DMSO
GSM28324 0.4mM NaN3 DMSO 4h
 Context-specific networks of protein-protein interactions in M.tb.
GEO-sample Description
GSM28325 PBS Tween80 DMSO DMSO 6h
GSM28326 25 µg/mL CPZ+ 0.1mM GSNO DMSO
GSM28327 10 µg/mL menadione + 0.1mM GSNO DMSO
GSM28328 0.4mM NaN3 DMSO
GSM28329 4d Dubos NRP-1 Dubos aerobic log phase
GSM28330 25 µg/mL CPZ DMSO 6h
GSM28331 0.1mM GSNO DMSO 4h
GSM28332 5 µg/mL Clofazimine + 0.1mM GSNO DMSO
GSM28333 0.4mM NaN3 DMSO 4h
GSM28334 25 µg/mL CPZ DMSO 6h
GSM28335 6 µg/mL Menadione DMSO 6h
GSM28336 25 µg/mL CPZ + 0.1mM GSNO DMSO
GSM28337 6 µg/mL Menadione + 0.1mM GSNO DMSO
GSM28338 2mM NaN3 DMSO 6h
GSM28339 2mM ZnSO4 DMSO 6h
GSM28340 25 µg/mL CPZ + 0.1mM GSNO DMSO
GSM28341 5 µg/mL Clofazimine + 0.1mM GSNO DMSO
GSM28342 0.1mM GSNO DMSO 3.5h
GSM28343 0.2mM NaN3 DMSO
GSM28344 25 µg/mL CPZ + 0.1mM GSNO DMSO
GSM28345 10 µg/mL menadione + 0.1mM GSNO DMSO
GSM28346 0.4mM NaN3 DMSO
GSM28347 25 µg/mL CPZ DMSO 6h
GSM28348 1mM DTT DMSO 6h
GSM28349 2mM NaN3 DMSO 6h
GSM28350 50µM Nigericin DMSO 6h
GSM28351 10 µg/mL menadione DMSO 6h
GSM28352 0.1mM GSNO DMSO 6h
GSM28353 5 µg/mL Clofazimine + 0.1mM GSNO DMSO
GSM28354 25 µg/mL CPZ + 0.1mM GSNO DMSO
GSM28355 10 µg/mL Menadione + 0.1mM GSNO DMSO
GSM28356 PBS Tween 7H9
Table 4.1: GEO samples discarded
4.5.2 Layers dictionary
Once filtered the useful information at hand, we have algorithmically grouped samples
constituting repetitions of the same experiments, so as to reconstruct one version (or
layer) of the original PPIN for each experiment. In the following table, we enlist those
layers (NA means that, for that experiment, no link passed the significance test):
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GSE14840 V14 24 hour phosphate starvation CDC1551 ION DEPRIVATION PHOSPHATE
GSE14840 V15 72 hour phosphate starvation CDC1551 ION DEPRIVATION PHOSPHATE
GSE8732 V97 inversion Comparison between
iron-sufficient(50 uM FeCl3)
and iron-deficient (2 uM
FeCl3) grew conditions
H37Rv ION DEPRIVATION IRON
GSE1642 NA 100uM Dipyridyl control 6h H37Rv ION DEPRIVATION IRON SCAV-
ENGERS
GSE1642 NA 200uM Dipyridyl control 6h H37Rv ION DEPRIVATION IRON SCAV-
ENGERS
GSE1642 V34 150uM Deferoxamine control
6h
H37Rv ION DEPRIVATION IRON SCAV-
ENGERS
GSE1642 V38 WT t=0h WT t=6h in TBST H37Rv RESPIRATION AR-
REST
NUTRIENT
STARVATION
GSE1642 NA Minimal medium (Succinate)
7H9-based medium
H37Rv MINIMAL MEDIUM MINIMAL
MEDIUM
GSE1642 NA 20mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE1642 NA 20mJ cm2 UV control (8h)
H37Rv
H37Rv DNA DAMAGE UV
GSE1642 NA 20mJ cm2 UV control (12h)
H37Rv
H37Rv DNA DAMAGE UV
GSE1642 NA 25mJ cm2 UV control (2h) H37Rv DNA DAMAGE UV
GSE1642 NA 25mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE1642 NA 40mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE1642 V35 40mJ cm2 UV control (8h)
H37Rv
H37Rv DNA DAMAGE UV
GSE1642 NA 40mJ cm2 UV control (12h)
H37Rv
H37Rv DNA DAMAGE UV
GSE1642 NA 60mJ cm2 UV control (2h) H37Rv DNA DAMAGE UV
GSE1642 NA 60mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE1642 NA 4mM H2O2 control (1h) H37Rv OXIDATIVE STRESS H2O2
GSE1642 V36 4mM H2O2 control (2h) H37Rv OXIDATIVE STRESS H2O2
GSE1642 V37 4mM H2O2 control (4h) H37Rv OXIDATIVE STRESS H2O2
GSE1642 NA 4mM H2O2 control (8h)
H37Rv
H37Rv OXIDATIVE STRESS H2O2
GSE1642 NA 4mM H2O2 control (12h)
H37Rv
H37Rv OXIDATIVE STRESS H2O2
GSE365 NA 20mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE365 NA 20mJ cm2 UV control (8h) H37Rv DNA DAMAGE UV
GSE365 NA 20mJ cm2 UV control (12h) H37Rv DNA DAMAGE UV
GSE365 NA 25mJ cm2 UV control (2h) H37Rv DNA DAMAGE UV
GSE365 NA 25mJ cm2 UV control (4h) H37Rv DNA DAMAGE UV
GSE365 NA 25mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE365 NA 40mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE365 V86 40mJ cm2 UV control (8h) H37Rv DNA DAMAGE UV
GSE365 NA 40mJ cm2 UV control (12h) H37Rv DNA DAMAGE UV
GSE365 NA 60mJ cm2 UV control (2h) H37Rv DNA DAMAGE UV
GSE365 NA 60mJ cm2 UV control (4h) H37Rv DNA DAMAGE UV
GSE365 NA 60mJ cm2 UV control (6h) H37Rv DNA DAMAGE UV
GSE365 NA 4mM H2O2 control (1h) H37Rv OXIDATIVE STRESS H2O2
GSE365 V87 4mM H2O2 control (2h) H37Rv OXIDATIVE STRESS H2O2
GSE365 V88 4mM H2O2 control (4h) H37Rv OXIDATIVE STRESS H2O2
GSE365 NA 4mM H2O2 control (8h) H37Rv OXIDATIVE STRESS H2O2
GSE365 NA 4mM H2O2 control (12h) H37Rv OXIDATIVE STRESS H2O2
GSE16146 V19 MTB strain1254 vs MTB
strain 1254 for DETA NO exp
control
1254 OXIDATIVE STRESS DETA NO
GSE16146 V21 MTB strain 1254 control vs
0.005 mM DETA NO 40min
1254 OXIDATIVE STRESS DETA NO
GSE16146 V22 MTB strain 1254 control vs
0.05 mM DETA NO 40min
1254 OXIDATIVE STRESS DETA NO
GSE16146 V24 MTB strain 1254 control vs 0.5
mM DETA NO 40min
1254 OXIDATIVE STRESS DETA NO
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GEO-serie Code Description Strain Type of environment Subtype
GSE16146 V27 MTB strain 1254 control vs 1.0
mM DETA NO 40min
1254 OXIDATIVE STRESS DETA NO
GSE16146 V30 MTB strain 1254 control vs 5.0
mM DETA NO 40min
1254 OXIDATIVE STRESS DETA NO
GSE16146 V25 MTB strain 1254 control vs 0.5
mM DETA NO 4hrs
1254 OXIDATIVE STRESS DETA NO
GSE16146 V20 MTB strain 1254 vs MTB
strain 1254 for H2O2 exp con-
trol
1254 OXIDATIVE STRESS H2O2
GSE16146 V23 MTB strain 1254 control vs
0.05 mM H202 40min
1254 OXIDATIVE STRESS H2O2
GSE16146 V26 MTB strain 1254 control vs 0.5
mM H202 40min
1254 OXIDATIVE STRESS H2O2
GSE16146 V31 MTB strain 1254 control vs 5.0
mM H202 40min
1254 OXIDATIVE STRESS H2O2
GSE16146 V28 MTB strain 1254 control vs
10.0 mM H202 40min
1254 OXIDATIVE STRESS H2O2
GSE16146 V33 MTB strain 1254 control vs
50.0 mM H202 40min
1254 OXIDATIVE STRESS H2O2
GSE16146 V29 MTB strain 1254 control vs
200 mM H202 40min
1254 OXIDATIVE STRESS H2O2
GSE16146 V32 MTB strain 1254 control vs 5.0
mM H202 4hr
1254 OXIDATIVE STRESS H2O2
GSE8839 V116 merged MTB1254 Day 0 1254 OXIDATIVE STRESS OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V117 mergedMTB1254 Day 0 vs low
Oxygen Day 4
1254 OXIDATIVE STRESS OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V130 merged MTB strain 1254 con-
trol vs 2hr Hypoxia
1254 OXIDATIVE STRESS HYPOXIA
GSE8839 V115 merged H37Rv control vs 0,05
mM DETA NO 40min
H37Rv OXIDATIVE STRESS DETA NO
GSE8839 V114 merged CDC1551 control vs
0,05 mM DETA NO 40 min
CDC1551 OXIDATIVE STRESS DETA NO
GSE8839 V118 merged MTB strain 1254 con-
trol vs 0,005 mM DETA NO
40min
1254 OXIDATIVE STRESS OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V119 merged MTB strain 1254 con-
trol vs 0,05 mM DETA NO
40min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V129 merged MTB strain 1254 con-
trol vs 1,0 mM DETA NO
40min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V131 merged MTB strain 1254 con-
trol vs 5,0 mM DETA NO
40min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V127 merged MTB strain 1254 con-
trol vs 0,5 mMDETA NO 5min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V122 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO
20min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V126 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO
40min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V121 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO 1hr
1254 OXIDATIVE STRESS DETA NO
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GSE8839 V125 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO 2hrs
1254 OXIDATIVE STRESS DETA NO
GSE8839 V128 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO 8hrs
1254 OXIDATIVE STRESS DETA NO
GSE8839 V120 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO
16hrs
1254 OXIDATIVE STRESS DETA NO
GSE8839 V123 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO
24hrs
1254 OXIDATIVE STRESS DETA NO
GSE8839 V124 merged MTB strain 1254 con-
trol vs 0,5 mM DETA NO
24hrs + 0,5 mM DNO 40min
1254 OXIDATIVE STRESS DETA NO
GSE8839 V132 merged MTB strain 1254 con-
trol vs high aeration
1254 OXIDATIVE STRESS OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V133 merged MTB strain 1254 con-
trol vs high aeration + 0,001
mM DETA NO
1254 OXIDATIVE STRESS DETA NO
GSE8839 V134 merged MTB strain 1254 con-
trol vs high aeration + 0,005
mM DETA NO
1254 OXIDATIVE STRESS DETA NO
GSE8839 V135 merged MTB strain 1254 con-
trol vs high aeration + 0,01
mM DETA NO
1254 OXIDATIVE STRESS DETA NO
GSE8839 V136 merged MTB strain 1254 con-
trol vs high aeration + 0,05
mM DETA NO
1254 OXIDATIVE STRESS DETA NO
GSE8839 V137 merged MTB strain 1254 con-
trol vs low aeration (0,2% oxi-
gen 2hr
1254 DORMANCY
MODEL OX STRESS
OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V138 merged MTB strain 1254 con-
trol vs low aeration + 0,001
mM DETA NO
1254 DORMANCY
MODEL OX STRESS
OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V139 merged MTB strain 1254 con-
trol vs low aeration + 0,005
mM DETA NO
1254 DORMANCY
MODEL OX STRESS
OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V140 merged MTB strain 1254 con-
trol vs low aeration + 0,01 mM
DETA NO
1254 DORMANCY
MODEL OX STRESS
OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8839 V141 merged MTB strain 1254 con-
trol vs low aeration + 0,05 mM
DETA NO
1254 DORMANCY
MODEL OX STRESS
OXIDATIVE
STRESS
AND RES-
PIRATION
ARREST
GSE8689 V96 Exposed to Diamide 5 mM
H37Rv wild type
H37Rv OXIDATIVE STRESS DIAMIDE
GSE15976 V16 H37Rv wild type Vs H37Rv
wild type
H37Rv CELL WALL DAM-
AGE
SDS
GSE15976 V17 H37Rv wild type control vs
0.05% SDS for 60 min
H37Rv CELL WALL DAM-
AGE
SDS
GSE15976 V18 H37Rv wild type control vs
5mM Diamide for 60 min
H37Rv OXIDATIVE STRESS DIAMIDE
GSE6750 V94 Rv-Control vs Rv-SDS treated H37Rv CELL WALL DAM-
AGE
SDS
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GSE8664 V95 Exposed to 0.05% SDS H37Rv
wild type
H37Rv CELL WALL DAM-
AGE
SDS
GSE50159 V89 WT 140 mM NaCl CDC1551 CELL WALL DAM-
AGE
NACL
GSE10391 V1 MS1 D01 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V2 MS1 D02 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V3 MS1 D03 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V4 MS1 D06 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V5 MS1 D12 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V6 MS2 D03 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V7 MS2 D09 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V8 MS2 D18 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V9 MS3 D03 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V10 MS3 D09 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE10391 V11 MS3 D18 H37Rv DORMANCY
MODEL HYPOXIA
RESPIRATION
ARREST
LOW PH AND
GLYCEROL
DEPRIVED
GSE5977 V90 Mtb late-log phase H37Rv RESPIRATION AR-
REST
STACIONARY
PHASE
GSE5977 V91 Mtb stationary phase H37Rv RESPIRATION AR-
REST
STACIONARY
PHASE
GSE21590 V74 H37Rv 1hour reareation H37Rv RESPIRATION AR-
REST
REAREATION
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GSE21590 V76 H37Rv 4hour reareation H37Rv RESPIRATION AR-
REST
REAREATION
GSE21590 V77 H37Rv 6hour reareation H37Rv RESPIRATION AR-
REST
REAREATION
GSE21590 V73 H37Rv 12hour reareation H37Rv RESPIRATION AR-
REST
REAREATION
GSE21590 V75 H37Rv 24hour reareation H37Rv RESPIRATION AR-
REST
REAREATION
GSE8786 V98 Growth curve 0 days Control H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V102 Growth curve 6 days Control H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V103 Growth curve 8 days Control H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V99 Growth curve 14 days Control H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V100 Growth curve 24 days Control H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V101 Growth curve 60 days Control H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V109 oxygen-depleted Wayne
Growth 4 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V110 oxygen-depleted Wayne
Growth 6 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V112 oxygen-depleted Wayne
Growth 8 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V104 oxygen-depleted Wayne
Growth 10 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V105 oxygen-depleted Wayne
Growth 12 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V106 oxygen-depleted Wayne
Growth 14 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V107 oxygen-depleted Wayne
Growth 20 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V108 oxygen-depleted Wayne
Growth 30 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE8786 V111 oxygen-depleted Wayne
Growth 80 days
H37Rv RESPIRATION AR-
REST
WAYNE
GROWTH
GSE9331 V145 H37Rv hypoxia 4hr H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE9331 V147 H37Rv hypoxia 8hr H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE9331 V142 H37Rv hypoxia 12hr H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE9331 V143 H37Rv hypoxia 1day H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE9331 V144 H37Rv hypoxia 4day H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE9331 V146 H37Rv hypoxia 7day H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE8829 V113 Hypoxic conditions experiment
of MTB wild type
H37Rv RESPIRATION AR-
REST
HYPOXIA
GSE13978 V13 MTB - cholesterol 3hrs H37Rv CHOLESTEROL CHOLESTEROL
GSE13978 V12 MTB - cholesterol 24hrs H37Rv CHOLESTEROL CHOLESTEROL
GSE6209 V93 H37Rv 4hrs after infection in
Mφ vs. H37Rv grown in 7H9
media biological 4h
H37Rv GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE6209 V92 H37Rv 24hrs after infection in
Mφ vs. H37Rv grown in 7H9
media biological 24h
H37Rv GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V78 14-day resting Mφ infection
2hr
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
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GSE35362 V82 14-day resting Mφ infection
Day 2
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V83 14-day resting Mφ infection
Day 4
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V84 14-day resting Mφ infection
Day 6
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V85 14-day resting Mφ infection
Day 8
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V79 14-day resting Mφ infection
Day 10
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V80 14-day resting Mφ infection
Day 12
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE35362 V81 14-day resting Mφ infection
Day 14
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V55 merged H37Rv extra vs intra-
cellular in resting Mφs
H37Rv GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V39 merged CDC1551 extra vs in-
tracellular in resting Mφs
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V40 merged Clinical isolate 10514-
01 Afri2 extra vs intracellular
in resting Mφs
AFRI2 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V41 merged Clinical isolate 10517-
01 Afri2 extra vs intracellular
in resting Mφs
AFRI2 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V52 merged Clinical isolate 5468-02
Afri2 extra vs intracellular in
resting Mφs
AFRI2 GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V53 merged Clinical isolate 947-01
EAI extra vs intracellular in
resting Mφs
EAI GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V44 merged Clinical isolate 1797-03
EAI extra vs intracellular in
resting Mφs
EAI GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V51 merged Clinical isolate 4850-03
EAI extra vs intracellular in
resting Mφs
EAI GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V42 merged Clinical isolate 12954-
03 Beijing extra vs intracellular
in resting Mφs
BEIJING GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V43 merged Clinical isolate 1500-03
Beijing extra vs intracellular in
resting Mφs
BEIJING GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V45 merged Clinical isolate 1934-03
Beijing extra vs intracellular in
resting Mφs
BEIJING GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V46 merged Clinical isolate 2169-99
Uganda extra vs intracellular
in resting Mφs
UGANDA GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V47 merged Clinical isolate 2191-99
Uganda extra vs intracellular
in resting Mφs
UGANDA GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V48 merged Clinical isolate 2333-99
Uganda extra vs intracellular
in resting Mφs
UGANDA GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
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GSE21112 V49 merged Clinical isolate 2336-02
Haarlem extra vs intracellular
in resting Mφs
HAARLEM GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V50 merged Clinical isolate 4130-02
Haarlem extra vs intracellular
in resting Mφs
HAARLEM GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21112 V54 merged Clinical isolate 9532-03
Haarlem extra vs intracellular
in resting Mφs
HAARLEM GRANULOMA MOD-
EL/REAL INFEC-
TION
RESTING
MACROPHAGE
GSE21113 V72 merged H37Rv extra vs intra-
cellular in activated Mφs
H37Rv GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V56 merged CDC1551 extra vs in-
tracellular in activated Mφs
CDC1551 GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V69 merged Clinical isolate 5468-02
Afri2 extra vs intracellular in
activated Mφs
AFRI2 GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V57 merged Clinical isolate 10514-
01 Afri2 extra vs intracellular
in activated Mφs
AFRI2 GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V58 merged Clinical isolate 10517-
01 Afri2 extra vs intracellular
in activated Mφs
AFRI2 GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V61 merged Clinical isolate 1797-03
EAI extra vs intracellular in
activated Mφs
EAI GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V68 merged Clinical isolate 4850-03
EAI extra vs intracellular in
activated Mφs
EAI GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V70 merged Clinical isolate 947-01
EAI extra vs intracellular in
activated Mφs
EAI GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V59 merged Clinical isolate 12954-
03 Beijing extra vs intracellular
in activated Mφs
BEIJING GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V60 merged Clinical isolate 1500-03
Beijing extra vs intracellular in
activated Mφs
BEIJING GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V62 merged Clinical isolate 1934-03
Beijing extra vs intracellular in
activated Mφs
BEIJING GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V63 merged Clinical isolate 2169-99
Uganda extra vs intracellular
in activated Mφs
UGANDA GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V64 merged Clinical isolate 2191-99
Uganda extra vs intracellular
in activated Mφs
UGANDA GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V65 merged Clinical isolate 2333-99
Uganda extra vs intracellular
in activated Mφs
UGANDA GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V66 merged Clinical isolate 2336-02
Haarlem extra vs intracellular
in activated Mφs
HAARLEM GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V67 merged Clinical isolate 4130-02
Haarlem extra vs intracellular
in activated Mφs
HAARLEM GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
GSE21113 V71 merged Clinical isolate 9532-03
Haarlem extra vs intracellular
in activated Mφs
HAARLEM GRANULOMA MOD-
EL/REAL INFEC-
TION
ACTIVATED
MACROPHAGE
Table 4.2: Dictionary of samples used.
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For some series, we analized them, but it resulted that no sample within them
contained any significant interaction. These were GSE8827, GSE10336, GSE14005,
GSE15642, GSE32236 and GSE34363.
4.5.3 layers ordering in figures 4.2 and 4.3
In the following table we list the position of each of the listed layers in dendrograms
represented in figures 4.2 and 4.3:
Position (from left) Figure 4.2 Figure 4.3
1 V78 V13
2 V80 V92
3 V81 V93
4 V82 V84
5 V79 V79
6 V83 V85
7 V84 V83
8 V85 V82
9 V44 V81
10 V49 V80
11 V54 V78
12 V55 V54
13 V45 V48
14 V53 V43
15 V40 V50
16 V52 V49
17 V39 V45
18 V47 V42
19 V46 V47
20 V42 V55
21 V43 V46
22 V50 V53
23 V48 V39
24 V51 V40
25 V57 V41
26 V58 V52
27 V69 V51
28 V70 V44
29 V63 V62
30 V64 V59
31 V67 V60
32 V65 V65
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33 V62 V71
34 V68 V64
35 V61 V63
36 V72 V67
37 V60 V66
38 V66 V72
39 V71 V70
40 V59 V68
41 V56 V56
42 V41 V61
43 V74 V69
44 V76 V58
45 V75 V57
46 V73 V76
47 V77 V74
48 V93 V113
49 V92 V12
50 V12 V77
51 V87 V73
52 V36 V75
53 V88 V137
54 V37 V132
55 V86 V97
56 V35 V107
57 V124 V108
58 V25 V101
59 V120 V111
60 V123 V99
61 V128 V100
62 V141 V102
63 V30 V103
64 V131 V110
65 V24 V112
66 V27 V104
67 V129 V105
68 V122 V106
69 V126 V109
70 V121 V117
71 V125 V145
72 V127 V144
73 V114 V146
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Position (from left) Figure 4.2 Figure 4.3
74 V22 V143
75 V119 V142
76 V139 V147
77 V140 V91
78 V130 V90
79 V115 V5
80 V136 V6
81 V133 V7
82 V134 V4
83 V135 V1
84 V138 V2
85 V33 V3
86 V29 V8
87 V32 V10
88 V31 V9
89 V28 V11
90 V18 V96
91 V96 V28
92 V94 V31
93 V17 V95
94 V95 V17
95 V147 V94
96 V142 V18
97 V143 V33
98 V146 V29
99 V144 V32
100 V145 V141
101 V117 V140
102 V109 V136
103 V105 V115
104 V104 V139
105 V106 V130
106 V112 V135
107 V110 V133
108 V113 V138
109 V108 V134
110 V107 V119
111 V101 V22
112 V103 V114
113 V102 V125
114 V100 V121
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Position (from left) Figure 4.2 Figure 4.3
115 V99 V126
116 V90 V122
117 V5 V24
118 V7 V131
119 V6 V30
120 V10 V129
121 V8 V27
122 V11 V128
123 V9 V123
124 V3 V120
125 V2 V25
126 V1 V124
127 V4 V127
128 V91 V35
129 V89 V86
130 V13 V37
131 V97 V88
132 V132 V36
133 V137 V87
134 V19 V89
135 V21 V14
136 V118 V15
137 V34 V19
138 V38 V21
139 V98 V118
140 V116 V34
141 V16 V38
142 V20 V98
143 V23 V116
144 V26 V16
145 V14 V20
146 V15 V23
147 V111 V26
Table 4.3: Layers’ positions in figures 4.2 and 4.3
4.5.4 Assignation to environment classification to stresses
In order to construct our consensus stress-response layers we have assigned some of the
experiments of our original multi-layer network to each one of the six stress-related con-
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Consensus layer Environmental subtype (see table 4.2)
Hypoxia Hypoxia
Starvation Stationary phase
Starvation Nutrient starvation
Hypoxia Reareation
Hypoxia Wayne growth (hypoxia model)
Cell wall damage Surfactants
Cell wall damage SPHEROPLAST INDUCED
Cell wall damage NACL
Cell wall damage SDS
Ions deprivation Phosphate deprivation
Ions deprivation Iron scavengers
Ions deprivation Iron
NO exposure DETA-NO
Oxidative stress H2O2
Oxidative stress Diamide
Starvation Minimal medium
Table 4.4: Sub-types of experiments associated to layers in the stress response multi-layer
system
sensus layers. In the following table, we list the environmental subtypes, as annotated
in table 4.2 that joins each consensus layer:
Part III
Transcriptional regulatory networks:
analysis and data reliability
No tengo a quién rezarle
pidiendo luz.
Ando tanteando
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Jorge Drexler.
Hermana Duda, en 12 segundos de Oscuridad, 2006.

 Topological effects of data incompleteness of gene regulatory networks
Chapter 5
Topological effects of data incompleteness of
gene regulatory networks
5.1 Background
In the second part of this thesis we undertook the study of different networks of bio-
molecular interactions ofMTB. Specifically, on the one hand we characterized the trans-
formations that take place on its PPIN as a consequence of transcriptional adaptation
to different environmental conditions. On the other hand we compiled and analyzed
a bibliography-based, updated version of the genome-wide TRN of the bacterium. In
what regards this last system, despite the systematic character of the bibliographic
revision made, current knowledge about MTB transcriptomics is only partial, and so,
as it has already been mentioned, genes included in the network hardly cover the 40%
of the genome. Additionally, the specific methodologies after which experimental ev-
idence is considered enough to endorse the presence of a given interaction are highly
heterogeneous, and certain link attributes -specifically signs- can not always be derived
from them.
In this third part of the thesis, our intention is that of addressing the reach of this
inherent data incompleteness of diverse nature that appears in TRNs; and its affection
on the outcomes of different topological analysis methods typically performed in the
field. In order to do so, we analyze the TRN of MTB, previously curated by ourselves
[3], and compare it to two of the best known prokaryotic TRNs: those of the model
bacteria Escherichia coli [314] and Bacillus subtilis [315].
Specifically, the general question we set to answer here is whether robust and biolog-
ically relevant conclusions about TRNs can be reached given the current incompleteness
of the data, going a step further with respect to other works that had somehow ad-
dressed this question previously [317]. Besides, we also show that some topological
metrics do depend on the level of detail incorporated in TR maps, in particular, the
structure of the mesoscale. Our findings show that extreme care should be taken when
strong claims are made based on partial data. This is the case of TRNs superfamilies,
which we argue are indeed grouped into a single class.
5.2 Community detection and link attributes
The identification of modules in complex networks has attracted much attention of the
scientific community in the last years. A modular view of a network offers a coarse-
grained perspective in which nodes are gathered not due to knowledge-based decisions
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–function, composition, etc.–, but rather on a topological basis –who is connected to
whom. To this end Newman put forward the concept of modularity Q [36], which
quantifies how far a certain partition is from a random counterpart. From this defini-
tion, algorithms and heuristics to optimize modularity (Q) have appeared ever faster
and more efficient [318], and generalizations to directed, weighted and signed networks
are also available in the literature [319, 320]. All these efforts have led to a consider-
able success regarding the quality of detected community structure in networks, and
thus a more complete topological knowledge at this level has been attained. Behind
this interest underlies the intuition that the relation between network structure and
dynamics is strongly mediated by the mesoscale, and that community structure plays
a central role in network formation and functioning. And yet, with few exceptions, link
attributes are seldom taken into account.
In this section we intend to underline that interaction direction and sign critically
shape the detected community structure of a network. This is even more dramatic in
the case of TRNs, where a sharp distinction must be made between regulators (which
mostly emit links) and the rest of the network, which mainly receives them. Also it is
peculiar (though not exclusive) of these systems to allow for positive (activating) and
negative (inhibitory) relationships. In practice, directions and signs are not always
available in the datasets. Regarding directionality, we analyze a system –the TRN
of MTB [3]– for which that is not an actual problem, as regulatory proteins are well
identified, i.e. their function as link sources is known. Nevertheless, there are many
cases of organisms whose regulatory pathways have not been explicitly identified, and
in those cases the real topology is usually replaced by a co-expression network, which
acts as an undirected proxy for the true underlying regulatory structure. Unavailability
of interaction signs is, on the other hand, a more persistent problem: there exist many
experimental approaches to infer a transcriptional regulation that do not inform about
the sign of the interaction. Furthermore, there are interaction signs which depend
on environmental conditions. Therefore, given the unavoidable incompleteness of the
data, we explore whether link attributes determine the network modular structure, and
to what extent.
To address the previous question, we perform a systematic comparison of the effects
of preserving the original information (sign and direction) in modularity measures and
community structure in TRNs. To this end, we will analyze the TRN of MTB [3],
for which we will consider three different topologies: one that preserves all available
information (directed-signed, DS); an intermediate one (preserving directions, but not
signs –directed-unsigned, DU); and a last one where all fine-grained information is
ignored (undirected-unsigned, UU). From the output of this analysis, we provide a way
to quantify how much biological information is lost when directions and/or signs are
dropped out. Note that the three versions of the network have the same number of
nodes N and number of links L, the only differences being those regarding direction
and/or the sign of the interactions. Interaction signs have been compiled from the
experimental works enlisted in [3], although signs were not reported there (see [279]).
The modularity expression used hereafter corresponds to its most general definition,
i.e. the one that accounts for the existence of directions, weights, signed relations and
 Topological effects of data incompleteness of gene regulatory networks
self-loops, preserving the original information [320]:
Q =
w+
w+ + w−
Q+ − w
−
w+ + w−
Q− (5.1)
This expression generalizes the concept of modularity, and simply computes the
contribution to group formation of positive (w+) and negative (w−) interactions sep-
arately, Q+ and Q− respectively, which can be interpreted as the tendency to form
communities (positive weights) and that of negative weights to dissolve them. For
more detail, Q+ is defined as
Q+ =
1
2w+
∑
i
∑
j
(
w+ij −
w+i w
+
j
2w+
)
)
(5.2)
which accounts for the deviation of actual positive weights w+ij against a null case ran-
dom network; the negative counterpart Q− is defined accordingly, just placing negative
weights in the expression. As for our current object of study, links in the network can
only take values +1 or -1, and are originally defined as directed.
An intrinsic limitation of modularity maximization, as posed in Eq. 5.1, is that it
provides a single snapshot of the modular structure of the network. However, several
topological descriptions of the network coexist at different scales, which is, in general,
a fingerprint of complex systems, and particularly relevant in biological ones [321]. A
method to overcome this fundamental drawback of typical modularity optimization was
put forth in [319]. A parameter r is introduced as a constant self-loop to each node,
thus changing the total strength in a network and avoiding the inherent resolution
limit of Newman’s modularity Q [322]. The shift only affects the property of each
node individually and in the same way for all of them. Thus, the original adjacency
matrix A is changed as a function of r: Ar = A+ Ir. The interesting property of the
rescaled topology is that its characteristic scale in terms of modularity has changed.
Then the topological structure revealed by optimizing the modularity for Ar is that of
large groups for small values of r, and smaller groups for large values of r, all of which
are strictly embedded in the original topology. As an example, the method can uncover
each significant resolution level in the well-known synthetic hierarchical network model
RB [323], see Figure one in [319]. To perform these costly calculations we have used a
mixture of heuristics, including extremal optimization and Newman’s fast algorithm,
as implemented in [324].
Figure 1 (top) represents the number of modules Nc that a combination of Q-
maximization heuristics [324] has detected for the three versions of the TRN of MTB.
Each topology has been scrutinized at different scales, screening the parameter r for
200 possible values, in a range such that it yielded an interpretable amount of modules.
This range changes for different topologies, thus r is normalized in the plot to allow
for comparison. On visual inspection it is apparent that the three topologies present
plateaus, where different r values yield similar partitions in terms of Nc. This indicates
that certain topological scales are robust and persistent, which might be a clue to
identify functionally relevant groups of nodes [319]. Notably, the UU topology presents
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a single plateau at Nc = 205 and then fails to stabilize for larger r’s. On the contrary,
DU and DS, which retain more information, yield stable partitions at many levels.
Although for different r values, these topologies exhibit almost the same behavior
regarding plateaus and the number of communities Nc these plateaus present. At this
point, one can say that the mesoscale analysis for DU and DS networks allows a richer
interpretation in terms of the grouping of nodes, but there is no way to confirm if these
are more or less biologically sound, than, for example, the UU topology.
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Figure 5.1: Top: number of detected modules Nc as a function of the normalized rescaling
parameter r. The mesoscale has been screened only for a range of r yielding an interpretable
amount of modules. DU and DS topologies show more than one persistent mesoscopic plateau,
whereas the UU topology only has a single plateau made up of around Nc ≈ 200 communities.
Beyond r = 0.5, no other stable plateau can be found for this topology. Bottom: the detected
community structures for the three versions of the TRN of MTB are compared to the func-
tional partitions in Tuberculist [325]. DS is the only network that shows significant values of
similarity, in terms of the Asymmetric Wallace Index, against the functional partition for a
large range of r values.
To address this last question, we asked whether the partitions inferred by our
method group genes with similar biological functions. The reason underlying this
possibility is that genes within a topological community are connected among them
by more regulations than average. This fact should imply that they tend to transcript
together, as a response to common stimuli and eventually, to perform closely related
functions. To do this, we compared the identified communities to the functional classi-
fication provided in the Tuberculist database [325]. There are many metrics and indices
to compare two clusterings [326, 327, 328, 329, 330]. However, we need to rely on an
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index that does not severely punish different resolution scales: our reference partition
categorizes genes in only NFc = 7 groups, which yields a coarse-grained functional
classification of the genome of MTB. We note that, for the comparison between topo-
logical partitions and functional classification, only genes belonging to truly structural
functions have been considered. So, “conserved hypotheticals” and “unknown” genes
have been excluded, as well as genes with regulatory roles (“regulatory proteins” and
“information pathways” genes), which are expected to join transversally the TRN. Any
partition with significantly more modules will show low resemblance to the functional
one if the index is biased toward literally similar partitions. Thus, we present our
results using the Asymmetric Wallace Index AW , which shows the inclusion of a parti-
tion into the other. The Asymmetric Wallace Index [331] is the probability that a pair
of elements in one cluster of partition A is also in the same cluster of partition B. Let
be a clustering A with cA communities and a clustering B with cB communities, and
let us define the confusion matrix M whose rows correspond to the communities of the
first clustering (A) and columns correspond to the communities of the second clustering
(B). Let the elements of the confusion matrix, Mαβ, represent the number of common
nodes between community α of the clustering A and community β of the clustering B;
the partial sums being Mα· =
∑
βMαβ and M·β =
∑
αMαβ. Then, AWA,B (how much
partition A is embedded in B) is defined as follows:
AWA,B =
cA∑
α=1
cB∑
β=1
Mαβ(Mαβ − 1)
cA∑
α=1
Mα(Mα − 1)
. (5.3)
The Asymmetric Wallace index can also be defined the other way around (AWB,A),
but in this case this is not considered, because detected partitions are systematically
more divisive than the functional one, i.e. we are interested in seeing how detected
partitions are embedded in the functional one.
Figure 1 (bottom) shows the results for the proposed scheme. Initial results (early
r) for the UU and DS networks are artificially high, because Nc < NFc . Besides this, the
plot indicates that only the partitions obtained from the DS topology are significantly
similar to the functional one. In fact, beyond the initial stages of the resolution levels,
both DU and UU’s community structures are far from being embedded in the functional
categorization. Quite surprisingly, resolution levels with similar Nc do not entail similar
AWA,B values. For instance, the three topologies show at some point a plateau with
Nc ≈ 200. But AWUU,F ≈ 0.1, AWDU,F ≈ 0.2 and finally AWDS,F ≈ 0.5.
These results suggest that the more complete knowledge about link attributes, the
richer representation of the mesoscale, in which different levels of topological coarse-
graining can be well identified, with possible bio-dynamical implications that need to
be explored.
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5.3 Motifs significance robustness vs. network growth
Exhaustive search of topologically common footprints and systematic differences be-
tween different real systems constitutes an important topic in network theory since its
very beginning [332]. Along these lines, the classification of networks in families bring
light into the evolutionary principles that ultimately yield to the complex topologies
that real, evolving systems like TRNs show today [90]. In this sense, the work by Alon
and coworkers [267] constitutes a milestone.
In their work, the statistical significance of 3-nodes motifs –triads– was analyzed.
The number of appearances of each of the thirteen possible directed structures in real
systems was compared to those observed in a null model. The null ensemble was
constructed by randomly rewiring the links of the original networks, preserving the
number of single links and mutual interactions (as it is done in [267]). The statistical
significance of each motif h is then defined as the Z-score of its number of appearances
when compared to the results found in the null ensemble:
Zscoreh =
nh − 〈nrand,h〉
σrand,h
(5.4)
Therefore, computing the Zscore for all possible triads in a network yields a 13-
dimensional vector that, when normalized, represents the so-called triad significance
profile (TSP). From the analysis of different systems’ profiles, four superfamilies were
identified with common TSPs: two families of non-biological networks –semantic ad-
jacency words maps and social systems– and two families of biological, information
processing networks.
Regarding the two biological networks superfamilies originally identified, TRNs
of three unicellular organisms were found to conform the first one: yeast, B.subtilis
and E.coli. In Figure 2, panel A, we plot the TSPs that belong to two of the four
datasets analyzed by the authors in their original work: yeast [333] and E.coli (available
at the authors’ web site [313]). The second group contains developmental TRNs of
eukaryotic cells belonging to pluricellular organisms, signal transduction maps and
synaptic networks. In Figure 2, panel B, the TSP of the synaptic wiring map of
the nematode C.elegans [334] is plotted, as an example of this second superfamily,
evidencing the differences with respect to panel A.
The biological interpretation of the emergence of the two superfamilies of TRNs
–or more generally, bio-information processing networks– proposed in [267] has to do
with the typical response times developed by each group of systems. These times are
similar to those of single interactions for the networks in the first group (rate-limited
networks) but remarkably greater than characteristic interaction times for the systems
within the second superfamily (unrate-limited networks).
The recent addition to this scheme of the TRN of MTB poses an intriguing ques-
tion. As it is visible to the naked eye in Figure 2 (panel B) its TSP, although belonging
to an unicellular organism, has a greater correlation with the representative of the
unrate-limited superfamily. The fact that MTB has these developmental-like topolog-
ical features at its TRN might be interpreted under a coherent biological picture [3].
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Figure 5.2: Panel A: E.coli (2004). TRN of E.coli as firstly published in [313, 269] (N = 423
operons, L = 519 regulations plus SL = 59 self-regulations). Yeast (2004) TRN of budding
yeast [262] (N = 688 genes, L = 1079 regulations [313, 335]). Panel B: C.elegans neural
network [334] (N = 279 neurons, L = 2990 synapses). MTB TRN [3] (N = 1624 genes, [336]
L = 3169 regulations plus SL = 43 self-regulations). Panel C: E.coli (2011). Updated TRN
of E.coli based on RegulonDB, release 7.2, dated on May, 2011 (N = 1037 operons, L = 2574
regulations plus SL = 113 self-regulations). B.subtilis (2011), updated TRN of B.subtilis,
based on DBTBS database [315], (accessed in October, 2011) (N = 814 operons, L = 1294
regulations plus SL = 80 self-regulations).
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The pathogen has an evolutive history tightly bound to its condition of a human in-
tracellular obligate parasite, which could eventually have caused an adaptation of the
bacterium to the rhythms and response dynamics of host cells. Indeed, certain stimuli,
like hypoxia, yield anomalously slow shifts in MTB gene expression patterns, which
can take as much as 80 days until stabilization [89].
The third panel in Figure 2 invalidates the previous hypothesis, and presents the
TSPs of the updated TRNs of two bacteria which were initially characterized as rate-
limited according to their TSPs. Visible at a glance, the update of the datasets has
shifted their TSPs from one superfamily to another, in a way that suggests that the
division of the information processing networks into two groups was an effect of data
incompleteness.
The key of the change observed in the TSPs stems from the small number of two
nodes feedback loops (FBLs) that are observed in unicellular organisms TRNs. In-
deed, this possibility was already foreseen in [267] (see footnote 12 there). When
FBLs are absolutely absent from the system under study, as the randomizing algo-
rithm preserves the number of them, FBLs will also be absent in the null ensemble.
This situation makes the Z-scores associated to triads 4, 5, 6, 9, 10, 11, 12 and 13
undefined, as in Figure 2, panel A. As time goes by, such cases have become obsolete:
new links have been discovered and added to the growing datasets, and some of them
generate FBLs, which are now present in the triads listed before. In the three updated
systems studied, we have found as many as 12 FBLs in E.coli TRN, 9 in B.subtilis
and 6 in MTB. The result, after the incorporation of these new FBLs, suppose that
the division between two superfamilies of biological information processing networks
according to their TSPs disappears, affecting the biological interpretation about the
eventual relationship between time responses and motifs statistics.
Beyond the discussion on the robustness of motifs statistics that is faced here with a
similar spirit of other previous works [317], much has been written about the eventually
deep biological implications of anomalous network motifs’ statistics as a ubiquitous,
topological property of gene regulatory networks. On the one hand, environmental
evolutionary adaptation has been claimed to lie underneath this ubiquitous topological
treat in gene regulatory circuits [275]. According to this point of view, different envi-
ronmental requirements could exert different evolutionary pressures to gene expression
dynamics which may be correlated to network‘s topologies at the level of motifs, each
of which is believed to offer different dynamical performances, as it has been observed
in several precise cases [275, 269, 337, 273]. Complementarily, recent theoretical studies
have addressed how functional, artificial networks required to drive different dynamical
functions yield divergent motifs contents [338].
However, as it has been stressed in several works, evolutionary pressures are not
the sole mechanism able to generate not-random statistics in networks motifs. Simple
models incorporating spatial distribution of nodes [339] or typical mechanisms of net-
work growth assimilable to those which drive gene-regulatory changes upon evolution-
ary time [340] have been found to generate network motifs without any evolutionary
pressure. Under this kind of interpretation, network motifs could appear, not as a
consequence of environmental adaptation but rather as a side-effect of some “intrin-
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sic constraints” related to typical mechanisms of genetic material transformation like
DNA fragments duplication, deletion, inversion etc [341]. Supporting this hypothesis,
a simple but powerful argument is often put forward: topological-bias at the level of
TRNs could hardly be a consequence of dynamics-based, natural selection, as in a vast
amount of cases transcriptional regulatory mechanisms constitute only one layer of
more complex regulatory pathways also coupling translational and post-translational
interactions, which are the ultimate responsible of the complex gene expression dynam-
ical patterns observed in the cell [342]. However, comparisons between motifs in gene
regulatory networks of different bacteria which should have suffered the effects of en-
tirely comparable “intrinsic constraints” yield slight “fine-tuning” differences in motifs
statistics that can be reasonably related to environmental adaptation [3].
In this chapter, we do not intend to introduce any additional argument in the de-
bate, which can hardly be considered closed. The reason may be that, as it has been
pointed elsewhere, intrinsic constraints and evolutionary pressures are not, definitely,
mutually exclusive mechanisms of network transformation [341], and to quantify the
relative relevance of each mechanism could result in even a harder task. Our main
purpose in this section is, however, to increase our understanding [317] about the
robustness of certain topological treats of gene regulatory networks against data in-
completeness, as well as to warn about how this analysis affects the network taxonomy
scheme proposed in [267].
5.4 Systematic correlations between topology and ex-
perimental evidence
Experimental techniques used in transcriptional regulation inference are numerous and
often subtle [343]. However, usual approaches can be grouped within two main cate-
gories. The first approach is based on the explicit detection of the physical protein-DNA
interaction between regulators and promoters of target genes. This presents the ad-
vantage that only direct operations of regulators on targets can be observed. However,
the existence of a protein-DNA interaction under certain in-vitro conditions does not
guarantee that it is physiologically relevant in terms of target expression levels.
The alternative approach is essentially based on the generation of mutant strains
in which the functionality and/or the expression levels of a certain binding factor are
significantly altered with respect to those of the wild type. Then, expression levels of
genes which are potentially regulated by the binding factor under study are registered
and compared between wild type and mutant strains. In this way, if these different
levels of regulator activity yield significantly different target expression measures, one
might assume that the regulator is actually acting on the target.
The main advantage of the latter approach is that the sign and strength of the
interaction can be determined. However, the analysis cannot distinguish direct reg-
ulatory interactions from indirect influences regulator-target mediated by secondary
regulatory pathways. Nonetheless, as it can be seen in Table 1, this second kind of
methods is responsible for the characterization of an important fraction of the links
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in our systems. Therefore, a relevant question is whether or not the appearance of
indirect, spurious links (as if they were real interactions) might suppose a systematic
error responsible of topological bias at a global level.
E.coli B.subtilis MTB
BA 914 499 726
TELC 1272 856 1290
WCLs 656 323 191
PCLs 1044 262 1344
Table 5.1: Number of links reported based upon binding assays (BA) or target expression
levels comparison (TELC). Well characterized links (WCLs) are those characterized at least
by one methodology of each group (for an exhaustive list of the experimental methods in each
group see [279]). Poorly characterized links (PCLs) are reported under methodologies that can
not be considered within neither of the two main groups (too generic methods, orthologies
based deductions, absence of experimental support etc.). Whilst B.subtilis and E.coli are
relatively well characterized systems, in order to get enough statistics for the MTB case, we
consider identification of consensus sequences as binding proofs.
These hypothetical spurious interactions should appear connecting nodes for which
a secondary regulation pathway exists, and its sign should be the same of that secondary
route (see Figure 3). So, in our networks, we can identify those “suspicious” links
(SLs) connecting nodes for which some secondary via has been already registered, and
verify for sign coherence. We will restrict our analysis to those secondary pathways
formed by a two-links cascade. The question is how we can know whether this subset
of SLs presents a higher rate of spurious links than on average. Indeed, among the
topologically SLs, only those that are characterized by at least one technique of each
methodological category –henceforth referred to as well-characterized links (WCLs)–,
can safely be considered as non-suspicious direct regulations.
Therefore, the idea is to compare the proportion of WCLs within and outside the
subset of topologically SLs using Fisher‘s exact test (see Table 2). As it can be seen,
SLs systematically present a slightly lower proportion of WCLs than non-SLs, which
could be associated to random fluctuations with respect to the average values with
probabilities lower than 2% in each of the systems, being remarkably lower in the case
of the TRN of E.coli.
E.coli B.subtilis MTB
WCLs No WCLs WCLs No WCLs WCLs No WCLs
SLs 104 628 43 188 11 252
No SLs 552 1285 280 774 180 2141
Ho p value < 10−17 Ho p value < 0.007 Ho p value < 0.019
Table 5.2: Null hypothesis Ho assumes that the proportion of WCLs is the same for SLs or
no-SLs. Only signed links are considered.
This indicates that SLs constitute a topologically defined subset of interactions
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Figure 5.3: Arrows represent activations and right angles inhibitions. Dotted lines corre-
spond to the links that are topologically suspicious, i.e., those for which a secondary regulatory
pathway mediated by a third gene is registered and whose sign is coherent. For example, the
link connecting nodes 1 and 2 is considered suspicious because of the existence of the pathway
1 to 3 and 3 to 2. The same happens for the link between nodes 3 and 4. In both cases, the
condition that the product of the two links making the secondary pathway should coincide
with that of the link being considered as suspicious is verified. In this sense, we have also
included a case in which the latter condition does not hold: the edge linking node 1 to node
5 is not suspicious because although a two-nodes cascade connecting the same nodes exists,
(i.e. 1 to 3 and 3 to 5) it is not sign coherent.
which is systematic and significantly less reliably characterized than on average in all
the systems under study. This observation is in agreement with the hypothesis that in-
sufficient experimental methods of transcriptional regulation inference can suppose the
systematical observation of topologically-biased spurious links. The problem addressed
here seems to critically affect the characterization of the activity of sigma factors. In
fact, when we reconstruct the networks under study by considering only transcription
factors as regulators and exclude sigma factors, the whole picture significantly changes.
Indeed, the percent of SLs which are better characterized is even greater than the back-
ground, both for B.subtilis (45.0% vs 42.2%) and for E.coli (46.0% vs 43.1%). For the
case of MTB, the analysis can be hardly conclusive due to the loss of statistics after
sigma factors removal (no WCL is located within the set of suspicious interactions,
now, less than 100 in the whole signed network). These findings, put together, suggest
that characterization of sigma factor regulons is more sensitive to the aforementioned
issues.
Another issue of interest is whether this experimental bias is topologically relevant.
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More precisely, we question if this systematic error could quantitatively affect motif
statistics in our systems. The key is that these spurious interactions could recurrently
transform some motifs into others, and more precisely, focusing on most prominent
motifs in number of appearances, this would suppose the systematic, spurious trans-
formation of three-nodes cascades (triad 3) into coherent feedforward loops (FFL, triad
7). To test the robustness of the TSPs to the presence of spurious links, we delete in
each network a fraction of partially characterized SLs up to the point in which the
proportion of WCLs among them is comparable to the average background level. This
suppose the removal of 324 SLs in the TRN of E.coli, 59 in the TRN of B.subtilis
and 114 for the MTB case. The links to be deleted are randomly chosen within the
set of partially characterized SLs. Finally, we recalculate the Zscores of all the motifs
and compare TSPs with their original values. The results of this process are shown
in Table 3, where it can be seen that the statistical significance of cascades and FFLs
are systematically affected. The interesting fact is that, after the correction, cascades
are yet significantly underrepresented while FFLs as a whole (i.e. independently of the
signs) continue to appear much more frequently than expected by random. Obviously,
the Zscore associated to the other triads also varies. But the striking point is that,
after normalization, in all the systems the effect of the correction on the TSPs are very
limited, as we can see in Figure 4. So, the conclusion is that this kind of systematic
error, although modifying the absolute values of motifs’ Zscores, does not affect their
ratios that are recovered after normalizing the TSPs.
E.coli B.subtilis MTB
Cascade (original) −4.7± 0.2 −6.9± 0.4 −2.2± 0.1
Cascade (corrected) −2.9± 0.4 −6.9± 0.8 −1.1± 0.3
FFL (original) 4.7± 0.2 6.9± 0.4 2.2± 0.1
FFL (corrected) 2.5± 0.7 7.0± 0.8 1.1± 0.3
Table 5.3: Changes in the Zscores of cascades and FFLs due to systematic mischaracterization
of Sls.
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Figure 5.4: Original systems present a lower proportion of WCLs than the background in
the set of links that connect nodes for which a secondary coherent regulatory pathway has
been registered. In corrected networks, the proportion of WCLs is paired to background levels
by randomly deleting poorly characterized interactions. This, however, do not affect the TSPs
significantly
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5.5 Conclusions
As we have shown here, sources of unreliability can be of diverse nature: from the
often unjustified lack of details in link attributes to the lack of key interactions, whose
inclusion radically modify motifs’ TSPs. As a matter of fact, our first finding convinc-
ingly shows that data incompleteness could exert a relevant influence on the topological
characterization of the mesoscale in prokaryotic TRNs. More precisely, we have shown
how a complete knowledge of link attributes (directions and signs) can yield richer
mesoscale structures in TRNs. Secondly, we have also shown that a mere updating of
the interactions that make up a TRN in which key regulatory interactions are incorpo-
rated, radically modifies previous results based on the analysis of motifs appearances.
In fact, some of the previous conclusions do not hold anymore. We have observed that
prokaryotic TRNs show motifs significance profiles very similar to those belonging to
multicellular, developmental TRNs, signal transduction and neural systems. Finally,
experimental mischaracterization of the links has also been studied, and yet, we have
found that its influence on motifs statistics is reduced. These results suggest that
the evolutionary interplay between topology and dynamics is more similar between
regulatory systems of multicellular and unicellular organisms than expected.
TRNs have been increasingly studied during the last several years. Nowadays,
however, their characterization can only be considered provisional, as they consist of
incomplete annotations of often heterogeneous and unreliable experimental evidences,
computational inferences and theoretical predictions. While working with still incom-
plete networks could be of valuable help to uncover unknown biochemical pathways,
there are situations in which reliable conclusions cannot be obtained. Moreover, we
don’t even know when the latter is the case. Accuracy and robustness of the results
thus require us to be able to assess what results are dependent on the noisy and un-
certain nature of some annotated links. This is crucial if deep biological implications
are to be claimed.
5.6 Methods
5.6.1 Topological analysis
We find the community structure of the networks studied using the modularity concept
introduced by Newman [36]. To perform these costly calculations we have used a
mixture of heuristics, including extremal optimization and Newman’s fast algorithm,
as implemented in [324]. On the other hand, the statistical significance of motifs has
been calculated as it is customarily done [262, 267]. Finally, for an exhaustive list of
the experimental methods that have been categorized in different groups, see [279].
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5.6.2 Experimental methods for link characterization in prokary-
otic TRNs
Experimental methods used in transcriptional regulation inference are numerous. For
the three updated networks analyzed in this chapter [314, 315, 3], we have listed as
many as 25 methods from the dataset of E.coli, 73 in B.subtilis repository and 22
method annotations for MTB (MTB) case. A complete list of them is included in a
separate file (see section 2).
Despite these relatively high numbers, methodology annotations of most of the links
in the three networks belong to two main groups: target expression level comparisons
(TELCs) and protein-DNA binding assays (BAs).
Concerning the first group, typical experiments have two phases. First, a mutant of
the organism has to be generated, in which the regulator under study presents expres-
sion levels or functionality significantly altered with respect to the wild type. The first
common option is to completely disrupt the transcription factor gene so as to impair its
function in the mutant strain. In the case that the regulator is essential for cell survival,
additional copies of the transcription factor gene can be attached to a strong promoter
and inserted into the organism within plasmids in order to produce a mutant in which
the regulator has an enhanced expression level. The second phase consists of studying
the expression of other genes, in order to identify those whose expression is modified
as a consequence of the changes associated to the transcription factor. In order to
do that, mRNA concentrations of a precise gene can be measured using RT-qPCR, or
mRNA concentrations of large amounts of genes can be simultaneously checked using
a microarray. In order to register expression changes in single genes, reporter genes are
usually attached to the promoter of the target under study. By measuring the signal
associated to the reporter –for example a fluorescence signal–, one obtains a relative
measure of how expression levels of that gene change due to the regulator function.
Alternative expression measurement approaches rely on mixture separation blotting
techniques to isolate the precise mRNAs of eventual targets (northern blot), or even
separate the target proteins from an heterogeneous cell extract (western blot). All the
method annotations that can be assimilated to this scheme have been marked in red
in the document “MethodsSummary.xls” (available at [279] and we call them TELCs.
The second approach –BAs– consists essentially of explicitly testing whether a
protein-DNA interaction between the transcription factor and target gene’s promoter
exists. Electrophoretic mobility shift assay (EMSA) represents the paradigm of this
approach to test whether a regulator binds to the promoter of a precise gene. ChiP-
on-chip technique gives the same information in a parallel fashion, on a high amount of
possible targets. In turn, foot-printing assays, besides proving a transcription factor is
binding to the DNA, informs about the precise position of the binding site. Once the
binding site of the regulator has been found –or once one has only partial evidence of
it–, directed mutagenesis techniques at the cis-regulatory element can be used to prove
the specificity of the interaction. Usually, a regulator recognizes specific sequences,
with small variations, which also allows us to computationally infer transcriptional
regulations according to the similarity of gene promoters sequences to those already
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identified as binding sites for the regulator under study. This kind of evidences can be
considered as binding proofs, as they are based on previous sequences experimentally
proved to be actually recognized by the regulator; but they are only weak evidences.
In our work, we only have considered them as binding proofs for the case of MTB. The
reason to proceed in this way is that this bacterium is clearly the worst characterized
of the three under study here, and explicit binding evidence for it are yet rare [3].
So, in order to recover a minimum statistics, we are forced to include computational
inferences of binding sites as evidences in this case. If we also consider computational
inferences as binding proofs in the other two systems, results do not significantly change
(results not shown). An alternative way to prove the physical implication of a certain
regulator on the transcription of a certain gene is to reproduce an in vitro transcription
assay (or a run off transcription assay) in which one can verify whether the presence
of a regulator (transcription factor or sigma factor) is required to start transcription
of a certain gene(s). All the annotations associated to this kind of methods have been
marked in blue at “MethodsSummary.xls” [279], and they have been associated to BAs
in the analysis.
For all datasets under study, there are method annotations that can not be associ-
ated to any of the described groups for many reasons. Some of them refer to methods
that can be used in combination to expression measures but also to binding assays.
That is the case of transcriptional initiation mapping techniques. These methods use
mRNA samples to infer the initiation sites of the genes from which they were tran-
scribed. The explicit implication of a transcription factor in the transcription of the
mRNA samples could be determined or not, using additional techniques; whilst the
technique can also be used (or not) to measure the mRNA concentrations and even-
tually compare it to that of other set-up. Other method annotations that have been
excluded from our analysis are those which are not direct references to experimental
support (like previous bibliographic generic references or orthology based inferences).
For last, some method annotations are too general or barely informative, or refer to
measurements related to precise physiological processes in which the genes involved in
the link take place. We have also excluded these annotations from our analysis.
In conclusion, we define WCLs as those which have been annotated, at least, with
a method belonging to each of the two main groups: TELCs and BAs. Thus, it must
be stressed that we focus, beyond the “strength” of the experimental evidences, on
the information about the aspects of the regulatory interaction each evidence gives us:
TELCs tell us what the influence of the presence/absence of a certain regulator on
target levels is like; while BAs tell us whether the interaction is direct or whether it
has not yet been found to be so.
5.7 Online data reporistory
In order to provide an open access to the methodoligal details related to this chapter
and chapter 3, we have rendered on-line a data repository [279] containing the following
items:
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• “MethodsSummary.xls” Contains the list with all methodological annotations pro-
vided by the databases [314, 315, 3] and analyzed here
• Updated version of the TRN of MTB first compiled in [3]. In this update we
provide interaction signs when possible. Exhaustive information ordered by ex-
perimental sources is provided in the spreadsheet “bibliographicalRevision.xls”.
A list of the genes of the network is found at “IDlistMtb.txt”, and the network
itself at “MtbTRnetwork.txt”. At “readme.txt“ information about the changes
incorporated to this second version of the dataset can be found.
Chapter 6
Data reliability in complex directed networks
6.1 Introduction
The lack of data quality and complete information about interactions is an ubiquitous
problem in most research areas where the framework of network modeling is applied,
that, as we have seen in the last section, often causes relevant problems and even
incorrect conclusions. For example, classical social survey methods must deal with
problems like sampling biases [349], or data loss [350, 351], which can compromise
network-level analyses. The problem is even more acute when moving from social to
biological systems like TRNs, in which the promise of high-throughput biochemical
techniques of revealing the system backbone (i.e., transcriptomes) has to deal with the
inaccuracy that these methods often show (or have, historically, shown). Microarray
essays −the main tool to quantitatively measure the activity of large amounts of genes
in a highly parallel fashion during the last decade− constitute a paradigmatic example
of a powerful, but sometimes inaccurate or not totally reproducible technique [352,
353, 354].
Focusing on the subfield of gene regulatory networks, one additional limitation to
the network approach is the diversity -even conceptual- of the high number of different
techniques used to infer regulatory interactions [3, 314, 6]. Lastly, the most important
issue is probably the fact that the environmental conditions under which regulatory
interactions take place are, in general, different for each interaction, and for a high
proportion of cases only roughly known. This leads to the paradox that in many
cases, reported regulations [3, 314, 358] identified through very diverse experimental
techniques, and under specific experimental conditions, are rarely similar when links
identified through different experiments are compared.
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It is then of utmost importance to develop new ways to assess data reliability in
complex directed networks, specially because most of the efforts up to now have been
directed towards solving the problem in undirected, unweighted graphs [363, 360, 361,
362], and there are only few works devoted to address the problem in directed systems
[365, 364]. In this chapter, we capitalize on a previous method proposed to study the
very same problem but for undirected systems [276]. Specifically, we generalize the
method proposed by Guimera & Sales-Pardo [276] based on Stochastic Block Models
(SBMs) to the case in which links are directed, like in a regulatory network. By doing
so, we are able to successfully identify missing and spurious interactions in several
real-world networks.
In this chapter we compare the performance of our method to that of previous
approaches [365, 364], one of which [365] we also adapt, in this case, so as to render it
able to analyze self-loop containing networks. Our results point out that, when using
our approach we obtain, with some exceptions, better results at predicting missing
and spurious interactions, paying the prize of greater computational requirements.
This exhaustive comparison allows us to give a general outlook of the problem of data
reliability determination on directed networks, identifying the strengths and weaknesses
of each method. Finally, we test whether the methods can be used to predict new links
in a genome-wide TRN like the one we have compiled and studied in chapters 3 and
5, providing a robust methodology that could help and guide the experimental search
for unnoticed regulations. Our results indicate that the approach proposed here is also
the best performing method when facing this kind of situation.
6.2 Models for identifying missing and spurious links
in directed networks
6.2.1 SBMs for reliability determination in directed networks
Following [276], let us suppose that we are working on a certain graph whose adjacency
matrix is Ao, which is just an imperfect realization of a certainly ideal, “true” network
A to which we have no access. Being X a certain measurable property of the network,
we will call p(X = x|Ao) the probability that, once observed the graph Ao, X is equal
to x in the ideal system A. Then we have:
p(X = x|AO) =
∫
M
p(X = x|m)p(m|AO)dm (6.1)
where p(m|AO) is the probability that m is the model in a class M that gave the
observation AO, and p(X = x|m) stands for the probability of model m to generate
networks in which X = x. It is worth noticing that, depending on the way the family of
models M is defined, eq. 6.1 can adopt the form of a sum instead of an integral. Since
the term p(m|AO) is certainly difficult to estimate, we must reformulate the problem
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by using the Bayes theorem, to get:
p(X = x|AO) =
∫
M
p(X = x|m)p(AO|m)p(m)dm∫
M ′ p(A
O|m′)p(m′)dm′ (6.2)
where p(A0|m) is the probability thatm gave AO among all possible adjacency matrices
and p(m) is the a priori probability of model m.
At this point, we need to select a class of models to integrate the former expres-
sion. The main hypothesis that lies beneath this method consists of assuming that the
required family is that of stochastic-blocks-models (SBM). In the case of undirected
networks, any of these SBM can be characterized by a partition P of the set of nodes
into blocks, and a probability matrix Q such that the element Qα,β defines the prob-
ability that any of the nodes belonging to the block α be connected to any of the
nodes within block β. So, the probability of two nodes being connected depends only
on the blocks these nodes belong to within the partition P . Note that under these
assumptions, Q is symmetric.
In order to deal with directed networks several possibilities are conceptually feasible.
Here, we propose the following variation of the model. Instead of considering one single
partition P of the nodes’ space, we will consider two partitions, a senders partition Ps
and a receivers partition Pr. Every node i must then belong, independently, to a block
in each partition: i ∈ σi with σi ∈ Ps and i ∈ ρi with ρi ∈ Pr, as it is sketched in
figure 6.1. The partitions just take into account the fact that in directed networks,
out-going and incoming links are treated separately. Thus out-going links of node i
will be determined by block σi to which it belongs in the partition Ps. On its turn,
and in an independent way, the in-degree will be given by the block ρi in the other
partition Pr in which the node i is located. Within this scheme, the probability of
node i sending a link to node j is Qσi,ρj . Remarkably, the probability of observing the
opposite link is different, and equal to Qσj ,ρi .
This scheme, yet having the virtue of its computational tractability, conceptually
captures the behavior of systems like TRNs in which the statistics associated to in-
degrees are very different to those regarding out-degrees [3, 314], being both relatively
uncorrelated. This can be easily understood if one considers that the biochemical prop-
erties that define the susceptibility of a protein to be regulated by others are different
to those that make the protein a regulator. While the information that will ultimately
define the identity and the strength of the transcriptional regulations affecting a pro-
tein reside in its promoter region, its eventual ability to bind to the promoters of other
target proteins depends on the presence and identity of a regulator domain within its
protein sequence. Consequently, these two eventual roles of the protein are determined
by DNA sequences that are independent and that, at least in principle, can evolve
separately, both in prokaryotic [90] and eukaryotic cells [366].
Links reliabilities
Each of the SBM is fully defined by determining the two partitions above and the
probability matrix, hence m = (Ps, Pr,Q). Additionally, we define the reliability of a
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certain link i→ j as the probability:
Ri→j = P (Ai,j = 1|Ao). (6.3)
On the other hand, let us consider a couple of nodes (i, j) so that i ∈ σi in the senders
partition Ps and j ∈ ρj in the receivers partition Pr. The probability of observing a
link from node i to node j in a network generated by our model is:
P (Ai,j = 1|Ps, Pr,Q) = Qσi,ρj . (6.4)
Consequently, the probability of observing the graph Ao as a realization of the same
model is given by the binomial product:
P (AO|Ps, Pr,Q) =
∏
σ∈Ps,ρ∈Pr
Q
lOσρ
σρ (1−Qσρ)rσρ−lOσρ , (6.5)
where lOσ,ρ is the number of links observed between nodes placed in σ in Ps, and nodes
placed in ρ in Pr. Regarding rσ,ρ it is the maximum possible value for lOσ,ρ, that is,
the product of the sizes of blocks σ ∈ Ps and ρ ∈ Pr. Substituting the three last
expressions into Eq. 6.2, we get, after integration over all possible probability matrices
for each case, that the reliabilities of links are:
Ri→j =
1
Z
∑
Ps ∈ PS
Pr ∈ PR
P (Ps, Pr)
lOσi,ρj + 1
rσi,ρj + 2
e−H(Ps,Pr), (6.6)
with PS and PR standing, respectively, for the spaces of all possible partitions of nodes
as link senders (S) and link receivers (R). Node i belongs to block σi in Ps; while node
j is located in ρj at Pr. Finally, P (Ps, Pr) is here the a priori probability of observing
a subset of models defined by Ps and Pr, under the assumption that once partitions
are fixed, all possible models that one can get by changing the probability matrices are
equally probable. In addition, the partition function Z in the last equation takes the
form:
Z =
∑
Ps ∈ PS
Pr ∈ PR
P (Ps, Pr)e
−H(Ps,Pr) (6.7)
and the hamiltonian function is:
H(Ps, Pr) =
∑
σ ∈ Ps
ρ ∈ Pr
[
ln (rσρ + 1) + ln
(
rσρ
lOσρ
)]
(6.8)
Up to this point, the scheme of the method is totally analogous to the baseline method
for undirected systems presented in [276]. However, the generalization of the method
to directed networks requires further refinements. More precisely, as it is detailed in
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the Appendix, we must adopt here the following hypothesis. Let ~χPx be the vector
whose components are the (ordered) number of nodes present in each of the blocks
within partition Px. We have that
P (Ps, Pr) = constant ∀(Ps, Pr) with ~χPs = ~χPr ,
P (Ps, Pr) = 0 ∀(Ps, Pr) with ~χPs 6= ~χPr . (6.9)
Then, the a priori probabilities cancel out in Eqs. (6.6) and (6.7), and thus, the math-
ematical forms of these expressions are identical to those given in [276], except for the
fact that here, sums and products are taken over the combination of two partition
spaces: Ps and Pr, with the additional constraint that the only couple of partitions
(Ps, Pr) that computes are those for which ~χPs = ~χPr (See Appendix).
Nevertheless, the reliabilities sums have always the form of a canonical ensemble
average, which allows us to use again a Metropolis algorithm to sample among all the
possible pairs of partitions compatible with the condition ~χPs = ~χPr , those yielding to
smaller hamiltonians and thus contributing the most to the sum (see Appendix). When
the sampling finishes, we recover the reliabilities of all possible directed links in the
network despite of their directionality –obviously, in general Ri,j 6= Rj,i–. Moreover,
by ranking the links one can test which are the more reliable ones, no matter whether
a given link was observed in our graph Ao or not.
6.2.2 Alternative methods: Zhang’s approach
In order to evaluate the performance of our proposed approach for links reliabilities
determination, we have to compare it with the more recent alternatives approach avail-
able in the literature. According to the first of these alternative methods, due to Zhang
et al. [365], the reliability of a link is thought to be proportional to the number of bi-
fans (graph formed by two senders and two receivers each one of which receives a link
from each sender[262]) in which each link participates. Similarly, the reliability of a
non existing link can be evaluated as the number of bi-fans that would be generated by
adding the absent interaction. The so evaluated scores are integers and obviously have
no absolute probabilistic interpretation; nevertheless, pairs of nodes can be ranked
by their scores and, in this sense, it is a useful tool for missing and spurious links
identification also.
In order to understand in depth the relationship between SBM and Zhang’s method,
let us recall some technical details of our approach. As it is thoroughly explained in the
Appendix, in the Metropolis algorithm used by the SBM-based method, the partitions
that give lower hamiltonians and thus mostly contribute to the reliability sums are
those that find a better compromise between two conflicting constraints. The first of
these constraints is that blocks in the partitions have to be as large as possible. The
second constraint forces the amounts of links loσ,ρ existing between any pair of blocks
σ ∈ Ps and ρ ∈ Pr to be either close to the maximum (i.e. equal to rσρ, the maximum
possible value given the size of the blocks) or to the minimum. Once said that, given
a certain partition, the bigger the quotient r = (loσi,ρj + 1)/(rσiρj + 2), the bigger the
reliability of the link i→ j will be. In the partition depicted in figure 6.1, for example,
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for the absent link 3 → 1, we have r = (8 + 1)/(9 + 2) = 9/11, while, for the link
3 → 6, r = (1 + 1)/(12 + 2) = 2/14. The example is relevant because it evidences
that a pair of nodes with a high link-reliability between them also tends to form a high
number of bi-fans, as it is the case of pairs of nodes between blocks 1 ∈ Ps and 1 ∈ Pr.
The reason is that, to have a high reliability, the number of links between the blocks
involved have to be saturated, or nearly saturated, (i.e. loσi,ρj near to rσiρj) and that,
additionally, as it has been said before, blocks tend to be as large as possible.
To show that this relationship between both methods exist, we have calculated the
correlation coefficients between Zhang scores and SBM-based reliabilities. The results,
given in table 6.1 for the six networks analyzed show a high correlation between the
outcome of both methods: links with high Zhang-scores tend to have high SBM-based
reliabilities and vice-versa. In order to perform an additional test, we can calculate
the probability of any pair of nodes (i, j) to co-occur in a common block either at the
senders partition:
Pσi=σj =
1
Z
∑
Ps ∈ PS
Pr ∈ PR
P (Ps, Pr)δ(σi − σj)e−H(Ps,Pr) (6.10)
or at the receivers partition:
Pρi=ρj =
1
Z
∑
Ps ∈ PS
Pr ∈ PR
P (Ps, Pr)δ(ρi − ρj)e−H(Ps,Pr) (6.11)
where δ stands for the Kronecker delta function. For the same pair of nodes (i, j)
we calculate the number of bi-fans that are generated with nodes i and j playing the
receivers roles N recbf (i, j), and we can compare it with the expected number of bi-fans
that they would generate at random in a network of N nodes given their in-degrees
kin(i) and kin(j). This expected value is N recbf |exp(i, j) = kin(i) · kin(j)/N , and the
deviation of the observed number of bi-fans coming from nodes (i, j) and the expected
value is ∆recbf (i, j) = N recbf (i, j) − N recbf |exp(i, j). To test whether bi-fans tend to be
formed by couples of receivers that share a common block in the senders partition,
we calculate the average of ∆recbf (i, j) for those receiver couples having a co-occurence
probability Pρi=ρj ≤ 0.5, and we compare it to the same quantity averaged on couples
with Pρi=ρj > 0.5. The results of this test, given in table 6.2, show that in most
networks a larger probability of co-existence at receivers’ partitions comes together
with a higher number of bi-fans formed by the couple of receivers.
After these observations, the reasons behind Zhang’s method performance could be
reinterpreted as a simple consequence of the existence of an underlying block structure.
Under this assumption, the mapping between both methods allows us to overcome one
of most clear limitations in [365], i.e. its inability to evaluate self-loops reliabilities (a
self-loop never joins a bi-fan). Once we have seen that the appearance of bi-fans around
highly reliable links can be rooted in the underlying block structure, we notice that the
structures sketched in figure 6.2, are, from the perspective of SBMs, absolutely iden-
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Figure 6.1: Stochastic block models for directed networks. In this example, partitions
count with two blocks of three and four nodes, respectively. Notice that the number of
occupied blocks and the number of nodes within them have to be the same both in senders
and receivers partitions. The partition represented has a low hamiltonian, because blocks
are large enough and the number of links between each pair of blocks l0σ,ρ is either close
to 0 or to the maximum possible value in each case rσ,ρ. We have: (lo1,1, r1,1) = (8, 9),
(lo1,2, r1,2) = (1, 12), (lo2,1, r2,1) = (0, 12), (lo2,2, r2,2) = (1, 16). According to this picture, links
from nodes of block 1 ∈ Ps to nodes in block 1 ∈ Pr are much more reliable than any others:
thus, the link 3 → 1 is a prototypical missing link, while the links 3 → 6 and 6 → 7 are
prototypical false positives.
Network Pearson coefficient
Radio calls 0.912
Glossary 0.917
Narragansett bay 0.904
Everglades 0.850
A.thaliana 0.920
MTB 0.943
Table 6.1: Correlations between SBM-based reliabilities and Zhang scores. To obtain these
correlation coefficients we calculate the average SBM-based reliabilities of all pairs of nodes
sharing a common Zhang score. The Pearson coefficients represented show the existence of
correlations between the scores and the averaged reliabilities. For the calculations, we have
considered the generalized Zhang scores, which also take into account the degenerated bi-fans
in figure 6.2.
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Network 〈∆recbf (i, j)〉 for Pρi=ρj ≤ 0.5 〈∆recbf (i, j)〉 for Pρi=ρj > 0.5 p-value
Radio calls 5.42± 0.37 10.3± 2.37 1.20 · 10−4
Glossary (1.80± 0.85) · 10−1 (3.12± 1.61) · 10−1 2.25 · 10−1
Narragansett bay (4.47± 1.10) · 10−1 1.63± 0.26 < ·10−5
Everglades 6.85± 0.58 31.1± 2.94 < ·10−5
A.thaliana (−5.11± 3.75) · 10−1 2.28± 1.60 8.48 · 10−2
MTB (3.31± 1.1) · 10−2 (1.40± 0.64) · 10−1 7.63 · 10−3
Table 6.2: Bi–fans tend to aggregate around pairs of receivers sharing common blocks.
∆recbf (i, j) is the difference between the number of bi–fans in which nodes (i, j) participate
as receivers N recbf (i, j) and the expected value of the same quantity N
rec
bf |exp(i, j) = kin(i) ·
kin(j)/N in the null case. Positive values of ∆recbf (i, j) mean that nodes (i, j) have more
common in-neighbors than expected at random. In this table we show that receiver pairs
with greater co-existence probabilities Pρi=ρj have greater ∆recbf (i, j) on average. The p-values
stand for the probability of the mean value of ∆recbf (i, j) for the first population (pairs (i, j)
with Pρi=ρj ≤) being equal or greater than the mean of the second population. We can repeat
the exercise to test the correlation between Pσi=σj and the deviation of the number of bi–fans
generated by receivers couples ∆sendbf (i, j) = N
send
bf (i, j)−N sendbf |exp(i, j); the results are very
similar; with all p-values under 20% and 4 out of 6 under 5%. Degenerated bifans have also
been taken into account.
tical. Recalling the example partition in figure 6.1, the “pure” bi-fan formed by nodes
(1, 2, 4, 5), appears as a consequence of links saturation between blocks 1 ∈ Ps and
1 ∈ Pr, just in the same way that the degenerated structure formed by nodes (1, 2, 4)
does. Thus, what we propose here is a variation of Zhang’s method in which degener-
ated bi-fans are treated in the same way that “pure” are, and therefore counted when
it comes to evaluate the scores, even when they violate one of the main requirements
of Zhang et al.’s original approach [365]. The last four rows of figure 6.3 show results
obtained for networks that contain self-loops. As it can be seen, the generalization of
the method has little impact on the food webs because of their low number of self-loops,
while in the regulatory networks analyzed, in which self-loops are more frequent, the
generalized method noticeably outperforms the original Zhang et al.’s proposal, thus
supporting our hypothesis.
Figure 6.2: Bi-fan degeneration. From a “pure” bi-fan (left), if the identity of one –or both–
of the couples sender-receiver coincides, we obtain these motifs, that we call degenerated
bi-fans.
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Network Nodes Time (s)
Radio calls 44 155
Glossary 67 113
Narragansett bay 32 50
Everglades 69 218
A.thaliana 15 2
MTB 65 302
Table 6.3: Computational time required for generating one single reliabilities rank using
SBM approach. In each case, 1000 partitions are sampled.
6.2.3 Alternative methods: KronEM algorithm
Instead of Zhang’s approach, –essentially based on local topological information–, the
so-called Kronecker expectation-maximization (KronEM) algorithm [364], is based on
a family of stochastic network models. These models have two main ingredients: a
Kronecker matrix built after the expansion of a low-dimensional matrix θ verifying
θi,j ∈ (0, 1)∀(i, j) via Kronecker multiplication by itself, and a bijection of the node
set Σ : i → σ(i). In order to describe a network of N nodes, if we are working with a
matrix θ of dimensions n× n (typically n = 2), we will need to iterate the Kronecker
product k times, being k the lowest integer higher than logn(N). Once done so, the
matrix elements θki,j –always verifying θki,j ∈ (0, 1)∀(i, j)– can be interpreted as links
reliabilities; more precisely, the matrix entry θkσ(i),σ(j) is the probability assigned to the
link i→ j.
It is worth noticing that, as exposed before, the so-constructed kronecker probability
matrix has, –unless N is an integer power of n–, more rows than nodes exist in the
network. This situation is used in [364] to make inferences on what they call “the hidden
part of the graph”, i.e. the part of the graph artificially described by the surplus of
rows of the matrix θk. However, the adaptation of the algorithm to the problem that
we face here is trivial, and allows us to focus only on the “real part” of the graph (as
it is already done in [364], section 4.3).
The algorithm proposed in [364] to determine link reliabilities is based on finding,
among all possible Kronecker models able to describe a certain network of adjacency
matrix Ai,j, one that maximizes the overall likelihood:
P (A|Σ, θ) = ΠAi,j=1(θkσ(i),σ(j))ΠAi,j=0(1− θkσ(i),σ(j)) (6.12)
and, as it can be shown from [364] such a maximization is feasible on computational
time of the order of the number of nodes. The computational requirements, as it can
be seen in table 6.3, are heavier for the SBM approach, as it was already determined
in [364] for the undirected version of the algorithm presented here.
The reason for this situation does not come from the behavior of the elemental step
of our Metropolis algorithm itself; which indeed scales with the number of occupied
blocks (i.e., at most, with the number of nodes as well). Most of the time requirements
of our algorithm come from the amount of iterations needed for uncorrelating two
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subsequent partitions in the sampling procedure. These decorrelated intervals depend
in not trivial ways not only on the number of nodes, but also on the number of links
and, in general, on the topology of the graph. This behavior explains the inexact
correlations between computational times and system sizes in table 6.3.
KronEM algorithm does not present, in principle, these problems. The reason is
that although both approaches are model-based bayesian methods, while the SBM
approach bases its predictions on recovering a whole ensemble of stochastic models,
kronEM algorithm aims at simply pick one optimal model to optimize the likelihood.
This situation, yet having the virtue of reducing the computational requirements of a
single run, makes the prediction of the algorithm more volatile, and sensitive to initial
conditions as it was already admited in [364].
6.3 Results
6.3.1 Method accuracy
In order to check the performance of our approach, we perform a series of tests on top of
different networks as in [276]. To this end, we use six well-known directed networks (see
Appendix): a social network of radio calls among a closed set of operators[26], a network
of hyperlinks in an on-line glossary [367, 368], the trophic webs of Narragansett bay[369]
and the Everglades[370], the cell-fate determination gene network of flower development
of Arabidopsis thaliana[371] and the regulatory network among transcription and sigma
factors of MTB [3].
Assuming that these networks are error-free, we randomly remove a certain pro-
portion of links. Then, we run our algorithm and rank the links reliabilities as coming
out of the algorithm. We define the accuracy of the method when it comes to iden-
tify missing interactions as the probability that removed links are assigned a higher
reliability ranking -i.e., they are false negatives- as compared to those that are true
negatives. On the contrary, to test whether the method is able to identify spurious
interactions accurately, we randomly add a proportion of links between nodes which
are already senders and receivers in the original network. As before, link reliabilities
are computed and the ordered ranking is used to check the accuracy of the method,
which in this case is given by the (mean) probability that spurious interactions -now
they are like false positives- are ranked lower than true links.
In order to evaluate the performance of our method, we compare its accuracy with
two of the latest (and to the best of our knowledge the only two dealing with directed
networks) alternative approaches to the problem, due to Zhang et al. [365] and Kim
and Leskovec [364], respectively.
Results of the accuracy tests are shown in Fig. 6.3. In the left panels, we have
represented the accuracy of the methods regarding the identification of missing links,
and in the right panels, we show the accuracies related to spurious links. Black series
correspond to the SBM-based algorithm presented here, red data series correspond to
the method in [365] and green series to KronEM algorithm developed in [364].
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As we can see, in the one hand, the SBM-based method systematically outperforms
that of Zhang et al., except for the case of the social network of radio calls, for which the
performance of the latter is slightly better, mainly regarding the prediction of spurious
links. In fact, a deeper analysis of the two methods, as we discuss next, show that
they give highly correlated outcomes. In the other hand, the SBM-based approach
outperforms KronEM algorithm in eight panels, and underperforms it in three. At the
last case -spurious links in the glossary network- both methods perform very similarly.
6.3.2 Guiding experiments
Once we have tested the general performance of the SBM-based method when compared
to KronEM, Zhang’s, and generalized Zhang’s approaches, we discuss their application
in an important and specific domain, that of TRNs. In this field of research, com-
putational data reliability tools could help mitigate either the relatively poor quality
and reduced size of some networks available [372, 373] or to integrate vast amounts of
information coming from high-throughput experimental techniques.
On the other hand, there are several organisms, –even relevant pathogens– for which
the whole TRN is not at hand, despite the fact that having the network would help in
the search of new drug targets or vaccines. This is the case of the TRN of MTB. The
bacillus of tuberculosis, responsible of one of the most threatening diseases worldwide,
is probably one of the bacteria whose transcriptome has been best studied during the
last years [316, 89, 3]. In 2008 the TRN of the pathogen consisted of 782 genes and 937
interactions [89], but the last updated version, published in 2011, contains as many as
1624 genes and 3212 interactions [3]. Moreover, the updated version, also added 357
new links between some of the 782 genes that were reported in 2008.
All the aforementioned facts, together with the running costs of experiments are
calling for methods that could optimize the search of new interactions. To test whether
and to what extent our algorithm could contribute to cure new datasets and guide
the experimental search of new transcriptional relations and regulators, we perform
a simple exercise with the M. Tb datasets of 2008 and 2011. Specifically, we check
whether the appearance of the 357 links in the 2011 compilation that connects pairs of
genes already integrated in the 2008 network could have been inferred from the analysis
of the 2008 network itself.
To simulate the way in which our method could help to identify these new inter-
actions, let us suppose that we are interested on a certain gene of the 2008 network
and we look for undiscovered regulations it might receive from any of the regulators
already present in the network in 2008 –obviously excluding those that had been al-
ready found to regulate its activity at the moment–. If no biological clue is available
about what regulators are the more likely candidates to act on our gene, we are forced
to experimentally try, one after another, all the possibilities. If the result of some of
these experiments is positive, and so the interactions exist, we will identify them at
a linear rate, as it is represented in grey in figure 6.4, panel a. In the same figure,
the black curve represents the rate at which all these novel interactions are detected
when the possible targets are checked according to their reliabilities calculated using
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Figure 6.3: Method accuracy in the detection of missing (left) and spurious interactions
(right) in six directed networks, according to the four methods explored in the text. The first
two networks (radio calls and glossary) lack self-loops by construction, and hence, it makes no
sense to generalize Zhang’s approach there. For the same reason, self-links are not allowed as
spurious interactions for these two networks. Not shown error bars are smaller than symbol
size or line thickness.
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the SBM approach. As it can be seen, the SBM-based method greatly enhances the
rate at which new links are discovered, with respect to the random case but also, to a
lower extent, with respect to KronEM and Zhang’s algorithms .
Figure 6.4: TRN of MTB : update analysis. Black: SBM-based seek. Red: Zhang’s scores.
Blue: generalized Zhang’s scores. Green: KronEM algorithm. Grey: random seek. (a):
Proportion of regulators checked versus proportion of new links found, when focusing on
targets receiving the new links.(b): Regulators based search: Proportion of targets checked
versus proportion of new links found, when focusing on regulators sending the new links.
In the insets, the Z-Score of the methods’ performance is computed, when compared to the
random procedures, whose error bars (σ = 1) are represented in grey. As it can be seen, all
three methods outperform the random procedure, mostly at first stages, and more remarkably
in the case of target based search (panel a).
If the situation is the opposite, and we are interested in unveiling new links coming
from any of the regulators of the network in 2008, the rate at which targets of the new
links could be experimentally found is represented in figure 6.4, panel b, when choosing
the candidates according to their SBM-based reliabilities, according to the alternative
methods and when the order is random. In this case, the performance of SBM and
Zhang’s methods slightly outperforms KronEm, which is not better than the random
procedure. These differences, though moderate, in practice could represent saving time
and resources. In fact, starting from the regulators (Fig. 6.4, panel b) and aiming at
finding 50% of the new targets, one has to seek the 39% of the targets with the highest
SBM-based reliabilities in each case. This implies that the SBM-based method uses
78% of the time and resources needed if the identification is made randomly. Going
back to the results shown in Fig. 6.4, panel a, that case produces even better results:
to find the 50% of the regulations received by a target gene, one must only seek a 20%
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of the total of regulators. Therefore, the SBM-based method remarkably outperforms
the random search by using as less as 40% of the resources spent in the null case, but
also the search orderings based on the alternative methods.
6.4 Conclusions
We have proposed an extension of the method in [276] to determine link reliabilities in
directed networks. This opens the path to the potential application of our technique
for the detection of missing and spurious interactions in systems as important as food-
webs, TRNs or certain social networks, all of which are directed networks. A related
and interesting problem that however remains to be explored is whether reliability
rankings are correlated with significance measures [374, 375, 376] of the links identified.
For instance, a genuine question is whether finding a highly ranked but lowly significant
link is worth the computational cost involved in the calculation. We let this kind of
questions for future works.
The accuracy and robustness of the method has been tested exhaustively on net-
works of different sizes and topological properties. Results of intensive numerical simu-
lations have shown that missing and spurious interactions can be detected successfully,
with higher precision than previous approaches in most cases. Additionally, we have
numerically shown that the method can be used to guide the experimental search for
missing links, as the reliability ranking resulting from the application of the algorithm
to an incomplete network provides a very good guideline for experimental tests that
eventually lead to the discovery of new interactions in a highly efficient way. This po-
tentiality has important implications for our current efforts to map out transcriptional
regulations, particularly, in cases such as that of MTB, where experimental lab proto-
cols are very slow and expensive. At a conceptual level, this exercise makes explicit the
ability of our method to predict real, arbitrarily correlated errors in complex directed
networks, rather than randomly generated missing or spurious interactions.
On the other hand, after an exhaustive comparison of our method with the method
proposed in [365], we have been able to provide a rationale for the latter approach: when
the topology of a real system can be successfully described by a block model, bi-fans
systematically appear around highly reliable links. Additionally, the mapping between
both methods makes it immediate the generalization of Zhang’s approach to deal with
self-loops. This generalization enhances the performance of the original algorithm when
self-loops are statistically relevant, as it happens in some gene regulatory networks (see
figure 6.3 lower row).
Our SBMs-based model has however an important limitation. It is prohibitively
costly in terms of computational time for large systems, and for sure much more expen-
sive than Zhang’s approach, or even than single runs of kronEM algorithm. Therefore,
the method proposed here is mainly aimed at relatively small systems. For larger
networks, Zhang’s generalized method, whose outcomes are highly correlated to our
approach in small systems, can be used as a low-cost resource. KronEM algorithm,
in turn, represents an intermediate solution, both in terms of computational expenses
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and method accuracy and consistence. This kind of situation in which the prize to
pay for reaching more accurate tools also appears when facing other problems such as
community detection in networks [318].
Alternatively, if more accuracy is required, we believe that the SBM-based method
presented in this chapter could also be applied to subgraphs, overcoming in this way
the size limitations. For instance, one can try to partition the whole system first by
using one of the many algorithms available for community detection and then apply
the reliability technique only to the detected communities. This kind of solutions will
be explored in future work.
6.5 Materials and methods
6.5.1 Phase space
In [276], the mathematical form of the hamiltonian, in the undirected model is, as said
before, equivalent to 6.8, except for the fact that there is only a partition family to
sum over. Let us write it as:
Hu(P ) =
∑
α<β
[
ln (rαβ + 1) + ln
(
rαβ
lOαβ
)]
(6.13)
The restriction α < β (both blocks belonging to the partition P ) appears only in
order not to sum each term of the sum twice. Let’s inspect the two different terms:
H1u(P ) =
∑
α<β
ln (rαβ + 1) (6.14)
H2u(P ) =
∑
α<β
ln
(
rαβ
lOαβ
)
(6.15)
The first term depends, essentially, on how “concentrated” the partition is. Briefly, it is
minimal when the nodes tend to concentrate in a few number of blocks. In the case of
having all the nodes on the same block, Eq. 6.14 gives ln(1 +N(N − 1)/2), where N is
the number of nodes, which is approximately equal to 2ln(N) when N is large enough.
Instead, if we have the opposite situation in which each node is assigned to a different
block, then H1 = N(N − 1)ln(2) >> 2ln(N). So, the term H1u minimizes when the
partitions are compact, and maximizes in the opposite case. As for the second term,
the picture is the opposite. The presence of the combinatory number implies that, to
minimize H2u, the partitions of nodes should be a kind of “straight fit” for the links
connecting blocks: given any two random blocks α and β, there should be a number
of links between the blocks near to the maximum -the product of the block sizes, i.e.
rα,β- or to the minimum (i.e. no link between the blocks). So, if we aim at getting the
minimum of this term alone, one must go to the segregated partition in which each
node belongs to a different block, for which the term directly vanishes.
6.5 — Materials and methods 
Therefore, minimizing the hamiltonian implies finding a compromise between ag-
gregation and segregation of nodes into blocks, as the two terms have clear opposite
effects, and no one of the extreme situations are globally convenient. How this picture
change when we move to the bipartite scheme? The addition of new degrees of freedom
to the system generates an undesirable situation in which, if we perform a Metropolis
algorithm letting freely evolve the two partitions, we will reach a situation in which in
the Ps space, all nodes gather together into a single block, while in the Pr space we
will get an split into as many blocks as nodes are. The reason is that, for the system,
such configuration is globally stable, because the two hamiltonian terms, under this
configuration, reach values that are far away of the possible maximum. However, in
this case, the final configuration is absolutely uninformative.
The above problem comes from the fact that the system is not constrained enough
and it is allowed to adopt partitions in each one of the subspaces with very different
degrees of aggregation. So, we should impose a further constraint so that the system
can only adopt couples of partitions with the same aggregation state (i.e. ~χPs = ~χPr),
the stable. This will allow to get partitions that give rise to minimum hamiltonians
being at the same time fully informative and having a compromise at intermediate levels
of aggregation between links assignments and block sizes. In this case, the algorithm
will be qualitatively analogous to that of the undirected case.
6.5.2 Metropolis algorithm
In order to perform our Metropolis algorithm, we start by assigning, at random, each
node to one block, for example in the space Ps. Then we copy the partition generated to
Pr. To ensure independence between the partitions but always verifying the constraint
~χPs = ~χPr , we proceed to randomize the partition Pr by iteratively changing the block
of couples of nodes (also chosen randomly) a high enough number of times. In this way,
the blocks numbered equally in both partitions contains the same number of nodes.
Thus, at each Metropolis step, we choose a couple of nodes belonging to the same block
in both the partitions Ps and Pr and we try to change both at the same time to the same
destination block (each one on its own partition). To ensure that any couples of nodes
has the same probabilities of being chosen, we proceed as follows: we start by choosing
randomly one node n1 in one partition. Then we move it to the twin block containing
the very same node n1 in the complementary partition. Inside this twin block, we
randomly choose the second node to move, n2. After the nodes n1, n2 are selected and
tentatively moved, we recalculate H and accept the move if H(t+1) < H(t). As usual,
if the hamiltonian raises up, we accept the move with probability P = e(H(t)−H(t+1)) in
the standard case. Such an algorithmic scheme guarantees an ergodic exploration of
the phase space, and ensures without problems detailed balance. In this way, after a
certain transient, the hamiltonian reaches its equilibrium value and at that point, we
start the sampling procedure, taking care that two consecutive samples are uncorrelated
enough.
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6.5.3 Technical aspects
While the method does not raise any problem when analyzing systems of small size (let
us say N < 200 nodes and E < 1000 links approx.), as those studied in section 2, for
larger networks, there sometimes appear some conceptual problems that can make the
sampling procedure more difficult. First, it has been observed that the amplitude of
oscillations of stationary hamiltonians, in general, increases with the size of the network
analyzed. This range can be near 1000 hamiltonian units for systems of less than 2000
nodes, such as those of E.coli [314] or MTB [3] TRNs. Since the distribution of the
hamiltonians is qualitatively normal around the average value (results not shown), the
higher the amplitude of the oscillation is, the lower the proportion of samples that
will contribute significantly to the sum is (let us say, those with H, at most, 10 units
greater than the minimum). This problem, when it comes to analyze big networks,
will force us to get a too high number of samples to get a minimum amount of relevant
ones. The latter can be prohibitive in terms of computational time (recall, in addition,
that the computational time of a single Metropolis step also increases with the size of
the system).
Here we propose an alternative procedure that can be implemented when the net-
works under study are too large and computational resources do not allow a full ex-
ploration of the phase space. The alternative is as simple as discarding all the samples
with H < 〈Hstat〉 − γ · σHstat , where γ is a coefficient that can be chosen depending
on the computational time we require and the number of samples we are looking for.
This resource, although in principle could limit the performance of the method, does
not affect it significantly, as showed in Fig. 6.5, panel a.
The black bars in figure 6.5, panel a, show the consistency of the standard method
of sampling without any threshold. We define this consistency as the proportion of
reliabilities pairs Ri,j Rk,l whose relative ordering is preserved in successive reliability
ranks obtained with the same method. Moreover, in red bars, the comparison is made
between a rank obtained with the standard procedure and another rank for which
only the samples that lie over a threshold 〈Hstat〉 − γ · σHstat have been preserved and
considered (here, γ = 2). Finally, the bars in blue show the internal consistency of
the threshold method, that is, the mean proportion of reliability pairs whose order is
conserved when we compare pairs resulting from two independent rankings generated
using the threshold criterium. As it can be seen, the three measures, for the six systems
shown, are consistently high and quantitatively similar between them, thus providing
evidence that the threshold method could help in situations where the required com-
putational time is prohibitively large if we aim at getting enough samplings. This kind
of procedure has been used for the analysis of the TRN update represented in figure
6.4, considering 10.000 partitions with hamiltonian over 〈Hstat〉 − γ · σHstat with γ = 2.
There is an additional problem that generally appears when the networks have
high mean connectivities, or, strictly speaking, when the mean connectivity is of the
order of half the number of total possible links in the network, that is, in a directed
network, N2/2. In these cases, the information stored in the adjacency matrix is high,
and so, being high the number of constraints, the dependency of the hamiltonian on
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Figure 6.5: Coherence of ranks defined as the proportion of reliabilities that preserve or-
dering in successive realizations obtained with diverse sampling strategies: Panel (a): black
bars: standard sampling procedure. Blue bars: Threshold sampling. We have set γ = 2.
See the text for further details. Red bars: relative coherence of standard sampling ranks vs.
threshold sampling ranks (γ = 2). Panel (b): black bars: standard sampling procedure. Red
bars: relative coherence of standard sampling ranks vs. Hot-threshold sampling ranks (T = 2,
γ = 2). Blue bars: Hot-threshold sampling.(T = 2, γ = 2). See the text and Appendix for
details.
the partitions defines a rough energy landscape that sometimes can become difficult
to deal with. This situation can lead the system to fall into a local minimum after the
thermalization process, and get trapped there. So, once arrived to the stationary state,
if the basin of that local minimum is small, we will observe that the system is not able
to uncorrelate sufficiently, and thus, even if its energy is small enough to consider it an
acceptable minimum, our sampling will be very poor. One solution to this issue would
be that of parallelizing the algorithm starting each parallel process from a random
initial configuration. In this way, the process will ideally reach independent minima
and thus the sampling would be N times reacher, being N the number of parallel
processes.
In the above solution is is not possible, the strategy would be to introduce a pseudo
temperature T > 1 in the Metropolis algorithm, just to ensure the system is able to
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abandon local minima and explore the whole configurational space looking for other
ones. The adoption of this strategy has the problem that, the higher is the temperature,
the higher is also the oscillation of amplitudes of the stationary hamiltonian, and
therefore the application of a threshold might also be needed.
In Fig. 6.5, panel b, we show the consistency of our method when the above strategy
is implemented (using T = 2) in combination with a threshold criterium to select the
samples, accepting only those with H > 〈Hstat〉 − 2σHstat . Though these operations,
again, could compromise the quality of our sampling, we found that the consistency of
the ranks generated with the method (Fig. 6.5, panel b, red bars) compared to those
generated by the standard procedure is higher than 85%. On its turn, when we check
the internal consistency of the ranks generated with the method is even better and
could be greater than that reached with a standard sampling.
6.5.4 Network models
• Killworth-Bernard radio calls network. In their work [26], the authors asked
to 44 radio operators (nodes) to rank from 0 to 9 the frequency they had used to
call the rest of operators during last month. We have reconstructed our network
by assigning a link when the rank associated to it was greater than 1, which
produces 400 connections. Dataset available at [368].
• Graph theory glossary network. This network is constructed based upon an
on-line glossary of definitions of technical terms about graph theory [367]. In the
network, each node represents one concept; and a link points from one concept
to another if the latter is linked in the definition of the former. The network has
67 nodes (5 of the 72 terms in the glossary are not connected to any other) and
122 links (114 unidirectional links and 4 reciprocal interactions). No self-link is
allowed since a defined concept cannot be used in its own definition. Dataset
available in [368].
• Narragansett bay trophic web. The system [369] originally contained 220
interactions between 35 nodes. We have removed the links involving the nodes
associated to input, output and respiration fluxes, in order to take into consider-
ation only the trophic relationships between organisms. The effective size of our
system is, thus, 32 nodes and 158 links. Dataset available in [368].
• Everglades trophic web. The network described in [370] contains 69 nodes and
916 interactions. It describes the trophic interactions of the Everglades ecosystem
in the wet season. Dataset available in [368].
• Arabidopsis thaliana flower development cell fate determination net-
work. The network contains 15 nodes and 37 interactions among the genes that
control cell-fate during the process of flower development of the model plant
Arabidopsis thaliana[371].
6.5 — Materials and methods 
• MTB transcriptional regulatory backbone. From the whole genome wide
network compiled in [3], we have extracted the subnetwork that connects the
transcription and sigma factors. The dataset analyzed is the giant component of
that network and contains 65 genes and 130 interactions.
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Part IV
Epidemic models of disease spreading
on complex populations
–Brava comparación –dijo Sancho–, aunque no tan nueva, que yo
no la haya oído muchas y diversas veces, como aquella del juego del ajedrez,
que mientras dura el juego cada pieza tiene su particular oficio,
y en acabándose el juego todas se mezclan, juntan y barajan,
y dan con ellas en una bolsa, que es como dar con la vida en la sepultura.
–Cada día, Sancho –dijo don Quijote–, te vas haciendo menos simple y más discreto.
Miguel de Cervantes.
El Ingenioso Hidalgo don Quijote de la Mancha, 1605.
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Chapter 7
Spreading of persistent diseases
7.1 Introduction
As it has been discussed in the introduction of this thesis, one of the main character-
istics of TB spreading is a strong conceptual “bimodality” in what regards the latency
periods that span between bacterial infection and development of the disease. In this
sense, depending of the kind and the intensity of immune response that the host im-
mune system performs after initial infection with MTB bacillus, the individual can
suffer different fates. In most cases, after infection, the immune system succeeds at
containing bacterial growth, and bacteria remain under a growth-arrest regime within
lung granuloma. In such a case, the individual neither suffer any clinical symptom nor
becomes infectious for long periods of time, even for his whole life. Instead, if immune
system’s response is not strong enough, bacteria rapidly proliferate in the lungs and the
host suffers clinical symptoms and can transmit the pathogen by air [379, 382] rapidly
after infection, in a process that is commonly referred to as primo-infection. In addi-
tion, latently infected individuals can, generally after an immune-depression episode,
reach the active disease phase, even many decades later they were infected first.
These different phenomenologies use to be modeled in the context of mathematical
epidemiology of TB by the introduction of two different latent states through which
individuals pass after infection, which corresponds to the periods in which within-host
infection process is evolving but the individuals neither are infectious yet nor develop
any clinical symptom. These states use to be labeled as “latent-fast” and “latent-slow”
[422, 22]. In some cases, specially for more schematic modeling schemes [45], and
taking into account the huge differences between the typical latency periods associated
to fast and slow progressions from latency to disease, the latent-fast state is omitted,
and individuals suffering primo-infection are considered to directly bypass latency.
Estimating the probability of developing primo-infection after a contact, or lifetime
risk of progressing from latency to disease are not easy tasks; although there exists
studies that reach to often accepted estimations. So, it is commonly considered that
only 5-10% of the infections directly produce active TB [379, 382], while the ranges
in concerning the estimation of typical “half life” of latent state rounds about 500 y
[60], which means that most of infected individuals die from causes foreign to TB.
Remarkably, relevant divergences exist for some of these quantities when measured in
different local settings [392, 393], and there have been observed relevant dependences for
some of these parameters with individuals’ age too [22]. Nevertheless, the consequences
of such variations are far beyond the scope of the present chapter, and they will be
further discussed in chapter thirteen.
Here, our first objective is to perform an exhaustive characterization of the dy-
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namical properties of the spreading of a persistent disease whose disease’s infection
cycle presents the mentioned cardinal properties of TB transmission, both on homo-
geneous and heterogeneous populations. In order to do so, we introduce a simplified
model in which latent-fast state is omitted, that is not directly assimilable neither to a
pure susceptible-infected-removed scheme (SIR), nor to a SEIR (susceptible-exposed-
infected-removed), but it can be conceived as an interpolation between these two cases
mediated by a primo-infection probability parameter. Additionally, latency times as-
sociated to slow progression to disease are so long (from 5 centuries for the case of TB
[60, 22]) that encourage us to consider open populations explicitly accounting for births
and deaths caused for any cause foreign to TB in the populations under study. Very
remarkably, the variability of total population’s volume over time makes proportions of
susceptible, latent and sick individuals with respect to the varying population size ap-
pear in the model as more suitable variables from a mathematical point of view, rather
than numbers of individuals of each type -an abundant approach commonly found in
the literature [48, 60, 378]-.
In what follows, we focus on the analytical characterization of the epidemic thresh-
old of the model, that adequately reduces to those of the SIR and SEIR cases when
the adequate parameters are turned off. For homogeneous systems, we also perform
numerical simulations on randomly rewired networks simulating the aerial spreading
of the disease within a demographically homogeneous area and show that they agree
with the stationary proportions of susceptible, latent and sick individuals analytically
predicted by the model. In what regards the case of structured populations, as we
will see, this kind of dynamics introduce new problems essentially different from other
treated before. In spite of these new problems, that constrict us to search new both
analytical and numerical methods, the results achieved in this chapter are consistent
and points in the same direction that previous works related to other kinds of spread-
ing dynamics did; leading to the conclusion that virtually unbounded fluctuations in
contacts networks have a important enhancing effect on the epidemic spreading also in
this case of persistent infections.
The increasingly alarming situation about TB epidemiology evidences the need to
increase the effort in TB research in a global way. In the context of the study of
its epidemiology, new models must be developed in order to gain predictive skills; in-
corporating the recent theoretical advances referring to disease spreading on complex
heterogeneous substrates as well as meta-population approaches and new computa-
tional tools for numerical analysis and simulation. In this sense, we aim to do a first
contribution by addressing the main influences that the topological structure of social
contacts in the network can exerts on its dynamics; and more specifically on one of the
most important parameters in epidemiological description: the epidemic threshold.
7.2 The model
In our model, we consider that individuals in the population are compartmentalized
into three groups: healthy, o uninfected -U(t)-, infected but not infectious -or latently
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infected L(t)- and sick individuals with TB T (t) which are infected and are infectious
as well. The transition between these subpopulations proceeds in such a way that a
healthy individual acquires the bacteria through a contact with an infectious subject
with probability λ. In its turn, this newly infected individual may join the class T
directly with probability p. However, the most common case is the establishment
of a dynamic equilibrium between the bacillus and the host’s immune system, which
allows the survival of the former inside the latter. When this happens, newly infected
individuals become latently infected, because despite harboring the bacteria within
them, neither becomes sick nor is able to infect others, as his sputum lacks bacterial
presence.
On the other hand, after a certain period of time (which may be, as we have already
noted, many years) and usually following an episode of immunosuppression, the balance
between the bacterium and its host can be broken. In this case, bacteria grow and
the individual falls ill beginning to develop the clinical symptoms of the disease. In
addition, if the infection attacks the lungs (pulmonary TB, which we consider as the
only possibility), the bacillus is present in the sputum, making the guest infectious.
Once the contagion dynamics is defined, we also consider that the population
size varies concurrent to the disease spreading. To take this variation into account,
we add to the model demographical fluxes −births and deaths not related with the
disease−. Hence, bN new individuals per unit time are added to the population −all
of them healthy− and µN are removed (i.e., deceased individuals are homogeneously
distributed among the three classes). According to this scheme, b represents the birth
rate of the population and µ its natural death rate. Finally, latent individuals go to
the active phase at a relapse rate r that represents, essentially, the inverse of the mean
latency period. This implies a flux of rL individuals per unit time abandoning the
latency class and entering into the active phase. Moreover, sick individuals die at a
rate µtb.
As it has been pointed out before, the model here described can be interpreted like
an interpolation between a simple SIR model and a chain-like SEIR model, in which any
infected individuals join the SIR or the SEIR branch according to the primo-infection
probability p. A formal characteristic of the model is that class R is not explicitly
considered, but associated to the class of individuals who have dead by the disease.
7.2.1 Model formulation for homogeneous populations
Once we have sketched the principal characteristics of the spreading dynamics of a
persistent disease like TB, and once we have outlined how to model it, one principal
feature to consider is the structure of the network of contacts upon which the disease
is going to spread over hosts populations.
The classical, first and simplest hypothesis regarding this particular consists of con-
sidering an homogeneous population within which each individual has the same number
of contacts with all his neighbors (let us call this homogeneous connectivity β). This
way, all the individuals in the system can be considered to be dynamically equivalent
as a first approximation. Such an hypothesis, thoroughly studied across XXth cen-
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tury since the seminal works by Kermack and McKendrick [61, 62], is commonly called
mean field (MF) hypothesis, as according to it, for example, the risk of infection of any
healthy individual is the same for all of them, and depends on the overall state of the
population, which defines an approximated mean field related to disease burden levels.
Figure 7.1 shows the flux diagram of the different transitions that define our epi-
demic model, according to a MF formulation:
Figure 7.1: Flux diagram of our model for spreading of persistent infections on homogeneous
populations. Labels represent the possible transitions between the compartments in which
the whole population is divided according to the individuals’ state. The model assumes a well
mixed population of varying size. Parameters are introduced in the main text.
The corresponding mathematical description is given by the following system of
ODEs:
dU(t)
dt
= bN(t)− λβU(t) T (t)
N(t)
− µU(t),
dL(t)
dt
= (1− p)λβU(t) T (t)
N(t)
− (µ+ r)L(t), (7.1)
dT (t)
dt
= pλβU(t)
T (t)
N(t)
+ rL(t)− (µ+ µtb)T (t),
in which:
N(t) = U(t) + L(t) + T (t) represents the total population at time t,
β is the number of contacts per time unit,
λ is the probability that the bacteria is transmitted to a new host after a contact with
an infectious subject,
b is the birth rate per capita and per unit time,
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µ is the natural death rate per capita and unit time,
µtb is the rate of disease-related deaths per capita and unit time,
r is the transition frequency of latent infection (i.e., the probability that a latently
infected individual becomes infectious),
with the closure relationship:
dN(t)
dt
= (b− µ)N(t)− µtbT (t). (7.2)
However, the description of the dynamical system in terms of the number of indi-
viduals is nevertheless not an optimal choice. To evaluate the impact of the spreading
process on a population of varying size, it is more reasonable -and mathematically
kinder- to study the temporal evolution of the densities of healthy, latent and sick
individuals, rather than the number of individuals of each type. In order to do that,
we define the respective densities as:
u(t) =
U(t)
N(t)
,
l(t) =
L(t)
N(t)
, (7.3)
t(t) =
T (t)
N(t)
.
In this way, we recover a non-dimensional closure relationship u+ l+ t = 1. Taking
into account that
du(t)
dt
=
1
N(t)
(
dU(t)
dt
− udN(t)
dt
)
,
dl(t)
dt
=
1
N(t)
(
dL(t)
dt
− l dN(t)
dt
)
, (7.4)
dt(t)
dt
=
1
N(t)
(
dT (t)
dt
− tdN(t)
dt
)
,
the temporal evolution of the system in terms of densities is finally given by:
du
dt
= b− (λβ − µtb)ut− bu,
dl
dt
= (1− p)λβut+ µtblt− (b+ r)l, (7.5)
dt
dt
= pλβut+ µtbt
2 − (b+ µtb)t+ rl.
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This kind of approach is specially suitable for open populations [48, 18], though
it is not the only possible choice [60, 381]. Note that in the previous equations the
natural death rate does not appear anymore, as natural deaths affect equally all the
subpopulations.
This model is probably the most simple that can be built, yet resembling TB
spreading dynamics at a conceptual level. An straightforward step to improve it would
consist on considering such eventual recovery fluxes in our model explicitly introduc-
ing the “hidden” class R; as well as the possibility of further relapses (the so called
endogenous reactivation). These phenomenologies are important, mainly for diseases
like TB, which only feasible treatment in many areas consists on the supplies of large
antibiotics series; the often scarce efficiency of which depends strongly on the constancy
of patients and the tracking capacity of public health systems. Further refinements,
like the inclusion of varieties of less infectious extra-pulmonary disease, could also have
important consequences on disease dynamics.
7.2.2 Reformulation for heterogeneous populations
The model exposed in the precedent lines describes the dynamics of the epidemics
in the homogeneous MF case. However, as argued in the introduction, the number
of contacts of a given individual in a population can vary; which is reflected in an
heterogeneous distribution of the number of contacts in the system. To account for this
fact, we substitute the single parameter β, corresponding to the number of contacts of
all individuals, with a connectivity parameter k, that is different for distinct individuals,
following a connectivity (or degree) distribution P (k). The system of equations 7.2 has
to be modified accordingly. Assuming that all individuals with the same number of
contacts, i.e., belonging to the same connectivity class k, are dynamically equivalent, we
pass from a pure MF approach to the so-called heterogeneous mean field approximation
(HMF), and the new system of differential equations is formulated for each degree class.
Therefore, for a structured population, we have that:
Nk(t) = P (k)N(t), (7.6)
with:
Uk(t) + Lk(t) + Tk(t) = Nk(t). (7.7)
Moreover, it is convenient to reformulate the model in terms of densities, also defined
within each connectivity class:
uk(t) =
Uk(t)
Nk(t)
,
lk(t) =
Lk(t)
Nk(t)
, (7.8)
tk(t) =
Tk(t)
Nk(t)
,
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so that the following closure relation for any value of k is verified:
uk(t) + lk(t) + tk(t) = 1 ∀(k, t). (7.9)
On the other hand, the probability Θ that any given link points to an infectious indi-
vidual is given by:
Θ(t) =
∑
k kTk(t)∑
k kNk(t)
=
∑
k kP (k)tk(t)N(t)∑
k kP (k)N(t)
=
∑
k kP (k)tk(t)
〈k〉 , (7.10)
which leads to the following set of equations that describes the dynamics within each
connectivity class:
dUk(t)
dt
= bP (k)N − λkΘ(t)Uk(t)− µUk(t),
dLk(t)
dt
= (1− p)λkΘ(t)Uk(t)− (µ+ r)Lk(t), (7.11)
dTk(t)
dt
= pλkΘ(t)Uk(t) + rLk(t)− (µ+ µtb)Tk(t).
Finally, the number of individuals with connectivity k evolves according to:
dNk(t)
dt
= (b− µ)Nk(t)− µtbTk(t) = (b− µ− µtbtk)Nk(t). (7.12)
At this point, and building on the previous equation, it is important to point out
a feature of the model: the influence of the infection dynamics on the connectivity
distribution P (k). First, if we add the above equation for all k, we obtain that the
total population evolves as:
dN(t)
dt
= (b− µ)N(t)− µtb
∑
k
Tk(t) =
(
b− µ− µtb
∑
k
P (k)tk
)
N(t). (7.13)
However, if we substitute Nk(t) = P (k)N(t) directly into Eq. (7.12) and assume P (k)
to be constant, we would arrive to:
P (k)
dN(t)
dt
= P (k) (b− µ− µtbtk)N(t). (7.14)
The last expression is only compatible with Eq. (7.13) under the unrealistic assumption
that all connectivity classes have the same proportion of sick individuals. We must
therefore assume that the distribution of connectivity is also a function of time: P (k, t),
and therefore:
dNk(t)
dt
=
d[P (k, t)N(t)]
dt
= N(t)
dP (k, t)
dt
+ P (k, t)
dN(t)
dt
, (7.15)
so, if we substitute Eq. (7.15) into Eq. (7.12) we get:
N(t)
dP (k, t)
dt
+ P (k, t)
dN(t)
dt
= P (k) (b− µ− µtbtk)N(t), (7.16)
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expression from which, if we replace dN(t)/dt from Eq. (7.13), we get the temporal
evolution of P (k, t) as:
dP (k, t)
dt
= −P (k, t)µtb [tk(t)− 〈tk〉(t)] , (7.17)
where
〈tk〉(t) =
∑
k
P (k, t)tk(t). (7.18)
The last step is to reformulate all the equations so as to express all of them in terms
of densities. Using the definitions of the densities given above, we rewrite the system
of equations for each dynamical state and degree class as:
duk(t)
dt
= b− uk(t)(b+ λkΘ(t)− µtbtk(t)),
dlk(t)
dt
= (1− p)λkΘ(t)uk(t)− (b+ r)lk(t) + µtblk(t)tk(t), (7.19)
dtk(t)
dt
= pλkΘ(t)uk(t) + rlk(t)− (b+ µtb)tk(t) + µtbtk(t)2.
7.3 Dynamics of persistent infections in homogeneous
populations
7.3.1 Epidemic threshold
Epidemiological models are aimed at reproducing actual epidemic outbreaks as accu-
rately as possible. Their final goal is to anticipate the course of an outbreak or even
make predictions in real time, which will provide health authorities with new means to
fight disease contagion. However, compartmental models in epidemiology share, despite
of particularities of each model, a common dynamical outcome [43, 44, 45]. Typically,
in these kind of models the parameter (phase) space is divided in two regions. In one
of them, an initially healthy population remains macroscopically unaffected after the
addition of a small fraction of infectious individuals, while, in the other, the disease is
able to spread to affect a macroscopic fraction of the population. That is, there are two
regions in the parameter space: a disease-free region and an active region. The critical
epidemic point or epidemic threshold divides the two regions of the phase space. The
determination of the epidemic threshold is one of the key goals of epidemiology, for
this would allow designing efficient vaccination campaigns and other countermeasures
[381]. This will also be our main objective. To this end, let us first characterize the
fixed points of the dynamics described in 7.6, which have to verify:
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du∗
dt
= 0 = b− (λβ − µtb)u∗t∗ − bu∗,
dl∗
dt
= 0 = (1− p)λβu∗t∗ + µtbl∗t∗ − (b+ r)l∗, (7.20)
dt∗
dt
= 0 = pλβu∗t∗ + µtbt∗
2 − (b+ µtb)t∗ + rl∗.
In Eq. 7.21. only two the equations are independent due to the closure relationship
u+ l + t = 1. The trivial solution for the system 7.21 is the fixed point corresponding
to a disease free population: (u∗, l∗, t∗) = (1, 0, 0). In order to look for not trivial fixed
points, we can work out u∗ from the first equation in 7.21 to obtain:
u∗ =
b
(λ− µtb)t∗ + b, (7.21)
which, after substitution in the third equation in 7.21 gives
dt∗
dt
= 0 = t∗
h
µtb(λβ − µtb)t∗2 + [µtbb− (µtb + b+ r)(λβ − µtb)]t∗ + [λβ(pb+ r)− (r + b)(µtb + b)]
i
. (7.22)
This equation is quadratic except for the common factor t∗, which in turns guar-
antees stationarity of the disease free fixed point. So, we could write down explicitly
the analytical expressions of the additional two solutions t∗1 and t∗2 of the quadratic
trinomial. However, if we call:
µtb(λβ − µtb)t∗2 + [µtbb− (µtb + b+ r)(λβ − µtb)]t∗ + [λβ(pb+ r)− (r + b)(µtb + b)] = ζt∗2 + ηt∗ + Θ, (7.23)
we can more easily determine the sign of the three coefficients ζ, η and θ depending on
the possible values of λβ:
• Main term ζ = 0←→ λβ = (λβ)1 = µtb.
• First order term η = 0←→ λβ = (λβ)2 = µtb µtb+2b+rµtb+b+r .
• Independent term Θ = 0←→ λβ = (λβ)3 = (r+b)(µtb+b)pb+r .
which, noting that for any parameter combination, it is verified that
(λβ)1 < (λβ)2 < (λβ)3, (7.24)
allows us to construct the following sign table for the phase portrait description of the
model’s dynamics:
Let us focus firstly on the point t∗ = 1, that apparently can appear as a dynamical
attractor for the physically meaningful range 0 ≤ t ≤ 1 in all the regions, with a basin
of attraction that corresponds, for regions 2 to 4, to values of t that are greater than
the largest solution of Eq. 7.22, that is, when ζ > 0 (i.e. λβ > µtb):
t∗max =
−η +√η2 − 4ζθ
2ζ
, (7.25)
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Region 1: 1→ 2 Region 2: 2→ 3 Region 3: 3→ 4 Region 4:
λβ < λβ1 λβ = λβ1 λβ1 < λβ < λβ2 λβ = λβ2 λβ2 < λβ < λβ3 λβ = λβ3 λβ3 < λβ
ζ - 0 + + + + +
η + + + 0 - -
θ - - - - - 0 +
ζ - 0 + + + + +
t∗1 + t
∗
2 = −η/ζ + N.d. - 0 + + +
t∗1t
∗
2 = θ/ζ + N.d. - - - 0 +
Phase portrait
Table 7.1: Stability characterization for t∗ values at stationarity.
or with minus sign before the root, when ζ < 0. In region 1, the basin of this hypo-
thetical disease free attractor corresponds to the values of t > t∗min, where we denote
by t∗min the smallest solution of 7.22. Note that, provided that t < 1, entering the basin
of attraction leads to t˙ > 0 until t = 1. However, we should also consider the temporal
evolution of N . More precisely, it is easy to see that, when proportion of infectious
individuals exceeds the threshold:
tlimit =
b− µ
µtb
, (7.26)
the spreading process is able to cause a demographical decay in the population, i.e.,
N˙ < 0. This behavior continues to be so until the annihilation of the whole population.
Therefore, as it can be seen from Table 7.1, when the proportion of sick individuals is
greater than t∗min −in region 1− or t∗max −in regions 2 to 4−, the proportion of sick
individuals grows up indefinitely. This growth of the density of infectious individuals
eventually causes that the whole population dies out. Therefore, the point t = 1 is
everything but an stable point of the dynamics, as it leads to population’s extinction.
So, at least in regions 1 to 3, the only −also stable− possible fixed point corresponds
to the disease free state, i.e., to t∗ = l∗ = 0.
The situation is different in region four, where there exist an additional stable
stationary value for t∗ > 0. Hence, in this region, the previous fixed point t∗ = l∗ = 0
is unstable and the transition between regions three and four defines the epidemic
threshold, which is given by the condition:
(λβ) = (λβ)c =
(r + b)(µtb + b)
pb+ r
. (7.27)
As a matter of fact, there is a simpler way to obtain the threshold Eq. 7.27. The
condition for the singularity of the Jacobian matrix in the vicinity of the disease-free
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fixed point reduces to: ∣∣∣∣∣∣
−b 0 −(λβ − µtb)
0 −(b+ r) (1− p)λβ
0 r −(b+ µtb) + pλβ
∣∣∣∣∣∣ = 0, (7.28)
that leads to the same threshold in Eq. 7.27., or expressed as it is usually found in the
literature:
(λ)c =
1
β
(r + b)(µtb + b)
pb+ r
. (7.29)
Finally, it is worth noticing that the result Eq. 7.29 reduces to the well-known threshold
for the SIR model [45] when we take b = µ = 0 and p = 1. In turn, when taking p = 1.
7.3.2 Numerical simulations.
In this section, we compare the analytical, stationary proportions predicted by the
model −those that constitute the solution of the system Eq. 7.21 and that can be
easily derived by explicitly working out t∗ at 7.22 and substituting it into 7.21− with
the results of numerical Montecarlo (MC) simulations.
We consider an initial population of No individuals distributed in the different
classes. At each time step, each sick individual contacts β randomly chosen individuals.
When one of these contacts is a healthy node −i.e., an individual belonging to U class−
the contagion is produced with a probability equal to the spreading rate λ. In the case
that contagion takes place, the newly infected node goes directly to the T class with
probability p. In the complementary case (with probability 1−p), the contagion causes
the individual to enter into latency. The results that follow have been obtained using
an initial population of No = 1000 individuals and we have taken β = 6. In addition
to the contagion dynamics, at each time step individuals of classes U and L leaves the
system with probability µ, while sick individuals die with a higher probability equal
to µ + µtb. Births are also simulated by introducing bN individuals −all of them into
class U−. Finally, the transition from latency to the infectious phase takes place with
probability r.
Regarding the parameter values, for birth and natural death rates −b and µ− we
have taken as a reference the typical values of a developed country like Spain: b = 0.01
and µ = 0.009 events per capita and year. The rest parameters −those directly related
to the disease spreading− are not easily measurable on real populations. In spite of
this, plausible approximations can be made, and usually, typical validity ranges are
accepted in the literature [60]: r = 0.002, p = 0.07 and, finally µtb = 0.8 deaths due
to TB per capita and year. Therefore, the spreading rate will be our free, control
parameter (in part because it is the most harder to obtain). In particular, we explore
the region between λ = 0.5 and λ = 1.
Given the previous selection of parameters, it can be easily shown that we are
between regions 3 and 4. So, taken into account the analytical characterization of the
dynamics of the model made in the previous section, the only caution one should have
in mind is that the initial proportion of sick individuals should not be bigger than t∗max.
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Figure 7.2: t∗ values at stationarity vs the spreading rate. The figure shows the predicted
values of t∗ from the model and those obtained from MC simulations. Error bars correspond
to two times the standard deviations for the 100 realizations carried out for each numerical
point. Results were obtained for an initial population of No = 1000 individuals distributed
as (uo, lo, to) = (0.5, 0.4, 0.1). The rest of parameters are those discussed in the main text.
This will guarantee that the state t = 1 will not become an attractor of the system
dynamics. In this sense, it can be easily calculated that, for our set of parameters, the
largest solution of 7.22 is always greater than unity and thus the eventual state t∗ = 1
will never be an attractor for the dynamics. Moreover, substituting the chosen model
parameters in Eq. 7.29 predicts λc = 0.6.
Figure 7.2 compares the results derived from the analytical solution of the model to
those obtained from MC simulations. As it can be seen, although the analytical curve
is systematically above the numerical values, it lies within the limits of the error bars,
and therefore both are in agreement. Regarding the epidemic threshold, MC results
predict a somewhat smaller value for λc. Although the differences are not large and
the agreement can also be considered good, it is likely that these deviations come from
finite size effects and that working with larger system sizes will reduce the gap.
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7.4 Spreading of persistent diseases on heterogeneous
populations
7.4.1 Evolution of the degree distribution
After having successfully characterized epidemic thresholds on homogeneous popula-
tions, at this point it is appropriate to point out one aspect that will hinder any
equivalent analysis on heterogeneous systems. Here, our main goal will be to calculate
both numerically and analytically the critical value λc beyond which the population
presents an endemic proportion of sicks individuals. However, we expect λc to be de-
pendent on the ratio 〈k〉〈k2〉 , (as in previous works [8, 57]) which is in turn a function of the
connectivity distribution P (k). The degree distribution, as previously shown, changes
in time as the dynamics of infection progress. As we should see, we can handle this
time dependence analytically, but we should be forced to design a simulation method
to account for the rate of births and deaths and the effects of these two processes on
the degree distribution.
The aforementioned features might lead to a situation in which the infection dynam-
ics would modify the underlying structure of the network through which the disease is
being spread. Therefore, λc could also vary as it is intrinsically related to the first two
moments of a seemingly time-dependent degree distribution. The reason why we con-
sider the distribution of contacts per unit time as heterogeneous, even for the current
airborne-transmitted disease is based on the observation that the number of contacts
a person can have per unit of time is subjected to relevant sources of heterogeneity.
Firstly, what we can call geo-demographic, macroscopic heterogeneity, in which the
number of contacts depends on the population density in the region in which an indi-
vidual inhabits. Secondly, at a more individual, microscopic level, the heterogeneity
arises because the number of contacts depends, in a region of constant population
density (i.e., a town or neighborhood in a city), on the daily activity pattern of the
individual within that region. These two factors will define, ultimately, the function
P (k). Having that said, the assumption implicitly incorporated in the system of equa-
tions 7.19 does not hold. Note that this equation implies the connectivity of individuals
is hereditary and therefore that the number of births within each k class equals the
birth rate times the number of individuals within each k class, Nk = P (k, t)N .
The above situation would be equivalent to assume that the dynamics of the disease
being studied is the only one that influences the demographic structure of a population,
which is false, since it is clear that there are countless cultural, economic and social
factors that ultimately define the above levels of heterogeneity. We therefore assume
in what follows that the individuals of each generation are distributed among the
k classes according to an invariant distribution function, which we further assume
to be the initial degree distribution of the original network: P (k, to). As we shall
see, this assumption besides being more plausible, has the advantage that makes the
connectivity distribution to be roughly stable, and so will be the critical value λc.
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So, we have the following reformulation of the system of differential equations (7.11):
dUk(t)
dt
= bP (k, to)N − λkΘ(t)Uk(t)− µUk(t),
dLk(t)
dt
= (1− p)λkΘ(t)Uk(t)− (µ+ r)Lk(t), (7.30)
dTk(t)
dt
= pλkΘ(t)Uk(t) + rLk(t)− (µ+ µtb)Tk(t),
with the definition of the number of individuals in each class of connectivity:
Nk(t) = N(t)P (k, t), (7.31)
and inside each class:
Uk(t) = Nk(t)uk(t),
Lk(t) = Nk(t)lk(t), (7.32)
Tk(t) = Nk(t)tk(t).
Now the total population within each connectivity class verifies:
dNk(t)
dt
= bNP (k, to)− µNP (k, t)− µtbTk(t), (7.33)
so that, if we add in k, the last modification has no effect on the variation of the total
volume of the population. The temporal evolution of the degree distribution is now
given as:
dP (k, t)
dt
= b [P (k, to)− P (k, t)]− P (k, t)µtb [tk(t)− 〈tk〉(t)] . (7.34)
Finally, the equations for the densities read as:
duk(t)
dt
= b
P (k, to)
P (k, t)
(1− uk(t))− uk(t) (λkΘ(t)− µtbtk(t)) ,
dlk(t)
dt
= (1− p)λkΘ(t)uk(t)−
(
b
P (k, to)
P (k, t)
+ r
)
lk(t) + µtblk(t)tk(t), (7.35)
dtk(t)
dt
= pλkΘ(t)uk(t) + rlk(t)−
(
b
P (k, to)
P (k, t)
+ µtb
)
tk(t) + µtbtk(t)
2.
The question of the structure and evolution of the networks of contacts relevant for
transmission of airborne diseases is a subtle matter of recent interest in the literature of
infectious diseases modeling. One of the factors more relevantly affecting individuals’
connectivities within these networks is age [12]. In this sense, more detailed models
of airborne diseases’ spreading usually associates connectivity classes with age groups,
[391], fully describing age-to-age mixing patterns correlations via detailed contact ma-
trixes. Even if we are getting rid of any age-structure of our populations in our model,
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the hypothesis of considering the degree distribution quasi-stationary would translate
-in the context of such age-degree association- into a constant demographic structure
for the populations. Such association, however, mustn’t be taken too far, as our model
neither contemplates age-structure nor any aging dynamics. In further sections, the
influence of these aspects -very relevant for TB spreading dynamics- will be thoroughly
assessed in the context of more detailed data driven models.
7.4.2 Characterization of the equilibrium points.
The previous set of differential equations tells us how the different densities of interest
evolves within each connectivity class. Their corresponding macroscopic quantities are
defined as
〈u〉(t) =
∑
kP (k, t)uk(t),
〈l〉(t) =
∑
kP (k, t)lk(t), (7.36)
〈t〉(t) =
∑
kP (k, t)tk(t),
where 〈u〉(t), 〈l〉(t) and 〈t〉(t) are the mean densities of healthy, latent and sick indi-
viduals, respectively.
Let us now go one step further and characterize the equilibrium points. The magni-
tudes of interest are the average densities, so that an equilibrium point (〈u〉∗, 〈l〉∗, 〈t〉∗)
must verify by definition: (
d〈u〉∗
dt
,
d〈l〉∗
dt
,
d〈t〉∗
dt
)
= (0, 0, 0). (7.37)
We also impose a further constraint which is that the degree distribution of the network
is stationary, that is:
dP (k)∗
dt
= 0 ∀k. (7.38)
At this point one must ask whether macroscopic stability also implies stability within
each connectivity class. The answer is yes, if we also demand stability of the degree
distribution. Admittedly, if we equate expression (7.34) to zero and solve for the
stationary P (k, t)∗ we get:
P (k, t)∗ =
bP (k, to)
b+ µtb(t∗k − 〈t〉∗)
, (7.39)
which shows that this value depends on the microscopic scale tk. Therefore, the stability
of the degree distribution imposes a stationary condition on tk for all k, which in its
turns extends to the other densities l∗k and u∗k. Hence, we have:(
du∗k
dt
,
dl∗k
dt
,
dt∗k
dt
)
= (0, 0, 0) ∀k. (7.40)
The above condition is trivially satisfied for the solution (u∗k, l∗k, t∗k) = (1, 0, 0) ∀k, which
leads to a degree distribution exactly as the initial distribution. We next analyze the
stability of this solution, which shall allow us to characterize the epidemic threshold.
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7.4.3 Epidemic threshold
As we have said, in this section we will study the stability of the solution (u∗k, l∗k, t∗k) =
(1, 0, 0) ∀k. In this point, as we have already discussed, we find that, while no latent
or infected individual is introduced in the network, the degree distribution does not
change in time; so that P (k)∗ = P (k, to). This situation allows us to work with the
system of differential equations given by (7.19) instead of working with system (7.36).
Case p = 1
For simplicity and to gain some preliminary insight into the problem, we first study
the case p = 1. The latent subpopulation disappears (lk = 0 ∀k) and using uk + tk = 1
we get:
duk
dt
= b− uk(b+ λkΘ− µtb)− µtbt2k, (7.41)
where we have omitted temporal dependences, as we will do from now on. Looking for
the stationary solution, we have that the condition duk
dt
= 0 implies:
uk = −
(
1
2µtb
)(
b+ λkΘ− µtb ±
√
(b+ λkΘ− µtb)2 + 4bµtb
)
, (7.42)
from which the meaningful solution is the one with the negative sign. The previous
expression is consistent with the meaning of u∗ since we recover the expected result
u∗ = 1 when Θ = 0. Moreover, if we calculate the derivative with respect to Θ we get:
du∗k(Θ)
dΘ
=
λk
2µtb
(
−1 + b+ λkΘ− µtb√
(b+ λkΘ− µtb)2 + 4bµtb
)
< 0, (7.43)
which guarantees that u∗ will always be less than unity and therefore is a real, valid
solution. The study of the value of Θ in the steady state help us to identify the epidemic
threshold. We write:
Θ∗ =
1
〈k〉
∑
k
kP (k)t∗k = 1−
1
〈k〉
∑
k
kP (k)u∗k, (7.44)
which, after substituting u∗k for its value, leads to:
Θ∗ = f(Θ) =
1
2
− b
2µtb
+
λ〈k2〉
2µtb〈k〉Θ−
− 1
2µtb〈k〉
∑
k
kP (k)
√
(b+ λkΘ− µtb)2 + 4bµtb. (7.45)
The graphical interpretation of the above equation indicates that the existence of
an equilibrium point in which Θ∗ > 0 is equivalent to the existence of a point at which
f(Θ) cross the bisector of the first quadrant. Evaluating the second derivative of f(Θ)
one gets:
d2f(Θ)
dΘ2
=
−2bλ2
〈k〉
∑
k
P (k)k3
[(b+ λkΘ− µtb)2 + 4bµtb] < 0, (7.46)
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which ensures that the condition for the existence of such intersection is reduced to:(
df(Θ)
dΘ
)
Θ=0
=
λ〈k2〉
〈k〉
1
b+ µtb
= 1, (7.47)
from which the epidemic threshold is derived as:
λc =
(b+ µtb)〈k〉
〈k2〉 . (7.48)
Note that apart from the factor (b + µtb), the previous result, coincides formally with
the SIR model.
Case p 6= 1
This is a somewhat more involved case. For structured populations, the resolution of
the system of differential equations (7.36) cannot be done explicitly. The system; in
its homogenous version conduces to a of a cubic equation, finding the roots of which
is too complicated to be a useful strategy to cope with the problem. We next find the
epidemic threshold for the case p 6= 1 using two approaches. On one hand, we study
the time derivative of Θ. On the other hand, we will also make use of the singularity
of the Jacobian at the point (uk, lk, tk) = (1, 0, 0) to argue that the expression for the
critical threshold is given by:
(λ)c =
〈k〉
〈k2〉
(r + b)(µtb + b)
pb+ r
. (7.49)
Time evolution of Θ in populations with a low number of sicks. A first
approach to characterize the epidemic threshold in heterogeneous networks when p 6=
1 is to study the sign of the derivative of Θ at the onset of an epidemic outbreak.
We consider an initially healthy population in which a small proportion of infectious
individuals are introduced so that tk << 1 ∀k. The derivative of Θ is:(
dΘ
dt
)
Θ∼0
=
∑
k P (k)k
dtk
dt
〈k〉 +
∑
k tkk
dP (k)
dt
〈k〉 −
[∑
k P (k)ktk
〈k〉
][∑
k k
dP (k)
dt
〈k〉
]
(7.50)
which, after substitution of the values of the derivatives of P (k, t) and tk(t) leads to:(
dΘ
dt
)
Θ∼0
=
∑
k P (k)klk
〈k〉 + pλΘ
∑
k P (k)k
2uk
〈k〉 − (b+ µtb) Θ + µtbΘ
2. (7.51)
At this point we make two simplifications. The first and most easily justifiable is to
neglect the term Θ2. The second is related to the presence of lk in the above equation,
that we have to transform in a dependency with respect to tk. Specifically, we assume
to be sufficiently close to the stationary point (uk, lk, tk) = (1, 0, 0) as to be able to
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assume that the three derivatives vanishes. In other words, and focusing our attention
on latent and sick classes, we assume that:(
dlk
dt
)
Θ∼0
= (1− p)λkΘuk − (b+ r)lk + µtblktk ' 0, (7.52)(
dtk
dt
)
Θ∼0
= pλkΘuk + rlk − (b+ µtb)tk + µtbt2k ' 0, (7.53)
from which:
lk =
(1− p)(b+ µtb) tk − (1− p)µtbt2k
r + pb− µtbptk . (7.54)
After expanding the previous equation and taking the leading term one arrives to:
lk =
(1− p)(b+ µtb)
r + pb
tk, (7.55)
which allows to express the derivative of Θ as:(
dΘ
dt
)
Θ∼0
= Θ
[
r (1− p)(b+ µtb)
r + pb
− (b+ µtb) + pλ
∑
k P (k)k
2uk
〈k〉
]
. (7.56)
In the limit uk ' 1 ∀k the third term within brackets is the ratio 〈k2〉/〈k〉, from which
the epidemic threshold condition may be derived as:(
dΘ
dt
)
Θ∼0
= Θ
[
r (1− p)(b+ µtb)
r + pb
− (b+ µtb) + pλc 〈k
2〉
〈k〉
]
= 0, (7.57)
finally leading to the expected expression for the threshold:
λc =
〈k〉
〈k2〉
(r + b)(µtb + b)
pb+ r
. (7.58)
Analysis of the Jacobian While for well-mixed populations the condition of singu-
larity of the Jacobian allows to get the epidemic threshold in a straightforward way, for
heterogeneous populations the analysis of the Jacobian is a difficult task because Θ is
a function of each and every one of the tkś which translates into the need of calculating
a determinant whose order is three times the number of connectivity classes. What we
can reasonably do is to verify is the threshold condition is verified for systems in which
there are two or three different connectivity classes.
Population with two degree classes (Jacobian (6x6)) In the first case in
which only two different classes of connectivity exist, the Jacobian is just a quite
distasteful 6x6 determinant that, after some cumbersome and lengthy algebra can be
reduced to the expression:
J = b2(b+ r)(b+ µtb)
[
(b+ r)(b+ µtb) +
λ〈k2〉
〈k〉 (pb+ r)
]
, (7.59)
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which equated to zero leads again to the previously obtained expression for the epidemic
threshold:
λc =
〈k〉
〈k2〉
(r + b)(µtb + b)
pb+ r
. (7.60)
Population with three degree classes (Jacobian (9x9)) If we consider a
population with three degree classes, the algebraic complexity of the problem largely
increases as we now have a determinant to solve of 9x9 degree. However, we can proceed
as before getting the following expression for the Jacobian:
J = b3(b+ r)2(b+ µtb)
2
[
(b+ r)(b+ µtb) +
λ〈k2〉
〈k〉 (pb+ r)
]
, (7.61)
which only differs from the previous case (two degree classes) in the first three factors,
obviously leading to the same value for the threshold.
7.4.4 Numerical simulations
When designing numerical simulations to simulate the dynamics of the system under
study, we have two difficulties not previously addressed in the literature. These nu-
merical issues with which we have to deal are derived from the fact that we have a
system that is simultaneously open and structured. As a result of dealing with an open
system, new individuals are being added to the population at a rate given by the birth
rate. Additionally, these new individuals must enter the network of contacts with a
predefined connectivity. While deciding how many nodes our new individuals connect
to is not a problem, it certainly is to decide what are those nodes the newcomers will
be linked to, as this will impact the degree distribution in a nontrivial way. This is an
unavoidable numerical complication that we should face relentlessly if the analytical
calculations are to be compared with Monte Carlo simulations.
To this end, we have adapted a simulation method based on transition probabilities
first proposed in [59] for SIR models in complex networks. The numerical approach
consider all transitions between states that take place during the dynamical evolution
of the subpopulations, defined by the system of differential equations (7.36). When
dealing with structured populations, these transition rates depend, in general, on the
connectivity class within which they occur. Moreover, within each k-class seven tran-
sitions are possible:
type 1 Birth of healthy individuals,
type 2 Natural death of healthy individuals,
type 3 Natural death of latently infected individuals,
type 4 Natural or disease-related death of sick individuals,
type 5 Transition from a healthy to the latent state,
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ω1,k = bNP (k, to)
ω2,k = µNP (k, t)uk
ω3,k = µNP (k, t)lk
ω4,k = (µ+ µtb)NP (k, t)tk
ω5,k = (1− p)λkNP (k, t)ukΘ
ω6,k = pλkNP (k, t)ukΘ
ω7,k = rNP (k, t)lk
Table 7.2: Transition frequencies
type 6 Transition from a healthy to the sick (infectious) state,
type 7 Transition from a latent to the sick (infectious) state.
Each of these transitions is characterized by a characteristic transition rate ωi,k that
can be directly derived from the system of equations that characterizes the rate at
which they occur i (i = 1, 2...7) within the class k as:
Figure 7.3: Set of allowed transitions in the epidemic model within each connectivity class
Similarly, we define the sum of all these transition rates as the average rate at which
one transition (of any kind) occurs:
Ω =
∑
i,k
ωi,k. (7.62)
This average transition rate in its turn defines the characteristic or average time τ
elapsed between any two consecutive transitions, the latter being defined as the inverse
of Ω:
τ =
1
Ω
. (7.63)
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µ = 0.009 years−1,
b = 0.010 years−1,
µTb = 0.200 years−1,
r = 0.002 years−1,
p = 0.070,
Table 7.3: Parameter values
Given the previous definitions, the Monte Carlo algorithm is implemented in such a
way that at each MC step (of duration τ) one single transition takes place. Finally,
the probability Πi,k that a given transition actually happens, is calculated as:
Πi,k =
ωi,k
Ω
= τωi,k, (7.64)
which determines what of all possible transitions is realized at each time step τ .
We have made extensive numerical simulations of the model starting from an initial
population made up ofN ' 106 individuals, whose network of contacts follows an initial
degree distribution P (k) ' k−3. Moreover, every newborn individual join the system
with a degree that verifies the same connectivity distribution. As for the values of the
parameters of the dynamics, and thinking of typical values for persistent diseases; we
have set the following values:
Demographical parameters b and µ are roughly those of a country like Spain, while
the parameters p, r are in the range of typical values for the case of TB. µtb has been
chosen attending to numerical convenience (TB reaches a disease related mortality rate
that reaches 0.8). In the other hand, we note that we must give a numerical criterion
to define the stationary. In our simulations we first let the system evolve for 4500 years
and later take averages in a window of 10000 Montecarlo steps (which corresponds,
roughly, with a temporal lapse of 100 years), for the mean densities of healthy, latent
and sick individuals defined in (7.36). This is a long enough time and ensures all of the
outputs to the left of the threshold are stabilized to the state (1, 0, 0) (this is achieved
almost surely already for t ≤ 4000y).
With the values for the parameters as specified above, the epidemic threshold is
λc = 0.305. In the figure below, we have plotted the stationary proportion of sick
individuals for values of the probability of transmission λ belonging to the interval
[0, 0.5]:
In this case, we can observe that the difference between the predicted value for λc
by the model and the value registered by the simulations reached not more than 15%
of the analytical value. Being, however, the method not enough accurate to evaluate
this error properly, we have been dealing with a variation of the algorithm focussed
on improving the accuracy of λc register. In this variation we essentialy focus our
attention in the surroundings of the critical value, instead of sweaping all the values
for λ.
More specifically, we start by calculating the analytical value for λc and we start the
simulation there. At each realization, we expect 6000 years at an eventual arrival of the
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Figure 7.4: Stationary proportion of sick individuals for λ ∈ [0, 0.5]; with p = 0.07, r =
0.002, µtb = 0.2, µ = 0.009 and b = 0.010 (λc = 0.305). We can see the critical point at
λ ' λc. Error bars are smaller than symbol size.
system to the state (〈u〉, 〈l〉, 〈t〉) = (1, 0, 0). In case of this state would not be reached
in the 6000 years simulation, we consider that we are to the right of the critical point
and so, we move to the left in λ just a little quantity δλ = 0.01. If, in the other case,
we register the entire set of 10 realizations stabilized at state (〈u〉, 〈l〉, 〈t〉) = (1, 0, 0),
we assume to be to the left of the critical point and, in consequence, we perform a δλ
switch to the right. Each time that the algorithm change direction, we divide by two
the value of δλ until we reach ten reversals; so as to converge to an enough accurate
numerical λc. In order to compute the error for different initial population sizes, we
have performed simulations for No = 103, 104, 2 ·104 and 105; results are shown in table
7.4:
As we could expect of a finite size-effect, the larger is the size of the population,
the smaller is the absolute error between numerical and analytical thresholds.
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No Analytical Numerical Absolute error Percentile
λcA λcN |λcA − λcN | relative error
1000 0.52903 0.46968 0.05935 11.2
10000 0.42559 0,37595 0.04964 11.7
50000 0,37620 0,33088 0,04532 12.0
100000 0,35854 0,31926 0,03929 11.0
Table 7.4: Numeric and analytic characterization of epidemic thresholds for different net-
work sizes
7.5 Conclussions
We have discussed a model for the spreading of persistent infections in homogeneous
and heterogeneous populations. This kind of approach is particularly suited for diseases
like TB, where one can have at the same time new ingredients such as long latency
periods and primoinfections.
As a general conclusion of this chapter, we have addressed the way in which the
different dynamical features of TB affect its epidemic thresholds, and particularly, we
have derived the kind of influence that the topology of the network exerts on the overall
behavior of the epidemic spreading. In addition, we have outlined a rationale way to
address the influence of simultaneously taking into account open and heterogeneous
populations, which gives us insight for the development of more sophisticated models.
Connectivity fluctuations of the network play a major role by strongly enhancing the
infection’s incidence. This issue assumes a particular relevance in the case of scale-free
(SF) networks that exhibit connectivity fluctuations diverging with the increasing size
N of the network. SF networks are therefore very weak in face of infections presenting
an effective epidemic threshold that is vanishing in the limit N → ∞. In the case
of an infinite population this corresponds to the absence of any epidemic threshold
below which major epidemic outbreaks are impossible. These results strengthen the
epidemiological framework for complex networks reported for the susceptible-infected-
susceptible (SIS) model [8] and proposed as well for the SIR model [57].
Although for airborne transmitted diseases, contact networks’ heterogeneity doesn’t
seem to reach the extreme levels observed for the networks of sexual contacts relevant
for sexually-transmitted diseases [11] (i.e. scale-freedom [8]), the emerging picture after
these studies stimulate the re-analysis of several concepts of standard epidemiology
such as the “core group” or the characteristic number of contacts that appears to be
ill-defined in SF networks. The high heterogeneity of SF networks finds signatures also
in the different relative incidence within populations of varying connectivity k.
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Chapter 8
Dynamics of interacting epidemics
8.1 Motivation and modeling framework
As it has been pointed in the introduction to this thesis, in the way towards the
achievement of epidemic modeling platforms with quantitative description and fore-
casting abilities, an emergent research line in the field is the development of models
for the description of the concurrent spreading of more than one disease over the same
population [64, 65, 66, 67, 68]. These theoretical advances obeys to the need of im-
proving our understanding of many relevant real examples of couples (or groups) of
diseases that simultaneously transmit over human populations being able to modify
each others’ transmission patterns and burden levels. Some relevant examples of these
systems of interacting epidemics are formed by the different influenza strains that com-
pete each winter over the same host populations [71] and the syndemic system formed
by the human immunodeficiency virus (HIV) and certain opportunistic pathogens that
take advantage of the immune depression of HIV infected individuals to attack them
[69, 70]. As a relevant case of these HIV-favoured infections, in the regions of the world
in which HIV reaches highest prevalence levels –mainly sub-saharan Africa–, the radi-
cal increase of TB burden levels in the last two decades appears as a deadly side-effect
of HIV irruption that constitutes a major concern for national and international public
health authorities.
In this chapter, we propose a modeling framework, based on an HMF approxima-
tion, for the spreading of two concurrent diseases that interact with each other. By this
way, we aim to explore epidemiological scenarios in which the dynamical parameters
(i.e. infectiousnesses and recovery rates) of the diseases modeled depend, at the level
of single individuals, on whether the agents involved are infected (or recovered from)
only one of the diseases or both. In addition, we consider that neither the mechanisms
behind each disease evolution nor the contact networks through which they spread
have to be (in general) the same, and thus, these are considered independently for each
disease. Let us then consider that we have two diseases (disease 1 and disease 2) which
spread over two different networks of contacts: disease 1 propagates over network 1,
which has a mean degree 〈k〉 = ∑k,l P (k, l)k; whilst disease 2 does so over network
2, whose mean connectivity is equal to 〈l〉 = ∑k,l P (k, l)l. The composed degree dis-
tribution P (k, l) gives the proportion of nodes (individuals) having k and l links in
networks 1 and 2, respectively [409].
Taking that in mind, we will analyze in detail the dynamics of such a two-layer sys-
tem that represents the networks of contacts on top of which either two coupled SIS or
SIR processes spread. Although the topological description we use has attracted a lot
of attention lately, i.e., the so-called multilayer networks [230, 408], the main focus is
 Dynamics of interacting epidemics
to study what are the effects of the complex interplay between the different interaction
mechanisms considered and the temporal and topological scales onto the dynamical be-
havior of the diseases. Specifically, we explicitly derive the epidemic threshold of each
disease in terms of the parameters that characterize their evolution and the topology
of the networks of contacts. Remarkably, we find that the epidemic thresholds in the
SIR case are different from those of the SIS case, which is a consequence of the emer-
gence of new mechanisms of interaction and to the transitory nature of the epidemic
outbreaks in the SIR case. Additionally, different scenarios and limiting cases of both
theoretical and epidemiological interest are scrutinized. Finally, results from numerical
simulations are presented to validate our analytical results. Our work thus shows how
the different interaction mechanisms considered can give rise to new phenomenological
insights regarding the dynamics of interacting diseases.
8.2 The SIS scenario
As a first step, we will consider the baseline scenario in which the isolated dynamics of
each disease, when the second is absent, is described by a simple S-I-S scheme. Each
individual belonging to a composed connectivity class (k, l) can be in four different
dynamical states: susceptible with respect to both diseases SS(k, l), infected of both
II(k, l), and infected with the first (second) one and still susceptible to catch the second
(first) disease, IS(k, l) (SI(k, l)), being these quantities the proportion of individuals
at each disease state with composed degree class (k, l). Thus, we have that SS(k, l) +
IS(k, l) + SI(k, l) + II(k, l) = 1 ∀(k, l). In addition, regardless of the connectivities of
the nodes involved, we have eight possible contagion transitions after a contact (four
for each disease).
Figure 8.1: SIS-SIS interacting diseases model (a) Each of the diseases spreads over a
different network. Each individual belongs simultaneously to each network and can be (or
not) infected with each of the diseases. (b) Set of transitions allowed in the model. The
variables (SS(k, l), IS(k, l), SI(k, l), II(k, l)) represent the densities of individuals of each
type in the system having k neighbors in network 1 and l neighbors in network 2.
On the other hand, four other possible transitions correspond to the cases in which
infected individuals go back to the susceptible class. This amounts to a total of twelve
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Parameter Dynamical meaning
λ1 Baseline infectiousness of disease 1
λ2 Baseline infectiousness of disease 2
µ1 Baseline recovery rate of disease 1
µ2 Baseline recovery rate of disease 2
βa1 Variation of disease 1 infectiousness due to the fact
that the susceptible individual exposed to disease 1
is infected with disease 2
βa2 Variation of disease 2 infectiousness due to the fact
that the susceptible individual exposed to disease 2
is infected with disease 1
βb1 Variation of disease 1 infectiousness due to the fact
that the spreader is also infected with disease 2
βb2 Variation of disease 2 infectiousness due to the fact
that the spreader is also infected with disease 1
η1 Variation of disease 1 recovery rate for individuals
also infected with disease 2
η2 Variation of disease 2 recovery rate for individuals
also infected with disease 1
Table 8.1: Definition of model parameters
elementary transitions, schematized as follows (see also Figure. 8.1):
IS + SS
λ1−→ IS + IS
IS + SI
βa1λ1−−−→ IS + II
II + SS
βb1λ1−−→ II + IS
II + SI
βa1β
b
1λ1−−−−→ II + II
SI + SS
λ2−→ SI + SI
SI + IS
βa2λ2−−−→ SI + II
II + SS
βb2λ2−−→ II + SI
II + IS
βa2β
b
2λ2−−−−→ II + II
IS
µ1−→ SS
SI
µ2−→ SS
II
η1µ1−−→ SI
II
η2µ2−−→ IS
The model thus contains two basic infection probabilities –λ1 and λ2– as well as
two basic recovery rates –µ1 and µ2–, one for each disease. In addition, infection
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probabilities are affected by scaling factors –the four β’s and combinations of them–
and so are the recovery rates –by the η’s–, as it is explained in detail in Table 8.4. These
parameters describe the interaction of the diseases through three different effects that
are concurrently taken into account. The first effect is the variation of the susceptibility
of healthy individuals to get infected with one disease as a consequence of being infected
with another. This mechanism is described by βa1 for the variation of the infection risk
of disease 1 caused by disease 2, and βa2 , for the symmetric case. The second effect
is the change of the spreading capabilities of double-infected individuals with respect
to single-infected ones, which is described by the parameters βb1 and βb2, for diseases 1
and 2, respectively. The last effect is the variation of the infectious periods of double-
infected individuals also with respect to single-infected ones, described by η1 and η2.
Therefore, these parameters exhaustively describe all the ways in which two diseases
can interact according to a SIS scheme, and allow us to isolate the different effects of
one disease on the spreading of the other by making infectious individuals more efficient
spreaders or by making susceptible individuals more prone to get sick. Once we have
defined the whole set of parameters in table 8.4, we have all possible transitions between
dynamical states well defined (see Figure 8.1).
According to the scheme depicted in the figure (in which simultaneous double conta-
gions and recoveries from both diseases have been explicitly excluded), we can consider
that all individuals within the same composed connectivity class (k, l) are dynamically
equivalent, in order to get a composed HMF for the dynamical description of both
diseases which neglects, as a first approximation, further correlations. In this way, the
set of differential equations describing the evolution in time of the four densities of
individuals (SS(k, l), IS(k, l), SI(k, l), II(k, l)) is as follows:
˙SS(k, l) = −kλ1θIS1 SS(k, l)− lλ2θSI2 SS(k, l)−
−kβb1λ1θII1 SS(k, l)− lβb2λ2θII2 SS(k, l) + µ1IS(k, l) + µ2SI(k, l)
˙IS(k, l) = kλ1θ
IS
1 SS(k, l) + kβ
b
1λ1θ
II
1 SS(k, l)−
−lβa2λ2θSI2 IS(k, l)− lβa2βb2λ2θII2 IS(k, l)− µ1IS(k, l) + η2µ2II(k, l)
S˙I(k, l) = lλ2θ
SI
2 SS(k, l) + lβ
b
2λ2θ
II
2 SS(k, l)−
−kβa1λ1θIS1 SI(k, l)− kβa1βb1λ1θII1 SI(k, l)− µ2SI(k, l) + η1µ1II(k, l)
˙II(k, l) = kβa1λ1θ
IS
1 SI(k, l) + lβ
a
2λ2θ
SI
2 IS(k, l) +
+kβa1β
b
1λ1θ
II
1 SI(k, l) + lβ
a
2β
b
2λ2θ
II
2 IS(k, l)− (η1µ1 + η2µ2)II(k, l) (8.1)
where the θ parameters are defined in Table 8.2.
Combining the probabilities θs and defining the following two new parameters σ1 =
λ1(θ
IS
1 + β
b
1θ
II
1 ) and σ2 = λ2(θSI2 + βb2θII2 ) we obtain the average probabilities per link
for SS-nodes to become infected with disease 1 (σ1) or disease 2 (σ2). This allows us
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θIS1 =
P
k,l P (k,l)kIS(k,l)P
k,l P (k,l)k
probability that a given link of network 1 points to an IS node
θII1 =
P
k,l P (k,l)kII(k,l)P
k,l P (k,l)k
probability that a given link of network 1 points to an II node
θSI2 =
P
k,l P (k,l)lSI(k,l)P
k,l P (k,l)l
probability that a given link of network 2 points to a SI node
θII2 =
P
k,l P (k,l)lII(k,l)P
k,l P (k,l)l
probability that a given link of network 2 points to an II node
Table 8.2: Definition of parameters θ.
to rewrite the system of differential equations as:
˙SS(k, l) = −(kσ1 + lσ2)SS(k, l) + µ1IS(k, l) + µ2SI(k, l) (8.2)
˙IS(k, l) = kσ1SS(k, l)− lβa2σ2IS(k, l)− µ1IS(k, l) + η2µ2II(k, l) (8.3)
S˙I(k, l) = lσ2SS(k, l)− kβa1σ1SI(k, l)− µ2SI(k, l) + η1µ1II(k, l) (8.4)
˙II(k, l) = kβa1σ1SI(k, l) + lβ
a
2σ2IS(k, l)− (η1µ1 + η2µ2)II(k, l) (8.5)
Due to the closure relationship SS(k, l) + IS(k, l) +SI(k, l) + II(k, l) = 1 ∀(k, l), only
three of these four equations are linearly independent for each composed connectivity
class (k, l). Taking this into account, we next analyze the time evolution of the vector
(IS(k, l), SI(k, l), II(k, l)), since SS(k, l) = 1− IS(k, l)− SI(k, l)− II(k, l).
8.2.1 Epidemic thresholds
In order to analyze the most relevant dynamical properties of the system, we look for
the values (IS∗(k, l), SI∗(k, l), II∗(k, l)) that define the stationary state:
( ˙IS
∗
(k, l), S˙I
∗
(k, l), ˙II
∗
(k, l)) = (0, 0, 0)∀(k, l) (8.6)
for the system Eq. (8.5). In order to do that, we are forced to consider σ1 and
σ2 as additional parameters, although these two quantities are linear combinations of
the other variables and the ultimate responsible of the coupling among all connectivity
classes. As it happens commonly in this kind of models [400, 395], there exists a
trivial fixed point of the dynamics in which there are no infected individuals in the
system: (II∗1 (k, l), II∗2 (k, l), II∗(k, l)) = (0, 0, 0) ∀(k, l). This fixed point represents
the absorbing state of our model. In addition, there are other possible fixed points
for which the densities of infected individuals could be written as a function of the σ
parameters: (II∗1 (k, l, σ1, σ2), II∗2 (k, l, σ1, σ2), II∗(k, l, σ1, σ2)) 6= (0, 0, 0).
It is thus possible to get self-consistent equations for the variables σ as:
σ1 = f1(σ1, σ2) =
λ1
〈k〉
∑
k,l
P (k, l)k(IS(k, l, σ1, σ2) + β
b
1II(k, l, σ1, σ2)) (8.7)
σ2 = f2(σ1, σ2) =
λ2
〈l〉
∑
k,l
P (k, l)l(SI(k, l, σ1, σ2) + β
b
2II(k, l, σ1, σ2)) (8.8)
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The condition σ1 = f1(σ1, σ2) > 0 implies the existence of a stable active state for the
dynamics of disease 1, i.e., a state in which disease 1 becomes endemic in the population.
For this situation to take place for disease 2, the condition σ2 = f2(σ1, σ2) > 0 must
be fulfilled. Given the symmetry between the two expressions in Eq. (8.8), we will
only focus on the analysis of the first equation. In fact, it can be shown that always
∂2f(σ1,σ2)
∂σ21
< 0, which means that, if we think of the graphical solution of the equation
σ1 = f1(σ1, σ2), for this non trivial solution to exist –given that, obviously f(σ1 =
0, σ2 = 0) = 0– it must be verified that
[
∂f(σ1,σ2)
∂σ1
]
σ1=0
> 1, as in [400]. After some
algebraic operations, this condition yields the following expression:
λ1
∑
k,l P (k, l)k
2 l
2σ22β
a
2β
a
1β
b
1+lσ2(η2µ2β
a
1 +β
b
1(β
a
1µ1+β
a
2µ2))+µ2(η1µ1+η2µ2)
l2σ22β
a
2 η1+lσ2(η1µ1+η2µ2+β
a
2 η1µ2)+µ2(η1µ1+η2µ2)
µ1〈k〉 > 1 (8.9)
that allows us to derive the epidemic threshold as:
λc1(σ2) = µ1
〈k〉∑
k,l P (k, l)k
2 l
2σ22β
a
2β
a
1β
b
1+lσ2(η2µ2β
a
1 +β
b
1(β
a
1µ1+β
a
2µ2))+µ2(η1µ1+η2µ2)
l2σ22β
a
2 η1+lσ2(η1µ1+η2µ2+β
a
2 η1µ2)+µ2(η1µ1+η2µ2)
(8.10)
Looking at the latter expression −which contains the underlying topologies in a more
intricate way than for the uncoupled, classical case−, the threshold dependence on
disease 2’s prevalence via σ2 becomes explicit. If we evaluate λc1(σ2 = 0) we recover
the classical result λc1 = µ1〈k〉/〈k2〉 [8, 400]. Therefore, in the following we will refer
to this baseline case as primary threshold, λc1(0), whereas the more general case will
be referred to as the secondary threshold, λc1(σ2) (with σ2 > 0). Obviously, the same
stands for the primary (λc2(0)) and secondary thresholds (λc2(σ1)) of the second disease.
A particular case for the topologies on top of which both diseases are spreading
corresponds to the homogeneous MF version of the system, i.e., P (k, l) = δ(k−ko)δ(l−
lo), for which the last expression can be rewritten as:
λc1 =
λ2lo
ko
η1µ1(βa2 (λ2lo − µ2) + µ1) + η2µ2µ1
µ2(η2µ2 + η1µ1) + (λ2lo − µ2)(βa2βa1βb1(λ2lo − µ2) + βa1βb1µ1 + η2µ2βa1 + βa2βb1µ2)
(8.11)
An independent derivation of this expression can be obtained by analyzing the Jacobian
matrix of the homogeneous MF system analogous to Eq. (8.5) as it is shown in the
Appendix A.
8.2.2 Numerical simulations
In order to explore the quality of the threshold prediction of our model, we have
designed a Monte-Carlo simulation scheme in which a single state transition is allowed
per individual per time step. First, infected individuals will eventually spread the
disease(s) that they carry. As double events are not allowed at a single time step,
forbidden double transitions from SS to II are resolved by choosing the disease that
an individual will catch proportionally to the status of her infected neighbors: the more
neighbors one individual has, say, carrying disease 1, the more likely she will become
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infected with disease 1 rather than with disease 2. After the spreading loop is completed
for both diseases, infected nodes who have not suffered any contagion at the present
time step eventually get back to the susceptible state of the disease(s) they carry. To
avoid forbidden double transitions from the II class to the SS class, in those cases
the only disease the individual is going to recover from is also chosen stochastically,
according to the probabilities p1 = η1µ1/(η1µ1 + η2µ2) for the first disease, and p2 =
1− p1 for the second one.
Let us then explore first a simple scenario in which we assume that the dynamical
effects of one disease on the other are totally symmetric. In terms of the parameters
of the model, this implies that βa1 = βa2 = βb1 = βb2 ≡ β and η1 = η2 ≡ η. In this case,
let’s focus on two opposite scenarios: i) mutual enhancement: η < 1 and β > 1 and ii)
mutual impairment η > 1 and β < 1. In the case of mutual enhancement, individuals
who are infected with the second disease spread and become infected with disease 1
more easily than those who are not (this is because β > 1). In addition, since also
η < 1, infected individuals of disease 1 remain so for longer times if they are also infected
with the second disease. These two effects imply that the appearance of disease 2 in
the system enhances the spreading capabilities of disease 1. The reciprocal situation
is also true, as the interaction between both diseases is symmetric. Finally, in the
case of mutual impairment, the effects on the infectiousness and recovery rates are the
opposite, and so the appearance of one of the diseases at a certain prevalence impairs
the spreading of the other disease. In Figures 8.2–8.3, we represent the prevalence of
each disease, as a function of the baseline infectiousnesses (λ1, λ2) for a given set of
parameters after the introduction of infection seeds in the order shown. The networks
through which diseases spread are, for this first case, two uncorrelated Erdös-Renyi
(ER) graphs.
For the case of mutual enhancement (Fig. 8.2), given our set of parameters, the
analytically-obtained curves for the secondary threshold remain below the primary
thresholds, leading to the appearance of two regions in the plane (λ1, λ2), for which
it is verified that λc1(σ2) < λ1 < λc1(0) and λc2(σ1) < λ2 < λc2(0), respectively. The
dynamical relevance of these regions is that within them, the appearance of an outbreak
of one of the diseases is conditional to the previous installation of the other infection
in the system. In this way we can observe that, after an initial seed of IS individuals,
disease 1 does not become endemic in the region λc1(σ2) < λ1 < λc1(0) (fig. 8.2, panel a),
but then, after the outbreak of the second disease in the network, the same seed leads
disease 1 to become endemic in that same region (fig. 8.2 panel C) as predicted by our
model. Regarding the conjugate region in which λc2(σ1) < λ2 < λc2(0), we can see in
figure 8.2, panel e, that disease 2 directly becomes endemic after the introduction of
an infection seed SI due to the fact that, previously, disease 1 was already introduced
in the system.
The situation for the mutual impairment case is the opposite, and the secondary
thresholds remain, in this case, above the primary ones. So, in this scenario, we have
another couple of relevant regions in which λc1(0) < λ1 < λc1(σ2) and λc2(0) < λ2 <
λc2(σ1), respectively. In fig. 8.3, it is represented the behavior of the system under
these conditions. In panel a, we can see how disease 1 becomes endemic after the
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introduction of an initial seed above its primary threshold. Then, after introducing a
seed of disease 2, as shown in panel b for the area comprised between λc1(0) and λc1(σ2),
the prevalence of disease 1 vanishes. In other words, in that region, the introduction
of disease 2 makes it possible for the system to recover from disease 1. If we look at
the behavior of the second disease in the region in which λc2(0) < λ2 < λc2(σ1), we
see how the disease is unable to become endemic as a consequence of the fact that
the first disease has already been introduced in the system. This situation suggests
that, as it has already been addressed in the context of computational sciences [410],
the introduction of an infectious agent designed to immunize its host with respect to
another, more harmful infection, might be a conceptually feasible option to reduce the
prevalence of the latter, or even to eradicate it. This has also been recently reported in
the context of multi-strain diseases, in which more than one strain of the same disease
compete for the host population [64, 74].
Once the dynamics of the model has been exhaustively characterized when the
diseases spread over homogeneous networks, we move on and explore the influence of
degree heterogeneity on the dynamics. To this end we also perform intensive numerical
simulations in an analogous way, but using SF graphs of the same size as before with
different exponents. In Figure 8.4 we represent the final prevalence for each disease
in two configurations: reciprocally enhanced diseases −panels a and c− and impaired
spreading −panels b and d−. In both cases, network 1 (γ = 2.7, panels a and b) has
a greater power law exponent than network 2 (γ = 2.5, panels c and d). As it can be
seen, for both diseases and for both configurations, secondary thresholds are closer to
primary ones than in the case of homogeneous networks.
8.2.3 System sizes and epidemic thresholds: general case
In the previous sections we have described the baseline cases in which none of the
dynamical parameters vanishes, and both networks are, in each case, of the same
kind –ER or uncorrelated SF graphs–. A relevant theoretical question yet remains
unanswered, i.e., how the epidemic thresholds behave when the system size grows
and eventually reaches the thermodynamic limit. Regarding this question, we present
an exhaustive analysis in section 8.7.2, in which it is shown what are the conditions
that lead to have vanishing small secondary thresholds as a function of the underlying
topologies and some of the dynamical parameters − note, however, that this question
is of interest from a theoretical viewpoint, as strictly speaking all real systems are finite
and thus an effective epidemic threshold exits. In addition, our approach is based on
an HMF approximation, and that means that influences of dynamical correlations on
the analysis are neglected.
The results show that the secondary epidemic threshold associated to any of the
diseases that is spreading over a SF network with 2 < γ ≤ 3 vanishes at the thermo-
dynamic limit, regardless of the topology of the network on top of which its conjugate
disease propagates and of the values of the dynamical parameters. In an analogously
robust way, power laws with γ > 3 −or homogeneous degree distributions− yield fi-
nite, non vanishing secondary thresholds at the thermodynamic limit, regardless of the
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conjugate topologies or parameter values, with some exceptions.
The relevance of this result relies on the fact that the model predicts the same
behavior for the epidemic thresholds in heterogeneous and homogeneous networks as
compared with HMF models of uncoupled (single) diseases that spread over simple
networks. In addition, our analysis shows that the eventual vanishing of the epidemic
thresholds for infinite systems is only determined by the topology of the network under
consideration rather than by any possible coupling with another disease that spreads
over any other possible conjugate network within our model framework. However, there
is an exception to this general behavior which is meaningful from an epidemiological
viewpoint. This is the case when both diseases spread over two highly and positively
correlated SF networks with composed degree distribution P (k, l) = δ(k − l)αk−γ,
where δ stands for the Kronecker δ-function and α is a normalization constant. In that
situation, if we focus, for example, in disease 1, there exist two different interaction
schemes of interest for which we recover finite epidemic thresholds λc1 > 0 at the
thermodynamic limit even for SF graphs with 2 < γ ≤ 3:
• Case 1: Individuals infected with disease 2 become immune to infection by disease
1. βa1 = 0 ; (βa2 , βb2, βb2) are free parameters.
• Case 2: If βa1 6= 0, individuals infected with both diseases can not cause contagion
of disease 1: βb1 = 0. In addition, disease 1 can not cause total immunity to disease
2: βa2 6= 0. βb2 is a free parameter.
To illustrate this situation, we take as an example a particular case of the first
scheme, a mutual cross-immunity scenario given by βa1 = βa2 = 0. In order to point
out the role of inter-layer degree correlations on this effect, we can directly compare
the expression for the threshold when both networks are totally correlated with the
analogous expression derived from an uncorrelated combined degree distribution:
P (k, l) = δ(k − l)αk−γ → λc1(σ2) = µ1
〈k〉∑
k α
1
k2−γ
µ2
kσ2+µ2
(8.12)
P (k, l) = αk−γl−Γ → λc1(σ2) = µ1
〈k〉∑
k,l α
1
k2−γ
1
lΓ
µ2
lσ2+µ2
(8.13)
In Figure 8.5, we represent the values predicted by these expressions for different
network sizes, when γ = Γ = 2.5. As we can see in panel a, for uncorrelated networks,
regardless of the value of σ2, the threshold continuously decreases as we increase net-
work sizes. The result thus shows that the existence of a coupling with another disease
present in the system with a certain prevalence proportional to σ2, does not play any
role, since the degree heterogeneities are still the main reason leading to the vanishing
of the threshold at the thermodynamic limit. This picture turns out to be remarkably
different when we introduce positive, strong correlations between the two networks. In
that case, as we can see in panel b, the appearance of the second disease, characterized
by a certain prevalence level σ2 > 0, implies a sudden change in the behavior of the
threshold, that does not vanish anymore, even when N →∞.
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The influence of degree correlations between networks for this case of full cross-
immunity becomes evident also at finite sizes, since the differences between primary
and secondary thresholds, as seen in Fig. 8.6, are also greatly amplified. Another
eventually relevant effect that can be observed in the last figure is that the transition
that takes place at the epidemic threshold is much sharper in the case of correlated
networks. All the previous results point out that the worst scenario for the spreading
of a disease when it interacts with a second one that confers immunity to the former
corresponds to the case in which there is a correlation between heterogeneous networks
of contacts. This finding is essentially equivalent to what was found previously in [66],
what we have shown here is that the effect comes to revert the vanishing threshold at
the thermodynamic limit for a disease spreading on top of SF networks. In addition,
we have found that it is not needed for this effect to take place that the second disease
confers full immunity to disease one.
Remarkably all these “pathological” cases can be identified without abandoning
HMF descriptions. Beyond HMF, the behavior of epidemic thresholds vary with re-
spect to MF predictions as a consequence of dynamical correlations [401, 419]. Here,
however, we identify that the interactions between diseases can modify the size scaling
of thresholds from the classical MF picture without the need to recurring to dynami-
cal correlations, which, for certain cases, remarkably modify the whole picture at the
thermodynamic limit, even in annealed networks in which adjacency matrices are only
fixed on average, and so, dynamical correlations do not exist.
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Prevalence
Figure 8.2: Reciprocally enhanced spreading. Dynamical parameters: µ1 = µ2 = 0.75,
βa1 = β
b
1 = β
a
2 = β
b
2 = 1.3, η1 = η2 = 0.8. Networks: ER graphs: N1 = N2 = 5000 agents,
〈k〉 = 7, 〈l〉 = 8. The color maps represent the prevalence levels of diseases 1 – upper panels –
and 2 – lower panels –, at different stages of the Monte-Carlo simulations. Step 1 (panels a,d):
stationary levels after the initial introduction of an infection seed of disease 1 (IS = 0.005).
Step 2 (panels b,e): once stage 1 is completed, an infection seed of disease 2 (SI = 0.005)
is introduced, and stationarity is recovered. Step 3: (panels c,f): after stage 2, an additional
seed of infection 1 is re-introduced (IS = 0.005), and the stationary prevalences plotted.
Dashed and solid lines represent respectively primary and secondary thresholds predicted by
the model.
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Prevalence
Figure 8.3: Reciprocally impaired spreading. Dynamical parameters: µ1 = µ2 = 0.75,
βa1 = β
b
1 = β
a
2 = β
b
2 = 0.8, η1 = η2 = 1.3. Networks: ER graphs: N1 = N2 = 5000 agents,
〈k〉 = 7, 〈l〉 = 8. The color maps represent the prevalence levels of diseases 1 – upper panels
– and 2 – lower panels –, at different stages of the Monte-Carlo simulations. As it is done in
figure 8.2, we introduce successively three infectious seeds (IS, SI, IS) = (0.005, 0.005, 0.005),
and plot the stationary prevalences after each fluctuation in the three columns of the figure.
As it can be seen, the reintroduction of the third seed of infection 1 in the system does not
affect the prevalence levels, as global stability is reached after the second stage.
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Figure 8.4: Panels a and c: reciprocally enhanced spreading with βa1 = βb1 = βa2 = βb2 = 1.3,
η1 = η2 = 0.8, represented at the final stationary state. Panels b and d: reciprocally impaired
spreading βa1 = βb1 = βa2 = βb2 = 0.8, η1 = η2 = 1.3, also at the final state. Scale-free
networks are generated using the uncorrelated configuration model with N1 = N2 = 5000
agents, 〈k〉 = 4.00, and 〈l〉 = 5.11. The figure represents the final prevalence of diseases 1
(panels a and b) and 2 (panels c and d) in each case.
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Figure 8.5: Primary and Secondary threshold values as a function of the size of the systems
N for different values of σ1: 0.0 (primary threshold), 0.2, 0.4, 0.6, 0.8 and 1.0. Networks
are uncorrelated SF graphs (panel a) without correlations between them –panel a– or with
them –panel b, fully correlated–. Diseases interact according to a full cross-immunity scheme
β1a = β
2
a = 0 and γ = Γ = 2.5. The rest of the parameters are the same as in figure 8.2.
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Prevalence
Figure 8.6: Effect of degree correlations between the two SF networks on the steady
prevalence levels. Dynamical parameters: µ1 = µ2 = 0.75, βa1 = βa2 = 0. The rest of
parameters are irrelevant, as no II individual will appear in the system. Panels a and c:
final prevalence of diseases 1 and 2, respectively for uncorrelated SF networks: P (k, l) =
P (k)P (l) = αk−γl−γ . Panels b and d: final prevalence of diseases 1 and 2, respectively for
fully correlated SF networks: P (k, l) = αδ(k − l)k−γ . In both cases γ = 2.5.
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8.3 The SIR scenario
In the previous section we have studied the behavior of systems of interacting diseases
that spread according to a SIS scheme, thus leading, above the epidemic threshold, to
stationary, endemic states with a prevalence greater than zero. In the following, we
will explore the case of transient, interacting epidemic phenomena.
In order to do so, we can extend the framework and describe the dynamics of two
SIR epidemics interacting among them. In classical, non-interacting systems –either
homogeneous or heterogeneous–, the resemblance of both types of models translates
into a strong mathematical symmetry between them that yields identical expressions
for the epidemic thresholds under MF descriptions (i.e. when neglecting the effects of
dynamical correlations). In this section we will see the way in which part of this sym-
metry is broken as a consequence of the interacting nature of the epidemic processes.
Figure 8.7: Set of transitions allowed in the double SIR-SIR model. Yellow: contagion
processes. Blue: recovery processes
In this case, the first new aspect to note is that not just the condition of being
infected with one disease can modify subjects’ susceptibility to the conjugate infection,
but also whether they have been infected and recovered. For instance, this might
represent situations in which some kind of immunological memory is acquired after
the first infection −for example, partial immunity in front of other strains is gained
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New parameter Dynamical meaning
φa1 Variation of disease 1 infectiousness due to the fact
that the susceptible individual exposed to disease 1
has been infected and recovered from disease 2
φa2 Variation of disease 2 infectiousness due to the fact
that the susceptible individual exposed to disease 2
has been infected and recovered from disease 1
φb1 Variation of disease 1 infectiousness due to the fact
that the spreader has been infected and recovered
from disease 2
φb2 Variation of disease 2 infectiousness due to the fact
that the spreader has been infected and recovered
from disease 1
ζ1 Variation of disease 1 recovery rate for individuals
that have been infected and recovered from disease
2
ζ2 Variation of disease 2 recovery rate for individuals
that have been infected and recovered from disease
1
Table 8.3: Parameters describing the influence of R classes on the conjugate infection
after suffering an influenza infection, specially if both are phylogenetically close enough
[418]. This new phenomenology translates into the need of introducing new parameters
(see Table 8.3) describing new eventual interactions and transitions, as shown in Fig
8.7. The system of equations describing the dynamics is now:
˙SS(k, l) = −(kσ1 + lσ2)SS(k, l) (8.14)
˙IS(k, l) = kσ1SS(k, l)− βa2 lσ2IS(k, l)− µ1IS(k, l) (8.15)
S˙I(k, l) = lσ2SS(k, l)− βa1kσ1SI(k, l)− µ2SI(k, l) (8.16)
˙II(k, l) = βa1kσ1SI(k, l) + β
a
2 lσ2IS(k, l)− (η1µ1 + η2µ2)II(k, l) (8.17)
R˙S(k, l) = µ1IS(k, l)− φa2lσ2RS(k, l) (8.18)
˙SR(k, l) = µ2SI(k, l)− φa1kσ1SR(k, l) (8.19)
R˙I(k, l) = φa2lσ2RS(k, l) + η1µ1II(k, l)− ζ2µ2RI(k, l) (8.20)
˙IR(k, l) = φa1kσ1SR(k, l) + η2µ2II(k, l)− ζ1µ1IR(k, l) (8.21)
where all the parameters and variables that were present in the SIS formulation
retain their original meaning, with the nuance that now σ1 and σ2 have an extra term
related to the appearance of classes IR and RI:
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where θIR1 is the probability of a link of network 1 pointing to an IR node and θRI2 is
the probability of a link of network 2 pointing to a node in the RI state.
8.3.1 Epidemic thresholds
In order to characterize the epidemic threshold of disease 2, we need to study the
dynamics of the system around any point in which no infected individual of disease
2 has yet been introduced and so (SI(k, l), II(k, l), RI(k, l)) = (0, 0, 0)∀(k, l) as well
as θSI2 = θII2 = θRI2 = 0. Around such a disease free point -either fixed or not-, it
is trivial to see that all the partial derivatives of classes SI(k, l), II(k, l) and RI(k, l)
with respect to the rest of dynamic classes vanish. This makes the subset of vari-
ables {SI(k, l), II(k, l), RI(k, l)} locally autonomous around that point, and so, its
linearization might serve us to address the stability inversion yielding the emergence
of the epidemic threshold.
In addition, the dimensionality of the system can be greatly reduced, if we write the
equations driving the time evolution of the probabilities θSI2 , θII2 , and θRI2 , as follows:
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˙θRI2 =
∑
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where we have substituted 〈klSI〉 by 〈kl〉θSI2 , approximation which is valid around
the point (SI(k, l), II(k, l), RI(k, l)) = (0, 0, 0)∀(k, l). Obviously, as happened for
{SI(k, l), II(k, l), RI(k, l)}, all of the partial derivatives of θSI2 , θII2 , and θRI2 with re-
spect to variables unrelated to θSI2 , θII2 , and θRI2 vanish, which allows us to study the sta-
bility of the system with respect to disease 2 by linearizing the system: ( ˙θSI2 , ˙θII2 , ˙θRI2 ) =
f(θSI2 , θ
II
2 , θ
RI
2 ). The corresponding Jacobian matrix J can be calculated this way, and,
by evaluating the condition J = 0 for stability shift, the epidemic threshold takes its
final value:
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λc2(〈l2SS〉, 〈l2IS〉, 〈l2RS〉, σ1) =
(η2µ2 + η1µ1)(µ2〈l〉+ βa1σ1〈kl〉)ζ2µ2〈l〉
∆(〈l2SS〉, 〈l2IS〉, 〈l2RS〉, σ1) (8.24)
where the denominator function ∆ takes the form:
∆(〈l2SS〉, 〈l2IS〉, 〈l2RS〉, σ1) =
= (η2µ2 + η1µ1)(ζ2µ2〈l〉〈l2SS〉+ φa2φb2〈l2RS〉(µ2〈l〉+ βa1 〈kl〉σ1)) +
+(βb2ζ2µ2 + φ
b
2η1µ1)(β
a
1 〈kl〉σ1〈l2SS〉+ βa2 (µ2〈l〉+ βa1 〈kl〉σ1)〈l2IS〉) (8.25)
As we see, the threshold depends on the initial prevalence of disease 1 via σ1, 〈l2IS〉,
〈l2RS〉 (and 〈l2SS〉). In the case of having non concurrent outbreaks, we have that the
second disease arrives to the system after the outbreak of the first disease has come to
an end. In that case, we have that IS(k, l) = 0 and RS(k, l) = R1∞,k,l ∀(k, l), where
R1∞,k,l is the fraction of recovered individuals at the end of an outbreak of disease one
alone, in the composed degree class (k, l). In such a case, the problem is much simpler,
as σ1 = 〈l2IS〉 = 0, and 〈l2SS〉 = 〈l2〉 − 〈l2R1∞,k,l〉; and the threshold reads as:
λc2(〈l2〉, 〈l2R1∞,k,l〉) =
µ2〈l〉
〈l2〉+ (φa2φb2−ζ2)
ζ2
〈l2R1∞,k,l〉
. (8.26)
Obviously, if disease 1 has not yet appeared in the system, the threshold for disease
2 becomes λc2 =
µ2〈l〉
〈l2〉 , as in the classical, non interacting HMF case [58]. As done for
the SIS model, we refer to the latter expression as the primary threshold of disease 2,
in counterposition to the secondary threshold of Eq. (8.25).
8.3.2 Numerical simulations
A remarkable property of the threshold for the SIR scenario is that its dependence on
the dynamical state of the conjugate disease is more complex than in the SIS case.
Specifically, once an outbreak of one influencing infection is unfolding, the epidemic
thresholds of the other disease may vary with time in non trivial ways, depending on
the nature and intensity of the different interaction mechanisms present. Figure 8.8
shows results from numerical simulations illustrating the previous phenomenology and
the agreement with the analytical thresholds. Specifically, each panel represents the
case in which the infection seed of the second disease is introduced in different moments
for each topology, coinciding with different stages of the outbreak of disease 1: early
phases (panel a, SF and panel c, ER), outbreak’s peak (panel b, SF) and at the end of
the outbreak (panel d, ER). As we can see, regardless of the topology, the parameters’
values or the moment of appearance of the infection seed, our model adequately foresees
the epidemic threshold and its variations with time. As in the SIS case, the influence
of the interactions on the epidemic threshold is smaller in the case of SF networks, due
to the smaller values of the primary thresholds in that case (in fact, primary thresholds
have not been represented in panels a and b for the sake of clarity, because its values
λ12c = 0.00316 virtually overlaps the secondary ones).
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Figure 8.8: Epidemic thresholds in the SIR-SIR interacting epidemic model. Upper
panels: temporal evolution of disease 1, in a SF (left) and in an ER network (ER, right):
I1 =
∑
k,l P (k, l)(ISk,l + IIk,l + IRk,l)(t), R1 =
∑
k,l P (k, l)(RSk,l +RIk,l +RRk,l)(t). Dis-
ease one enhances the spreading of disease two in both cases, but still is not influenced by
the second infection. Lower panels: total number of affected individuals by disease 2 as a
function of λ2 in each network: R∞2 = limt→∞
∑
k,l P (k, l)(SRk,l + IRk,l +RRk,l)(t). Dy-
namical parameters: panels a, b: SF network: N = 5000, 〈k〉 = 4.00,〈l〉 = 5.11, λ1 = 0.02
µ1 = µ2 = 0.05, βa2 = βb2 = φa2 = φb2 = 1.3 η2 = ζ2 = 0.8 , panels c,d: ER network: N = 5000,
〈k〉 = 7,〈l〉 = 8, λ1 = 0.02 µ1 = µ2 = 0.05, βa2 = βb2 = 3, φa2 = φb2 = 1.2, η2 = 0.33,
ζ2 = 0.8. As said before, in both cases, disease 1 is not influenced by disease 2, and so:
βa1 = β
b
1 = φ
a
1 = φ
a
1 = η1 = ζ1 = 1.
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8.4 Conditions for disease enhancement and impair-
ment
Finally, it is interesting to analyze what combinations of parameters give raise to
situations in which there is either enhancement or impairment of the diseases, as well
as some other cases in which both effects are possible. This can be done for both the
SIS and the SIR scenarios by studying the sign of the difference between the primary
and the secondary thresholds.
For the SIS case, if we focus, for example, on the second disease, we have:
λc2(σ1)− λc2(0) =∑
k,l
C(k, l)σ1
[
βa1 (η2 − βa2βb2)kσ1 + (η2 − βa2βb2)µ2 +
(
η1(1− βa2 ) + βa1 (η2 − βb2)
)]
(8.27)
where C(k, l) is always positive. In this sense, λc2(σ1)− λc2(0) > 0 implies that disease
1 is reducing the epidemic threshold of disease 2, thus enhancing its spreading. In
the opposite case λc2(σ1) − λc2(0) < 0, disease 1 makes the secondary threshold for
disease 2 to be bigger than the primary one, hence impairing its spreading. As we can
see, the condition yielding one or another case involves a complex combination of the
parameters. However, it is trivial to show that, provided that βa2 > 1, βb2 > 1 and
η2 < 1, disease 1 enhances disease 2 spreading for any value of σ1 greater than zero.
We call this scenario coherent enhancement, because all the interaction mechanisms
contribute to enhance the spreading of disease 2. In a similar way, if βa2 < 1, βb2 < 1
and η2 > 1, the interaction has the opposite sign regardless of σ1, and we have a
situation of coherent impairment. Noticeably, if none of these conditions is fulfilled,
there exists the possibility that the sign of the influence that disease 1 exerts on the
spreading of disease 2 depends on its prevalence via σ1 (see below). In Fig. 8.9 we have
represented λc2(σ1)− λc2(0) for different parameter combinations that cover all possible
phenomenologies.
For the SIR case, the proliferation of dynamical classes and the possibility that
other mechanisms (i.e., those including R individuals) carry the interaction between
both disease makes the equivalent expression more complex, but still derivable as:
λc2(〈l2SS〉, 〈l2IS〉, 〈l2RS〉, σ1)− λc2(〈l2〉, 0, 0, 0) = C ′[µ2〈l〉(η1µ1 + η2µ2) ·
· (ζ2βa1σ1〈kl〉〈l2〉+ ζ2µ2〈l〉〈l2IS〉+ ((ζ2 − φa2φb2)µ2〈l〉 − βa1 〈kl〉σ1)〈l2RS〉) − (8.28)
−〈l〉µ2(φb2η1µ1 + βb2ζ2µ2)
(
βa1σ1〈kl〉〈l2SS〉+ βa2 (µ2〈l〉+ σ1〈kl〉)〈l2IS〉
)
]
where C ′ is always positive too.
As we have already said, in the interacting SIR model, once an outbreak of one
disease has started, the temporal dependence of the epidemic threshold of the second
infection depends on the dynamic state of the system as well as on the parameter values
that account for the mechanisms of interaction that are present in the system and their
intensities. In such a case, if the interaction between the diseases is mediated by the
class R, (i.e. being recovered of one disease is what makes subjects dynamics with
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Figure 8.9: Relative variation of epidemic threshold of disease 2 as a function of σ1 for
different parameter sets. Black: (coherent enhancement of disease 1 over disease 2): λ1 = 0.2,
µ1 = µ2 = 0.3, βa2 = βb2 = βa1 = βb1 = 1.1, η1 = η2 = 0.9. Blue: (coherent impairment of
disease 1 over disease 2): λ1 = 0.2, µ1 = µ2 = 0.3, βa2 = βb2 = βa1 = βb1 = 0.9, η1 = η2 = 1.1.
Red: λ1 = 0.2, µ1 = 0.4, µ2 = 0.2, βa2 = βb2 = 1.5, βa1 = 4, βb1 = 0.5, η1 = 0.4, η2 = 2. Green:
λ1 = 0.2, µ1 = 0.4, µ2 = 0.2, βa2 = 0.5, βb2 = 1.5, βa1 = 4, βb1 = 0.5, η1 = 0.4, η2 = 1. The
networks are two ER graphs: N1 = N2 = 5000 agents, 〈k〉 = 7, 〈l〉 = 8.
respect to the other infection to be altered, and so β and η parameters are equal to 1),
the density of individuals belonging to the R class is a monotonically increasing function
of time. This trivially implies that, in general, the closer to its end is the epidemic
process for one disease, the deeper its impact on the conjugate one. However, if it is
the I class the one that carries the interaction, it is easy to see that that interaction
will take place if and only if the outbreak of disease two happens within a time window
that -at least partially- overlaps with that characterizing the outbreak of disease 1. In
such a situation, the interaction between the two diseases is a transitory property of
the system, and the shift in the epidemic threshold crucially depends on the temporal
co-occurrence of the outbreaks of both diseases.
A similar time-dependent shift of the epidemic thresholds can also take place in the
SIS model, for example for the thresholds of disease 2, if the difference λc2(σ1)− λc2(0)
changes its sign during an outbreak of disease 1, as a consequence of the evolution of
σ1. This is the scenario given by the green and red curves in Fig. 8.9. However, it
is worth remarking that such combinations of parameters are somehow pathological,
as they imply the appearance of diverse non-coherent mechanisms of interaction (i.e.
one disease simultaneously enhances subjects susceptibility to disease but, at the same
time, it reduces their infectiousness, etc.) that are epidemiologically less plausible. On
the contrary, in the SIR framework, this transitoriness is an intrinsic property of the
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system when the infected class is the responsible of influencing the dynamics of the
conjugate disease. This transitory nature of the interactions constitutes an essential
difference between the double SIR model with respect to the SIS one, which is at the
root of the remarkable difference between their corresponding thresholds and the richer
phenomenology of two interacting SIR-like processes.
8.5 Conclusions
In this chapter, we propose a composed HMF model to describe the simultaneous
spreading of two diseases over the same population but driven by independent mech-
anisms of transmission taking place on different networks of contacts. Within this
framework, we have thoroughly studied extensions of the SIS and SIR models, where
the parameters defining the infectious and recovery transitions of one disease depend
on the state of each node with respect to the conjugate disease, establishing in this way
a coupling between both diffusion processes. Our modeling approach presents different
advantages with respect to previous models [65, 66, 67, 68], as it simultaneously allows
analytical derivations of the epidemic thresholds and an approximate description of
the temporal evolution of the system, besides providing a way to isolate the effects
on spreading dynamics of each possible interaction mechanism, such as variations of
infectivity, susceptibility or infectious periods. In addition, it enables us to solve the
two paradigmatic modeling scenarios (SIS and SIR), identifying relevant differences
between the two cases that arise as a consequence of disease interactions.
The model here presented and analyzed, even if it is based on an HMF and so,
constitutes a first approximation to the problem that neglects dynamical correlations
among nodes, is able to identify novel phenomena qualitatively different to what is
found on HMF descriptions of non interacting systems. First, our model foresees
different thresholds for SIR and SIS models, which arises from the asymmetry between
the interaction mechanisms that take place under both models. Additionally, in what
regards size scaling of epidemic thresholds, at least in the SIS case, we have identified
some relevant situations that yield threshold dependences on network’s size which are
different from what is found in HMF models for single diseases. At this particular, it
is worth mentioning that asymmetries between SIS and SIR critical properties [419,
401], or a different behavior with respect to that predicted by the HMF for epidemic
thresholds [405] have also been identified in the context of single diseases spreading
over one network, if the HMF approach is abandoned.
The situation here is qualitatively different, as all these divergent results with re-
spect to classical HMF models of single diseases do not arise as a consequence of
considering any dynamical correlation but as a consequence of disease-disease inter-
actions. This has two relevant implications. On the one hand, deviations from HMF
results on epidemic thresholds on single diseases identified as a consequence of consid-
ering dynamical correlations are of quantitatively residual relevance, precisely because,
at the epidemic threshold, those correlations tend to vanish and, there, HMF models
perform consistently well [405]. Instead, in our case, differences between SIS and SIR
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thresholds, for example, are totally different, as they even may depend on conceptually
different interaction mechanisms. On the other hand, HMF is exact when dealing with
annealed networks [401], and so, on these type of networks which lack, by definition,
dynamical correlations, both SIS-SIR asymmetries and eventually anomalous threshold
dependences with size that we have identified in this chapter constitute phenomena not
found before.
In addition, for the first time, the modeling framework proposed here allows to
isolate the independent effects of the different mechanisms of interaction that can
determine the critical properties of the model. On the one hand, this allows us to foresee
that, in a SIS model, certain interaction schemes may yield to effects of one disease on
another of different sign as a function of the prevalence levels of the former. On the
other hand, for the SIR model, we have also discussed how the interaction between the
two diseases and the different dynamical classes give rise to a richer phenomenology. In
particular, we have shown that due to the transitory nature of SIR spreading processes,
the moment at which the interaction of the two diseases is made effective might greatly
determine the values of the epidemic threshold of the disease whose course is modified
by the other one.
Further advances in the field should address the influences of dynamical correlations
between nodes on the spreading of interacting epidemics. This constitutes a truly
conceptual challenge as, for example, pairwise descriptions of the disease dynamics
[419], should transform into quadruplet-based descriptions, as, in this case, dynamical
correlations go beyond the dynamical state of neighbors in a network, but comprises
both dynamical states on the two networks involved, which multiplies the complexity
of the description.
8.6 Confronting the model to data: the case of HIV-
TB syndemics in South-Africa
To illustrate the usefulness of our approach, let us discuss a real and relevant scenario in
which two diseases coexist in the same host population: that of the interaction between
the acquired immunodeficiency syndrome (AIDS) and certain infections that spread
from person to person and that are caused by opportunist pathogens usually associated
to the immunodeficiency syndrome in advanced phases of the disease. Examples of
these kind of diseases are respiratory disorders caused either by bacteria (like TB [251])
or fungi (like pneumonia caused by Pneumocystis [70]). Other examples of pathologies
that appear commonly associated to advanced stages of AIDS are infections generated
by the two variants of human herpes virus [69] and candidiasis [70], which is due to
the fungal pathogen Candida albicans.
In some regions, the increase of the epidemiological risk related to some of the
previous diseases after the irruption of HIV in the last decade of the XXth century
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TB prev. ·105 HIV prev. (%) % of HIV+ of new TB cases(%)
(1990 - 2000) (1990 - 2000) (1990 - 2000)
Malawi 352 - 356 6.08 - 9.80 51 - 69
Ethiopia 434 - 427 0.68 - 1.98 13 - 33
Tanzania 322 - 238 2.51 - 4.41 31 - 45
Kenya 243 - 262 1.19 - 5.12 17 - 52
Zimbabwe 239 - 328 5.54 - 15.19 69 - 92
Nigeria 287 - 307 0.41 - 1.86 2.2 - 25
South Africa 435 - 536 0.13 - 8.71 3.6 - 55
Table 8.4: Evolution of active TB and HIV infection prevalences in most-populated, high
HIV-burden countries in sub-saharan Africa (more than 1 million people estimated to live
with HIV). Data extracted from public databases for Tuberculosis (WHO TB database: [24])
and HIV (UNAIDS database curated by United Nations [411])
has reached the dimension of a major threat for public health. The paradigmatic case
is the recent boost of TB burden in sub-Saharian Africa, which is tightly related to
the dramatic prevalence levels of HIV in that region, as it can be seen in figure 8.10.
Given that our main purpose is to model these variations in the endemic prevalence
level of one disease due to the irruption of another infection, our SIS-based modeling
framework is the simplest way to recover an endemic equilibrium of a disease. In our
case, this endemic equilibrium can be altered as a consequence of the irruption of the
conjugate infection, in the same way that the appearance of HIV supposed an increase
of TB burden in certain countries like the Republic of South Africa.
Figure 8.11 shows a comparison of the results obtained with our model with real
data for the case of the Republic of South Africa during the period 1990-2011. In
particular, we represent the results of a run of the MF model with a set of parame-
ters obtained through a Levenberg-Marquard [413] least-squares fitting approach (see
Figure caption).
A first obvious conclusion extractable after a first glance on figure 8.11 is that, even
if a simple SIS is a caricatural simplification of the much more complex natural histories
of both diseases, our model is remarkably accurate at reproducing the disease burden
evolution for both pathologies and their combinations, after an adequate fitting pro-
cedure. This shows that our conceptual modeling framework is essentially compatible
with the observation of that the interaction between HIV and TB is the major force
responsible of TB enhancement in South-Africa; something which is currently accepted
as a dramatic, incontrovertible fact.
But even more relevant than the ability of the model to reproduce the burden
curves (fitting procedures –specially those that are highly parametric– many times
make wrong models reproduce real data), are the values of the parameters obtained
after the fitting procedure. The values of the parameters obtained through the fitting
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Figure 8.10: Scatter plot for the variation of active TB prevalence rates, HIV infection
prevalence and TB-HIV coinfection in the countries listed in table 8.4. The increase of HIV
infection and related immunodeficiency syndrome on the population in the last decade of
the XXth century has been identified as the main cause of the increase of TB incidence
and prevalence rates [157], as is evidenced not only by the correlation between HIV-infection
and active TB prevalences but also by the correlation between TB burden and HIV-TB
association frequencies. Remarkably, there exist some countries (Tanzania, Ethiopia) in which
HIV irruption has not been strong enough to prevent the decay of TB burden levels due to
other causes -paradigmaticaly socio-economic improvements and effective implementation of
specific public healths programs, generally speaking-, that is observed in most of the countries
worldwide (see chapter 9). Data extracted from table 8.4.
present two relevant features perfectly compatible to what is actually observed for the
syndemics HIV-TB.
On the one hand, the driving effect in the interaction between both epidemics, in
terms of our fitted model, seems to be the increased susceptibility of individuals to
get infected with one disease once infected with the other, rather than a significant
increment in the spreading capabilities of double-infected individuals (βa1 > βb1 and
βa2 > β
b
2). If we think about TB susceptibility of HIV-positive individuals, we have
that they are much more prune to develop TB (either after infection or endogenous
reactivation of disease) than HIV negative individuals [171], which is mapped, within
our modeling framework with a high value for βa1 . Instead, the lack of lymphocytes
that doubly infected individuals suffer (because of HIV) imposes a great limitation to
the magnitude of the immune response against TB bacilli, specially to its acquired
component. This immune system underperformance translate into an inability for the
host to adequately contain bacterial growth within lung granuloma, which have two
consequences: on the one hand, doubly infected individuals have a greater tendency to
develop extended forms of milliar TB, in which bacteria spread through the whole host
body; causing a medical condition with a very serious medical prognosis. On the other
hand, doubly infected individuals have great difficulties to contain bacterial growth
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within granuloma, which, at the end, means that smaller and lesser tuberculous cavi-
ties are formed in the lungs than what is found for HIV negative, TB patients. This
ultimately make doubly infected individuals much less infectious than HIV negative pa-
tients, as we remarkably attain after our fitting procedure (βb1 < 1). These phenomena
have been widely reported in medical literature [415, 416, 417], and even incorporated
on models for TB-HIV syndemics spreading [171] on homogeneous populations.
The explanation of how TB influences HIV contagion dynamics is, however, more
speculative. Although the enhancement of the infectiousness of doubly infected indi-
viduals (described by βb2) is the most modest effect among all infectiousness variations
of the model, the fitting procedure evidences a very strong increase for TB sick indi-
viduals’ susceptibility to HIV (βa2 > 30). This extreme enhancement effect seems to be
associated to an enhanced probability of receiving an HIV diagnosis corresponding to
a medical condition previously unnoticed, after a severe health worsening associated
to TB disease.
The second key feature of the parameter set we obtain as a result of the fitting
procedure is a reduced infectious period for doubly infected individuals for both dis-
eases, which translates in values for η parameters greater than one. This feature is also
perfectly compatible with real observations about HIV-TB syndemics in South Africa,
because of two reasons. The first of these is the heavy increase of the mortality rates
associated to TB-HIV co-infection [414], with respect to any of the diseases separately.
This crucial factor in the interaction between both diseases, although it is not explic-
itly described by our model, obviously contributes to reduce the infectious periods of
both diseases for TB-HIV co-infected individuals. The second reason is the increased
detection rate that is described for doubly infected individuals [171], which is related
with a faster tendency to recur to the health services associated after the fast health
decay that follows TB-HIV co-infection.
It is worth remarking that the actual interaction between both diseases is much
more complex than the description provided by our model, as it involves many different
phases of the natural history of the diseases, which are in turn much more complex
than a simple SIS. Therefore, this makes the precise values of model parameters rather
contingent. However, as we see in figure 8.11, our model remarkably captures the
effects of one disease on the dynamics of the other. Therefore, this framework helps
understanding what ingredients are basic and what others can be thrown out in a first
approximation − it seems that for the real case here discussed, adding the coupling
of the two diseases to simple models is effective enough to understand the coupled
temporal evolution of both diseases. The previous comparison also indicates that
modeling approaches like the one here introduced can be used to develop applied,
data-driven models aimed at evaluating the increase in epidemiological risk due to
AIDS high-prevalence levels on other diseases, like TB [22].
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Figure 8.11: Prevalence percentages for HIV infection and active TB in the Republic of
South Africa from 1990 to 2011. In black, we represent the prevalence levels of both diseases,
as available online at public databases for Tuberculosis [24] and HIV surveillance [411]. Even
if the natural history of both pathologies are much more complex than a naive SIS model
[22, 412], our model is able to reproduce the interactions between both diseases, and more
specifically, the increment in TB’s prevalence as a consequence of the irruption of HIV, mostly
associated to co-infection. In the figure, in red, we represent the results of a run of the MF
model with the following parameters, obtained through a Levenberg-Marquard [413] least-
squares fitting approach: 〈k〉λ1 = 6.011, 〈l〉λ2 = 1.177, βa1 = 21.56, βa2 = 30.76, βb1 = 0.03451,
βb2 = 1.719, µ1 = 29.97, µ2 = 5.734, η1 = 1.476, η2 = 2.548. The first disease represents TB
and the second one, HIV. The initial conditions are settled in 1988 for TB, (0.5% of prevalence
of IS individuals) and, a year after, a 0.03% of SI individuals (HIV first carriers) is introduced.
In this exercise the fraction of prevalent cases of TB being HIV+ has been approximated by
the fraction of new TB cases being HIV+, available at the database [24]. This is a reasonable
first approximation due to the fact that the order of magnitude of TB infectious period is of
the order of 1 year (see chapter 9). See the text for further discussions.
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8.7 Supplementary analysis
8.7.1 Epidemic thresholds on regular networks (SIS case)
In the particular case in which both networks are regular graphs, an independent
derivation of the epidemic threshold can be obtained by a linear stability analysis. In
that case, for which P (k, l) = δ(k− ko)δ(l− lo), the dynamics can be described by the
following system of four equations:
˙SS = −koλ1SS · IS − loλ2SS · SI − koβb1λ1SS · II − loβb2λ2SS · II + µ1IS + µ2SI,
˙IS = koλ1SS · IS + koβb1λ1SS · II − loβa2λ2SI · IS − loβa2βb2λ2IS · II − µ1IS + η2µ2II,
S˙I = loλ2SS · SI + loβb2λ2SS · II − koβa1λ1IS · SI − koβa1βb1λ1SI · II − µ2SI + η1µ1II,
˙II = koβa1λ1IS · SI + loβa2λ2IS · SI + koβa1βb1λ1SI · II + loβa2βb2λ2IS · II − (η1µ1 + η2µ2)II, (8.29)
one of which is linearly dependent of the rest. Thus, we will only analyze the system
constituted by the three last equations and use s = 1 − IS − SI − II. In order to
perform a linear stability analysis we first linearize the system around the equilibrium
point and we calculate the Jacobian to get:
J =
∣∣∣∣∣∣
λ1ko − µ1 0 koβb1λ1 + η2µ2
0 λ2lo − µ2 loβb2λ2 + η1µ1
0 0 −(η1µ1 + η2µ2)
∣∣∣∣∣∣ (8.30)
which, taking advantage of the fact that the Jacobian itself is just the product of the
elements in the diagonal, yields the stability conditions detailed in table 8.7.1.
If we look carefully at the results sketched in table 8.7.1, we firstly recognize the
appearance of a couple of critical values for the infectiousnesses λc1i and λ
c
2i which
will be referred to in what follows as the primary thresholds of their respective dis-
eases, just like in the general case described in the main text. These threshold values
stand for the minimum values of the infectiousnesses that yield epidemic outbreaks
after the introduction of infinitesimal seeds of infected individuals of each disease in
an initially healthy population. Therefore, the condition λ1 > λc1i must be verified
in order to have an epidemic outbreak for the first disease once an infinitesimal seed
Eigen-value Eigen-vector (IS, SI, II)
ξ1 = λ1ko − µ1 ~ψ1 = (1, 0, 0)
ξ2 = λ2lo − µ2 ~ψ2 = (0, 1, 0)
ξ3 = −(η1µ1 + η2µ2) ~ψ3 =
(
− η2µ2+βb1λ1ko(λ1ko−µ1)+(η1µ1+η2µ2) ,−
η1µ1+βb2λ2lo
(λ2lo−µ2)+(η1µ1+η2µ2) , 1
)
Table 8.5: Linear stability analysis of the fixed point (IS, SI, II) = (0, 0, 0).Threshold
values correspond to stability inversion points, and are reached for λ1 = λc1i = µ1/ko (stability
inversion in the direction of ~ψ1) and λ2 = λc2i = µ2/lo (stability inversion in the direction of
~ψ2). In the direction of the third eigenvector, the system is always stable.
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(IS, SI, II) = (, 0, 0) has been introduced on a system being at the disease-free fixed
point (IS, SI, II) = (0, 0, 0). On the other hand, the condition λc2i plays an equivalent
role for the second disease with respect to a seed (IS, SI, II) = (0, , 0).
The fixed point (IS, SI, II) = (0, 0, 0) is, strictly speaking, not the only possible
disease-free fixed point in our model. Other two partially disease-free fixed points
can exist: a first fixed point in which disease 1 is installed in the system at a cer-
tain prevalence pi1 whilst disease 2 is absent (IS, SI, II) = (pi1, 0, 0) and its cognate
(IS, SI, II) = (0, pi2, 0), for which there is no individual infected with disease 1. As
we are going to show, the stability of these fixed points depends on the prevalence
fractions pi1 and pi2, which are the stationary proportions of sick individuals of each
disease:
pi1 =
λ1ko − µ1
λ1ko
(8.31)
pi2 =
λ2lo − µ2
λ2lo
(8.32)
Considering that, let us study the stability of the first fixed point (IS, SI, II) =
(pi1 =
λ1ko−µ1
λ1ko
, 0, 0) as a function of λ1: the Jacobian, around this fixed point takes the
following form:
J =
˛˛˛˛
˛˛˛ (µ1 − λ1ko) (µ1 − λ1ko)(1 + β
a
2
λ2lo
λ1ko
) βb1λ1ko + η2µ2 + (µ1 − λ1ko)(βb1 + 1 + βa2βb2 λ2loλ1ko )
0 (λ2lo − µ2) + (µ1 − λ1ko)( λ2loλ1ko + β
a
1 ) β
b
2µ1
λ2lo
λ1ko
+ η1µ1
0 (λ1ko − µ1)(βa2 λ2loλ1ko + β
a
1 ) (λ1ko − µ1)βa2βb2 λ2loλ1ko − (η1µ1 + η2µ2)
˛˛˛˛
˛˛˛
(8.33)
By solving the equation derived from imposing that J = 0, we obtain the values of the
parameters leading to stability inversion. As it can be shown at naked eye, (µ1−λ1ko)
is the eigenvalue ξ1 associated to the eigenvector ~ψ1 = (1, 0, 0), and the condition
ξ1 = 0 yields again the same condition λ1 = µ1/ko, thus defining the threshold of the
classical SIS model. Regarding the other two eigenvalues ξ2 and ξ3, the result is more
cumbersome. Despite of that, the vanishing of the 2x2 determinant of the right-inferior
corner of the Jacobian matrix 8.33 yields:
λ2 = λ
c
2ii =
λ1ko
lo
η2µ2((βa1 (λ1ko − µ1) + µ2) + η1µ1µ2
µ1(η1µ1 + η2µ2) + (λ1ko − µ1)(βa1βa2βb2(λ1ko − µ1) + βa2βb2µ2 + η1µ1βa2 + βa1βb2µ1)
, (8.34)
to which the general expression presented in the main text for the epidemic threshold
reduces when P (k, l) = δ(k−ko)δ(l−lo). The agreement between numerical simulations
and the analytic expression of the threshold presented here is only accurate when
λ1ko ' µ1, and the reason is easily understandable. Let us compare the reaction of the
system to the introduction of a small seed of SI individuals when both diseases are
absent ((IS, SI, II) = (0, 0, 0), case 1) or when the first disease was already installed
in the system ((IS, SI, II) = (pi1, 0, 0), case 2). As we have argued in the precedent
sections, the epidemic threshold is different in each case, and the reason is simply
the presence, in the second case, of a fraction pi1 of IS of individuals for which the
infectiousness and recovery rates for disease 2 are different with respect to the rest of
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individuals. As a consequence, the mean values of the dynamical parameters averaged
over the whole population 〈λ2〉 and 〈µ2〉, are different in both cases and will yield
different values for the epidemic thresholds. Thus, in order to accurately evaluate the
secondary threshold for disease 2 it is essential to know with enough precision the
prevalence pi1 corresponding to a single SIS model, as a function of λ1. The problem
arises from the fact that, precisely, the derivation of 8.34 explicitly assumes that the
bijection between pi1 and λ1 is governed by the MF stationary expression 8.31 which is
only precise when λ1ko ' µ1 [75]. In fact, a way to rebuild a more accurate secondary
threshold curve can be achieved if, from equation 8.31 we substitute λ1 as a function
of pi1, and then introduce the so obtained expression into 8.34 to get:
λc2ii(pi1) =
1
lo
η2µ2(βa1
µ1pi1
(1−pi1) + µ2) + η1µ1µ2
(1− pi1)(η1µ1 + η2µ2) + pi1(βa1βa2βb2 µ1pi1(1−pi1) + βa2βb2µ2 + η1µ1βa2 + βa1βb2µ1)
(8.35)
which allows to evaluate directly the threshold as a function of pi1 rather than of λ1.
Thus, by introducing in equation 8.35 the pi1 values obtained from the simulations
instead of the theoretical prediction of the MF (equation 8.31), we recover the curves
for the secondary threshold represented with red lines in Figures 8.2 and 8.3 of the
main text, in quantitative agreement with results from simulations.
Obviously, the same arguments stand for the secondary threshold of the first disease,
which obeys the following expression:
λc1ii(pi2) =
1
ko
η1µ1(βa2
µ2pi2
(1−pi2) + µ1) + η2µ2µ1
(1− pi2)(η2µ2 + η1µ1) + pi2(βa2βa1βb1 µ2pi2(1−pi2) + βa1βb1µ1 + η2µ2βa1 + βa2βb1µ2)
(8.36)
When the networks are heterogeneous, this reformulation of the threshold curves as
a function of pi1 or pi2 can not be done straightforwardly as no analytical bijection
λ1(pi1) or λ2(pi2) can be reached. The best we can do is to use a numerically built-up
relationship λ1(θ1) (or λ2(θ2)), and introduce it into the general expression for the
threshold. Although the accuracy of the curves for the secondary threshold is very
satisfactory in Fig. 8.4, we identify this effect to be the source of the slight divergence
between the analytical and numerical secondary thresholds shown in Fig. 8.6.
8.7.2 Vanishing conditions for epidemic thresholds (SIS case)
Here we provide a systematic analysis of the behavior of the secondary threshold in our
model for large SF networks. In particular, we inspect whether the coupling between
the spreading of the two diseases in the terms described in our model can modify
the classical, single-disease scheme, and, if so, under what conditions. The epidemic
threshold for the first disease in our model reads as:
λc1(σ2) = µ1
〈k〉∑
k,l P (k, l)
k2l2σ22β
a
2β
a
1β
b
1+lk
2σ2(η2µ2βa1 +β
b
1(β
a
1µ1+β
a
2µ2))+k
2µ2(η1µ1+η2µ2)
l2σ22β
a
2 η1+lσ2(η1µ1+η2µ2+β
a
2 η1µ2)+µ2(η1µ1+η2µ2)
(8.37)
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and we have to address its behavior in the limitN →∞. Substituting sums by integrals
in Eq. (8.37), one gets:
lim
N→∞
λc1(σ2) = lim
(kmax,lmax)→∞
µ1
∫ kmax
kmin
∫ lmax
lmin
P (k, l)k dk dl
∆′
. (8.38)
where the denominator function ∆′ takes the form of the following double integral:
∆′ =
Z kmax
kmin
Z lmax
lmin
P (k, l)
k2l2σ22β
a
2β
a
1β
b
1 + lk
2σ2(η2µ2βa1 + β
b
1(β
a
1µ1 + β
a
2µ2)) + k
2µ2(η1µ1 + η2µ2)
l2σ22β
a
2 η1 + lσ2(η1µ1 + η2µ2 + β
a
2 η1µ2) + µ2(η1µ1 + η2µ2)
dk dl (8.39)
To study the behavior of the threshold in the thermodynamic limit, we present here an
analysis which is essentially based on the following result, whose proof is an exercise of
elementary algebra that we present for the sake of completeness in the last appendix.
Given two polynomials P (k), Q(k), we have that:∣∣∣∣ limkmax→∞
∫ kmax
kmin
P (k)
Q(k)
dk
∣∣∣∣ =∞↔ deg(Q)− deg(P ) ≤ 1 (8.40)
Focusing on SF connectivity distributions, we will distinguish two different scenarios
in this section: uncorrelated and totally correlated layers. In the first case, both
networks present a SF distribution in which the connectivity of a node in a layer
is essentially independent of its degree on the other layer, in such a way that the
composed connectivity distribution verifies P (k, l) = Cok−γl−Γ. Instead, in the second
case, although both layers are also SF networks, the degree of any given node in both
layers is forced to be the same. Therefore, nodes which are hubs in a layer are so in the
other, and the composed degree distribution is P (k, l) = Coδ(k − l)k−γ. In addition,
we assume that both γ and Γ exponents are rational, hence, we can write γ = w/x
and Γ = y/z with (w, x, y, z) ∈ N. By addressing these two opposite scenarios, our
aim is to characterize the difference, in terms of the spreading dynamics, between the
coupling of two diseases that spread by independent means –which will give place to
different networks of contacts– and the coupling of two related diseases –or variations
of the same disease– that spread following the very same mechanisms and, thus, they
do so over highly correlated networks of contacts.
Uncorrelated SF layers
If we substitute P (k, l) = Cok−γl−Γ into eq. 8.38, we can factorize the double integrals
into independent terms:
lim
N→∞
λc1(σ2) = lim
(kmax,lmax)→∞
µ1
∫ kmax
kmin
k1−γdk
∫ lmax
lmin
l−Γdl
∆′′
(8.41)
and this time the denominator ∆′′ takes the following form:
∆′′ =
Z kmax
kmin
k2−γdk
Z lmax
lmin
l2σ22β
a
2β
a
1β
b
1 + lσ2(η2µ2β
a
1 + β
b
1(β
a
1µ1 + β
a
2µ2)) + µ2(η1µ1 + η2µ2)
lΓ
`
l2σ22β
a
2 η1 + lσ2(η1µ1 + η2µ2 + β
a
2 η1µ2) + µ2(η1µ1 + η2µ2)
´ dl (8.42)
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The condition for the numerator to diverge is γ ≤ 2 ∨ Γ ≤ 1. These conditions are
verified by networks whose mean connectivity diverges in the thermodynamic limit.
For this reason, networks with those small exponents neither are reasonable systems
to be used to describe any information diffusion process over them nor are found
in real systems. Taking this into account, we will restrict our analysis to the more
epidemiologically relevant scenario in which γ > 2 and Γ > 2, although our reasoning
is generalizable to any value of the exponents.
Thus, in the scenario γ > 2 and Γ > 2, the numerator remains always finite and
the only phenomenon of interest that could be found is an eventual vanishing of the
threshold due to a divergence in the denominator ∆′′. The double integral ∆′′ can be
factorized as the product of two integrals: one in k and the other in l, as it can be
seen from Eq. 8.42: we will schematically refer this like follows: ∆′′ = ∆′′k∆′′l . The
integral in k, ∆′′k =
∫ kmax
kmin
k2−γdk will diverge if and only if γ ≤ 3, but the integral in l,
∆′′l , might independently diverge under some conditions. That situation would suppose
the vanishing of the threshold of the first disease as a consequence of its coupling to
the second rather than to internal, dynamical or topological features. To find out the
conditions for ∆′′l , lets make the following change of variable:
m = l1/z (8.43)
so as to change the dependence of the denominator ∆′′ = ∆′′k∆′′l in Eq. 8.42 to ∆′′ =
∆′′k∆
′′
m:
∆′′ =
Z kmax
kmin
k2−γdk
Z l1/zmax
l
1/z
min
`
m2zσ22β
a
2β
a
1β
b
1 +m
zσ2(η2µ2βa1 + β
b
1(β
a
1µ1 + β
a
2µ2)) + µ2(η1µ1 + η2µ2)
´
zmz−1
my
`
m2zσ22β
a
2 η1 +m
zσ2(η1µ1 + η2µ2 + βa2 η1µ2) + µ2(η1µ1 + η2µ2)
´ dm
(8.44)
The last expression has the advantage that the argument of the integral in m, ∆′′m is
just the quotient of two polynomials, and thus, its behavior in the limit lmax → ∞ is
governed by Eq. (8.40) and depends only on the difference of degrees of the denominator
and the numerator. If
∆′′m =
Z l1/zmax
l
1/z
min
`
m2zσ22β
a
2β
a
1β
b
1 +m
zσ2(η2µ2βa1 + β
b
1(β
a
1µ1 + β
a
2µ2)) + µ2(η1µ1 + η2µ2)
´
zmz−1
my
`
m2zσ22β
a
2 η1 +m
zσ2(η1µ1 + η2µ2 + βa2 η1µ2) + µ2(η1µ1 + η2µ2)
´ dm =
=
Z l1/zmax
l
1/z
min
P (m)
Q(m)
dm (8.45)
we have that –in the general case in which none of the β and η parameters vanishes–
deg(Q)− deg(P ) = 1 + y − z, and hence, the conditions for ∆′′m to diverge are
lim
(kmax,lmax)→∞
∫ l1/zmax
l
1/z
min
P (m)
Q(m)
dm =∞↔ y − z + 1 ≤ 1↔ Γ = y/z ≤ 1 (8.46)
Therefore, in the region of interest γ > 2 ∧ Γ > 2, the factor ∆′′m can not diverge and
make the threshold vanishes. It is worth noticing that the condition Γ < 1 does not
guarantee the vanishing of the threshold, as it also makes the numerator to diverge.
Expression 8.46 is valid for the case in which none of the β and η parameters of the
model vanishes. If this is not the case, i.e., if some of the infectiousness variations β do
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(βa1 , β
b
1, β
a
2 )
parameters
deg(Q)− deg(P )
in ∆′′m =
∫
P (m)/Q(m)
Divergence condition
(βa1 , β
b
1, β
a
2 )
(βa1 , β
b
1, 0)
(βa1 , 0, 0)
y − z + 1 γ ≤ 3 ∨ Γ ≤ 1
(0, βb1, β
a
2 )
(βa1 , 0, β
a
2 )
(0, βb1, 0)
(0, 0, 0)
y + 1 γ ≤ 3 ∨ Γ ≤ 0
(0, 0, βa2 ) y + z + 1 γ ≤ 3 ∨ Γ ≤ −1
Table 8.6: Divergence conditions for ∆′′m for disease 1. Case 1: uncorrelated SF layers
P (k, l) = Cok−γl−Γ, γ = (w/x), Γ = (y/z).
vanish −the rest of the parameters can not do that within a realistic epidemiological
framework−, the degrees of the numerator and the denominator in Eq. 8.45 could vary.
In table 8.6 we systematically address all possible combinations of null parameters, and
the composed conditions yielding a vanishing threshold for each case.
Once again, we see that, whatever the interacting scheme between both diseases
is, the denominator remains always finite provided that Γ > 2. In conclusion, if no
degree correlation is introduced between layers, and for realistic systems characterized
by double power laws verifying γ > 2 ∧ Γ > 2, the behavior of the thresholds in the
thermodynamic limit is essentially the same of the uncoupled systems: the threshold
associated to the first disease vanishes if and only if the exponent of its own network
verifies γ ≤ 3, whatever the exponent of the second network. The coupling will intro-
duce, in general, only a finite pre-factor. The symmetric situation obviously stands for
the threshold of the second disease.
Totally correlated SF layers
If we consider the case in which P (k, l) = Coδ(k−l)k−γ, where γ = w/x with (w, x) ∈ N,
the epidemic threshold reads as:
lim
N→∞
λc1(σ2) = lim
(kmax,lmax)→∞
µ1
∫ kmax
kmin
k1−γdk
∆′′′
(8.47)
where the denominator ∆′′′ adopts now the following form:
∆′′′ =
∫ kmax
kmin
k2σ22β
a
2β
a
1β
b
1 + kσ2(η2µ2β
a
1 + β
b
1(β
a
1µ1 + β
a
2µ2)) + µ2(η1µ1 + η2µ2)
kγ−2
(
k2σ22β
a
2η1 + kσ2(η1µ1 + η2µ2 + β
a
2η1µ2) + µ2(η1µ1 + η2µ2)
) dk (8.48)
hence, we do not recover the factorization of the denominator previously observed.
Instead, after changing the variable to m = k1/x, we transform ∆′′′ to express it as an
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(βa1 , β
b
1, β
a
2 )
parameters
deg(Q)− deg(P )
in ∆′′′m =
∫
P (m)/Q(m)
Divergence condition
(βa1 , β
b
1, β
a
2 )
(βa1 , β
b
1, 0)
(βa1 , 0, 0)
w − 3x+ 1 γ ≤ 3
(0, βb1, β
a
2 )
(βa1 , 0, β
a
2 )
(0, βb1, 0)
(0, 0, 0)
w − 2x+ 1 γ ≤ 2
(0, 0, βa2 ) w − x+ 1 γ ≤ 1
Table 8.7: Divergence conditions for ∆′′′m for disease 1. Case 2: totally correlated SF layers
P (k, l) = Coδ(k − l)k−γ , γ = (w/x).
integral in m (in what follows ∆′′′m):
∆′′′ =
∫ k1/xmax
k
1/x
min
(
m2xσ22β
a
2β
a
1β
b
1 +m
xσ2(η2µ2βa1 + β
b
1(β
a
1µ1 + β
a
2µ2)) + µ2(η1µ1 + η2µ2)
)
xmx−1
mw−2x (m2xσ22β
a
2η1 +mxσ2(η1µ1 + η2µ2 + β
a
2η1µ2) + µ2(η1µ1 + η2µ2))
dm
(8.49)
In expression 8.47, the numerator diverges for γ ≤ 2. In turn, for ∆′′′m, we have that it
has the following form:
∆′′′m =
∫ k1/xmax
k
1/x
min
P (m)
Q(m)
dm (8.50)
which diverges, according to equation 8.40, if and only if deg(Q) − deg(P ) ≤ 1. In
the general case in which none of the β parameters vanishes, we have that deg(Q) −
deg(P ) = w − 3x+ 1, and thus:
lim
N→∞
λc1(σ2) = 0↔ γ ≤ 3 (8.51)
As in the previous case, different combinations of null β parameters can change this
result, as it can be seen in Table 8.7. Here, the phenomenology is remarkable different
for all the cases in which at least one of the two variations of disease 1 infectiousness,
βa1 or βb1, cancel (except for the case βa2 = βb1 = 0 but βa1 6= 0, for which eq. 8.51
also stands). In those cases, θ > 0 guarantees that, provided that γ > 2, no threshold
vanishing is observed in the thermodynamic limit, even when the exponent is within
the interval 2 < γ ≤ 3. In the case in which βa1 = βb1 = βa2 = 0, the situation will
be reciprocal, and thus, the epidemic threshold of the second disease will not vanish
either for γ > 2.
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8.7.3 Proof of eq. 8.40
Given two polynomials P (k), Q(k), we have to prove that∣∣∣∣ limkmax→∞
∫ kmax
kmin
P (k)
Q(k)
dk
∣∣∣∣ =∞↔ deg(Q)− deg(P ) ≤ 1 (8.52)
First, we have that, if deg(P ) ≥ deg(Q) the integral diverges, as the argument of the
integral can be expressed in that case as:
P (k)
Q(k)
= C(k) +
P ′(k)
Q′(k)
(8.53)
with deg(P ′) < deg(Q′) and deg(C) ≥ 0. When substituting the last expression into
eq.8.40, the integral in C(k) automatically diverges. Therefore, to prove this result for
the case in which deg(P ) < deg(Q), let us consider the general decomposition of Q(k):
Q(k) = Qo
i∗∏
i=1
(k − ai)ni
j∗∏
j=1
(k2 + bjk + cj)
mj (8.54)
where Qo is a constant, kmin > 0 and b2j − 4cj < 0 ∀j. The values i∗ and j∗ stand for
the number of different elemental factors of first and second order, respectively. So,
the degree of the polynomial reads as follows:
deg(Q) =
i∗∑
i=1
ni + 2
j∗∑
j=1
mj, (8.55)
where ni and mj denote the multiplicity of each of the factors of first and second
order, respectively. The factorization of Q(k) yields the following decomposition of the
quotient P (k)/Q(k) into partial fractions:∫ kmax
kmin
P (k)
Q(k)
dk =
i∗∑
i=1
ni∑
n=1
∫ kmax
kmin
Ai,n
(k + ai)n
dk +
j∗∑
j=1
mj∑
m=1
∫ kmax
kmin
Bj,mk + Cj,m
(k2 + bjk + cj)m
dk (8.56)
where the coefficients Ai,n, Bj,m, Cj,m have to be calculated by expanding this expression
into a single fraction, and comparing the coefficients of the numerator obtained with
those of P ′(k) = P (k)/Qo. With the aim of understanding what are the conditions
that make these partial integrals to diverge, let us analyze them term by term. The
first sum yields logarithmic and rational functions:
i∗∑
i=1
ni∑
n=1
∫ kmax
kmin
Ai,n
(k + ai)n
dk =
i∗∑
i=1
Ai,1 ln
(
kmax + ai
kmin + ai
)
+
+
i∗∑
i=1|ni>1
ni∑
n=2
−Ai,n
(n− 1)
(
1
(kmin + ai)n−1
− 1
(kmax + ai)n−1
)
(8.57)
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and, in the limit kmax →∞, only the logarithmic term diverges:
lim
kmax→∞
i∗∑
i=1
ni∑
n=1
∫ kmax
kmin
Ai,n
(k + ai)n
dk =
i∗∑
i=1
Ai,1 ln (kmax) + ϑ (8.58)
where ϑ stands for a finite term, negligible when compared to ln(kmax). On the other
hand, the second sum in eq. 8.56 can be rewritten as:
j∗∑
j=1
mj∑
m=1
∫ kmax
kmin
Bj,mk + Cj,m
(k2 + bjk + cj)m
dk =
j∗∑
j=1
mj∑
m=1
Bj,m
2
∫ kmax
kmin
2k + bj
(k2 + bjk + cj)m
dk + (8.59)
+
j∗∑
j=1
mj∑
m=1
(
Cj,m − Bj,m2
)∫ kmax
kmin
dk
(k2 + bjk + cj)m
dk
In turn, the integrals in the first sum of last equation can be easily solved:
j∗∑
j=1
mj∑
m=1
Bj,m
2
∫ kmax
kmin
2k + bj
(k2 + bjk + cj)m
dk =
j∗∑
j=1
Bj,m
2
ln
(k2max + bjkmax + cj)
(k2min + bjkmin + cj)
+ (8.60)
+
j∗∑
j=1|mj>1
mj∑
m=1
Bj,m
2
(
1
k2min + bjkmin + cj
− 1
k2max + bjkmax + cj
)
and, again, when taking the limit kmax →∞, only the logarithmic terms diverge:
j∗∑
j=1
mj∑
m=1
Bj,m
2
∫ kmax
kmin
2k + bj
(k2 + bjk + cj)m
dk =
j∗∑
j=1
Bj,m
2
ln (k2max) + ϑ =
j∗∑
j=1
Bj,m ln (kmax) + ϑ (8.61)
Finally, we have to analyze the last integrals in eq. 8.59. After the following linear
transformation:
v =
2k + bj√
4cj − b2j
(8.62)
we can rewrite: (
Cj,m − Bj,m
2
)∫ kmax
kmin
dk
(k2 + bjk + cj)m
=
=
(
Cj,m − Bj,m
2
)(
cj −
(
bj
2
)2)1/2−m ∫ 2kmax+bj√
4cj−b2j
2kmin+bj√
4cj−b2j
1
(v2 + 1)m
dv (8.63)
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and, though it is not possible to write an explicit solution for the integrals of the form∫
1/(v2 + 1)m, integrating by parts we get:∫
1
(v2 + 1)m
dv =
v
(2m− 2)(v2 + 1)m−1 +
2m− 3
2m− 2
∫
dv
(v2 + 1)m−1
(8.64)
which allows to solve the integrals, yielding the appearance of rational and arctangent
terms none of which diverges in the limit kmax → ∞. Thus, only logarithmic terms
from equations 8.58 and 8.61 contribute to the divergence of the initial limit of Eq.
8.40, that can be finally rewritten as follows:∣∣∣∣ limkmax→∞
∫ kmax
kmin
P (k)
Q(k)
dk
∣∣∣∣ = ln (kmax)
∣∣∣∣∣
i∗∑
i=1
Ai,1 +
j∗∑
j=1
Bj,m
∣∣∣∣∣+ ϑ (8.65)
Thus, recalling that |ϑ| << ln(kmax) stands for finite terms, the only requisite for the
limit to diverge is that: (
i∗∑
i=1
Ai,1 +
j∗∑
j=1
Bj,m
)
6= 0 (8.66)
which is precisely the coefficient of the monomial of degree equal to deg(Q) − 1 in
the numerator P ′(k) = P (k)/Qo, as can be easily shown after grouping the partial
fractions in Eq. 8.56 into a single one. Therefore, we have demonstrated the initial
statement: the condition for the integral in Eq. (8.52) to diverge is that deg(P ′) =
deg(P ) ≥ deg(Q)− 1.
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Part V
Novel models of tuberculosis spreading
One of the historic ironies of tuberculosis research is that it has always been assumed
that the current interventions would eliminate this disease as a major public health
problem. BCG, an attenuated bovine tuberculosis strain, was discovered in 1908, and
was thought to be the vaccine for tuberculosis. Streptomycin in the 1940s was hailed
as the wonder drug for tuberculosis. Yet even with better antibiotics, tuberculosis
remains a major global health problem. Concomitant with these historically
shortsighted miscalculations were reductions in support for research on new tools and
strategies, based on the assumption that with existing interventions the disease would
disappear. It has not.
Barry Bloom
First Blueprint for Tuberculosis Vaccine Development, 1998.
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Chapter 9
Novel models for the description of TB spread-
ing
9.1 Introduction
Among the vaccine candidates currently under development, there are very diverse
projects that find their effectiveness on disparate biochemical and immunological prin-
ciples. One of the aspects that could exert a greater influence on the vaccine impacts
is the age of the vaccination target populations, which eventually could be different
for some of the novel vaccines [428]. Actually, these drugs can be grouped into two
classes: immunogenic booster vaccines -aimed at being administrated on individuals
previously vaccinated with the bacillus Calmette-Guérin vaccine (BCG) so as to en-
hance its effects– and substitutive vaccines –in principle to be applied on non-vaccinated
newborns instead of BCG–. Thus, in principle, booster vaccines could be implemented
on massive vaccination campaigns over all ages while substitutive vaccines would be
limited to newborns, which would limit and slow down their impact in terms of deaths
and cases prevented [97].
However, some eventualities may modify that scheme. For example, some teams
involved in the development of substitutive vaccines are outlining the possibility of
testing this kind of drugs on individuals previously vaccinated with BCG, which could
extent their application range from newborns to individuals of any age [421]. In addi-
tion, the first, disappointing results about immunogenic efficacy of booster vaccines on
children [213] suggest that, eventually, the application of this kind of drugs may have to
be restricted to older individuals. Moreover, any vaccine should demonstrate its safety
and efficacy when applied on seropositive individuals: in case some problems appear
related to the interaction between TB and HIV, any vaccination campaign involving
adults would be seriously compromised, specially in areas of high HIV endemicity like
sub-Saharan Africa.
All the uncertainties mentioned above will be solved in the following years, once
the clinical trials come to an end. When that moment comes, computational tools
and spreading models should be able to offer a vaccine impact forecast as reliable as
possible, taking into account both the vaccine efficacy and the age of the individuals on
which its application is safe, feasible and effective. The precision of these forecasting
tools, at that point, may be a crucial resource for the health authorities to count with in
order to make the proper decisions about the design of the final vaccination campaign.
Hence, if we want to address how the impact of a vaccine depends on the age of the
vaccination target population, it is more necessary than ever a precise understanding
of the dependence of the disease dynamics on the age of single individuals and on the
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demographic structure of the whole population. In order to accomplish that goal, in
this chapter we develop an epidemiological model of TB spreading based on previous
works [422, 22] in which several classical simplifications regarding the dependence of the
spreading dynamics on age structure have been eliminated, capitalizing recent works
and public data sources [12, 23] that provides some of the information needed to adopt
more realistic modeling hypothesis.
These new ingredients consists of contemplating the explicit evolution of the age
structure of the population analyzed, as well as the heterogeneity of the contacts driving
the infections among the different age groups and the possibility of that the system
lies in a dynamical state arbitrarily far away from the stationary. As we will see in
the following sections, the introduction of these new ingredients relevantly modifies the
model outcomes, making evident that these ingredients have to be taken into account
if any age-dependent measure is going to be done or any age-focused intervention has
to be analyzed.
9.2 Modeling framework overview
In order to undertake the impact evaluations mentioned, we have developed an age-
structure model which is initially based on previous works on this topic [422, 22]. The
model essentially obeys to an HMF scheme according to which all individuals within the
same age group are dynamically equivalent. in this sense, this type of age-structured
models differs from those developed in chapters 8 and 7 in the implementation of an
aging dynamics that allows individuals to transit among the different dynamically dis-
tinct groups (i.e. age-groups) of the model. Its natural History scheme can be checked
on figure 9.1, while a detailed description, as well as the proper model uncertainty and
sensitivity analysis can be found in section 9.3.
Besides the age-structure of the population, the model contemplates the differ-
ent kinds of TB disease: pulmonary –either smear positive and negative– and non-
pulmonary. Fast and slow progression are contemplated, as well as smear progression,
exogenous reinfections, endogenous reactivations, mother-child transmission, different
treatment outcomes and natural recovery [96, 422, 22, 423, 424].
Model parameters have been obtained from bibliographical sources with three ex-
ceptions: the infectiousness, the diagnosis rate and the initial distance from the sta-
tionary, which have been fitted [413] so as to reproduce incidence and mortality series
registered by health systems and available at the world health organization database
for TB; from 2001 to 2011 [167, 24]. Very remarkably, the diagnosis rate d(t) and
the infectiousness β(t) are assumed to vary over time, so as to describe the temporal
evolution of public health systems, overall socioeconomic conditions, etc, which defines
at the end the response that human societies are able to offer to the disease. This
time variation is obtained trough two annual rates of variation αd and αβ that are
independently fitted to the initial values d(2001) = do and β(2001) = βo. Additional
details about the meaning of all parameters and the way in which they are obtained,
are available at section 9.3.
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In what regards the age-structure of the population, the model takes as an explicit
input the expected evolution of the demographic pyramid during the period under
analysis: in this way, the disease dynamics is simulated over a population whose de-
mographic structure evolution is known a priori. This allows us to introduce in our
model the demographic predictions the the UN population division [23] makes for the
different countries for the next century, and so we can explicitly evaluate the influence
of that evolution on the disease burden without making any simplification or assuming
that the structure of the population is different from the one expected, as it is usually
done in previous models [422, 22].
In a similar way, we abandon in our model other classical hypothesis of TB modeling
that suppose a strong simplification of reality, i.e., the homogeneity of the contact
patterns among the different age groups that composes a society. Indeed, since some
years ago, the remarkable heterogeneity of the number and intensity of the contacts
between different age groups is a well known fact [12, 425] that has had a powerful
impact in the spreading modeling of other diseases like influenza [426, 427]. After
these works, we know that contact patterns among individuals of different ages are
strongly assortative, more intense in young individuals and relatively robust in different
countries. Capitalizing the results of one of these works, we are able to recover a
plausible and more realistic heterogeneous contact structure on top of which we can
model the spreading of the disease.
These two new modeling ingredients fall upon the age structure of the population,
which is crucial for the measure of any age-dependent quantity or the impact and
cost-effectiveness evaluation of any epidemiological intervention focused on specific age-
groups, as an eventual vaccine. As a third relevant novelty, initial conditions are not
forced to lie on an attractor of the dynamics, but the initial distance to stationary is
determined as an additional tunable parameter.
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Figure 9.1: Schematic representation of the non immune branch of the natural History
of the disease as described by our model. S: susceptible L: latent, either fast or slow. D:
undiagnosed disease (either pulmonary, smear positive Dp+, pulmonary smear negative Dp−
or non pulmonary Dnp). T: treated disease. R: recovered individuals, either naturally (RN ),
after successful treatment (RS), or after treatment default (RD). F: treatment failure. The
figure represents the dynamical states and transitions of the non-immune branch of a single
age group. Further details are available at the Supplementary information appendix.
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9.3 Model description
9.3.1 Model dynamics
Natural history of the disease
Our work is essentially based on previous models by C. Dye and colleagues [422, 22], on
which new ingredients –heterogeneous contact patterns [12] and an explicit coupling of
the demographical evolution and the disease dynamics– have been incorporated in order
to avoid systematic biases that affect certain model predictions and outcomes critically
dependent on the age structure of the populations. The natural history scheme has
also been refined so as to render it more suited to the definitions by WHO, mostly in
what regards to treatment outcomes.
Summarizing, we deal with an ordinary differential equations based, age-structured
model of TB infection in which we consider three different classes of unexposed indi-
viduals, –susceptible and vaccinated, either keeping immunity or having lost it–, two
different latency paths to disease –fast and slow– and six different kinds of disease, de-
pending on its etiology: -non pulmonary, pulmonary (smear positive) and pulmonary
(smear negative)–, and depending on whether it is untreated or treated. After the
disease phase, we consider explicitly the main treatment outcomes contemplated by
WHO data schemes: treatment completion, default, failure and, of course, death.
The model presents two branches: the non vaccinated branch and the immune
branch, to which individuals retaining the immunogenic effect of the vaccine belong to.
Each state X in the unvaccinated branch has its homologue Xv in the immune branch.
For example, at time step t, non vaccinated susceptible individuals, unexposed to TB
infection are denoted by S(a, t), while vaccinated, immune susceptible individuals are
Sv(a, t). Finally, susceptible vaccinated individuals whose induced immunity to the
disease due to vaccination has waned are Sw(a, t). The integer a ∈ [0, 13], is the index
representing any of the fourteen age groups which individuals belong to, each of them
covering τ = 5 years; which yields the description of a demographic pyramid up to 70
years old.
In the following, we detail the natural history ingredients and transitions between
states that we have considered to build up our model; whose natural history is schema-
tized in figure 9.2
Primary Tuberculosis infection We call primary the infection of an individual
who was not previously exposed to the bacterium: i.e. individuals of classes S,Sv and
Sw. If we denote the force of infection λ(a, t) as the probability per unit time of any
unexposed individual of age group a of being infected, then, for example, the total
number of unvaccinated susceptible individuals getting infected per unit time will be
equal to λ(a, t)S(a, t). We will address the explicit form of λ(a, t) in the following
sections.
Of these newly infected individuals, a fraction p(a) ∈ [0, 1] will develop the so-called
primo-infection, i.e. a quick development of the disease after a short course latency
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Figure 9.2: Global scheme of the TB spreading model: S: susceptible. L: latent. D:
(untreated) disease, T (treated) disease, R recovered, F: failed recovery W: waned immunity.
period (fast latency Lf in what follows) shorter than a year and characterized by the
inability of the host’s immune system to restrain mycobacterial growth. In the rest of
the cases, newly infected individuals’ immune system succeeds at containing bacterial
proliferation so establishing a host-pathogen dynamic equilibrium that is characterized
by a asymptomatic latency state –slow latency Ls in what follows– that can last for
the rest of the host’s life, or be broken even decades after the infection, typically after
an episode of immune-depression. In conclusion, the primary infection of unvaccinated
individuals is described as follows:
• Primary infection of unvaccinated individuals (primo-infection): transition from
S(a, t) to Lf (a, t): p(a)λ(a, t)S(a, t) individuals/unit time.
• Primary infection of unvaccinated individuals (to slow latency): transition from
S(a, t) to Ls(a, t): (1− p(a))λ(a, t)S(a, t) individuals/unit time.
In what regards the infection of susceptible, immune individuals Sv, the vaccine
benefits consist in reducing the probability of an individual to get infected (i.e. the force
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of infection). We model this as the only effect provided by vaccination, by introducing
the observed efficacy coefficient  ∈ [0, 1] of the vaccine, which stands for the fraction
of the probability of infection that an immunized individual presents with respect to
a non vaccinated subject. Therefore, the transitions describing primary infections of
immune individuals in age group a are described like this:
• Primary infection of immune individuals (primo-infection): transition from Sv(a, t)
to Lvf (a, t): p(a)λ(a, t)Sv(a, t) individuals/unit time.
• Primary infection of immune individuals (to slow latency): transition from Sv(a, t)
to Lvs(a, t):  (1− p(a))λ(a, t)Sv(a, t) individuals/unit time.
At this point, it is worth noticing that our model aims to evaluate the impacts gen-
erated by novel TB vaccines. This implies that our non-immunized branch corresponds
to the population group not receiving the novel vaccine, and so, BCG immunized people
(who are the vast majority in most countries in the world, in which BCG vaccination is
mandatory) belong to this branch. This implies that BCG is not explicitly considered
in our model, and its influence is embedded as a background effect in the dynamics
of the non-immunized branch. Thus,  reflects the protection provided by the novel
vaccine that is observed in a comparison to BCG. -induced protection levels at each
age. In chapter 11 we deepen in the implications of this definition, and, remarkably,
how  is affected as a function of the background performance of BCG.
Finally, regarding the class Sw, we consider that it is dynamically equivalent to
class S, except for the fact that individuals in Sw can not be vaccinated again. So, we
have:
• Primary infection of vaccinated individuals who have lost immunity (primo-
infection): transition from Sw(a, t) to Lf (a, t): p(a)λ(a, t)Sw(a, t) individuals/u-
nit time.
• Primary infection of vaccinated individuals who have lost immunity (to slow
latency): transition from Sw(a, t) to Ls(a, t): (1 − p(a))λ(a, t)Sw(a, t) individu-
als/unit time.
It worths remarking that individuals in latency classes do not have TB disease: they
do not develop any disease symptom and they are not infectious at all. Indeed, as we
will see in the following sections, they can even suffer ulterior re-infections (to which,
for example, individuals in Lv classes will be protected with respect to individuals in
L classes, as we will see, being this the reason because of which Lv classes must be
differentiated from L classes).
Progression from latency to (untreated) disease Either from fast or slow la-
tency, infected individuals can fall sick and so, progress to three different active forms
of the disease. In the first of these forms, the non-pulmonary disease Dnp, the pathogen
can grow in disparate parts of the host body, including the nervous system, bones, kid-
neys and other organs foreign to lungs. The main characteristic of this kind of TB is
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that, since the bacilli can not reach the respiratory tract, the individuals are considered
unable to transmit the disease. However, if the pathogens proliferate in the lungs, they
can eventually reach the upper respiratory tract making its host able to transmit the
disease. According to the presence of viable bacilli in the sputum, we have the other
variants of TB: pulmonary disease, smear negative Dp−, or pulmonary disease smear
positive Dp+; being the latter more infectious than the former.
This scheme allows six different transitions from the two latency classes to the three
untreated TB disease classes:
• Progression from Lf (a, t) to Dnp(a, t): ωfnp(a)Lf (a, t) individuals/unit time.
• Progression from Lf (a, t) to Dp−(a, t): ωfp+(a)Lf (a, t) individuals/unit time.
• Progression from Lf (a, t) to Dp+(a, t): ωfp−(a)Lf (a, t) individuals/unit time.
• Progression from Ls(a, t) to Dnp(a, t): ωsnp(a)Ls(a, t) individuals/unit time.
• Progression from Ls(a, t) to Dp−(a, t): ωsp−(a)Ls(a, t) individuals/unit time.
• Progression from Ls(a, t) to Dp+(a, t): ωsp+(a)Ls(a, t) individuals/unit time.
where the ω parameters represent the different rates at which the progressions to
disease take place.
In the immune branch, the transitions are the same, not influenced by the vaccine;
which only protects from infection:
• Progression from Lvf (a, t) to Dvnp(a, t): ωfnp(a)Lvf (a, t) individuals/unit time.
• Progression from Lvf (a, t) to Dvp−(a, t): ωfp+(a)Lvf (a, t) individuals/unit time.
• Progression from Lvf (a, t) to Dvp+(a, t): ωfp−(a)Lvf (a, t) individuals/unit time.
• Progression from Lvs(a, t) to Dvnp(a, t): ωsnp(a)Lvs(a, t) individuals/unit time.
• Progression from Lvs(a, t) to Dvp−(a, t): ωsp−(a)Lvs(a, t) individuals/unit time.
• Progression from Lvs(a, t) to Dvp+(a, t): ωsp+(a)Lvs(a, t) individuals/unit time.
These progression rates, as well as their respective confidence intervals have been
obtained from the product of the overall rates of progression from latency to whatever
kind of disease and the fractions of individuals that develop each type of disease, as
available at [22].
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Death of untreated individuals Individuals in D states suffer the effects of the
disease by three ways: they develop disease symptoms; they –except the individuals
in Dnp– infect other individuals and some of them die because of the disease. In the
model, we consider that any of the three kinds of disease has a specific mortality rate,
so deaths of D individuals are modeled by introducing three independent fluxes:
• Deaths of untreated non pulmonary disease: µnpDnp(a, t) individuals/unit time.
• Deaths of untreated smear negative pulmonary disease:
µp−Dp−(a, t) individuals/unit time.
• Deaths of untreated smear positive pulmonary disease:
µp+Dp+(a, t) individuals/unit time.
where µnp, µp− and µp+ are the TB-related death rates of Dnp, Dp− and Dp+
individuals, respectively.
Individuals who got infected despite being immune and develop disease can also die
because of TB; as likely as anyone else:
• Deaths of untreated non pulmonary disease (immune branch):
µnpD
v
np(a, t) individuals/unit time.
• Deaths of untreated smear negative pulmonary disease (immune branch):
µp−Dvp−(a, t) individuals/unit time.
• Deaths of untreated smear positive pulmonary disease (immune branch):
µp+D
v
p+(a, t) individuals/unit time.
Tb diagnosis and treatment For what regards our model, we consider that an
individual belongs to D classes until she receives his diagnosis, moment in which it
joins the corresponding treated TB class T . That corresponds to the following set of
three transitions:
• Diagnosis of non pulmonar TB: transition from Dnp(a, t) to Tnp(a, t):
ηd(t)Dnp(a, t) individuals/unit time
• Diagnosis of smear negative pulmonar TB: transition from Dp−(a, t) to Tp−(a, t):
ηd(t)Dp−(a, t) individuals/unit time
• Diagnosis of smear positive pulmonar TB: transition from Dp+(a, t) to Tp+(a, t):
d(t)Dp+(a, t) individuals/unit time
This means that the diagnosis rate d(t) is the inverse of the “mean life time” of
Dp+, mentioned before. This corresponds, essentially, to the time that sick individuals
pass ignoring that they have TB disease, either because they suffer symptoms but
they have not visited any doctor yet, or because, after recurring to medical services,
a TB diagnosis has not been yet provided. This diagnosis refractory times are region
9.3 — Model description 
Regions χp+ χp− η
AFRH 0.51 0.43 0.843 (0.717-0.97 c.i.)
AFRL 0.49 0.25 0.510 (0.434-0.587 c.i.)
EMR 0.45 0.53 1.178 (1.001-1.354 c.i.)
SEAR 0.64 0.51 0.797 (0.677-0.916 c.i.)
WPR 0.78 0.50 0.641 (0.545-0.737 c.i.)
Table 9.1: Relative variation of the diagnosis rate for different types of TB in each region.
dependent, as they depend, among other factors, on the agility of the diagnosis services
of public health systems. Indeed, it is a well known fact that, in countries with lower
TB burden, diagnosis times tend to be higher, because of that pulmonary TB tends to
be confounded, at its early stages, with more venial respiratory pathologies.
In the other hand, this time needed for TB diagnosis, is known to vary depending
the type of disease, essentially because the diagnosis tools used in each type are different
too. In our model η represents the variation for the diagnosis rate that is observed for
the detection and diagnosis of non smear positives types of disease.
Our estimations for the parameter η are based upon the case detection ratios χ for
each type of disease –Dp+, Dp− and Dnp– reported in [22]. The case detection ratio is
commonly defined as the ratio of the number of notified cases of TB to the number of
incident TB cases in a given year. In [22], estimations for the case detection ratios are
provided for each type of disease and regions: χp+, χp− and χnp; and it turns out that
according to that source χnp ' χp− in all regions. Therefore, if we compare the case
detection ratios of non smear positive and smear positive types of the disease we can
obtain an estimation for the parameter η for each region:
η =
χp+
χp−
(' χp+
χnp
) (9.1)
In table 9.3.1, the values of η so calculated are listed for the different regions
under analysis. The errors have been estimated by considering a 15% as the typical
uncertainty of both χp+ and χp−[22], and propagating the error from there:
It is noticeable that the diagnosis rate is allowed to vary in time, as it has been
done in other previous models. By doing this, case detection rates are allowed to vary
independently to the total volume of classes T and the incidence rates. This is achieved
through the introduction of an exponential variation term: d(t) = doe(αdt), as we will
explain in detail in the subsection devoted to the fitting scheme.
Once again, the transitions are the same in the immune branch:
• Diagnosis of non pulmonary TB (immune branch): from Dvnp(a, t) to T vnp(a, t):
ηd(t)Dvnp(a, t) individuals/unit time
• Diagnosis of smear negative pulmonary TB (immune branch): from Dvp−(a, t) to
T vp−(a, t): ηd(t)Dvp−(a, t) individuals/unit time
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• Diagnosis of smear positive pulmonary TB (immune branch): from Dvp+(a, t) to
T vp+(a, t): d(t)Dvp+(a, t) individuals/unit time
Treatment outcomes Right after diagnosis, and supposing that anti-biotic treat-
ments are available immediately, sick individuals start their treatment. In terms of
our model, individuals under current treatment lie into Tnp, Tp− or Tp+, depending on
the type of disease they receive treatment to be cured from. During their stage at T
classes, either by the effect of treatment or by the common quarantine measures that
use to follow a TB diagnosis, individuals are not considered able to spread the disease.
Typical anti-biotic series last six months; let Ψ be the rate associated to that
treatment time. Once the treatment is completed, different results are possible, and
the World Health Organization groups these treatment outcomes into four main groups:
• Success: the treatment has been completed and bacilli are not present in the
sputum.
• Default: the treatment has been abandoned before completion.
• Death.
• Failure: bacilli persist -or appear- in the sputum at the end of the treatment
(month five or later).
plus an additional treatment outcome for individuals whose treatment outcome is
not well known, either because they have been geographically transferred during the
treatment (“transferred”) or because their treatment outcome has not been properly
evaluated (“not evaluated”).
Therefore, let us denote as fp+S , f
p+
D , f
p+
F and f
p+
µ , the normalized fraction of
pulmonary, smear positive TB sick individuals who finish their treatments belonging
respectively to success, default, failure and death groups, as they are available, on a
yearly basis, at [24], once normalized so as to discard the unknown outcomes to get
fp+S + f
p+
D + f
p+
F + f
p+
µ = 1 what allows us to substitute f
p+
S = 1− (fp+D + fp+F + fp+µ )
so as to work just with these three fractions of unsuccessful treatment outcomes. For
pulmonary, smear positive and non pulmonary TB cases, [24] does not differentiate
the fractions of treatment outcomes, and so we have fp−S , f
p−
D , f
p−
F and f
p−
µ standing
for the fraction of individuals undertaking each outcome both from pulmonary, smear
negative and from non pulmonary classes of TB. Again, we have the closure relationship
fp−S + f
p−
D + f
p−
F + f
p−
µ = 1 that yields the substitution f
p−
S = 1 − (fp−D + fp−F + fpµ).
The values of the fractions of non successful outcomes have been averaged during the
fitting time window (from 2000 to 2011), their values are provided in table 9.3.3, where
confidence intervals correspond to two typical deviations of the time average of each
parameter.
Therefore, we can enumerate all the possible treatment outcomes from all the dif-
ferent kinds of unvaccinated patients to get:
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• Early treatment abandon (default) of smear positive TB: transition from Tp+(a, t)
to Rp+D(a, t): Ψfp+D Tp+(a, t) individuals/unit time.
• Failed treatment completion of smear positive TB: transition from Tp+(a, t) to
F (a, t): Ψfp+F Tp+(a, t) individuals/unit time.
• Death during treatment of smear positive TB:
Ψfp+µ Tp+(a, t) individuals/unit time.
• Successful treatment completion of smear positive TB: transition from Tp+(a, t)
to Rp+S(a, t): Ψ(1− fp+D − fp+F − fp+µ )Tp+(a, t) individuals/unit time.
• Early treatment abandon (default) of smear negative TB: transition from Tp−(a, t)
to Rp−D(a, t): Ψfp−D Tp−(a, t) individuals/unit time.
• Failed treatment completion of smear negative TB: transition from Tp−(a, t) to
F (a, t): Ψfp−F Tp−(a, t) individuals/unit time.
• Death during treatment of smear negative TB:
Ψfp−µ Tp−(a, t) individuals/unit time.
• Successful treatment completion of smear negative TB: transition from Tp−(a, t)
to Rp−S(a, t): Ψ(1− fp−D − fp−F − fp−µ )Tp−(a, t) individuals/unit time.
• Early treatment abandon (default) of non pulmonary TB: transition from Tnp(a, t)
to RnpD(a, t): Ψfp−D Tnp(a, t) individuals/unit time.
• Failed treatment completion of non pulmonary TB: transition from Tnp(a, t) to
F (a, t): Ψfp−F Tnp(a, t) individuals/unit time.
• Death during treatment of non pulmonary TB:
Ψfp−µ Tnp(a, t) individuals/unit time.
• Successful treatment completion of non pulmonary TB: transition from Tnp(a, t)
to RnpS(a, t): Ψ(1− fp−D − fp−F − fp−µ )Tnp(a, t) individuals/unit time.
where the different Rxy variables stand for the groups of individuals that have com-
pleted their treatment for disease of type x (pulmonary smear positive p+ or negative,
p− or non-pulmonary np) with an outcome denoted by y (Success, S, default D, fail
F or death µ).
Immunity, once the infection (and the progression to disease and the diagnosis)
took place, does not affect the treatment outcomes transitions, which are equivalent in
both branches of the model:
• Early treatment abandon (default) of smear positive TB: transition from T vp+(a, t)
to Rvp+D(a, t): Ψf
p+
D T
v
p+(a, t) individuals/unit time.
• Failed treatment completion of smear positive TB: transition from T vp+(a, t) to
F (a, t): Ψfp+F T
v
p+(a, t) individuals/unit time.
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• Death during treatment of smear positive TB:
Ψfp+µ T
v
p+(a, t) individuals/unit time.
• Successful treatment completion of smear positive TB: transition from T vp+(a, t)
to Rvp+S(a, t): Ψ(1− fp+D − fp+F − fp+µ )T vp+(a, t) individuals/unit time.
• Early treatment abandon (default) of smear negative TB: transition from T vp−(a, t)
to Rvp−D(a, t): Ψf
p−
D T
v
p−(a, t) individuals/unit time.
• Failed treatment completion of smear negative TB: transition from T vp−(a, t) to
F (a, t): Ψfp−F T
v
p−(a, t) individuals/unit time.
• Death during treatment of smear negative TB:
Ψfp−µ T
v
p−(a, t) individuals/unit time.
• Successful treatment completion of smear negative TB: transition from T vp−(a, t)
to Rvp−S(a, t): Ψ(1− fp−D − fp−F − fp−µ )T vp−(a, t) individuals/unit time.
• Early treatment abandon (default) of non pulmonary TB: transition from T vnp(a, t)
to RvnpD(a, t): Ψf
p−
D T
v
np(a, t) individuals/unit time.
• Failed treatment completion of non pulmonary TB: transition from T vnp(a, t) to
F (a, t): Ψfp−F T
v
np(a, t) individuals/unit time.
• Death during treatment of non pulmonary TB:
Ψfp−µ T
v
np(a, t) individuals/unit time.
• Successful treatment completion of non pulmonary TB: transition from T vnp(a, t)
to RvnpS(a, t): Ψ(1− fp−D − fp−F fp−µ )T vnp(a, t) individuals/unit time.
It is worth noticing that recovered individuals are still susceptible to suffer further
reinfection, from which, as it happens with L individuals, a vaccine might protect them.
Because of this reason, it is necessary to differentiate R classes from Rv classes; as well
as D and T classes from Dv and T v.
Natural recovery In certain occasions, natural recovery from TB is possible with-
out medical intervention or treatment. This is modeled by introducing three new
classes of naturally recovered individuals in the first branch: RnpN(a, t), Rp−N(a, t)
and Rp+N(a, t), which undiagnosed, sick individuals of each type of TB join after nat-
ural recovery as follows:
• Natural recovery of non pulmonary TB: transition from Dnp(a, t) to RnpN(a, t):
νDnp(a, t) individuals/unit time.
• Natural recovery of smear negative pulmonary TB: transition from Dp−(a, t) to
Rp−N(a, t): νDp−(a, t) individuals/unit time.
9.3 — Model description 
• Natural recovery of smear positive pulmonary TB: transition from Dp+(a, t) to
Rp+N(a, t): νDp+(a, t) individuals/unit time.
Once again, the same stands for the immune branch:
• Natural recovery of non pulmonary TB: transition from Dvnp(a, t) to RvnpN(a, t):
νDvnp(a, t) individuals/unit time.
• Natural recovery of smear negative pulmonary TB: transition from Dvp−(a, t) to
Rvp−N(a, t): νDvp−(a, t) individuals/unit time.
• Natural recovery of smear positive pulmonary TB: transition from Dvp+(a, t) to
Rvp+N(a, t): νDvp+(a, t) individuals/unit time.
Endogenous reactivations after treatment or natural recovery Nonetheless,
naturally recovered individuals may experience an endogenous reactivation of the dis-
ease, since disease recovery does not suppose the total elimination of the bacilli from
the host organism, generally speaking. If we denote as rN the endogenous relapse rate
of naturally recovered individuals we have:
• Endogenous reactivation of non pulmonary TB after natural recovery: transition
from RnpN(a, t) to Dnp(a, t): rNRnpN(a, t) individuals/unit time.
• Endogenous reactivation of smear negative TB after natural recovery: transition
from Rp−N(a, t) to Dp−(a, t): rNRp−N(a, t) individuals/unit time.
• Endogenous reactivation of smear positive TB after natural recovery: transition
from Rp+N(a, t) to Dp+(a, t): rNRp+N(a, t) individuals/unit time.
In the other hand, endogenous relapse is also possible after anti-biotic treatment.
Once the treatment has finished the probabilities of experiencing an endogenous re-
activation of the disease are related to the treatment outcome of the initial disease
episode.
Individuals who have experienced a failed treatment (F (a, t) class), regardless the
type of TB they originally had are considered as infectious as smear positive untreated
individuals, (because they present viable bacilli in the sputum at the end of the treat-
ment), and their mortality risk due to TB is also the same of an smear positive un-
treated individual. In consequence, eventual relapses from F to Dp+ class do not make
sense, and they experiences a TB-related mortality described by µp+F (a, t) individ-
uals/unit time. Within our modelling framework, ulterior re-diagnosis, re-infections
or re-treatments for F (a, t) individuals are not considered, and so, once an individual
joins this class, its dynamics does not depend any more on the type of disease she
previously had or on whether she was vaccinated or not.
Instead, recovered individuals after successful completion of treatment are consid-
ered functionally cured (i.e. they neither present an specific mortality risk due to TB
nor are infectious). However, they may undergo ulterior endogenous reactivations of
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the disease, caused by the proliferation of the very same bacilli of the original episode,
not completely eliminated from the host organism. In that case, we have the following
transitions:
• Endogenous reactivation of non pulmonary TB after successful treatment: tran-
sition from RnpS(a, t) to Dnp(a, t): rSRnpS(a, t) individuals/unit time.
• Endogenous reactivation of smear negative TB after successful treatment: tran-
sition from Rp−S(a, t) to Dp−(a, t): rSRp−S(a, t) individuals/unit time.
• Endogenous reactivation of smear positive TB after successful treatment: tran-
sition from Rp+S(a, t) to Dp+(a, t): rSRp+S(a, t) individuals/unit time.
Where rS is the endogenous relapse rate after successful treatment completion. In
what regards its estimation, there exist many epidemiological studies based on the
surveillance of cohorts of TB patients after treatment completion during defined follow
up periods, which are aimed at determining the relapse rates, as well as the main risk
factors associated to its increasing.
In the exhaustive meta-analysis by Korenrop and colleagues [96], an ensemble of
such studies is considered. In that work, it is reported that, in all the works re-
analized, an average of 4.2% (3.1 − 5.3 c.i.) of HIV uninfected subjects have a TB
relapse episode during the follow up period of the study, of which, the 73% (63 − 91
c.i.) is due to endogenous reactivation. This means that the fraction of population
that do not develop a relapse is the 96.77% (95.73− 97.80).
Another relevant result of the meta-analysis is the finding that, for HIV uninfected
TB patients, the risk for TB relapse after treatment decreases with time. This can be
seen from the fact that the relapse rates calculated in the different studies considered
tend to be lower as the follow-up period of the trials is higher. This would imply that
most of patients that experiments a relapse after treatment, do it within the first years
after the initial episode.
This second result allows us to assume that the risk of developing a relapse during
the follow up period of an epidemic surveillance study (100 − 97.77 = 2.23% of the
population) can be associated to the total risk of developing such relapse during the
entire life of an individual. So, our task is to calculate an annual risk of relapse such as,
when applied over the whole period of life expectancy of a recovered individual, yields
the same 2.23% of relapse cases. In order to do so, we estimate that the average life
expectancy of individuals within classes R is equal to 35 years, estimation to which we
come after assuming that infection and further recovery are events that occur uniformly
in all ages.
Therefore, and as we are assuming that the relapse rate is constant in age and time,
we have an exponential decay describing the relapse of RxS individuals (Rp+S, Rp−S or
RnpS) of the form: RxS(t) ∼ e−rSt. Therefore, after a period t = 35 years assimilable
to the average life expectancy of a individual in R, from an initial fraction of RxS = 1,
there remains RxS(t = 35) ∼ e−rS35 = 0.9677. This calculation yields the actual value
of rS used in this chapter, rS = 9.4 ·10−4 1/year (6.4 ·10−4−1.3 ·10−3). The confidence
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interval of rS has been obtained after the propagation of the fraction of not relapsing
population as the main source of uncertainty.
Finally, recovered individuals after treatment default are considered partially in-
fectious, although it is assumed that they do not have an explicit mortality risk due
to TB. However, their endogenous relapse risk is higher, which can be modeled by
introducing a parameter rD > rS as follows:
• Endogenous reactivation of non pulmonary TB after treatment default: transition
from RnpD(a, t) to Dnp(a, t): rDRnpD(a, t) individuals/unit time.
• Endogenous reactivation of smear negative TB after treatment default: transition
from Rp−D(a, t) to Dp−(a, t): rDRp−D(a, t) individuals/unit time.
• Endogenous reactivation of smear positive TB after treatment default: transition
from Rp+D(a, t) to Dp+(a, t): rDRp+D(a, t) individuals/unit time.
rD stands for the endogenous relapse rate after treatment default, which has been
calculated as the product of rS and the relative risk factor for endogenous relapse
related to treatment noncompliance, –4.02 (1.79-9.01 c.i.)– taken from [423], which
yields the final value of rD = 3.8 · 10−3 1/year (1.4 · 10−3 − 8.6 · 10−3).
Finally, endogenous reactivation of disease transitions in the immune branch are
equivalent to those of the unvaccinated branch:
• Endogenous reactivation of non pulmonary TB after natural recovery (immune
branch): from RvnpN(a, t) to Dvnp(a, t): rNRvnpN(a, t) individuals/unit time.
• Endogenous reactivation of smear negative TB after natural recovery (immune
branch): from Rvp−N(a, t) to Dvp−(a, t): rNRvp−N(a, t) individuals/unit time.
• Endogenous reactivation of smear positive TB after natural recovery (immune
branch): from Rvp+N(a, t) to Dvp+(a, t): rNRvp+N(a, t) individuals/unit time.
• Endogenous reactivation of non pulmonary TB after successful treatment (im-
mune branch): from RvnpS(a, t) to Dvnp(a, t): rSRvnpS(a, t) individuals/unit time.
• Endogenous reactivation of smear negative TB after successful treatment (im-
mune branch): from Rvp−S(a, t) to Dvp−(a, t): rSRvp−S(a, t) individuals/unit time.
• Endogenous reactivation of smear positive TB after successful treatment (immune
branch): from Rvp+S(a, t) to Dvp+(a, t): rSRvp+S(a, t) individuals/unit time.
• Endogenous reactivation of non pulmonary TB after treatment default (immune
branch): from RvnpD(a, t) to Dvnp(a, t): rDRvnpD(a, t) individuals/unit time.
• Endogenous reactivation of smear negative TB after treatment default (immune
branch): from Rvp−D(a, t) to Dvp−(a, t): rDRvp−D(a, t) individuals/unit time.
• Endogenous reactivation of smear positive TB after treatment default (immune
branch): from Rvp+D(a, t) to Dvp+(a, t): rDRvp+D(a, t) individuals/unit time.
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Exogenous reinfection of infected individuals Individuals belonging to classes
Ls and R classes have been previously exposed to TB bacilli, although they are not
sick while within these classes. In addition, their rates of progression to disease due
to eventual endogenous reactivations are slower than the rates ωfnp, ωfp− an ωfp+
of fast progression to disease from Lf . For those reasons, an eventual exogenous re-
infection of an individual in classes Ls, R or N may cause faster progression to disease,
if primo-infection takes place, than endogenous reactivation. This can be modeled by
introducing the following transitions:
• Exogenous re-infection of Ls(a, t) individuals yielding primo-infection: from Ls(a, t)
to Lf (a, t): p(a)q(a)λ(a, t)Ls(a, t) individuals/unit time.
• Exogenous re-infection of RnpN(a, t) individuals yielding primo-infection: from
RnpN(a, t) to Lf (a, t): p(a)q(a)λ(a, t)RnpN(a, t) individuals/unit time.
• Exogenous re-infection of Rp−N(a, t) individuals yielding primo-infection: from
Rp−N(a, t) to Lf (a, t): p(a)q(a)λ(a, t)Rp−N(a, t) individuals/unit time.
• Exogenous re-infection of Rp+N(a, t) individuals yielding primo-infection: from
Rp+N(a, t) to Lf (a, t): p(a)q(a)λ(a, t)Rp+N(a, t) individuals/unit time.
• Exogenous re-infection of RnpS(a, t) individuals yielding primo-infection: from
RnpS(a, t) to Lf (a, t): p(a)q(a)λ(a, t)RnpS(a, t) individuals/unit time.
• Exogenous re-infection of Rp−S(a, t) individuals yielding primo-infection: from
Rp−S(a, t) to Lf (a, t): p(a)q(a)λ(a, t)Rp−S(a, t) individuals/unit time.
• Exogenous re-infection of Rp+S(a, t) individuals yielding primo-infection: from
Rp+S(a, t) to Lf (a, t): p(a)q(a)λ(a, t)Rp+S(a, t) individuals/unit time.
• Exogenous re-infection of RnpD(a, t) individuals yielding primo-infection: from
RnpD(a, t) to Lf (a, t): p(a)q(a)λ(a, t)RnpD(a, t) individuals/unit time.
• Exogenous re-infection of Rp−D(a, t) individuals yielding primo-infection: from
Rp−D(a, t) to Lf (a, t): p(a)q(a)λ(a, t)Rp−D(a, t) individuals/unit time.
• Exogenous re-infection of Rp+D(a, t) individuals yielding primo-infection: from
Rp+D(a, t) to Lf (a, t): p(a)q(a)λ(a, t)Rp+D(a, t) individuals/unit time.
where q(a) stands for the coefficient of variation of the infection risk of individuals
who has been previously infected in a previous episode.
In what regards the immunized branch, the individuals in classes Lvs and Rv are
supposed to have a lower risk of being reinfected, as a consequence of the effect of the
vaccine, that is modeled by the presence of the  factor in the following transitions:
• Exogenous re-infection of Lvs(a, t) individuals yielding primo-infection: from Lvs(a, t)
to Lvf (a, t): p(a)q(a)λ(a, t)Lvs(a, t) individuals/unit time.
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• Exogenous re-infection of RvnpN(a, t) individuals yielding primo-infection: from
RvnpN(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)NnpN(a, t) individuals/unit time.
• Exogenous re-infection of Rvp−N(a, t) individuals yielding primo-infection: from
Rvp−N(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)Rvp−N(a, t) individuals/unit time.
• Exogenous re-infection of Rvp+N(a, t) individuals yielding primo-infection: from
Rvp+N(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)Rvp+N(a, t) individuals/unit time.
• Exogenous re-infection of RvnpS(a, t) individuals yielding primo-infection: from
RvnpS(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)RvnpS(a, t) individuals/unit time.
• Exogenous re-infection of Rvp−S(a, t) individuals yielding primo-infection: from
Rvp−S(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)Rvp−S(a, t) individuals/unit time.
• Exogenous re-infection of Rvp+S(a, t) individuals yielding primo-infection: from
Rvp+S(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)Rvp+S(a, t) individuals/unit time.
• Exogenous re-infection of RvnpD(a, t) individuals yielding primo-infection: from
RvnpD(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)RvnpD(a, t) individuals/unit time.
• Exogenous re-infection of Rvp−D(a, t) individuals yielding primo-infection: from
Rvp−D(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)Rvp−D(a, t) individuals/unit time.
• Exogenous re-infection of Rvp+D(a, t) individuals yielding primo-infection: from
Rvp+D(a, t) to Lvf (a, t): p(a)q(a)λ(a, t)Rvp+D(a, t) individuals/unit time.
In the other hand, if primo-infection after the secondary infection does not take
place, even if the initial state of the individual is one of the possible R states, the rule
is that no transition must be considered from these states to Ls, because it is always
more likely an endogenous reactivation from those initial states to disease than from Ls,
as either rN , rS or rD are greater than any of the rates of transition from slow latency
to disease ωsnp, ωsp− and ωsp+, (or even greater than the sum ωsnp + ωsp− + ωsp+).
Smear progression In certain cases, it is documented that TB patients of smear
negative pulmonary TB progress to smear positive, even after being treated. In order
to describe this phenomenon, we introduce the smear progression by considering the
following two transitions in the non immune branch of the model:
• Smear progression of untreated individuals: transition fromDp−(a, t) toDp+(a, t):
θ(a, t)Dp−(a, t) individuals/unit time.
• Smear progression of individuals under treatment: transition from Tp−(a, t) to
Tp+(a, t): θ(a, t)Tp−(a, t) individuals/unit time.
where θ(a) stands for the smear progression rate. In the immune branch we have
the same behavior:
 Novel models for the description of TB spreading
• Smear progression of untreated individuals (immune branch): from Dvp−(a, t) to
Dvp+(a, t): θ(a, t)Dvp−(a, t) individuals/unit time.
• Smear progression of individuals under treatment (immune branch): from T vp−(a, t)
to T vp+(a, t): θ(a, t)T vp−(a, t) individuals/unit time.
General and newborn vaccination. Mother-child disease transmission The
vaccine described in the model has the only effect of diminishing the probability of
infection –or reinfection– of immunized individuals. At a certain time t, the flux of
susceptible individuals of age a S(a, t) per unit time which gain immunity after having
been vaccinated is described by the following transition from the unvaccinated branch
to the immune one:
• Immunization of susceptible individuals: transition from S(a, t) to Sv(a, t):
f(a)S(a, t) individuals/unit time.
Under this point of view, the rate f(a) defines the rhythm at which the population
is immunized: S(t) ' e−f(a)t . For example, if f(a) =1/year, within the 5 years during
which individuals belong to age group a, a fraction equal to 1 − e−5 = 0.993 of the
initial amount of susceptible individuals is immunized.
In addition, our model contemplates the description of newborn focused vaccina-
tion campaigns, like that required to introduce a novel BCG-substitutive vaccine on
a population. In order to do so, if we have a number of ∆N(a = 0, t) newborns at
time-step t, we start by splitting them between the non immune branch and the im-
mune branch: fneo represents the fraction of newborns that are immunized. Among
the fraction (1− fneo) of children who are not vaccinated, a percentage of them will be
infected right after birth by their mothers, as it is a well known fact that a mt fraction
of sick women who are pregnant transmit the disease to their children within the first
weeks of their lives [424]. This fraction of infected newborns obviously depend on the
fraction of mothers who have the disease and are able to transmit it at time step t, but
this opens the question of how is the relative risk for women in each of the infectious
classes contemplated in our model to transmit the pathogen to their offspring. Since it
is not a trivial question at all (note that mother child transmission does not even have
to be necessarily airborne), we adopted the hypothesis of considering the total number
of newborn infections proportional to the fraction md:
md(t) =
∑a=7
a=3Dp+(a, t) +Dp−(a, t) +Dnp(a, t) +Rp+D(a, t) +Rp−D(a, t)∑a=7
a=3N(a, t)
+ (9.2)
+
∑a=7
a=3 RnpD(a, t) + F (a, t) +D
v
p+(a, t) +D
v
p−(a, t)∑a=7
a=3N(a, t)
+
+
∑a=7
a=3D
v
np(a, t) +R
v
p+D(a, t) +R
v
p−D(a, t) +R
v
npD(a, t)∑a=7
a=3N(a, t)
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that accounts to the fraction of infected individuals present in the age groups
a ∈ [3, 7] associated to women fertility (between 15 and 40 years old), regardless their
relative infectiousnesses, that would act when talking about airborne disease trans-
mission, which is generally not the case, since we hypothesize that other mechanisms
besides airborne transmission may act in this case.
Therefore, this yields following the distribution of the (1 − fneo)∆N(a = 0, t) un-
vaccinated newborns among S and L classes:
• Birth of S(0, t) individuals (susceptibles who will not be vaccinated right after
birth): (1−mtmd(t))(1− fneo)∆N(a = 0, t)
• Birth of Lf (0, t) individuals (infected after birth who will develop primo-infection):
mtmd(t)p(0)(1− fneo)∆N(a = 0, t)
• Birth of Ls(0, t) individuals (infected after birth who will not develop primo-
infection): mtmd(t)(1− p(0))(1− fneo)∆N(a = 0, t)
In what regards the immune branch of the system, if we suppose that vaccination
has also a prophylactic effect –i.e. it diminishes the probability for a sick mother to
transmit the disease to her child from mt to mt– on impairing the mechanisms of
transmission between mother and child, we have that the fneo∆N(a = 0, t) newborns
that are immunized at time step t are distributed among Svand Lv classes like follows:
• Birth of Sv(0, t) individuals (susceptible, vaccinated right after birth):
(1− mtmd(t))fneo∆N(a = 0, t)
• Birth of Lvf (0, t) individuals (vaccinated, yet infected after birth who will develop
primo-infection): mtmd(t)p(0)fneo∆N(a = 0, t)
• Birth of Lvs(0, t) individuals (vaccinates, yet infected after birth who will not
develop primo-infection): mtmd(t)(1− p(0))fneo∆N(a = 0, t)
Finally, individuals of all ages in the immune branch have, according to our model,
a reduced probability of getting infected (or re-infected) with TB: i.e. a partial (or
absolute) immunity to infection or reinfection. But the immunogenic action of actual
vaccines is not always a lifelong effect. In order to take this phenomenology into
consideration, we have introduced the following set of transitions from any state Xv
–except Sv– of the immune branch to any state X of the unvaccinated branch:
• Loss of immunity of vaccinated groups Xv (except Sv): transition from Xv(a, t)
to X(a, t): γ(a)Xv(a, t) individuals/unit time.
where γ(a) is the immunity waning rate (i.e. the inverse of the vaccine immunity
duration). In addition, we have an additional class Sw(a, t) that does not belong to the
unvaccinated or the immune branch; that represents the susceptible individuals who
have lost their immunity without ever being infected with TB. Therefore, the immunity
waning of Sv individuals is described like this:
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• Loss of immunity of vaccinated susceptible individuals: transition from Sv(a, t)
to Sw(a, t): γ(a)Sv(a, t) individuals/unit time.
The reason for the need of this additional class is that, in case you describe the
immunity waning of susceptible individuals by making them return to the unvaccinated
branch, –as we do with the rest of the classes– then, the model would allow them to
be vaccinated again, which eventually would cause a looped, unrealistic succession of
immunization gain and loss transitions depending on the parameters values. Summa-
rizing, the class Sw(a, t) suffer the same risk of infection of S(a, t), but individuals
within it cannot be vaccinated again. With the rest of classes, instead, we can describe
the immunity loss as a return to the first branch, because after being infected once;
the model do not allow individuals to be vaccinated, and so, they will never be allowed
to be vaccinated again.
Force of infection
The force of infection λ(a, t) is, as it has been said before, the probability of being in-
fected at time step t of a susceptible individual. This magnitude is calculated according
to the following expression:
λ(a, t) = β(t)
∑
a′
ξ(a, a′)Υ(a′, t) (9.3)
being Υ(a′, t) the weighted sum of all the infectious individuals within age-group a′
at time step t:
Υ(a′, t) = Dp+(a′, t) + F (a′, t) + φp−Dp−(a′, t) + φDRp+D(a′, t) + φp−φDRp−D +
+Dvp+(a
′, t) + φp−Dvp−(a
′, t) + φDRvp+D(a
′, t) + φp−φDRvp−D (9.4)
where, in the one hand, φp− ∈ [0, 1] is the coefficient of infectivity reduction of
smear negative sick individuals with respect to smear positive ones, and φD ∈ [0, 1] the
infectivity reduction of individuals who have defaulted the treatment, –Rp+D individu-
als with respect to smear positive, undiagnosed individuals Dp+–. Diagnosed patients
of smear negative TB who had defaulted their treatment have a infectivity reduction
that is the product of the two terms φp−φD.
In the other hand, ξ(a, a′) represents the number of contacts per year that an indi-
vidual within the age group a maintains with individuals in age group a′. In addition,
β(t) represents the scaled based infectiousness, that is considered to exponentially vary
as follows:
β(t) = βoe
αβt (9.5)
where βo is the initial value of β(t) at the beginning of the period studied (t = 2001)
and αβ represents the annual rate of variation of β(t). The reason for which we call
β(t) as the "scaled" infectivity is that it is can be interpreted as the actual infectivity
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–i.e. the probability of disease transmission per Dp+-S contact, which we can call λo–
per a certain scaling factor σξ which, under this conception would represent an average
scaling factor of the contact matrix ξ(a, a′). Under this assumption, β(t) = λo(t)σξ(t).
However, as it is by definition indistinguishable the contribution of both factors λo and
σξ, what it is used in the equations is β(t) and the parameters that are explicitly fitted
by the model are βo and αβ.
Aging
The model considers 14 different age groups, one of each of a duration T of 5 years,
in such a way that individuals aging is described up to 70 years old; moment in which
people is assumed to die because of natural causes. The relevance of such an age
structured description of the system comes from the fact that some of the most relevant
dynamic parameters take different values in the different age groups. As time goes by,
individuals get older and pass trough the different age groups; this situation is modelled
by the introduction on the system of equations of the following aging transitions, that
stands for the promotion of individuals within whatever dynamic class of the model
X(a, t) to the next age class X(a+ 1, t)
• Aging of individuals belonging to class X(a, t) transition from X(a, t) to X(a +
1, t): X(a, t)/∆t individuals/unit time.
Obviously, each class X(a, t) receive people from X(a − 1, t) and sends people to
X(a + 1, t), except X(0, t), that only receives newborns and X(13, t), from which the
exit flow represent the death of the eldest individuals in the system.
Demographic evolution
Once all the transitions among the different dynamical states of the system have been
described, as well as the aging fluxes, it is necessary to provide a global description of
the evolution of the demographic pyramid, given by the evolution of the set of variables
N(a, t), defined as the total amount of individuals within age group a in the population,
no matter their states regarding TB dynamics:
N(a, t) = S(a, t) + Lf (a, t) + Ls(a, t) +Dp+(a, t) +
+Dp−(a, t) +Dnp(a, t) + Tp+(a, t) + Tp−(a, t) + Tnp(a, t) +
+F (a, t) +Rp+N(a, t) +Rp−N(a, t) +RnpN(a, t) +Rp+S(a, t) +
+Rp−S(a, t) +RnpS(a, t) +Rp+D(a, t) +Rp−D(a, t) +RnpD(a, t) +
+Sw(a, t) + Sv(a, t) + Lvf (a, t) + L
v
s(a, t) +D
v
p+(a, t) +
+Dvp−(a, t) +D
v
np(a, t) + T
v
p+(a, t) + T
v
p−(a, t) + T
v
np(a, t) +
+F v(a, t) +Rvp+N(a, t) +R
v
p−N(a, t) +R
v
npN(a, t) +R
v
p+S(a, t) +
+Rvp−S(a, t) +R
v
npS(a, t) +R
v
p+D(a, t) +R
v
p−D(a, t) +R
v
npD(a, t) (9.6)
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the evolution of N(a, t) -in addition to aging and death by TB– is subject to other
driving forces related to aspects like vegetative variation of population –births and
non-TB deaths– as well as migration. In order to provide a description of the temporal
evolution of the demographic pyramid, previous models have turned to different sim-
plifying hypothesis to describe the system. One of them consists of forcing the system
to preserve at any time the total number of individuals N (t) [22]:
N (t) =
∑
a
N(a, t) (9.7)
by imposing that N (t) = N (t = 0)∀(t). Another one [422] is based on forcing the
system to preserve the initial age structure of the population by imposing that, in each
age group: N(a, t) = N(a, t = to)∀(t). Our approach, however is based on forcing the
temporal evolution of the variables N(a, t) to follow the predictions that are made for
them by the United Nations Population Division, available at their on-line databases
[23]: N(a, t) = NUN(a, t), which are represented in figure 9.3.
Figure 9.3: Population pyramids evolution projected by UN population division [23] for the
next decades in each of the region under study.
As we can see from figure 9.3, population ageing is a common feature in all the
regions under study.
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In the following sub-sections, we detail the three different schemes, and, after that,
we proceed to quantify the biases that are due to the adoption of either of the two
simplifying hypothesis (approaches 1 and 2) with respect to the last, more realistic
modeling strategy.
Approach 1: populations of constant volume: N (t) = N (t = 0)∀(t) The way
to implement this type of coupling is to calculate the total number of individuals dead
because of TB (and abandon of the system of the last age class a = 13) at time step t:
N˙o(t) = −N(a = 13, t)/τ −∑
a
[Ψfp+µ (Tp+(a, t) + T
v
p+(a, t)) +
Ψfp−µ (Tp−(a, t) + T
v
p−(a, t) + Tnp(a, t) + T
v
np(a, t)) +
+µp+(Dp+(a, t) + F (a, t) +D
v
p+(a, t)) +
+µp−(Dp−(a, t) +Dvp−(a, t)) + µnp(Dnp(a, t) +D
v
np(a, t))]
and balance it by introducing the same number of individuals at age group a = 0
as newborns:
∆N(a = 0, t) = −N˙o(t) (9.8)
so as to get:
N˙ (t) = N˙o(t) + ∆N(a = 0, t) = 0 (9.9)
All the individuals introduced can be introduced as susceptible as it is done in [22],
or, according to our model, they can be distributed among S, L, Sv and Lv classes.
The problem with this kind of approach is that, during the dynamic process, the
demographic pyramid is distorted in a way that is not under control. This situation,
given that the dynamic parameters are dependent on age ultimately affects the model
forecasts. In addition, by neglecting the population growth, without further informa-
tion, no measures –i.e. incidence, mortality or even disease prevalence– can be done
in terms of raw number of individuals, but only in terms of rates; at least, without
further information about the actual volume of the population under study.
Approach 2: Constant demographic pyramid A typical alternative approach
consists in imposing that, not just the total volume of population, but the demographic
pyramid itself has to remain constant during the dynamical process: i.e. N(a, t) =
N(a, to)∀t. This is what is done in some previous works, like [422], in which, the
dynamical states indicates densities rather than numbers of individuals. In that work,
the force of infection calculated as an average of the densities of sick individuals in
each age group, weighted by the number of individuals within each age class of the
demographic pyramid. This way, authors of [422] provide a way for calculating infection
and mortality rates that takes into account the initial demographic structure of the
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population; and these rates can be eventually transformed into numbers by using data
about the evolution of the total population under consideration.
In order to provide an equivalent description based upon our model –in which
states represent number of individuals rather than densities–, we start by calculating
the variation of population due to TB and aging in each age group:
N˙o(a, t) = ((1− δ(a))N(a− 1, t)−N(a, t))/∆t − (9.10)
−µp+(Dp+(a, t) + F (a, t) +Dvp+(a, t))−
−µp−(Dp−(a, t) +Dvp−(a, t))− µnp(Dnp(a, t) +Dvnp(a, t))−
−Ψfp+µ (Tp+(a, t) + T vp+(a, t))−Ψfp−µ (Tp−(a, t) + T vp−(a, t) + Tnp(a, t) + T vnp(a, t))
being δ(a) the Kronecker delta function. In order to preserve the number of individ-
uals within each age group at any moment, we simply introduce a term ∆N(a, t) that
is intended to balance N˙o(a, t) within each age group: ∆N(a, t) = −N˙o(a, t), yielding:
N˙(a, t) = N˙o(a, t) + ∆N(a, t) = 0∀(a, t) (9.11)
The key question is how do we distribute these correction terms ∆N(a, t) among
the different dynamical states X(a, t) within age-class a: these increments have to
be distributed among X(a, t) dynamical states respecting the relative volume of these
states within the age group so as not to introduce external, undesired biases on states
densities. If we call ∆X(a, t) the fraction of ∆N(a, t) that is introducing in stateX(a, t),
we have:
∆X(a, t) = ∆N(a, t)
X(a, t)
N(a, t)
(9.12)
and obviously:
∆N(a, t) =
∑
X
∆X(a, t) (9.13)
This scheme has the advantage, with respect to consider N (t) = N (t = 0)∀(t),
that, at least, the initial structure of the population is conserved. However, as in
the first case, population growth is not explicitly considered, and further information
about population volume is required so as to scale rates into numbers, as done in
[422]. Additionally, the main problem with this approach comes from the fact that
no variation of the age structure of the population can be considered by proceeding
this way, which might introduce significant biases, specially when studying regions
subjected to strong processes of demographic aging or rejuvenation.
Approach 3: Demographic pyramid as an external constraint Starting from
the last scheme for modeling the demographic evolution, it is easy to obtain a final
approach that explicitly takes into account not only the influence of the age structure
into the spreading but also the population growth and the variation of the demographic
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pyramid itself. In order to do that, obviously, it is necessary to know the actual –or
projected– evolution of the demographic pyramid of the population during the period
under analysis. In our case, we are modeling TB dynamics from 2001 to 2050; and the
official annual projections for the population per age group of any country are available,
up to 2100, at the UN population division database [23]. After adequately grouping
the countries, we obtain the actual annual population series expected by the UN for
the populations at each age group, that can be trivially fitted to a continuos function
NUN(a, t), from which we can derive an analytical derivative N˙UN(a, t) at any moment.
For the purpose of this chapter, a polynomial of degree 10 is more than enough for
building the continuous function NUN(a, t) from the annual data series from [23] during
the period under study.
So, if we recover the variation of population due to TB and aging in each age group,
initially provided by the model:
N˙o(a, t) = ((1− δ(a))N(a− 1, t)−N(a, t))/∆t − (9.14)
−µp+(Dp+(a, t) + F (a, t) +Dvp+(a, t))−
−µp−(Dp−(a, t) +Dvp−(a, t))− µnp(Dnp(a, t) +Dvnp(a, t))−
−Ψfp+µ (Tp+(a, t) + T vp+(a, t))−Ψfp+µ (Tp−(a, t) + T vp−(a, t) + Tnp(a, t) + T vnp(a, t))
now, we also introduce a term ∆N(a, t), but this time, it is not aimed at balancing
N˙o(a, t), but to force the total temporal evolution of N(a, t) to follow precisely the
function NUN(a, t). That is achieved by defining, at each time step:
∆N(a, t) = N˙UN(a, t)− N˙o(a, t) (9.15)
and introducing those ∆N(a, t) terms into the system dynamics, so having: N˙(a, t) =
N˙o(a, t) + ∆N(a, t) = N˙UN(a, t). Finally, provided that the initial conditions have been
properly set: N(a, t = 0) = NUN(a, t = 0)∀a, this yields the desired behavior for the
demographic pyramid; i.e. N(a, t) = NUN(a, t)∀(a, t).
Again, the ∆N(a, t) forcing terms have to be introduced into the different dynamical
states within the same age class preserving their proportions, at least in the age groups
a > 0:
∆X(a, t) = ∆N(a, t)
X(a, t)
N(a, t)
∀a > 0 (9.16)
and, under this assumption, the terms ∆N(a, t) for a > 0, represents the variations
of volume of the age group a due to whatever causes foreign to TB infection and
individuals aging; which would include all death not caused by TB, and migration,
assuming that these factors affect all the dynamics classes regardless their state with
respect to TB infection.
The situation is different for the first age class a = 0. In the first age group, the
introduction of newborn individuals is the main cause of population variation and it
is not distributed uniformly among the different dynamical states, but only among S
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and L states. For these reasons, and once observed that ∆N(a = 0, t) > 0∀t in all
regions under consideration, for simplicity ∆N(a = 0, t) is directly associated to the
number of newborns, as it was previously done in the section devoted to immunization
and mother-child disease transmision, in which we describe the way in which these
∆N(a = 0, t) newborns are distributed among classes S, Sv, L and Lv.
The uncertainty of United nations demographic projections is also reported at [23],
which allows us to reconstruct the demographic pyramids at the extreme of the confi-
dence interval N lowUN (a, t) and N
high
UN (a, t). Therefore, its influence on the model forecasts
is also evaluable, as we will discuss on the section devoted to uncertainty and sensitivity
analysis.
Overall ODEs system
The following system of differential equations describe evolution of the different dy-
namical states of the model:
S˙(a, t) = −f(a)S(a, t)− λ(a, t)S(a, t)−
− (S(a, t)− (1− δ(a))S(a− 1, t))/τ +
+ δ(a)(1−mtmd(t))(1− fnew)∆N (a, t) +
+ δ(a)∆N (a, t)S(a, t)/N(a, t) (9.17)
L˙s(a, t) = γLvs(a, t) + (1− p(a))λ(a, t)(S(a, t) + Sw(a, t))−
− p(a)qλ(a, t)Ls − (ωsp+(a) + ωsp−(a) + ωsnp(a))Ls(a, t)−
− (Ls(a, t)− (1− δ(a))Ls(a− 1, t))/τ +
+ δ(a)mtmd(t)(1− p(a))∆N (a, t) + δ(a)∆N (a, t)Ls(a, t)/N(a, t) (9.18)
L˙f (a, t) = γLvf (a, t) + p(a)λ(a, t)(S(a, t) + S
w(a, t))−
− (ωfp+(a) + ωfp−(a) + ωfnp(a))Lf (a, t) +
+ p(a)qλ(a, t)(Ls(a, t) +Rp+N (a, t) +Rp−N (a, t)) +
+ p(a)qλ(a, t)(RnpN (a, t) +Rp+S(a, t) +Rp−S(a, t)) +
+ p(a)qλ(a, t)(RnpS(a, t) +Rp+D(a, t) +Rp−D(a, t) +RnpD(a, t))−
− (Lf (a, t)− (1− δ(a))Lf (a− 1, t))/τ +
+ δ(a)mtmd(t)p(a)∆N (a, t) + δ(a)∆N (a, t)Lf (a, t)/N(a, t) (9.19)
D˙p+(a, t) = γDvp+(a, t) + ωfp+(a)Lf (a, t) + ωsp+(a)Ls(a, t)− µp+Dp+(a, t)−
− d(t)Dp+(a, t)− νDp+(a, t) + rNRp+N (a, t) +
+ rSRp+S(a, t) + rDRp+D(a, t) + θDp−(a, t)−
− (Dp+(a, t)− (1− δ(a))Dp+(a− 1, t))/τ +
+ ∆N (a, t)Dp+(a, t)/N(a, t) (9.20)
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D˙p−(a, t) = γDvp−(a, t) + ωfp−(a)Lf (a, t) + ωsp−(a)Ls(a, t)− µp−Dp−(a, t)−
− ηd(t)Dp−(a, t)− νDp−(a, t) + rNRp−N (a, t) +
+ rSRp−S(a, t) + rDRp−D(a, t)− θDp−(a, t)−
− (Dp−(a, t)− (1− δ(a))Dp−(a− 1, t))/τ +
+ ∆N (a, t)Dp−(a, t)/N(a, t) (9.21)
D˙np(a, t) = γDvnp(a, t) + ωfnp(a)Lf (a, t) + ωsnp(a)Ls(a, t)− µnpDnp(a, t)−
− ηd(t)Dnp(a, t)− νDnp(a, t) + rNRnpN (a, t) +
+ rSRnpS(a, t) + rDRnpD(a, t)−
− (Dnp(a, t)− (1− δ(a))Dnp(a− 1, t))/τ +
+ ∆N (a, t)Dnp(a, t)/N(a, t) (9.22)
T˙p+(a, t) = γT vp+(a, t) + d(t)Dp+(a, t)−ΨTp+(a, t) + θTp−(a, t)−
− (Tp+(a, t)− (1− δ(a))Tp+(a− 1, t))/τ +
+ ∆N (a, t)Tp+(a, t)/N(a, t) (9.23)
T˙p−(a, t) = γT vp−(a, t) + ηd(t)Dp−(a, t)−ΨTp−(a, t)− θTp−(a, t)−
− (Tp−(a, t)− (1− δ(a))Tp−(a− 1, t))/τ +
+ ∆N (a, t)Tp−(a, t)/N(a, t) (9.24)
T˙np(a, t) = γT vnp(a, t) + ηd(t)Dnp(a, t)−ΨTnp(a, t)−
− (Tnp(a, t)− (1− δ(a))Tnp(a− 1, t))/τ +
+ ∆N (a, t)Tnp(a, t)/N(a, t) (9.25)
F˙ (a, t) = Ψfp+F (Tp+(a, t) + T
v
p+(a, t)) +
+ Ψfp−F (Tp−(a, t) + T
v
p−(a, t) + Tnp(a, t) + T
v
np(a, t))−
− (F (a, t)− (1− δ(a))F (a− 1, t))/τ + ∆N (a, t)F (a, t)/N(a, t) (9.26)
R˙p+N (a, t) = γRvp+N (a, t) + νDp+(a, t)− rNRp+N (a, t)−
− p(a)qλ(a, t)Rp+N (a, t)−
− (Rp+N (a, t)− (1− δ(a))Rp+N (a− 1, t))/τ +
+ ∆N (a, t)Rp+N (a, t)/N(a, t) (9.27)
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R˙p−N (a, t) = γRvp−N (a, t) + νDp−(a, t)− rNRp−N (a, t)−
− p(a)qλ(a, t)Rp−N (a, t)−
− (Rp−N (a, t)− (1− δ(a))Rp−N (a− 1, t))/τ +
+ ∆N (a, t)Rp−N (a, t)/N(a, t) (9.28)
R˙npN (a, t) = γRvnpN (a, t) + νDnp(a, t)− rNRnpN (a, t)−
− p(a)qλ(a, t)RnpN (a, t)−
− (RnpN (a, t)− (1− δ(a))RnpN (a− 1, t))/τ +
+ ∆N (a, t)RnpN (a, t)/N(a, t) (9.29)
R˙p+S(a, t) = γRvp+S(a, t) + Ψ(1− fp+D − fp+F − fp+µ )Tp+(a, t)−
− rSRp+S(a, t)− p(a)qλ(a, t)Rp+S(a, t)−
− (Rp+S(a, t)− (1− δ(a))Rp+S(a− 1, t))/τ +
+ ∆N (a, t)Rp+S(a, t)/N(a, t) (9.30)
R˙p−S(a, t) = γRvp−S(a, t) + Ψ(1− fp−D − fp−F − fp−µ )Tp−(a, t)−
− rSRp−S(a, t)− p(a)qλ(a, t)Rp−S(a, t)−
− (Rp−S(a, t)− (1− δ(a))Rp−S(a− 1, t))/τ +
+ ∆N (a, t)Rp−S(a, t)/N(a, t) (9.31)
R˙npS(a, t) = γRvnpS(a, t) + Ψ(1− fp−D − fp−F − fp−µ )Tnp(a, t)−
− rSRnpS(a, t)− p(a)qλ(a, t)RnpS(a, t)−
− (RnpS(a, t)− (1− δ(a))RnpS(a− 1, t))/τ +
+ ∆N (a, t)RnpS(a, t)/N(a, t) (9.32)
R˙p+D(a, t) = γRvp+D(a, t) + Ψf
p+
D Tp+(a, t)− rDRp+D(a, t)−
− p(a)qλ(a, t)Rp+D(a, t)−
− (Rp+D(a, t)− (1− δ(a))Rp+D(a− 1, t))/τ +
+ ∆N (a, t)Rp+D(a, t)/N(a, t) (9.33)
R˙p−D(a, t) = γRvp−D(a, t) + Ψf
p−
D Tp−(a, t)− rDRp−D(a, t)−
− p(a)qλ(a, t)Rp−D(a, t)−
− (Rp−D(a, t)− (1− δ(a))Rp−D(a− 1, t))/τ +
+ ∆N (a, t)Rp−D(a, t)/N(a, t) (9.34)
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R˙npD(a, t) = γRvnpD(a, t) + Ψf
p−
D Tnp(a, t)− rDRnpD(a, t)−
− p(a)qλ(a, t)RnpD(a, t)−
− (RnpD(a, t)− (1− δ(a))RnpD(a− 1, t))/τ +
+ ∆N (a, t)RnpD(a, t)/N(a, t) (9.35)
S˙w(a, t) = γSv(a, t)− λ(a, t)Sw(a, t) + ∆N (a, t)Sw(a, t)/N(a, t)
− (Sw(a, t)− (1− δ(a))Sw(a− 1, t))/τ (9.36)
S˙v(a, t) = f(a)S(a, t)− γSv(a, t)− λ(a, t)Sv(a, t)−
− (Sv(a, t)− (1− δ(a))Sv(a− 1, t))/τ +
+ δ(a)(1−mtmd(t))fnew∆N (a, t) + δ(a)∆N (a, t)Sv(a, t)/N(a, t) (9.37)
L˙vs(a, t) = −γLvs(a, t) + (1− p(a))λ(a, t)Sv(a, t)−
− (ωsp+(a) + ωsp−(a) + ωsnp(a))Lvs(a, t)− p(a)qλ(a, t)Lvs(a, t)−
− (Lvs(a, t)− (1− δ(a))Lvs(a− 1, t))/τ + ∆N (a, t)Lvs(a, t)/N(a, t) (9.38)
L˙vf (a, t) = −γLvf (a, t) + p(a)(a)λ(a, t)Sv(a, t)− (ωfp+(a) + ωfp−(a) + ωfnp(a))Lvf (a, t) +
+ p(a)qλ(a, t)(Lvs(a, t) +R
v
p+N (a, t) +R
v
p−N (a, t) +R
v
npN (a, t)) +
+ p(a)qλ(a, t)(Rvp+S(a, t) +R
v
p−S(a, t) +R
v
npS(a, t)) +
+ p(a)qλ(a, t)(Rvp+D(a, t) +R
v
p−D(a, t) +R
v
npD(a, t))−
− (Lvf (a, t)− (1− δ(a))Lvf (a− 1, t))/τ + ∆N (a, t)Lvf (a, t)/N(a, t) (9.39)
D˙vp+(a, t) = −γDvp+(a, t) + ωfp+(a)Lvf (a, t) + ωsp+(a)Lvs(a, t)− µp+Dvp+(a, t)−
− d(t)Dvp+(a, t)− νDvp+(a, t) + rNRvp+N (a, t) + rSRvp+S(a, t) + rDRvp+D(a, t) +
+ θDvp−(a, t)− (Dvp+(a, t)− (1− δ(a))Dvp+(a− 1, t))/τ +
+ ∆N (a, t)Dvp+(a, t)/N(a, t) (9.40)
D˙vp−(a, t) = −γDvp−(a, t) + ωfp−(a)Lvf (a, t) + ωsp−(a)Lvs(a, t)− µp−Dvp−(a, t)−
− ηd(t)Dvp−(a, t)− νDvp−(a, t) + rNRvp−N (a, t) + rSRvp−S(a, t) + rDRvp−D(a, t)−
− θDvp−(a, t)− (Dvp−(a, t)− (1− δ(a))Dvp−(a− 1, t))/τ +
+ ∆N (a, t)Dvp−(a, t)/N(a, t) (9.41)
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D˙vnp(a, t) = −γDvnp(a, t) + ωfnp(a)Lvf (a, t) + ωsnp(a)Lvs(a, t)− µnpDvnp(a, t)−
− ηd(t)Dvnp(a, t)− νDvnp(a, t) + rNRvnpN (a, t) + rSRvnpS(a, t) +
+ rDRvnpD(a, t)− (Dvnp(a, t)− (1− δ(a))Dvnp(a− 1, t))/τ +
+ ∆N (a, t)Dvnp(a, t)/N(a, t) (9.42)
T˙ vp+(a, t) = −γT vp+(a, t) + d(t)Dvp+(a, t)−ΨT vp+(a, t) + θT vp−(a, t)−
− (T vp+(a, t)− (1− δ(a))T vp+(a− 1, t))/τ +
+ ∆N (a, t)T vp+(a, t)/N(a, t) (9.43)
T˙ vp−(a, t) = −γT vp−(a, t) + ηd(t)Dvp−(a, t)−ΨT vp−(a, t)− θT vp−(a, t)−
− (T vp−(a, t)− (1− δ(a))T vp−(a− 1, t))/τ +
+ ∆N (a, t)T vp−(a, t)/N(a, t) (9.44)
T˙ vnp(a, t) = −γT vnp(a, t) + ηd(t)Dvnp(a, t)−ΨT vnp(a, t)−
− (T vnp(a, t)− (1− δ(a))T vnp(a− 1, t))/τ +
+ ∆N (a, t)T vnp(a, t)/N(a, t) (9.45)
R˙vp+N (a, t) = −γRvp+N (a, t) + νDvp+(a, t)− rNRvp+N (a, t)−
− p(a)qλ(a, t)Rvp+N (a, t)−
− (Rvp+N (a, t)− (1− δ(a))Rvp+N (a− 1, t))/τ +
+ ∆N (a, t)Rvp+N (a, t)/N(a, t) (9.46)
R˙vp−N (a, t) = −γRvp−N (a, t) + νDvp−(a, t)− rNRvp−N (a, t)−
− p(a)qλ(a, t)Rvp−N (a, t)−
− (Rvp−N (a, t)− (1− δ(a))Rvp−N (a− 1, t))/τ +
+ ∆N (a, t)Rvp−N (a, t)/N(a, t) (9.47)
R˙vnpN (a, t) = −γRvnpN (a, t) + νDvnp(a, t)− rNRvnpN (a, t)−
− p(a)qλ(a, t)RvnpN (a, t)−
− (RvnpN (a, t)− (1− δ(a))RvnpN (a− 1, t))/τ +
+ ∆N (a, t)RvnpN (a, t)/N(a, t) (9.48)
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R˙vp+S(a, t) = −γRvp+S(a, t) + Ψ(1− fp+D − fp+F − fp+µ )T vp+(a, t)− rSRvp+S(a, t)−
− p(a)qλ(a, t)Rvp+S(a, t)− (Rvp+S(a, t)− (1− δ(a))Rvp+S(a− 1, t))/τ +
+ ∆N (a, t)Rvp+S(a, t)/N(a, t) (9.49)
R˙vp−S(a, t) = −γRvp−S(a, t) + Ψ(1− fp−D − fp−F − fp−µ )T vp−(a, t)−
− rSRvp−S(a, t)− p(a)qλ(a, t)Rvp−S(a, t)−
− (Rvp−S(a, t)− (1− δ(a))Rvp−S(a− 1, t))/τ +
+ ∆N (a, t)Rvp−S(a, t)/N(a, t) (9.50)
R˙vnpS(a, t) = −γRvnpS(a, t) + Ψ(1− fp−D − fp−F − fp−µ )T vnp(a, t)−
− rSRvnpS(a, t)− p(a)qλ(a, t)RvnpS(a, t)−
− (RvnpS(a, t)− (1− δ(a))RvnpS(a− 1, t))/τ +
+ ∆N (a, t)RvnpS(a, t)/N(a, t) (9.51)
R˙vp+D(a, t) = −γRvp+D(a, t) + Ψfp+D T vp+(a, t)− rDRvp+D(a, t)− p(a)qλ(a, t)Rvp+D(a, t)−
− (Rvp+D(a, t)− (1− δ(a))Rvp+D(a− 1, t))/τ +
+ ∆N (a, t)Rvp+D(a, t)/N(a, t) (9.52)
R˙vp−D(a, t) = −γRvp−D(a, t) + Ψfp−D T vp−(a, t)− rDRvp−D(a, t)− p(a)qλ(a, t)Rvp−D(a, t)−
− p(a)qλ(a, t)Rvp+D(a, t)− (Rvp−D(a, t)− (1− δ(a))Rvp−D(a− 1, t))/τ +
+ ∆N (a, t)Rvp−D(a, t)/N(a, t) (9.53)
R˙vnpD(a, t) = −γRvnpD(a, t) + Ψfp−D T vnp(a, t)− rDRvnpD(a, t)− p(a)qλ(a, t)RdnpD(a, t)−
− (RvnpD(a, t)− (1− δ(a))RvnpD(a− 1, t))/τ +
+ ∆N (a, t)RvnpD(a, t)/N(a, t) (9.54)
sdvsdcdscd
where δ(a) stands for the Kronecker delta function, and the four quantities that
depend on time are the force of infection λ(a, t), the proportion of mothers with TB
md(t), the diagnosis rate d(t) and the correction terms ∆N(a, t) standing for any de-
mographic variation in the population due to causes foreign to TB and aging. The
force of infection is constructed like follows:
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λ(a, t) = βoeαβt
∑
a′
ξ(a, a′)Υ(a′, t) (9.55)
where Υ(a′, t) stands for the weighted sum of infectious individuals:
Υ(a′, t) = Dp+(a′, t) + F (a′, t) + φp−Dp−(a′, t) + φDRp+D(a′, t) + φp−φDRp−D + (9.56)
+Dvp+(a
′, t) + φp−Dvp−(a
′, t) + φDRvp+D(a
′, t) + φp−φDRvp−D(a
′, t)
Additionally, the proportion of mothers who are responsible of mother-child disease
transmission reads as:
md(t) =
∑a=7
a=3 Dp+(a, t) +Dp−(a, t) +Dnp(a, t) +Rp+D(a, t) +Rp−D(a, t)∑a=7
a=3N(a, t)
+ (9.57)
+
∑a=7
a=3 RnpD(a, t) + F (a, t) +D
v
p+(a, t) +D
v
p−(a, t)∑a=7
a=3N(a, t)
+
+
∑a=7
a=3D
v
np(a, t) +R
v
p+D(a, t) +R
v
p−D(a, t) +R
v
npD(a, t)∑a=7
a=3N(a, t)
Instead, we have, for the diagnosis rate:
d(t) = doe(αdt) (9.58)
And finally, the demographic correction terms ∆N(a, t) obeys the following expres-
sion:
∆N (a, t) = N˙UN (a, t)− [((1− δ(a))N(a− 1, t)−N(a, t))/∆t − (9.59)
−µp+(Dp+(a, t) + F (a, t) +Dvp+(a, t))−
−µp−(Dp−(a, t) +Dvp−(a, t))− µnp(Dnp(a, t) +Dvnp(a, t))−
−Ψfˆµ(Tp+(a, t) + T vp+(a, t) + Tp−(a, t) + T vp−(a, t) + Tnp(a, t) + T vnp(a, t))]
It is interesting to define two additional variables, fully dependent on the dynamical
state of the system, such as the accumulated number of TB incident cases in each age
group, from the beginning of the period under analysis I(a, t), and the accumulated
number of TB deaths equally defined M(a, t). Their respective temporal evolution
reads as follows:
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I˙(a, t) = d(t)(Dp+(a, t) +D
v
p+(a, t) +
+ η(Dp−(a, t) +Dvp−(a, t) +Dnp(a, t) +D
v
np(a, t)) (9.60)
M˙(a, t) = µp+(Dp+(a, t) + F (a, t) +D
v
p+(a, t)) + µp−(Dp−(a, t) +D
v
p−(a, t)) +
+ µnp(Dnp(a, t) +D
v
np(a, t)) + Ψf
p+
µ (Tp+(a, t) + T
v
p+(a, t)) +
+ Ψfp−µ (Tp−(a, t) + T
v
p−(a, t) + Tnp(a, t) + T
v
np(a, t)) (9.61)
Because of that, from these variables, once summed over all age groups, we explicitly
get the incidence rate as the number of new cases per year i(t), and the annual mortality
rate as the total number of TB deaths per year m(t), both normalized by 100.000
individuals:
i(t) =
100.000 ·∑a (I(a, t+ 1)− I(a, t))
(N (t+ 1) +N (t))/2 (9.62)
m(t) =
100.000 ·∑a (M(a, t+ 1)−M(a, t))
(N (t+ 1) +N (t))/2 (9.63)
The sums of I(a, t) and M(a, t) over all ages at the end of the period under study
provide the total number of cases and deaths due to the disease during the whole
period.
Initial conditions setup
Once we have detailed the forces driving the time evolution of our state variables,
it remains pendent answer how do we set the initial conditions X(a, t = 0) for each
possible state X. This problem is traditionally solved [422, 22] just by considering
that, at the beginning of the period analyzed, the system is at the stationary that
is reached after blocking the temporal evolution of the time dependent parameters to
their values at the beginning of the period: d(t = 0) = do and β(t = 0) = βo, as well
as the demographic boundary conditions ~N(a, t) = ~N(a, 0), where ~N(a, t) represents
the vector of the different populations at each age group. We denote those stationary
levels as X∗(a, do, βo, ~N(a, 0)), so we have X˙∗(a, do, βo, ~N(a, 0)) = 0 (provided that
the time "freezing" of time-dependent parameters and the demography is acting), and
this approach consists in using them to set up the initial conditions of the system:
X(a, 0) = X∗(a, do, βo, ~N(a, 0)) for any dynamic state X. From this point on, it is
worth noticing that no variation in the dynamic state of the system would be achieved
if the parameters d and β as well as the demographic pyramid remains constant; because
of, in this point, the dynamical system has reached a stationary state. When this kind
of approach is used, instead, the only way of modifying this stationary state is to
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trigger both the temporal evolution of d(t) and β(t) and/or the temporal evolution of
the demographic constraints ~N(a, t), which is precisely what it is done so as to start
the dynamical description during the period under analysis.
In this work we also abandon this initial stationarity assumption and we do not
impose that the system must lye at the stationary in t = 0. Instead of that, we
calculate the stationary values of all states X∗(a, do, βo, ~N(a, 0)), and we set up an
initial state that can correspond either to higher or lower levels of disease prevalence.
So as to map these possible variations on TB burden from the stationary vector of
states ~X∗, we distinguish the unexposed state S(a, t), from the rest of the states in the
non immune branch joined by individuals that, at least, have been infected with the
bacillus once. Additionally, we consider that, at the immune branch Xv(a, t = 0) = 0,
(also Sw(a, t = 0) = 0), as any vaccination campaign is introduced for some time t > 0.
Additionally, we define a parameter ζ ∈ [−1, 1]. In case ζ < 0, it means that the initial
conditions correspond to a state with lower TB burden than the stationary, which we
build as follows:
X(a, t = 0) = (1 + ζ)X∗(a, do, βo, ~N(a, 0)) ∀(X 6= S) (9.64)
S(a, t = 0) = S∗(a, do, βo, ~N(a, 0))
(
1− ζ
∑
X 6=S
X∗(a, do, βo, ~N(a, 0))
)
(9.65)
Instead, if ζ > 0, the initial conditions are displaced up to higher burden levels
from the stationary:
S(a, t = 0) = S∗(a, do, βo, ~N(a, 0))(1− ζ) (9.66)
X(a, t = 0) = X∗(a, do, βo, ~N(a, 0))
(
1 +
ζS∗(a, do, βo, ~N(a, 0))∑
X 6=S X
∗(a, do, βo, ~N(a, 0))
)
(9.67)
9.3.2 Fitting procedure
Fitting scheme
Our model is based in the determination of the initial distance of the system from the
stationary ζ, the diagnosis rate d(t) and the scaled infectivity β(t), for each region
that are adequate to make the model reproduce certain disease burden measurements
on a certain time window which we take as an input. The last two time dependent
parameters are supposed to vary exponentially: d(t) = doe(αdt) and β(t) = βoe(αβt),
which means that the total amount to parameters to fit is five: (ζ, do, βo, αd, αβ)
The goal of the fitting procedure is to minimize the overall error H of the model
outcome with respect to the input burden measurements, calculated as follows:
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H =
tF∑
t=to
(
i(t)− i¯(t)
σ¯i(t)
)2
+
(
m(t)− m¯(t)
σ¯m(t)
)2
(9.68)
where the fitting window spans from to to tF (in years); and i¯(t) and m¯(t) stand for
the annual incidence and mortality rates, calculated by grouping the national estima-
tions available at the the WHO database for TB research [24], corresponding to the dif-
ferent countries within each region. These measurements of TB incidence and mortality
have their correspondent confidence intervals (¯ilow(t), i¯high(t)) and (m¯low(t), m¯high(t)),
which are not necessarily symmetrical with respect to the central values i¯(t) and m¯(t).
Using these confidence intervals, and taking into consideration their asymmetry, the
correspondent terms σ¯i(t) σ¯m(t) are constructed like follows:
σ¯i(t) =
{
i¯(t)− i¯low(t) if i(t) ≤ i¯(t)
i¯high(t)− i¯(t) if i(t) > i¯(t) (9.69)
σ¯m(t) =
{
m¯(t)− m¯low(t) if m(t) ≤ m¯(t)
m¯high(t)− m¯(t) if m(t) > m¯(t) (9.70)
The conceptual scheme for the fitting of these parameters (see figure 9.4) essen-
tially consists in an iterative evaluation of the model across the parameter space
(ζ, do, βo, αd, αβ), which is navigated according to a certain "routing" that eventually
guarantees the localization of a certain parameter set that yields an error H which
is small enough. In our case, we have used a Levemberg-Marquardt algorithm [413],
implemented, as for the rest of the model, in programming language C.
Figure 9.4: Schematic representation of the fitting procedure.
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The temporal window chosen for the fitting spans from 2001 to 2011, for which
burden data is available in [24]. The fitting window could be arbitrarily extended
backwards in time -even beyond the limits of the registers of the database [24], if the
appropriate data sources or estimations were used-, but the exercise would lose sense as
the window grew and grew. The reason is that the values of the parameters fitted reflect
the socio-economic situation of the populations under study, as well as the capacity of
the health systems to contain the epidemics and their paces of improvement; all these
factors quantified during the time window of the fitting. For this reason, the eventual
extension of the time window to the past is not a convenient strategy, because, as we
go back in the past, all these socio-economic factors diverge from what they are in the
current times and ultimately, to intend that their values were representative of what
it is expected to happen in the next decades is less and less reasonable. In this sense,
the choose of a ten years time window is a convention that takes into account the
compromise between a window short enough to represent a period stable enough from
a socio-economic point of view in most countries, and a period large enough to offer a
reasonable agreement between number of data and number of tunable parameters.
Disease burden estimations
The reproduction by our model of the temporal evolution of the variables i¯(t) and m¯(t)
represent the main goal of the fitting procedure. However, a problem regarding the
association of TB disease and HIV infection and the way in which these magnitudes
are registered at the World Health Organization database for TB [24]. Indeed, the
cases of TB+HIV confection are currently accounted as TB cases when speaking about
incidence in the database, but, when these patients dead, the event is not accounted
as a TB related death, as, by convention, these deaths are attributed to HIV and so,
WHO avoids registering the same death twice across its databases.
Taking that into account, so as to calculate m¯(t), we are constricted to perform
the sum m¯(t) = m¯exc.TB+HIV (t) + m¯TB+HIV (t). Indeed the contribution of the cases
of TB excluding coinfection, m¯exc.TB+HIV (t) is explicitly available at [24], while the
estimation of m¯TB+HIV (t) is more concerned. Indeed, the estimation of the relative
mortality rates among HIV+ positive individuals by TB, compared to HIV uninfected
individuals is not trivial. In a recent work, Au-Yeung et al. [414] estimate the quotient
x(t) = m¯TB+HIV (t)/m¯exc.TB+HIV (t) for the different WHO-regions, also used in this
chapter, in the period 2006-2008. Taking 2007 as reference, we can complement this
information with the data about HIV+TB confection occurrence among incident TB,
TB +HIV (t), available at [24], to reach the following final estimation of m¯(t):
m¯(t) = m¯(t)exc.TB+HIV
(
1 + x(2007)
HIV (t)
HIV (2007)
)
(9.71)
Leaving apart the well known fact that HIV status has a critical influence on indi-
viduals epidemic risk related to TB at many stages of its natural history, our aim is not
to describe these dynamical differences or to evaluate the differential risks due to HIV
infection of a certain segment of the populations under study. Instead of that, we just
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provide an "average" description of TB burden, as we do not explicitly differentiate, as
a first approximation, the dynamics of HIV+ and HIV- individuals. However, this does
not make a reasonable approach to consider the incidence of new active cases of TB
associated to TB+HIV coinfection and, simultaneously, to neglect the deaths occurred
as a result of that coinfection, and by this reason we are constricted to introduce this
additional contribution to m¯(t) due to HIV-TB coinfection.
In figure 9.5, we represent, for each region, the contribution to m¯(t) of deaths due
to TB alone and to TB+HIV coinfection. As it is can be seen from there, TB+HIV
coinfection supposes a dramatically high fraction of all deaths related to TB in AFRH
region, which is nonetheless the region with highest levels of HIV prevalence in the
world. Errorbars in m¯(t) has been propagated from equation 9.71 from the uncertainties
of m¯(t)exc.TB+HIV , x(2007) and the quotient HIV (t)/HIV (2007)
Figure 9.5: Red: m¯exc−TB+HIV (t) Mortality rates excluding TB plus HIV confection. Blue:
total mortality rates m¯(t)
9.3.3 Model states and parameters summary
In this section we list all the dynamical states and parameters used in the model, along
with their values, definitions, confidence intervals and bibliographical sources:
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Dynamic states
In table 9.2 all dynamic states of the model are detailed. It is worth emphasizing that
Xv states are described as "immune" states, which means that, after being vaccinated,
individuals in this second branch have a partial immunity to infection that translates
into a reduced probability of getting infected or re-infected, regardless they were pre-
viously infected or not. In contrast, states labeled as non-immune contains individuals
that not have been vaccinated ever and also those that, despite having received the
vaccine, have lost its immunogenic effect.
State Definition
S(a, t) Susceptible (not previously exposed to infection) unvaccinated individuals
Sv(a, t) Susceptible (not previously exposed to infection) vaccinated individuals re-
taining vaccine’s (partial) immunity
Sw(a, t) Susceptible (not previously exposed to infection) vaccinated individuals
whose immunity has waned
Ls(a, t) Non-immune Infected individuals (slow latency)
Lf (a, t) Non-immune Infected individuals who will develop primo-infection (fast la-
tency)
Lvs(a, t) Immune Infected individuals (slow latency)
Lvf (a, t) Immune Infected individuals who will develop primo-infection (fast latency)
Dps+(a, t) Non-immune untreated sick individuals: Smear positive pulmonar disease
Dps−(a, t) Non-immune untreated sick individuals: Smear negative pulmonar disease
Dnp(a, t) Non-immune untreated sick individuals: non pulmonar disease
Dvps+(a, t) Immune untreated sick individuals: Smear positive pulmonar disease
Dvps−(a, t) Immune untreated sick individuals: Smear negative pulmonar disease
Dvnp(a, t) Immune untreated sick individuals: non pulmonar disease
Tps+(a, t) Immune sick individuals under treatment: Smear positive pulmonar disease
Tps−(a, t) Non-immune sick individuals under treatment: Smear negative pulmonar
disease
Tnp(a, t) Non-immune sick individuals under treatment: non pulmonar disease
T vps+(a, t) Immune sick individuals under treatment: Smear positive pulmonar disease
T vps−(a, t) Immune sick individuals under treatment: Smear negative pulmonar disease
T vnp(a, t) Immune sick individuals under treatment: non pulmonar disease
F (a, t) Patients who faultily finished their treatment.
Rp+S(a, t) Non-immune patients of smear positive pulmonary TB who successfully
finished their treatment.
Rp+D(a, t) Non-immune patients of smear positive pulmonary TB who defaulted their
treatment by two consecutive months or more.
Rp+N (a, t) Non-immune patients of smear positive pulmonary TB that naturally –i.e.
without treatment– recovered from the disease.
Rvp+S(a, t) Immune patients of smear positive pulmonary TB who successfully finished
their treatment.
Rvp+D(a, t) Immune patients of smear positive pulmonary TB who defaulted their treat-
ment by two consecutive months or more.
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State Definition
Rvp+N (a, t) Immune patients of smear positive pulmonary TB that naturally –i.e. with-
out treatment– recovered from the disease.
Rp−S(a, t) Non-immune patients of smear negative pulmonary TB who successfully
finished their treatment.
Rp−D(a, t) Non-immune patients of smear negative pulmonary TB who defaulted their
treatment by two consecutive months or more.
Rp−N (a, t) Non-immune patients of smear negative pulmonary TB that naturally –i.e.
without treatment– recovered from the disease.
Rvp−S(a, t) Immune patients of smear negative pulmonary TB who successfully finished
their treatment.
Rvp−D(a, t) Immune patients of smear negative pulmonary TB who defaulted their
treatment by two consecutive months or more.
Rvp−N (a, t) Immune patients of smear negative pulmonary TB that naturally –i.e. with-
out treatment– recovered from the disease.
RnpS(a, t) Non-immune patients of non pulmonary TB who successfully finished their
treatment.
RnpD(a, t) Non-immune patients of non pulmonary TB who defaulted their treatment
by two consecutive months or more.
RnpN (a, t) Non-immune patients of non pulmonary TB that naturally –i.e. without
treatment– recovered from the disease.
RvnpS(a, t) Immune patients of non pulmonary TB who successfully finished their treat-
ment.
RvnpD(a, t) Immune patients of non pulmonary TB who defaulted their treatment by
two consecutive months or more.
RvnpN (a, t) Immune patients of non pulmonary TB who naturally –i.e. without
treatment– recovered from the disease.
N(a, t) Total number of individuals in age group a
I(a, t) Accumulated number of detected TB cases in age group a from the begin-
ning of the period.
M(a, t) Accumulated number of TB deaths in age group a from the beginning of
the period.
i(t) Tuberculosis incidence rate per 100000 individuals.
m(t) Tuberculosis mortality rate per 100000 individuals.
Table 9.2: List of all the dynamic variables contemplated in our model.
Global parameters
Regional parameters
Region dependent parameters are the following
• η: Coefficient of modification of the diagnosis rate modification for smear positive
and extrapulmunoray TB types with respect to smear possitive [22]
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Table 9.3: List of global parameters whose values are considered not to depend on the
geographic area being modeled
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Region η fp+D f
p+
F f
p+
µ
AFRH 0.843 (0.717-0.970) 0.081(0.045-0.118) 0.016 (0.006-0.026) 0.063(0.023-0.085)
AFRL 0.510 (0.434-0.587) 0.099 (0.044-0.154) 0.024 (0.013-0.035) 0.061 (0.048-0.074)
EMR 1.178 (1.001-1.354) 0.067 (0.038-0.095) 0.016 (0.013-0.018) 0.036 (0.033-0.039)
SEAR 0.797 (0.677-0.916) 0.061 (0.040-0.077) 0.019 (0.015-0.021) 0.042 (0.032-0.049)
WPR 0.641 (0.545-0.737) 0.013 (0.008-0.018) 0.009 (0.006-0.011) 0.017 (0.014-0.020)
Region fp−D f
p−
F f
p−
µ
AFRH 0.079 (0.042-0.116) 0.003 (0.001-0.006) 0.087 (0.054-0.120)
AFRL 0.076 (0.044-0.108) 0.004 (0.001-0.007) 0.096 (0.055-0.137)
EMR 0.076 (0.046-0.107) 0.004 (0.001-0.007) 0.033 (0.024-0.042)
SEAR 0.062 (0.047-0.075) 0.005 (0.002-0.009) 0.034 (0.032-0.035)
WPR 0.017 (0.008-0.026) 0.002 (0.002-0.003) 0.014 (0.011-0.017)
Table 9.4: Regional parameters in each region
• (fp+D , f
p+
F , f
p+
µ ): fraction of default, failure and death outcomes for smear positive
pulmonary TB [24]
• (fp−D , f
p−
F , f
p−
µ ): fraction of default, failure and death outcomes for smear negative
pulmonary and non pulmonary TB [24]
and their values, for each of the regions analyzed are listed in table 9.3.3:
Other inputs for the model, that are not formally model parameters but that also
has to be determined for the model to work are the following:
• NUN(a, t): Demographic pyramid projected for each region by the UN population
division [23]
• i¯(t), m¯(t): incidence and mortality rates, estimated by the WHO [24]
Fitted parameters
Once fixed all the mentioned parameters, we have proceeded to fit the diagnosis rate
d(t) = doe
αdt and the base infectivity β(t) = βoeαβt that reproduces more accurately
the burden time series of incidence and mortality estimated by the WHO. The results,
in each of the regions analysed are listed in table 9.5
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Table 9.5: Fitted parameters of the model.
Region d0
(
y−1
)
αd β0
(
y−1
)
αβ ς
AFRH 0.281 (0.037-1.007) 0.082 (0.034-0.101) 5.330 (3.481-10.056) -0.009 (-0.030–0.005) 0.136 (-0.032-0.425)
AFRL 0.965 (0.354-3.085) 0.043 (0.039-0.055) 18.972 (11.371-41.478) -0.012 (-0.016–0.007) 0.051 (0.018-0.104)
EMR 0.379 (0.126-1.328) 0.099 (0.078-0.131) 4.896 (3.215-9.915) 0.013 (0.005-0.024) 0.130 (0.056-0.208)
SEAR 0.679 (0.342-1.322) 0.073 (0.069-0.087) 1.962 (1.340-3.042) 0.003 (-0.004-0.013) 0.053 (0.006-0.127)
WPR 3.034 (0.981-3.560) 0.038 (0.032-0.039) 4.245 (3.215-5.418) 0.001 (-0.006-0.009) 0.132 (0.092-0.190)
Strategy f (a) a ∈ [0, 13] fneo 
Mass vaccination 1 y−1 ∀a 0 0.2 ∀a
Children-focused campaign 1 y
−1 a = 0
0 a 6= 0 0 0.2 ∀a
Adolescent-focused campaign 1 y
−1 a = 3
0 a 6= 3 0 0.2 ∀a
Newborn-focused campaign 0 ∀a 1 0.2 ∀a
Newborn+Teenager mixed campaign 1 y
−1 a = 3
0 a 6= 3 1
0.2 if a < 3
¯ (tvac, a) if a ≥ 3
Table 9.6: Vaccine description under different immunization strategies
Vaccine descriptors
We have applied different vaccination strategies in this chapter but all of them have
the following features in common:
• The year of beggining of the vaccination campaign: 2015
• The immunity waning rate: γ (a) = 0.015 y−1∀a
The difference between the different strategies will be given by the dependence of
the immunity acquisition rate f (a) with the age group, –introduced to describe the
age at which individuals are immunized– and the fraction of newborns fneo that are
vaccinated. In table 9.4.4 summarizes the different vaccines:
A further description is needed in the case of a combined strategy adolescent+newborn,
in which two vaccines are foreseen –a BCG substitutive vaccine applied on newborn
and a booster vaccine on adolescents–; as we wish to take into account the cooperation
between them. We consider that both vaccines act with the same observed efficacy
coefficient  = 0.2, as in the other strategies considered but we take the assumption
that individuals receiving both vaccines will gain an enhanced immunity described by
an observed efficacy coefficient  = 0.22 = 0.04.
Individuals within the first three groups –children less than 15 years old–, will
only benefit from the BCG substitutive vaccine of observed efficacy equal to  = 0.2.
Instead, for the other age groups, we will eventually have doubly immunized individuals,
if enough time from the vaccination campaign start has passed so as the people who
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have received the newborn vaccine gets older and receive the adolescent vaccine. The
function ¯ (tvac, a) gives us the dependence of the effective efficacy coefficient with the
age group, a, and the time since the beggining of the campaign, tvac:
¯ (tvac, a) =

0.2
0.2
(
1− tvac−∆ta
∆t
)
+ 0.04 tvac−∆ta
∆t
0.04
if tvac < ∆ta
if∆ta < tvac < ∆t (a+ 1)
if tvac > ∆t (a+ 1)
Contact patterns
Perhaps, one of the most pervasive simplifying hypothesis in the mathematical mod-
elling of TB spreading is the homogenous mixing of the populations under study. In
this chapter, we abandon this hypothesis by defining an heterogeneous contact matrix
between different age groups denoted as ξ(a, a′). The matrix elements ξ(a, a′) ∈ [0, 1]
represent the fraction of all possible contacts between individuals within age groups a
and a′ that actually take place. For example, if we have N(a, t) and N(a′, t) in each
group at a certain moment, then we count as many as ξ(a, a′)N(a, t)N(a′, t) between
these two groups of individuals.
For the computation of the contact matrix used in our model, we take advantage
from the data of the survey performed in the so-called Polymod proyect [12]. In this
survey people is asked how many contacts they have had in a certain time window, and
the ages of the people who have maintained these contacts with them. Let us denote as
P (a, a′) the elements of this matrix, which represents the average number of contacts
that an individual in the age group a has, per unit time, with people in the age group
a′. These matrices P (a, a′) are provided in [12] for different countries. In the following,
we explain how do we get our contact matrix ξ(a, a′) from these Polymod data.
First of all, it is important to note that, for any country, the matrix P (a, a′) is not,
–in general–, symmetrical, due to the different number of people in each age group.
The number of total contacts between two age groups a and a′ can be computed in
two different ways: if we rely on the reports of class a we would write it as the product
P (a, a′)N(a, t), where N(a, t) is the number of individuals in age group a at moment
t. Instead, if we rely our estimation of the number of contacts on the reports by class
a′ individuals, we would obtain P (a′, a)N(a′, t). Obviously, if the survey has enough
quality, one should find:
P (a, a′)N(a, t) ' P (a′, a)N(a′, t)⇒ P (a, a
′)
N(a′, t)
' P (a
′, a)
N(a, t)
(9.72)
So, if ts is the moment in which surveys took place, we can construct the following
matrix, with the same units of ξ(a, a′) (i.e. fraction of total contacts between age
groups a and a′ per unit time):
A(a, a′) =
P (a, a′)
N(a′, ts)
(9.73)
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which is not perfectly symmetrical. Indeed, what we do is consider the expected
value of the fraction of total contacts as its symmetric part, denoted as B(a, a′):
B(a, a′) = B(a′, a) =
A(a, a′) + A(a′, a)
2
(9.74)
And use the asymmetric part, (which is the measure of the incoherence between the
reports of age groups a and a′ when referring the number of contacts between them)
as an estimation of the error:
δB(a, a′) = δB(a′, a) =
1√
2
√
(A(a, a′)−B(a, a′))2 + (A(a′, a)−B(a, a′))2
2
(9.75)
Polymod project collected and rendered publicly available [12] the matrices P (a, a′)
for eight different european countries, as resulted from the surveys performed between
2005 and 2006. The mixing patterns are highly coherent among the eight countries
analysed, which allows us to build the following average, which we assimilate to ξ(a, a′):
ξ(a, a′) =
∑
c [B(a, a
′)]c [N(a, ts)]c [N(a
′, ts)]c∑
c [N(a, ts)]c [N(a
′, ts)]c
(9.76)
where c is an index that indicates the country. Finally, we consider B(a, a′) as the
only source of error:
δξ(a, a′) =
√√√√∑
c
(
∂ξ(a, a′)
∂ [B(a, a′)]c
[δB(a, a′)]c
)2
=
=
√∑
c ([δB(a, a
′)]c [N(a, ts)]c [N(a
′, ts)]c)
2∑
c [N(a, ts)]c [N(a
′, ts)]c
(9.77)
So, our hypothesis is that we can use the matrix ξ(a, a′) (see figure 9.3.3) to under-
take a first approximation to the description of the mixing patterns heterogeneity in
any part of the world. In relation to this, it is worth noticing different aspects of our
approximation. In the one hand, by scaling the original matrices P (a, a′) towards the
final matrix ξ(a, a′) using the demographic pyramids of the countries surveyed N(a, t)
at t = ts (available at [23]), we eliminate the influence of the demographic structure of
these countries on the mixing matrix, and so, we come up with an object that is useful
to describe the age dependent mixing patterns regardless its specific demographical
details. In conclusion, the fact that other regions have different demographic struc-
tures different from Europe impose no limitation to the generalisation of ξ(a, a′) out
from Europe. In the other hand, the overall intensity of the mixing terms is modulated
by the common factor β(t), which is fitted independently for each region: this is of
utmost relevance, given that the average strength and frequency of social interactions
is, undoubtedly, highly dependent on cultural and socio-economic factors.
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Figure 9.6: Normalized contact matrix ξ(a, a′)/ξ(a, a′)max
In any case, even if we account for eventual variations on the overall contact strength
by fitting the parameter β(t), it is also obviously true that the structure of the specific
mixing patterns in regions foreign to Europe could present differential variations among
the different fields of the matrices with respect to the european case calculated as
ξ(a, a′). Our hypothesis is that, however, the relevance of these differential variations
might not be very relevant, as the main features of the contact matrixes are stable from
a country to another and obey to very general characteristics of our society that can be
very reasonably extrapolated to any part of the world. These are 1. a strong trend of
people to be in contact with people of their same age 2. the presence of more frequent
and intense contacts during the childhood and 3. the appearance of inter-generational
contacts stablished between parents and children (or grandparents and grandchildren).
In this sense, and recalling again the fact that the average strength of the contact
is modulated independently in each region via β(t), our usage of ξ(a, a′) in all regions
as the age dependent contact matrix, is a first approximation to the description of
heterogeneous contact patterns and its influence of model outcomes, which is, as we
shown in the main text, of quantitative relevance.
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9.3.4 Regions
The definition of the regions used in this study have been taken from [22]. We have
analyzed the five regions of highest TB burden levels worldwide. These are the countries
that form each of the regions analysed:
• AFRH: Africa, high HIV prevalence: Botswana, Burundi, Cameroon, Central
African Republic, Congo, Cote d’Ivoire, Democratic Republic of the Congo,
Ethiopia, Gabon, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Rwanda,
South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zim-
babwe.
• AFRL: Africa, low HIV prevalence: Algeria, Angola, Benin, Burkina Faso, Cape
Verde, Chad, Comoros, Equatorial Guinea, Eritrea, Gambia, Ghana, Guinea,
Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauritius, Niger, Sao
Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo.
• EMR: Eastern Mediterranean Region: Bahrain, Djibouti, Egypt, Iraq, Islamic
Republic of Iran, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan,
Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab Republic, Tunisia, United
Arab Emirates, Occupied Palestinian Territory, Yemen
• SEAR: South-Southeast Asia Region: Bangladesh, Bhutan, India, Democratric
People’s Republic of Korea, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka,
Thailand, Timor-Leste
• WPR Western Pacific Region: Brunei Darussalam, Cambodia, China, Fiji, Lao
People’s Democratic Republic, Malaysia, Micronesia, Mongolia, New Caledonia,
Papua New Guinea, Philippines, Polynesia, Republic of Korea, Solomon Islands,
Vanuatu, Viet Nam.
For each region, besides the set of regional parameters, –adapted from [22]–, the
demographic pyramid N(a, t)UN has to be constructed by summing up the national
data available at the database of the population division of UN [23]. Additionally,
the series of measured incidence and mortality rates i¯(t) and m¯(t) has also to be
built up, in this case, by summing the national data from the TB database curated
by the World Health Organization [24], weighted by the countries populations (and
corrected for accounting TB+HIV related deaths). For some regions, however, there
exist some issues with the databases, mostly regarding small territories for which not
all the data are available as well as countries that have experienced process of division
or emancipation:
• Some small countries do not appear in the databases of population by age group
in [23]. These are Seychelles, in AFRL; and Anguilla, Antigua and Barbuda,
Bermuda, British Virgin Islands, Cayman Islands, Dominica, Montserrat, Saint
Kitts and Nevis and Turks and Caicos Islands in AMR. For these countries, –
which nonetheless represent around 0.1% of the total population of their regions–,
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we have supposed that their total populations –which are, instead, available at
[23]– are distributed among the different age groups following the same propor-
tions than the rest of the countries belonging to their regions AFRL and AMR,
respectively.
• Some countries are denoted in a different way in the demographic database of
population by age of [23] and in the TB database [24]. That is the case of the
island territories of Polynesia and Micronesia, that appear under these names
at the population by age files in [23] but, either in the files of total population
series in [23] or in the WHO TB database, [24], they appear broke down by
the countries that belong to each one: American Samoa, Cook Islands, French
Polynesia, Niue, Samoa, Tokelau, Tonga, Tuvalu and Wallis and Futuna Islands;
which are the Polynesian Islands and Guam, Kiribati, Marshall Islands, Federated
States of Micronesia, Nauru, Northern Mariana Islands and Palau, which are the
Micronesian ones.
• Some countries have experienced processes of division or independence that –at
least in the case of [24]– are reflected in the databases. These are the cases of
the independence of Timor-Leste in 2010 (previously it belonged to Indonesia)
and the division of the Netherlands Antilles in 2010 (which gives rise to Bonaire,
Saint Eustatius and Saba; Sint Maarten –Dutch part– and Curacao).
9.4 Results
9.4.1 Model fitting and generic vaccination impact evaluations
If we focus on the South East Asia Region (SEAR)[24], the figure 9.4.1, panels A-B
show the projection of the incidence and death rates associated with the disease up
to year 2050. As we can see, the model captures the behavior of the incidence and
mortality curves during the fitted window, and foresees the decline of the disease up
to circa 2025, moment in which incidence and mortality levels remarkably stop their
decay.
The dynamical reason underlying that behavior shift is the evolution of the sta-
tionary levels, represented in red in figure 9.4.1, as a function of the time dependent
parameters and the demographic pyramid at each time step. As a result of the fitting
procedure (see supplementary information), in South east Asia, both time dependent
parameters are increasing functions of time. This result, in the case of β(t), contributes
to enhance disease burden as time goes by, while, in the case of d(t) contributes to re-
duce it. In addition, the marked process of demographic aging which is expected to
take place in the region during the whole XXI century (see supplementary informa-
tion) has an influence on disease burden levels that is not trivial at all. On the one
hand, as the proportion of older individuals grow in the population, the probability
of them to have been exposed to infection also increases, which would contribute to
enhance disease burden levels. However, the structure and strength of social contacts
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Figure 9.7: Model fitting and forecasts in South East Asia region. Panels A,B: Incidence
and mortality rates, respectively: blue: model forecasts. Black: WHO estimations during
the fitting window (2001-2011). Red: stationary levels at each time step. Error bars in
model forecasts are due to the propagated uncertainties of model parameters (yellow) WHO
burden and treatment outcomes estimations themselves (red) and demographic data (green).
Panels C,D: vaccine impacts foreseen for different vaccination strategies. The vaccines are
applied either on newborn individuals, adolescents (15-20 years old), or all the population.
Simulations corresponding the vaccination strategy focused simultaneously on newborns and
adolescents are designed to describe cooperative effects between both vaccines.
of an individual changes with age, which will also modify her attitudes to transmit
the disease to others. A complex interplay of these factors is responsible, in this case,
of this worrying behavior according to which the burden levels associated to the sta-
tionary attractors of the dynamics show an initial decreasing up to an inversion point
that prevents the region to reach the final conditions for disease eradication; provided
that the time dependent parameters maintain their time variation rates during the
time window analyzed. Another relevant conclusion that is derived from the figure is
that stationary values vary in time much faster than burden levels themselves, which
show a very strong inertia. This implies that the location of the dynamic state of the
system on the stationary may be a more unlikely event than expected, which gives us
an additional argument so as to abandon the classical hypothesis of initial stationarity.
In the same figure, panels C and D represent the variation of the same magnitudes
that would be achieved after the introduction of a vaccine able to reduce the probability
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of infection of immunized individuals up to a 20 percent of the base case (80% efficacy)
applied according to vaccination strategies focused on different age groups. Although
the long term levels of disease burden are similar among all the strategies considered, a
much faster fall in either incidence or mortality rates is achieved after a mass vaccina-
tion campaign on all age groups, rather than any alternative strategy, as expected. The
combined vaccination campaign on newborns and adolescents is designed to simulate
the implementation of two cooperative vaccines, one substitutive vaccine to be applied
on newborns instead of BCG (newborn-focused vaccine, or NFV in what follows) and
a booster vaccine to be administrated on adolescents regardless their primary vaccine
was BCG or its novel substitute (adolescents-focused vaccine, AFV). In figure 9.4.1 the
accumulated impact of each vaccination campaign is represented as a function of the
vaccine efficacy.
Figure 9.8: Impact evaluation of different immunization campaigns in South east Asia as a
function of the efficacy of the vaccine, in terms of infectiousness reduction.
Finally, in addition to south east asia we have extended our analysis to the other
four regions of greater TB burden in absolute terms: AFRL (Africa, low HIV), AFRH
(Africa, high HIV), EMR (East Mediterranean region) andWPR (West pacific region)[22].
A summary of the results is annotated in table 9.4.1.
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. Measure SEAR AFRH AFRL EMR WPR
Number of TB cases (in millions) 165 (149-179) 82 (68-93) 27 (24-29) 46 (37-54) 56 (45-66)
Number of TB deaths (in millions) 17 (11-24) 15 (9-32) 4 (2-6) 4 (2-6) 4 (3-5)
Incidence rate (2001) 2191 (1900-2524) 3876 (2578-5928) 1606 (1269-1985) 1198 (970-1464) 1286 (1066-1538)
Mortality rate (2001) 462 (268-719) 1243 (421-2763) 355 (143-657) 293 (118-520) 121 (90-166)
Incidence rate (2030) 1527 (1349-1621) 1513 (1103-1982) 1641 (1451-1738) 1068 (815-1248) 613 (470-733)
Mortality rate (2030) 118 (80-142) 199 (153-335) 228 (112-349) 67 (44-78) 31 (20-47)
Vacc. impact (NFV) (in millions) 14 (9-19) 12 (3-19) 6 (5-8) 8 (4-11) 2 (1-3)
Vacc. impact (AFV) (in millions) 32 (27-37) 19 (6-32) 11 (9-12) 15 (9-19) 5 (4-6)
Vacc. impact (NFV+AFV) (in millions) 37 (30-42) 23 (8-37) 12 (11-14) 17 (10-22) 6 (4-7)
Vacc. impact (mass) (in millions) 64 (55-71) 30 (11-46) 16 (14-18) 25 (16-32) 15 (12-18)
Vacc. doses (AFV) (in millions) 963 (803-1126) 615 (544-685) 224 (200-249) 434 (375-493) 600 (486-718)
Vacc. doses (mass) (in millions) 2292 (1916-2707) 1370 (1167-1577) 523 (457-594) 1043 (900-1197) 1785 (1536-2056)
Vacc. performance (AFV) (in thousands) 34 (29-37) 32 (10-51) 42 (38-44) 34 (21-43) 9 (6-11)
Vacc. performance (mass) (in thousands) 28 (24-31) 19 (9-28) 31 (28-33) 24 (16-30) 9 (6-10)
Table 9.7: Model forecasts on different regions. Number of TB cases (TB deaths): total
number of TB cases (deaths) from 2001 to 2050. Incidence rate: number of new TB cases
per 1.000.000 individuals. Mortality rate: number of TB deaths per 1.000.000 individuals.
Vaccine impact: number of TB cases prevented from 2015 to 2050. Vaccine doses: number
of vaccines needed from 2015 to 2050. Vaccine performance: number of cases prevented from
2015 to 2050 per 1.000.000 vaccines applied. Newb.: vaccination campaign on newborns.
Teen.: vaccination campaign on adolescents (15-20 years old). Newb.+adol.: combined vac-
cination campaign on newborn and adolescents. Mass: mass vaccination campaign on all age
groups.(See supplementary information).
9.4.2 Influence of novel hypothesis: demographic evolution
As we have annotated before, one of the driving forces influencing the temporal trends
of disease burden is the evolution of the demographic structure of the population. In
order to address the quantitative influence of that factor on disease burden rates, we
compare the results from our model to what it is obtained by looking at the original
population pyramid in 2001 and taking it as constant during the dynamic evolution
of the system, neglecting its time evolution, as it is made in some other former works
[422].
As we can see in table 9.4.2, the variations both in number of cases and deaths under
no intervention, are minimum regardless the structure of the population is heteroge-
neous or not. This is logical, as these forecasts are the extrapolation of the incidence
and mortality curves that have been fitted between 2001 and 2011, and so, regard-
less the contact patterns, the fitting procedure forces them to converge. The situation
is very different when we enter at evaluating the impact of different age-specific vac-
cination strategies, and the bias in model forecasts introducing after neglecting the
social structure of the contact patterns can reach up to the 84%. This can be also
easily understood, as the degree of connectedness of each age group strongly differs
if heterogeneous contact patterns are considered, and so does their infectious poten-
tial. The errors in impact evaluation of mass vaccination campaign are, again, smaller,
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Measure
Demographic
evolution
neglected
Demographic
evolution
considered
Relative error
Average incidence rate over all
ages (2001-2050)
1725 (1568-
1830)
1686 (1532-
1823)
2.3% (-1.2-5.2)
Average mortality rate over all
ages (2001-2050)
189 (120-264) 188 (118-265) 0.7% (-1.5-2.7)
Average incidence rate for
children <5 y. old (2001-2050)
673 (570-759) 622 (532-711) 8.2% (3.4-12.0)
Average mortality rate for
children <5 y. old (2001-2050)
52 (33-78) 51 (31-78) 2.4% (-2.3-6.8)
Fraction of cases prevented
with a newborn vaccine in
2015
22% (20-24) 12% (8-15) 85% (44-155)
Fraction of deaths prevented
with a newborn vaccine in
2015
16% (14-18) 9% (6-12) 84% (41-134)
Fraction of cases prevented
with a AFV in 2015
40% (36-44) 28% (25-31) 44% (36-52)
Fraction of deaths prevented
with a AFV vaccine in 2015
34% (30-38) 24% (21-27) 44% (36-51)
Fraction of cases prevented
with a NFV+AFV vaccine in
2015
47% (43-50) 32% (29-35) 49% (38-61)
Fraction of deaths prevented
with a NFV+AFV vaccine in
2015
39% (35-43) 26% (23-30) 47% (37-59)
Fraction of cases prevented
with a mass vaccine in 2015
65% (60-69) 56% (51-61) 16% (12-19)
Fraction of deaths prevented
with a mass vaccine in 2015
58% (52-63) 51% (45-56) 14% (11-17)
Table 9.8: Effects of demography coupling of model outcomes
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as the fact that all age groups are simultaneously immunized hinders the aforemen-
tioned effect. Taken together, these results make evident that the impact assessment
of any age-specific intervention needs an accurate description of the time variation of
the demographic pyramids to avoid the introduction of systematic biases.
9.4.3 Influence of novel hypothesis: contact heterogeneity and
impact evaluations of age focused vaccines.
As we have already said, different factors can limit, or even make unfeasible a massive
administration of an eventual new anti-tubercle vaccine on individuals of any age.
Foreseeing an eventual scenario in which a new vaccine has to be applied on a specific
age group, it is obviously necessary to know, as reliably as possible, the way the impact
of a drug of this kind depends on the age of the target population. In order to tackle
this forecast task, it is clear that the selected model must make a description of the age
structure of the population as precise as possible. This requires not only an explicit
consideration of the evolution of the demographic pyramid as it has been explained,
but also reflecting the heterogeneity of the contact patterns between individuals of
different ages with the highest accuracy [12, 425]. For this reason, it is a mandatory
exercise to test the way in which the heterogeneity of contacts, as described in this
chapter, influences the impact of age focused vaccination campaign.
In figure 9.4.3, we represent the impact of a eventual vaccine applied in 2015 in
South East Asia, applied over an specific age group, in terms of number of cases and
deaths prevented up to 2050. Black dots represent the model forecasts when, as it
is done in previous models, the contact patterns are considered homogeneous. Blue
lines, instead, in this figure stand for the case in which the description contemplates
heterogeneity in the mixing patterns.
As we can see, a proper description of the heterogeneity in the contact patterns
among age groups modify substantially the relative impact of vaccines applied over dif-
ferent age groups. More specifically, while impacts associated to vaccination campaigns
focused on children of 0-5 years old are slightly lower than predicted by homogeneous
models, the impact of the same vaccine, when applied to adolescents is 19% higher
than predicted by models with homogeneous mixing. This makes that the difference of
impact between both vaccination strategies is a 71% higher (16.5 million individuals)
when the model to estimate it contemplated contact heterogeneities than when it does
not (9.7 million individuals).
9.4.4 Model forecasts for different regions
Base scenario
In figure 9.4.4, we represent the projected incidence and mortality rates for the five
regions in the world with highest TB burden levels.
The red, solid curves represent the stationary values i∗(t) = i∗(d(t), β(t), {N(a, t)})
and m∗(t) = m∗(d(t), β(t), {N(a, t)}), calculated on each time point by letting the
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Figure 9.9: Impact of different vaccination campaigns focused on individuals of different
ages in terms of number of cases prevented. Black: homogeneous mixing model. Blue:
heterogeneous mixing model. Red: difference.
dynamics to relax up to the stationary when the parameters and the demographic
pyramids are frozen on the values of each time point. As we can see, the temporal
evolution of the stationary values –that illustrates the shift due to parameters and
demography variations of the attractor of the dynamics– is surprisingly faster than
the dynamics itself, with relevant implications and divergent behaviors in the different
regions under study; which noticeably shows that the classical hypothesis of initial
stationarity in hardly justifiable. The figure evidences that the high inertia of the
system will force health authorities worldwide to maintain high standards of disease
control and containment even decades after the burden levels will fall beneath really
low limits; if eventual future relapses of the global epidemiological situation wants to
be avoided.
Alternative scenarios
The reliability of our temporal forecasts presents, however, an intrinsic limitation re-
layed to the extrapolation of present time variation trends of the fitted parameters β(t)
and d(t) to the future. Within the scenario showed up to this point, we assume that
the annual rates of variation of both parameters αβ and αd remain constant during
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Figure 9.10: Fitted forecast curves for incidence and mortality rates in Africa, low HIV
(A), Africa, High HIV (B), Euro-mediterranean region (C), South East Asia (D), West pacific
region (E)
the whole period of the projection. However, there are two relevant caveats regarding
this point. On the one hand, future social, economical, political and scientific changes
might modify the outlook in the following decades in a way that is, by definition, unpre-
dictable. On the other hand, at the long term, the maintenance of constant variation
rates for these parameters, will make them explode; and more specifically, parameter
values –mostly d(t)– start taking rather unrealistic values even a few decades in the
future. Taking into account these questions, in figure 9.4.4 we sketch how incidence
and mortality rates would be affected by a modification in the annual rates of variation
of β(t) and d(t). by deriving two alternative scenarios: a first scenario according to
which the time evolution of time-dependent parameters stops from 2030 on and a third,
extreme scenario according to which, since 2030, time evolution of β(t) and d(t) reverts
its trend up to recover, in 2050, the initial values of 2001.
In order to interpret these forecasts, it is convenient to highlight that, for most
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Figure 9.11: Alternative forecast scenarios for incidence and mortality rates.
regions, the fitting outcomes correspond to a increase in detection rates as well as to
a remarkably lower variation of infectivity (|αβ| < |αd|), that can either be positive
or negative. In that sense, stopping the time evolution of the parameters or reverting
it, has the effect of enhancing disease spreading, as the more important effect is that
due to stabilize d(t) (or revert its temporal trend).This implies that the two alternative
scenarios are, in general, more pessimistic than the base case; with the exception of the
trend stabilization of the parameter trends in the east Mediterranean region, in which,
the effect of stabilizing β –a increasing function with time– contributes to contain
disease burden up to the point of counteracting the effect of stopping time decay of
the detection rate d(t). As it can be seen in 9.4.4, the decay in TB burden is tightly
associated, in terms of our model, to the time evolution of these parameters, which,
from an epidemiological point of view, means that the decay in TB burden observed
during the last decades around the world has to be interpreted as an achievement as
fragile as precious. The stabilization of detection rates and infectivities, from 2030 on,
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disturbingly yields to relevant disease relapses in at least three regions, in addition to
the relapse in TB burden which is observed in the east mediterranean region and low
HIV Africa, also in the base case. In addition, when the time variations accumulated
up to 2030 are reverted from that point on, the relapse of the burden levels raises the
burden levels even beyond their initial values.
In conclusion, if the final goal of public health authorities is that of maintaining
the disease burden decay in the following decades so as to walk the way to disease
eradication, public health efforts must be maintained in the future days; or otherwise,
all the achievements reached to this date could even disappear.
Vaccine impacts forecasts
In figure 9.4.4, the incidence and mortality rates projected in the different regions are
represented; after the simulation of different vaccination strategies applied in 2015 in
each case.
Figure 9.12: Incidence and mortality rates after vaccination, for different vaccination strate-
gies in each region.
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9.4.5 Model uncertainty and sensitivity analysis
The model parameters –both regional and global–, as well as the demographic data and
the TB burden estimations carry intrinsic uncertainties whose influence on the model
fitting and forecast has to be evaluated. In order to accomplish that task, we have
performed an exhaustive uncertainty and sensitivity analysis that allows us to evaluate
a confidence interval for our model forecasts as well as the part of this uncertainty that
is originated by each of the model inputs.
Uncertainty sources analysis
In our model, we consider four main different types of inputs, which constitute uncer-
tainty sources that are mutually independent:
• Global parameters (and regional parameter η): each of the estimation of these
parameters is based on independent bibliographic sources. This makes a total
amount of 21 parameters, each of them treated as an independent uncertainty
source ui, i ∈ [1, 21].
• Burden and treatment outcomes estimations provided by WHO: based upon a
number of case notifications and treatment outcomes of finite cohorts surveilled
in each country, the World Health Organization provides estimations for inci-
dence and mortality rates i¯(t) and m¯(t) and for the treatment outcome fractions
(fp+D , f
p+
F , f
p+
µ ) , and (f
p−
D , f
p−
F , f
p−
µ ). For the purpose of our model, we have
grouped these WHO-curated measurements and considered them as a single un-
certainty source, labeled as u22
• Demographic pyramids N(a, t): which are also considered as a single uncertainty
source, labeled as u23.
• Contact matrix Υ(a, a′); the last single uncertainty source u24
By proceeding this way, we count with 24 uncertainty sources ui, i ∈ [1, 24] consid-
ered independent, whose contributions to the uncertainty of a certain model measure-
ment x can be evaluated by defining the variables dlowi (x) = x(u1, ..., ulowi , ..., u24) −
x(u1, ..., ui, ..., u24) and dupi (x) = x(u1, ..., u
up
i , ..., u24) − x(u1, ..., ui, ..., u24), which rep-
resent the differences of the measurement x (i.e. an incidence or mortality rate, either
temporal or accumulated, for example), evaluated after the only variation of the uncer-
tainty source ui, which takes the values of the lower and upper limits of its confidence
interval ulowi and u
up
i , respectively.
At this point it worths mentioning two relevant aspects. On the one hand, it has to
be noted that each uncertainty source is not a single parameter, but a group of them
of related origin, whose confidence intervals plausibly carry strong correlations. For
example, some of the parameters are age-dependent, WHO estimations comprise sev-
eral measurements of different nature (treatment outcomes fractions, mortalities and
incidence rates), and either demographic pyramids or contact matrixes are multidimen-
sional objects too. This means that, when evaluating, for example x(u1, ..., ulowi , ..., u24),
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all the “components” of ui (i.e. the value of a parameter on all ages, or all the entries of
the contact matrix, for example) are simultaneously evaluated at the bottom of their
confidence intervals.
On the other hand, the evaluation of x(u1, ..., ulowi , ..., u24) or x(u1, ..., u
high
i , ..., u24)
–for example– implies the repetition of the fitting procedure after variating ui so as
precisely to address the influence of the error associated to the input represented by
ui on the reliability of the whole fitting and forecasting procedure of our model. This
implies that the sign of the factors dupi (x) is not trivial for any uncertainty source, and
even can coincide with the sign of dlowi (x), due to that, after the shifts in ui the fitting
is iterated and will produce results of x which may be equally greater or lower than
the central value.
Taking that into consideration; we can evaluate the uncertainty in measure x that
is due to the uncertainty of the parameters reported in the bibliography. In order to
do so, we have to sum up the contributions to the error of the first uncertainty source
–the bibliographic parameters–, by performing the following partial sums:
∆param,upx =
√√√√ 21∑
1
δ
( |dlowi (x)|
dlowi (x)
− 1
)
dlowi (x)
2 + δ
( |dupi (x)|
dupi (x)
− 1
)
dupi (x)
2 (9.78)
∆param,lowx =
√√√√ 21∑
1
δ
( |dlowi (x)|
dlowi (x)
+ 1
)
dlowi (x)
2 + δ
( |dupi (x)|
dupi (x)
+ 1
)
dupi (x)
2 (9.79)
and, in a similar way, we can isolate the contribution to the model uncertainty when
determining x of the other uncertainty sources as follows:
∆WHO,upx =
√
δ
( |dlow22 (x)|
dlow22 (x)
− 1
)
dlow22 (x)
2 + δ
( |dup22(x)|
dup22(x)
− 1
)
dup22(x)
2 (9.80)
∆WHO,lowx =
√
δ
( |dlow22 (x)|
dlow22 (x)
+ 1
)
dlow22 (x)
2 + δ
( |dup22(x)|
dup22(x)
+ 1
)
dup22(x)
2 (9.81)
∆demo,upx =
√
δ
( |dlow23 (x)|
dlow23 (x)
− 1
)
dlow23 (x)
2 + δ
( |dup23(x)|
dup23(x)
− 1
)
dup23(x)
2 (9.82)
∆demo,lowx =
√
δ
( |dlow23 (x)|
dlow23 (x)
+ 1
)
dlow23 (x)
2 + δ
( |dup23(x)|
dup23(x)
+ 1
)
dup23(x)
2 (9.83)
∆contacts,upx =
√
δ
( |dlow24 (x)|
dlow24 (x)
− 1
)
dlow24 (x)
2 + δ
( |dup24(x)|
dup24(x)
− 1
)
dup24(x)
2 (9.84)
∆contacts,lowx =
√
δ
( |dlow24 (x)|
dlow24 (x)
+ 1
)
dlow24 (x)
2 + δ
( |dup24(x)|
dup24(x)
+ 1
)
dup24(x)
2 (9.85)
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Along this chapter (see fig. 9.4.4), turquoise areas represent the error bars in inci-
dence (∆lowi ,∆
high
i ) and mortality projection curves (∆lowm ,∆highm ), which are calculated
by summing up all the contributions:
∆lowx =
√
(∆param,lowx )2 + (∆
WHO,low
x )2 + (∆
demo,low
x )2 + (∆
contacts,low
x )2 (9.86)
∆upx =
√
(∆param,upx )2 + (∆
WHO,up
x )2 + (∆
demo,up
x )2 + (∆
contacts,up
x )2 (9.87)
In figure 9.4.5, we represent the total amount of error due to each of the three main
uncertainty sources -bibliographic parameters, WHO estimations and demography– to
the total:
• Bibliographic parameters contribution: red area: (∆param,lowx ,∆param,upx )
• WHO contribution: yellow area:„„q
(∆
param,low
x )2 + (∆
WHO,low
x )2 −
q
(∆
param,low
x )2
«
,
„q
(∆
param,up
x )2 + (∆
WHO,up
x )2 −
q
(∆
param,up
x )2
««
• Demography contribution: blue area:„„
∆lowx −
q
(∆
param,low
x )2 + (∆
WHO,low
x )2
«
,
„
∆upx −
q
(∆
param,up
x )2 + (∆
WHO,up
x )2
««
The contribution to the total error bars due to the uncertainty in the contact matrix
fields is negligible when compared to the other three.
Model (empiric) sensitivity
Additionally to distinguishing the amount of uncertainty derived from each type of
input, we have to isolate the model sensitivity to each of the parameters. More specifi-
cally, we estimate the sensitivities ςx of model measurement x to the uncertainty source
ui as the following percentages:
ςupx (ui) = 100 ·
dupi (x)
x({ui}) (9.88)
ς lowx (ui) = 100 ·
dlowi (x)
x({ui}) (9.89)
where x({ui}) represents the value of measurement x when all the inputs ui are
evaluated at their central, expected values. In figure 9.4.5, we see the sensitivities of
the total incidence (ς lowI (ui), ς
up
I (ui) and mortality (ς
low
M (ui), ς
up
M (ui) with respect to all
uncertainty sources, in all the regions studied.
As we see, the uncertainty of WHO estimations of disease burden and treatment
outcomes constitute the main single source of uncertainty for both incidence and mor-
tality projections, which is a logical result, provided that the uncertainties in the burden
levels has a direct correlate on the burden projections by the model.
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Figure 9.13: Model projections and uncertainty sources.
Intrinsic sensitivity
The confidence intervals of the different inputs of the model, which have been used in
the last section to evaluate model sensitivities, are of disparate relative width. In that
sense, the sensitivity calculated there is not an intrinsic sensitivity of the model to each
input, but an empirical sensitivity influenced by the degree of accuracy of each model
input estimation.
In order to isolate that factor and evaluate an intrinsic sensitivity of our model to
the variation of each input, we have repeated the sensitivity analysis by substituting the
disparate confidence intervals of each model input by intervals of equivalent width–in
relative terms– equal to the 15% of each uncertainty source. The results are represented
in figure 9.4.5
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Figure 9.14: Model sensitivity analysis. In panels labeled as AFRH, AFRL,EMR, SEAR
and WPR we represent the model sensitivity to the variation of each model input according
to their confidence intervals. Bottom panels, represented by WHO contains the sensitivity of
the model, within each region, to the uncertainty of the estimations provided by the WHO at
[24].
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Figure 9.15: Intrinsic model sensitivity analysis. The variations in model measurements are
calculating after equivalent variations equal to a 15% of each model input.
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9.5 Conclussions
In this chapter we introduce a new model for the description of TB spreading that gets
rid of certain oversimplifications responsible of relevant biases on model outcomes. As
it has been previously discussed, either the explicit consideration of the temporal evo-
lution of the demographic structure and the incorporation of realistic, heterogeneous
mixing patters among different age groups in the model, relevantly modify model fore-
casts, which make obvious the need to improve the classical models of TB spreading
towards a more faithful description of the disease dynamics and its dependence on the
age structure of the populations.
In this sense, the incorporation of the mentioned heterogeneous patterns of inter-
action spotted in former works [12], remarkably influences the comparison of different
age-specific vaccination campaigns impacts.
In fact, the impact of a vaccine applied to adolescents is the highest, and it is a
19% higher than predicted by homogeneous models. This is due to the co-ocurrence of
two factors. First, it is a well known fact that children are less prune to develop the
infectious forms of the disease than adults [22]. Being adolescents the first adult-like
age group, they are the first at having high probabilities of developing infectious forms
of pulmonary TB; which make them –also in homogeneous models– an optimal target
for immunization strategies. In addition, once contacts heterogeneity is considered,
adolescents are one of the most strongly connected classes, and most of their contacts
are established with adult individuals (prune to develop infectious TB), which enhances
the impact of adolescent focused vaccination campaigns (AFV) with respect to previous
models without contact structure.
On the contrary, impacts of age focused vaccines, when applied on younger and
younger individuals, decay faster as a consequence of the contact structure. The rea-
son is again related to the assortative structure of the contact matrix, according to
which children tend to interact among them rather than with adults. This implies a
prophylactic effect on children, because, as they oddly develop infectious forms of TB,
to concentrate their social interactions among them maintains them protected from TB
infection; which finally makes the impact of any children focused vaccine to be lower
than expected by homogeneous models [422, 22].
Taken together, these effects causes differences between AFV and NFV that are 71%
higher than expected, which makes evident the relevance of discarding over-simplifying
hypothesis in TB spreading modeling, always considering the data available which
models must always confront to. However, further model refinements have to be imple-
mented before vaccine impact assessments provided by our model could be considered
relevant from a quantitative point of view. Remarkably, for an age-focused vaccine to
be evaluated by the model, this must offer a faithful description of the disease bur-
den distribution among the different age groups, prior to vaccination, something that
has been neither explored in this chapter nor in previous literature of TB spreading
modeling at a global scale [22, 422]. Fortunately, WHO TB database [24] contains
the information needed to accomplish that goal, and that will be precisely our main
objective for the following chapter.
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Chapter 10
Age-focused vaccine impact estimations
10.1 Introduction
As we commented in the previous chapter, in the current portfolio of novel vaccines
under development we can find candidates designed to substitute current BCG on new-
borns and booster vaccines whose intended application on previously BCG immunized
people may allow their administration to older individuals [428, 429, 430, 186]. Ad-
ditionally, prime vaccines aimed at substituting BCG could be also applied on people
previously vaccinated with BCG [421], which makes the debate about what segments
of the populations constitute optimal targets for age-focused immunization campaigns
a global question that will must be faced by all the successful candidates for novel anti
TB vaccines. The implications of vaccinating one age group or other may differ, as
individuals’ susceptibility to disease depends on age, as well as their social behavior
-e.g. the number and nature of contacts [12]- does.
Two age groups appear concurrently as most promising targets for such new immu-
nization campaigns: newborns and adolescents (i.e. 15-20 years old), with arguments
in favor of both of them. On the one hand, adolescents and young adults concentrate
more incidence of active TB than any other group, mainly because they are the first
population segments for whom highly infectious pulmonary tuberculosis is the preva-
lent form of the disease. Also, these individuals maintain a larger number of contacts,
making them the main spreaders of the disease. Therefore, to accomplish an immedi-
ate immunization of them would derive in faster, greater vaccine impact in terms of
number of TB cases and casualties prevented.
But, on the other hand, a vaccination strategy focused exclusively in adolescents
would leave unprotected a significant segment of the population -i.e. children-, creating
a reservoir for the disease that is unreachable for the vaccine, which could compromise
the goal of eradicating TB by 2050. A vaccination campaign focused on newborns
would immunize, at the long term, all the age groups in the population, provided that
its effects are persistent enough. Besides, recent epidemiological studies conducted in
Cape Town (South Africa) indicate that in such a high-burden setting, incidence of
TB in children between 0 and 4 years old may be almost as high as that of adolescents
[159], which would highlight the relevance of immunizing people from their infancy.
The context of this disjunctive takes place after the publication of the results of
the Phase IIb clinical trials of the novel booster vaccine MVA85A [213], which are the
first trials of this kind –aimed at determining not just vaccine safety but also efficacy–
conducted since the implementation of BCG, one century ago. These trials, conducted
in Worcester (South Africa) over almost 3000 BCG-vaccinated infants (6 months old),
concluded that the protective effects of the novel vaccine were very reduced (a 17.3%
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of protection against disease and no protection against infection). These disappointing
results have made the entire community of TB research enter in a state of alarm, and,
as a consequence, rethink about the need of establish more stringent criteria that, for
the sake of resources saving, were able to identify failed candidates before they enter in
the costly phases II and IIb of the production pipeline. This may include an exclusive
focalization in vaccines designed to be applied on specific age groups: ideally newborns
or adolescents.
The question is complex and delicate, as there are powerful arguments supporting
both types of vaccination campaigns. In the following sections we refine and use the
model developed in chapter 9 to quantitatively explore these arguments and discuss
their implications.
10.2 Methods
All the vaccine impact estimations conducted in this manuscript up to this point have
been obtained through the model developed in the previous chapter, which offers a
faithful picture of overall TB spreading dynamics. However, the model still presents an
essential limitation that hinders its usage for quantitatively meaningful comparisons
among age-focused vaccines. This limitation has to do rather than with the model
itself, with the design of the fitting procedure. As portrayed in chapter 9, the fitting
algorithm is designed to make the model reproduce the total incidence and mortality
rates over time, and so, the procedure offers no means to control how the disease burden
is distributed among the different age segments of the population. In figure 10.1 we see
how the TB burden distribution among age groups offered by the model, as presented
in chapter 9 for the case of high South East Asia region (SEAR) is remarkably deficient,
mostly for what regards some age groups (e.g. people between 15 and 24 y.o.).
This problem becomes crucial when trying to evaluate age-focused vaccine impacts
on a quantitative basis, as the initial distribution of TB incident and prevalent cases
among the different age groups will definitely influence the impact that a vaccine ap-
plied on each group is able to offer. Therefore, if an age-detailed reproduction of TB
burden levels is desired, some of the parameters should be age-specifically fitted. This
supposes to go beyond the classical fitting scheme proposed by Dye and colleagues
[422, 22], and, somehow, to question the universal validity of the parameter values
accepted in these works and also used by us in chapter 9. In this line, two relevant
modifications to the parameter set globally used in the last chapter are proposed here:
On the one hand, in chapter 9, we calculated the rates of disease progression from
latency (fast or slow) to active disease (extrapulmonary or pulmonary, smear positive
or negative) as the product of two magnitudes reported in [22] as global parameters,
non dependent on the geographical setting: 1) the fast and slow crude transmission
rates from latency, regardless the class of disease that infected individuals will develop
( that is 0.9 y−1 from fast latency, c.i. 0.765 − 1.035 and 7.5 · 10−4 y−1 from slow
latency, c.i. (6.38 · 10−4 − 8.63 · 10−4) and 2) the fractions of progressing individuals
joining each type of TB class. However, for the case of the probabilities of developing
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Figure 10.1: TB burden distribution among the different age-groups for the model following
the fitting procedure presented in chapter 9 and according to data collected in [24] in SEAR
region. Although the overall trend is qualitatively similar between the model and the database,
relevant divergences arise, mostly for the age segment between 15 and 24 y.o. Y axis indicates
total number of TB cases between 2006 and 2012, only period in which age-structured data
in [24] are globally available significantly enough.
each type of TB, there is no justification to adopt a general value for every region as
these fractions tend to vary in different geographic basins and, more important, the
information needed for calculating these fractions in each country is available in the
WHO database for TB surveilling [24].
Admittedly, this sophistication, even if constitute a more plausible estimation of
the progression rates as a function of age, does not solve yet the main limitation of our
model, i.e. its inability to offer an adequate picture of TB burden distribution among
age groups, as the new progression rates are also an a priori input. However, further
inspection of parameter sources allowed us to identify primo-infection probabilities as
a strongly age-dependent parameter for whose values in the different age segments a
remarkable low consensus can be tracked in the literature. For example, we find that
for children younger than 5 y.o., reported values are highly divergent, between 5% [392]
and 24% (and even 43% for children younger than one year old) [393]. This points to a
strong dependence of this parameter on the particular geographical conditions in which
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it is measured, as these studies were conducted in United Kingdom and South Africa,
respectively.
This issue motivated us to discard global bibliographical sources of p(a) and re-
construct a fitting procedure based on fitting primo-infection probabilities in each re-
gion and age group with the aim of reproducing age-distributed TB burden levels.
What we aim to reproduce is, more explicitly, total active TB cases between 2006 and
2012, the only burden metrics for which enough information distributed by age-segment
is available at [24].
10.2.1 Determination of the primo-infection probabilities
The primo-infection probabilities are fitted to make the model reproduce the proportion
of active cases in the different age groups between 2006 and 2012. It is not immediate
to obtain such proportions, as some difficulties arise. The database is structured as a
matrix where the rows represent the countries and years, and the columns represent
age group, sex and type of disease. The value of every cell gives us the number of
notifications that fulfill the characteristics given by the row and column where it belongs
-i.e. country, year, sex, age and type of disease-. Unfortunately, many cells of the
database are empty, especially before 2000. To deal with this issue we had to discard
many data. The following criterion is taken: we only accept rows that have at least one
notification in every box. The reason behind this rule is that there are many countries
that failed to identify some type of disease (sometimes just in some age groups), leaving
many empty cells in their data, specially, as said, before 2000. Proceeding this way
we avoid the introduction of bias due to technical limitations in the reports of some
countries. The data that we found reliable under this criterion are bounded between
the years 2006 and 2012, and many countries -some of them with huge populations as
India- are completely discarded.
In addition, the age groups used by the database do not correspond exactly to the
age groups used in the spreading model. The database uses an age window of 10 years,
except for the first group that is 0 to 4 years old; and in the spreading model an age
window of 5 years is implemented -that concur with the age groups used by the UN
population database [23]-. To compare the results of the model with the data obtained
we have to merge some age groups, as it is shown in table 10.1:
Finally, it is important to note that the last group has no upper limit of age in the
database, but it is constrained in a 5 year window in the spreading model, which forces
us to leave it out of the fitting process (otherwise, the primoinfection probabilities at
this age-group would present strong biases). Anyway, burden levels in individuals older
than 65 years constitute a reduced fraction of the total and so, this only supposes a
residual error in the age distribution of TB burden.
We define the proportions of cases of the age group α and the year y, as:
fα,y =
∑
c
Iα,c,y∑
c
6∑
α′=0
Iα′,c,y
=
I ′α,y
6∑
α′=0
I ′α′,y
(10.1)
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Model structure Database structure
Age Index: a Age Index: α
0-4 0 0-4 0
5-9 1 5-14 110-14 2
15-19 3 15-24 220-24 4
25-29 5 25-34 330-34 6
35-39 7 35-44 440-44 8
45-49 9 45-54 550-54 10
55-59 11 55-64 660-64 12
65-70 13 +65 7
Table 10.1: Age groups reparametrization.
where Iα,c,y is the number of cases in the age group α, in the country c and the year
y. To obtain the total fractions we perform a weighted average:
fα =
∑
y
fα,y
(∑
α′
∑
c
Nα′,c,y
)
∑
α′
∑
c
∑
y
Nα′,c,y
=
∑
y
fα,y
(∑
α′
N ′α′,y
)
∑
α′
∑
y
N ′α′,y
(10.2)
where Nα,c,y is the population of the group age α, in the country c and the year y.
The notation I ′ or N ′ is referring to quantities aggregated to all countries in the region
of interest.
The fitting algorithm is the following:
1. We choose initial values of pα
2. With these values we used the spreading model -after a proper fitting of the
parameters, as explained in chapter 9- to obtain certain outcomes of incidence.
3. We used the incidence obtained in each age group to construct the proportion of
cases given by the model: fmodelα
4. We compare the fractions provided by our model to those coming from the
database fα, by calculating the ratio fαfmodelα :
(a) If it is constrained between 0.99 and 1.01 for all the age groups -except the
last one (which we are constrained to neglect)-, we stop.
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Age p Confidence interval
0-4 0.039 (0.030-0.060)
5-14 0.014 (0.013-0.019)
15-24 0.051 (0.049-0.054)
25-34 0.073 (0.070-0.078)
35-44 0.081 (0.079-0.083)
45-54 0.125 (0.119-0.128)
55-64 0.177 (0.169-0.184)
+65 0.177 (0.169-0.184)
Table 10.2: Primo-infection probabilities fitted for South East Asia Region.
(b) In any other case, we construct new pα -for α ∈ [0, 6]- and go to step 2:
pnewα = pα
fα
fmodelα
(10.3)
For pα=7 we choose the value of the previous age group, α = 6.
Finally, we have to define the confidence interval for these primo-infection probabil-
ities. First we define the confidence interval for the cases I ′α,y assuming a multinomial
distribution:
∆I ′α,y =
√
I ′α,y (1− fα,y) (10.4)
and we propagate these errors in the calculation of fα,y, taken them as independent
sources of error. After that, for every age group, we took the minimum and the
maximum value of fα,y ±∆fα,y as the confidence interval of fα.
Then we obtained the upper and lower limit of pα -called pupα and plowα - with the
following formula:
pupα = pα
fα + ∆f
+
α
fmodelα
(10.5)
plowα = pα
fα −∆f−α
fmodelα
(10.6)
By completing this new fitting algorithm, we obtained the following primoinfection
probabilities in SEAR, which we show in table 10.2:
10.2.2 Determination of the progression rates
As the database [24] reports the division of the notified cases according to the type of
disease (pulmonary smear positive, negative and extra-pulmonary), we can also obtain
the probability of progression to each kind of disease for each country and region. Then,
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we multiplicate these probabilities per the net transition rates from latency to active
disease regardless the type of disease, which are
As a first approximation it would seem that these probabilities are just the propor-
tion of cases of each type; but as we have different diagnosis rates we have to rescale
these numbers of cases with the parameter η introduced in chapter 9:
pp+ (α, t) =
ip+ (α, t)
ip+ (α, t) + ip− (α, t) + inp (α, t)
(10.7)
pp− (α, t) =
ip− (α, t)
ip+ (α, t) + ip− (α, t) + inp (α, t)
(10.8)
pnp (α, t) =
inp (α, t)
ip+ (α, t) + ip− (α, t) + inp (α, t)
(10.9)
where:
ip+ (α, t) = Ip+ (α, t) (10.10)
ip− (α, t) =
Ip− (α, t)
η
(10.11)
inp (α, t) =
Inp (α, t)
η
(10.12)
As we did in the previous section, we obtain the uncertainty of Ix (α, t) by assuming
a multinomial distribution but in this case the categories are the types of disease instead
of the age groups.
Iupnew,x (α, t) = Inew,x (α, t) +
√√√√√
1− Inew,x (α, t)∑
x
Inew,x (α, t)
 Inew,x (α, t) (10.13)
I lownew,x (α, t) = Inew,x (α, t)−
√√√√√
1− Inew,x (α, t)∑
x
Inew,x (α, t)
 Inew,x (α, t) (10.14)
Then we obtain the errors of pp+ (α, t),pp− (α, t) and pnp (α, t), by propagating 4
independent sources of error, Ip+ (α, t), Ip− (α, t), Inp (α, t) and η. Also, the outcomes
for the age groups from 25 years old, are merged.
We obtain the following results:
The use of these parameters of tables 10.2 and 10.3 allows us to obtain more reliable
age-detailed results, which is imperative in this kind of work. As a result, we recover
a more accurate distribution for the TB burden among the different age groups, as we
see in figure 10.2. Differences between model and database in figure 10.2 arise from
truncating our model at 70 years old.
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Age SP SN EP
SEAR
0-4 0.024 (0.010-0.053) 0.930 (0.912-0.947) 0.046 (0.021-0.060)
5-14 0.157 (0.126-0.205) 0.654 (0.585-0.787) 0.188 (0.083-0.253)
15-24 0.658 (0.595-0.714) 0.239 (0.191-0.335) 0.103 (0.038-0.146)
25+ 0.685 (0.618-0.731) 0.249 (0.201-0.341) 0.065 (0.016-0.092)
Table 10.3: Probabilities of developing each type of TB when progressing from latency in
South East Asia region.
Figure 10.2: TB burden distribution among the different age-groups for the model presented
here and according to data collected in [24] in SEAR, once progression rates and primo-
infection probabilities have been re-calculated. An adequate fit of the age-structured data in
[24] is recovered. For individuals older than 65 y.o., lower accuracy is obtained, as for this age
group no fit for p(a) is feasible because of model truncation at 70 y.o. What is fitted is the
distribution of TB durned among the different classes younger than 65 y.o.
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10.3 Vaccine impacts evaluations of vaccines of equal
observed efficacy
In this section we will explore the different vaccine impacts that two vaccines with
the same observed efficacy (i.e. equal  = 0.3) are able to offer when applied over the
two population groups that are considered the most promising candidates to constitute
optimal targets in an age-structured vaccination campaign: newborns and adolescents
(15-20 y.o.)
10.3.1 Global and age distributed impacts of AFVs and NFVs
As we mentioned before, the common assumption that adolescents and young adults
might suppose an optimal group for age-focused antituberculosis vaccination campaigns
obeys to the fact that, typically, highest incidence and mortality rates of tuberculosis
are concentrated on these age groups, as it is the case of SEAR between 2006 and 2012
(figure 10.2).
Figure 10.3: Model outcomes in SEAR. (a): incidence rate foreseen by the fitted model.
(b) TB-related mortality rate foreseen by the fitted model.(c) Incidence rate after different
vaccination strategies. (d) Mortality rate after different vaccinations strategies. Vaccine
efficacies are 70% protection against infection ( = 0.3). Multiplicative protection is predicted
for doubly vaccinated individuals (NFV+AFV)
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Figure 10.4: Impact of new tuberculosis vaccines of 70% efficacy ( = 0.3) applied on
newborns and adolescents in 2023, measured as number of cases prevented up to 2050 in
SEAR.
As we can see in figures 10.3 and 10.4, our model confirms this commonly admitted
situation: the impact of an adolescents-focused vaccine (AFV) is higher than the impact
of a newborn focused vaccine (NFV), when measured as the number of active TB cases
prevented up to 2050 in both cases. However, as we see in figures 10.4 and 10.6, that
does not mean that the impact of a NTV was negligible; neither when measured over
the total population nor when it is detailed by ages. For a more general picture of
how vaccine impacts depend on age (not only on newborns or adolescents), and, more
remarkably, how model forecasts are affected by the re-parametrization proposed in
this chapter, in figure 10.5, we represent the number of TB cases prevented up to 2050
by a vaccine introduced in 2020:
Indeed, from figure 10.6, we see that NFV’s may also generate measurable effects
on adult age groups, and on the other hand, leaving children unvaccinated reduces
the impact of AFVs on the first age groups to a marginal side effect due to general
reduction of transmission in the population. This situation could be specially relevant
in certain high-burden settings, since, according to recent epidemiological studies con-
ducted in Cape Town (South Africa) [159], incidence of TB in children between 0 and
4 years old can be almost as high as that of young adults in certain areas: in such
a setting, taking into account the results of figure 10.6 in comparison to the burden
distribution by ages represented in figure 10.2, the burden reduction in the youngest
age groups would represent a more important fraction than found here, which would
derive in reducing impact differences between AFVs and NFVs. Furthermore, from the
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Figure 10.5: Vaccine impacts depending on age: both heterogeneous contact patterns and
a proper description of the TB burden distributed by ages exert relevant influences on age
focused vaccine impacts. For the sake of comparison with figure 9.4.3, vaccines are now
introduced in 2015. (Blue series here and in 9.4.3 are the same.
lower panel of figure 10.6, a long-term problem of AFVs becomes evident: by leaving
unvaccinated children youngest than 15 years old; a permanent reservoir of mycobac-
teria is guaranteed, compromising the final goal of total disease eradication within the
next decades.
10.3.2 Time horizon for impact evaluations
In the precedent lines, we have concluded that, in general, AFVs get greater impacts
than NFVs paying the prize of sacrificing the youngest age segments of the population.
However, in case vaccine-derived immunity is persistent enough, part of the outperfor-
mance of AFV is only a matter of the time scale at which it is evaluated, as it only
appears as a consequence of that, by quickly immunizing adolescents, adult segments
of population -who are responsible of the bulk of disease transmission- get immune
sooner. In figures 10.4 and 10.6, impacts are evaluated as number of active TB cases
and infections prevented up to 2050; however, if this time horizon is expanded, the
difference in the performance of both vaccination strategies is reduced, and finally,
reversed (figure 10.7, upper panel).
Looking to the lower panel in figure 10.7, the reason of that situation becomes
clearer. AFV produces a fast initial fall in disease incidence, but, later, the decline of
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Figure 10.6: Number of incident cases (up) and infections (low) prevented in each age group,
for the different vaccination strategies considered. (Vaccine efficacy: 70% protection against
infection:  = 0.3).
incidence associated to the NFV is more sustained, until the point in which incidence
rate after NFV is lower than that of the AFV; which is due to the fact that, as decades
gone by, the immunization of the whole population is only available after a NFV based
strategy.
Summarizing, each type of vaccine provides complementary advantages: to immu-
nize adolescents provide fast impacts, while NFVs, instead, left covered the age groups
unprotected by AFVs; which would guarantee a better long term performance. There-
fore, the only way of reaching a fast decline, yet sustained in the long term, is to
implement a combined strategy targeting both age groups, as shown in figures 10.6
and 10.7.
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Figure 10.7: Effects on impact evaluations of the end point of the evaluation timespan. (a):
impacts measured as number of cases prevented up to different moments for adolescents and
newborn focused vaccines. (b) Impact ratio adolescents/newborns. (c) temporal projections
for different vaccination strategies extended up to 2100. (Vaccine efficacy: 70% protection
against infection:  = 0.3).
10.4 Discussion
As we have seen before, even when AFVs provide a faster impact, there exist reasons
- in terms of vaccine impact- advising the deepening in the development of vaccines
designed to be applied on newborns.
Although less performant at the short term, vaccination campaigns focused on
newborn individuals offer beneficial effects which other vaccination strategies focused
on older age groups, like adolescents, lack. In this sense, although AFVs are expected
to have faster impacts than NFVs, the difference tends to be mitigated as impact
estimations are evaluated on larger timespans. This situation emerges as a consequence
of that, at the long term, while NFV campaigns assure fully coverage to all age groups,
AFV leave unprotected the first age groups, which results in lower long-term impacts.
Leaving children unprotected from infection, in addition to the problems related to
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pediatric disease, guarantees the survival of an infection reservoir, which ultimately
compromises our chances to finally eradicate TB, at least within the present century.
The results here presented strongly suggest that the optimal strategy to follow
would ideally be that of contemporary combining the two vaccination strategies on
newborns and adolescents, as the only way of simultaneously providing a fast impact,
yet sustained in the long term on all age segments of the populations.
Nonetheless, impact evaluations performed in this chapter correspond to different
vaccines of identical levels of observed efficacy (i.e. identical , in terms of our spreading
model), that are essentially persistent in time (γ = 0.015, which corresponds to a period
of immunity of 67 years after vaccination). However, different biological factors affect
differently the performance of a vaccine when it is intended to be applied on different
age groups, so modifying its observed efficacy and its persistence in time. In the
following chapter we will explore these effects and we will quantify their affections on
vaccine impact forecasts.
Chapter 11
Age-dependent effects on vaccine efficacy: mask-
ing, blocking and efficacy waning
11.1 Introduction
In the last section, we argued how vaccine impact evaluations, when two vaccines having
identical observed efficacy (i.e. offering the same levels of protection against infection)
are compared, depend on the precise age on the people being immunized. The analysis
indicated that AFVs are expected to provide higher impacts than NFVs, but certain
advantages which are privative of the last type of vaccination strategy would ideally
advise the adoption of a combined immunization campaign over both age groups.
In the comparison between the performance of AFVs and NFVs made in the last
section, there persists, however, a fundamental issue missed, i.e. the existence of in-
trinsic effects that modify the efficacy of a vaccine as a function of the age of the
individuals being immunized. Additionally to the immunity waning of vaccine pro-
tection as time after vaccination passes by, there exist other effects that may reduce
the observed efficacy of vaccines when applied on older age groups, which appear as
a consequence of prior exposure of individuals to non-tubercle mycobacteria (or other
sources of mycobacterial antigens) that are common in the environment, specially in
tropical and/or high TB-prevalent areas. That is the case of the blocking and masking
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effects, identified as likely major causes for the observed variation in BCG efficacy, as
discussed in the introduction of this thesis.
According to these hypothetical effects [139], human immune response of individuals
previously exposed to environmental mycobacteria interfere with the vaccine, impairing
its protective performance in different ways. On the one hand, according to masking
hypothesis, environmental sensitization confers a significant protection against TB that
can not be mensurably improved by the application of a vaccine. On the other hand,
the blocking hypothesis postulates that prior exposition to mycobacteria may trigger
an immune response capable to block correct vaccine “take”, impairing its performance.
As a consequence, the older the target populations are, the stronger their sensitization
to environmental mycobacteria is, and so, the stronger the vaccine efficacy’s loss, no
matter the precise mechanism driving it. Similarly, these effects are more intense
in lower latitudes, as environmental mycobacteria are more abundant in these areas.
All these trends, as previously discussed, have been identified for the case of BCG
[194, 195], which reinforces the hypothesis of these effects being the main responsible
for the enormous variations among different efficacy measurements –that span from 0
to 80% of protection– for the old M.bovis derived vaccine.
Therefore, given that these issues have been identified for BCG, there wouldn’t be
surprising to find them in the novel vaccines currently under development. If that
was the actual case, as resulting from blocking and masking, an eventual vaccine of
given efficacy , measured in newborns, would have a different efficacy ′ if applied on
a different age group, typically associated to lower levels of protection (in our model,
 stands for the infectivity reduction due to the vaccine, which means that the lower
is  the greater is vaccine’s protection, and so, we’ll typically have, in this context
 < ′). The existence of these age-dependent effects would make of limited relevance
the strict comparison of impacts between equally-efficient vaccines, as, for their cause,
two identical vaccines will have different efficacies when applied on different age groups
(the older the target population, the lower the vaccine efficacy), or, in other words, for
an AFV to present the same efficacy offered by an NFV, the vaccine applied on the
older age group would have to be intrinsically better so as to compensate the efficacy
loss due to prior sensitization to environmental mycobacteria.
In this chapter we aim at studying these effects, and quantifying the affection
that they could exert, in terms of vaccine impact, on an hypothetical novel vaccine
of a given efficacy level. In order to do so, we start by studying the case of efficacy
variation in BCG, so as to estimate the most likely levels of masking and blocking that
are compatible with current observations [195]. Then, using these results, we will study
the behavior of different novel vaccines, both primes aimed at substituting BCG and
BCG-booters.
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Trials Efficacy measured in Salvador Efficacy measured in Manaus
Newborn vaccination 40% (22-54%) 36% (11-56%)
First-dose at school age 34% (7-53%) 8% (-39 to 40%)
Second-dose at school age 19% (3-33%) 1% (-27 to 23%)
Table 11.1: Results of the trial performed by Barreto et al. [195]
11.2 Masking and blocking quantification in BCG
11.2.1 A mathematical model for blocking and masking
To demonstrate the existence and importance of the masking and blocking effects, in a
recently published work [195], Barreto and colleagues have conducted a set of clinical
trials, specifically designed to measure BCG efficacy when applied on populations on
different ages in two cities of a big country -Manaus and Salvador, in Brazil- of different
latitude. In this section, we use the data of these clinical trials to extract the levels of
masking and blocking in the populations of the trials, based on a simple mathematical
model; and we discuss the implications for other BCG clinical trials.
As we say, the trials conducted by Barreto et al. were designed to explore the causes
of BCG efficacy variation. First they choose a population of non-infected schoolchildren
between 7 and 14 years old. In this population we can find individuals that have been
vaccinated as newborns (they present a BCG scar), and individuals that have not been
vaccinated yet. Then a BCG vaccine is applied in half -approx.- of each one of these two
subgroups. So, there are 4 cohorts in total: non vaccinated, newborn vaccinated, first-
dose at school age and second-dose at school age -after a newborn vaccine-. Then, the
follow-up period of these cohorts is 9 years. By comparing the different ratio of diseased
individuals in these cohorts, 3 different trials are performed: a newborn vaccination trial
-comparing the newborn vaccinated with the non-vaccinated-, a first-dose school age
trial -comparing the first-dose at school age vaccinated with the non-vaccinated-, and
a revaccination at school age trial -comparing the second-dose at school age vaccinated
with the newborn vaccinated-. As we say, this study is conducted simultaneously in
two different cities of Brazil: Salvador and Manaus -which is expected to have a higher
level of environmental mycobacteria-. The results of these trials are shown in table
11.1
From these data, we build a simple mathematical model to describe how masking
and blocking effects could, hypothetically, explain these variations in BCG efficacy.
The dependence of the outcomes of these trials with the levels of masking and blocking
is described, according to our model, by a series of splittings applied in each cohort.
For example, in what regards individual infection status, people within a cohort might
face different fates: 1)not being exposed to MTB during the follow-up period. 2)Be-
ing exposed but protected from infection due to prior sensitization to environmental
mycobacteria. 3)being exposed and protected by a vaccine or 4)being exposed and in-
fected (because of vaccine inefficacy, intrinsic or due to blocking). Then, people within
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each of these subgroups splits into two groups, as they might progress to active disease
or not.
Entering into the details, the first splitting is common in every cohort: the N
individuals is divided in a fraction x of exposed individuals -tentatively infected- and
a fraction 1 − x of non-exposed individuals. In the non vaccinated cohort, a fraction
m of the exposed individuals is protected by the masking effect.
For a vaccinated cohort, a fraction e of individuals is protected by the vaccine,
where e is the base efficacy of the vaccine. However, this efficacy will not be the same
in every vaccinated cohort due to the immunity waning rate of BCG. In the case of a
newborn-vaccine, an average of 15 years have past during the follow-up period since
the administration of the vaccine, and in the case of school vaccination this time lapse
is 4.5 years. So, we will distinguish two different efficacies: e(15) and e(4.5).
When we applied a revaccination we have an additional splitting for not protected
individuals in e′ and 1 − e′. This revaccination efficacy is calculated to recover the
levels of protection of the previous vaccine -we assume that the revaccinating process
works as a reset of the vaccine-. Essentially, we impose that the fraction of people
protected by the combination of the newborn vaccination (of efficacy e(15) at the
middle of the follow up) and the revaccination, of efficacy e′ is the same that the
fraction protected in a first dose, school age vaccination (of efficacy e(4.5)). So, we
have that e′(1− e(15)) + e(15) = e(4.5) which yields e′ = e(4.5)−e(15)
1−e(15) .
Notwithstanding that, for a vaccine applied on school age -first dose or revaccination-
we will have blocking, described through another splitting in fractions b and 1−b. This
will not happen in newborn vaccine, as newborns have not been exposed to mycobac-
teria in the moment of the vaccination.
Finally, an additional splitting is added in the infected individuals of each cohort: a
fraction r will progress to disease, a fraction 1−r will not. The endpoint of the trials is
measurement of disease, not infection, and that is why this last division is conceptually
needed: however, it will not affect the results of the trials, as it is common to every one
of them. This means that we consider that both vaccines and protections due to prior
sensitization (masking) have the only effect of reducing the infection risk at the level
of single individuals, and not to reduce the progression rates from latency to disease.
Though this is the simplest case to analyze, vaccines and prior sensitization might also
affect the progression to disease. The problem is that to be capable to discriminate
between effects over infection or effects over progression to disease, data from trials
with several endpoints would be needed (i.e. trials registering final fractions of sick
and latently infected individuals, like done in Worcester for the novel vaccine MVA85A
[213]), which unfortunately is not the case: the only trials that have been specifically
designed to look for masking and blocking effects are –up to our knowledge– the trials
of Barreto et al., and they only consider the endpoint of disease (i.e. they only explore
fractions of active disease after the follow-up period).
A schematic, yet comprehensive representation of the splitting model is shown in
figure 11.1.
The masking effect, parametrized through m ∈ [0, 1] will be, in principle, an in-
creasing function of the age of the individual -in the case of a trial, a function of the
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Figure 11.1: Schematic representation of the model of the masking and blocking effects in
the different cohorts under study
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average age of the individuals during the follow up period: 15 years old for our case
[195]-. For the blocking effect -described by b ∈ [0, 1]–, we have an slightly different
situation, as it is an increasing function of the age at the moment of the vaccination:
10.5 years in these trials as a raw average of the limiting ages of the vaccinated chil-
dren (7 and 14 y.o.[195]). Both, masking and blocking, should be different for each city
-higher in Manaus than in Salvador- as the exposition level to mycobacteria differs due
to the lower latitude of Manaus.
The proportions of people that finish the trial being sick in each cohort (D1:non
vaccinated, D2:newborn vaccination, D3: first dose at school age, D4: revaccination at
school age) are given by:
D1 = (1−m(15))rx (11.1)
D2 = (1− e(15))rx (11.2)
D3 = (1− e(4.5))rx+ rb(10.5)e(4.5)x (11.3)
D4 = rb(10.5)(1− e(15))e′x+ r(1− e(15))(1− e′)x (11.4)
The efficacy of a clinical trial is determined by e¯ = 1 − Dv
Dc
where Dv and Dc are
the proprortions of sick individuals the vaccinated group and the control group. Using
our branching model, it is straightforward to derive the following expressions for the
efficacies measured by the trials of Barreto et al. as a function of vaccine efficacies,
blocking and masking effects.
e¯1,M = 1− D2
D1
=
e(15)−mM(15)
1−mM(15) (11.5)
e¯2,M = 1− D3
D1
=
e(4.5)(1− bM(10.5))−mM(15)
1−mM(15) (11.6)
e¯3,M = 1− D4
D2
=
e(4.5)− e(15)
1− e(15) (1− bM(10.5)) (11.7)
e¯1,S = 1− D2
D1
=
e(15)−mS(15)
1−mS(15) (11.8)
e¯2,S = 1− D3
D1
=
e(4.5)(1− bS(10.5))−mL(15)
1−mS(15) (11.9)
e¯3,S = 1− D4
D2
=
e(4.5)− e(15)
1− e(15) (1− bS(10.5)) (11.10)
where numeric subscripts indicate newborns vaccine (1), first dose at school age
(2) and second dose at school age (3), respectively. In turn M stands for Manaus
and S for Salvador. Thus, we have a system of 6 equation with 6 variables (e(15),
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e(4.5), mM(15), mS(15), bM(10.5) and bS(10.5)). As all these parameters are defined
as fractions of individuals, they will be ranged between 0 and 1.
11.2.2 Masking and blocking quantification
Once we have obtained the system of equations that depends on different parameters
of masking, blocking and base efficacy, the next step is to fit these parameters to obtain
the best possible agreement with the data of the trials.
So as to do that task, let us consider a certain set of parameters e(15), e(4.5),
mM(15), mS(15), bM(10.5) and bS(10.5) that produces a corresponding set of efficacies
as predicted by our model e¯modeli,j . For every individual trial, we perform an elementary
hypothesis test according to which the probability for e¯modeli,j being compatible to the
corresponding Barreto’s observation e¯datai,j is assimilable to:
pi,j = 1− 2 1√
2piσdatai,j
∫ |Zi,j |
0
e−Z
′2
i,jdZ ′ (11.11)
where Zi,j corresponds to the Z-score associated to the model prediction of trial
type i in city j:
Zi,j =
e¯modeli,j − e¯datai,j
σdatai,j
(11.12)
and σdatai,j corresponds to the typical deviation associated to the gaussian, here
assimilated to one half the radius of the confidence interval reported by Barreto et al.
As these intervals are not symmetric, we have:
σdatai,j =

e¯datai,j −e¯data,lowi,j
2
if Zi,j ≤ 0
e¯data,highi,j −e¯datai,j
2
if Zi,j > 0
(11.13)
where [e¯data,lowi,j , e¯
data,high
i,j ] is the confidence interval reported by Barreto et al. for
each trial. So, it is trivial that pi will be maximum -equal to 1- if the exact data
of the trial is reproduced, and it will decrease with the difference between the real
observation and the value given by a set of parameters according to our model. From
these measures we construct a global error function Z as follows:
Z = 1−
∏
i
∏
j
pi,j (11.14)
Which can be interpreted as the probability of at least one trial reporting values
incompatible to the model. We search the set of parameters that gives us the minimum
possible value of Z -for the moment, using a Levemberg-Marquadt algorithm [413]-,
and we call it ~p0. Thse values are the following:
~p0 = (e(4.5), e(15),mM (15),mS(15), bM (10.5), bS(10.5)) = (0.60, 0.40, 0.01, 0.07, 0.88, 0.41)
(11.15)
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which seems to indicate that blocking is the driving effect for the observed variations
in BCG efficacies.
However, LM algorithm only guarantees that ~p0 represents a local minimum for
Z. Therefore, if we are in a situation when there are several local minima of Z, the
solution given in the previous section could not be considered as a solid answer and we
are forced to look after every possible minimum in the landscape of Z
Considering the asymmetric character of the confidence intervals by Barreto et al.
makes Z be strictly non-differentiable. For this reason, although an analytic addressing
of all the eventual minima of Z is feasible, such an operation should be repeated 26
times, i.e. one for each of the regions of the parameter space in which the piece-wise
definition of σi,j generates a different version of Z.
Instead of doing that we consider reasonable to follow a numeric procedure based
on mapping the error landscape on a network. To explore the total space of parameters
we construct a directed network, in which nodes are points of the parameters’ space
and edges represent proximity between two nodes. The algorithm used to construct
the network is the following (see figure 11.2, panel A):
• We divided the total space of parameters in a grid, and we find the minimum
of Z inside every different box. Each one of these points will be a node. We
define these nodes by iteratively dividing the hyper-cube in other smaller ones,
a fixed number of times, retaining each time, the cube associated to the smallest
Z found at each step.
• We represent a edge between nodes if the difference between them for every one
of the six parameters is less than the side of a box.
• The edges will be directed, from the highest to the lowest value of Z
Following this algorithm, two nodes corresponding to consecutive boxes are not
necessarily linked. If they are attracted by different basins,they might be attracted in
different directions, so the distance between them could be bigger than the side of a
box, and therefore, they would not be linked. This construction could drive to different
communities -or even disconnected components- for every minimum of Z (panel B in
figure 11.2. In addition, if the resolution of the grid is enough, nodes with kout = 0
can be associated to local minima and, ultimately, an overall outlook of the energy
landscape can be achieved. The complex network for our model is represented in figure
11.2, panel C. Fortunately, the network presents only one minimum; which corresponds
to a unique solution for the set of parameters, that is precisely the one found using the
LA algorithm, which corresponds to a value Z = 0.27.
11.2.3 Confidence intervals
Once we have seen that there is only one minimum in our parameter space (~p0), it is
time to study the local surroundings of the minimum found. In a local region near
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Figure 11.2: (A) Network reconstruction of error function Z landscape. A local minimum
of Z is found in the interior of each of the hyper-cubes (six-dimensional) schematized in the
figure. Then, directed links are stablished pointing from point of higher Z to points of lower
Z, provided they are closer than the size of the hypercube in the six axis. B) Two possible
scenarios of the complex network: a unique solution (left) or more than one minima (right)
(C) Error function Z landscape network for the masking-blocking problem. The network is
is a fully connected graph with only one minimum-like node -representing with a bigger size-.
Color of a node represents the value of P , red being the minimum and blue the maximum.
Only points that corresponds to P < 0.95 are represented
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~p0 the surfaces of constant Z can be approximated to hyper ellipsoids -generally not
aligned with the axis of the parameters [437]-, as it is shown in figure 11.3. To obtain
an estimation of the uncertainties of the parameters, the following numerical procedure
is performed.
First, we change the value of every parameter individually until a value of Z = 0.95
is reached (see figure 11.3). We call this increment Ai (i ∈ [1, 6]). These values will
not be symmetrical, and we will distinguish between A+i and A
−
i . Then, we construct
an asymmetrical Gaussian distribution for every parameter, centered in pi,0 and with a
variance given by σ±i = cA
±
i at each side.c represents here a modulating factor equally
affecting all the variances. Iteratively, we generate sets of points in the parameter space
for which the coordinates in each parameter’s axis are generated using the mentioned
asymmetric gaussian distributions. Through an iterative process we search the value of
c, for which a 95% of the points verifies Z < 0.95. The uncertainty of each parameter
will be given by ±2σ±i .
Figure 11.3: Schematic representation
in a bidimensional parameters’ space of
the ellipsoids of constant Z
Parameter Value Uncertainty range
e(4.5) 0.60 (0.54-0.64)
e(15) 0.40 (0.36-0.43)
mM (15) 0.01 (0-0.08)
mS(15) 0.07 (0-0.15)
bM (10.5) 0.88 (0.70-1)
bS(10.5) 0.41 (0.32-0.53)
Table 11.2: BCG masking, blocking
and intrinsic efficacy estimations along
with their confidence intervals
The parameters and their uncertainties obtained after this process are shown in
table 11.2.3. As we can see, the levels of masking predicted are low -1% and 7%-, and
their totally overlapping confidence intervals contain the no-masking scenario. On the
contrary, blocking is remarkably higher -88% and 41%- as it was qualitatively foreseen
by Barreto et al. [195]. It is also observed that the level of blocking is consistently
higher in Manaus than in Salvador, as it was expected.
11.2.4 Universality of intrinsic efficacies
In addition to quantifying masking and blocking in the cities under study, our analysis
of Barreto’s trials has also allowed us to obtain two values of the intrinsic efficacy of
BCG at two different times since vaccination -on average- e(4.5) = 0.6 and e(15) = 0.4.
These intrinsic efficacies are defined as universal magnitudes, not subject to a particular
location (i.e. Manaus or Salvador) according to our model. The question of whether
these measures represent a global property of BCG that could be extrapolated to the
results of other trials is pertinent.
In order to answer this question, we have studied an exhaustive meta-analysis of
BCG clinical trials by Mangtani et al. [194], from which we can recover data from
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Figure 11.4: Results of different BCG clinical trials (black points) as a function of time
since vaccination (average). The blue points are the two values of the base efficacy (without
masking or blocking) obtained from the trials of Barreto et al [195]. The green line corresponds
to the superior limit of the efficacy, if only blocking and masking occur.
19 different clinical trials aimed at determining BCG efficacy in different settings,
countries and, very relevantly, in cohorts of individuals of different ages at different
moments after vaccination. Using these data, we have represented, in a scatter plot, the
efficacy determined by each trial vs. the time between vaccination time and the middle
of the follow-up period (figure 11.4). If the only cause underlying variation of BCG
efficacy were masking and blocking effects, and our estimation of the intrinsic efficacy
from Barreto’s data could be considered universal, then the two points determined by
our model (e(4.5) = 0.6 and e(15) = 0.4) should constitute an upper bounds for the
observed efficacies at similar ages.
In figure 11.4, the green line represents the superior possible value of BCG efficacy,
defined by our base efficacy inferences (e(4.5) = 0.6 and e(15) = 0.4), coherent with
such hypothesis. As we can see, we have found at least two trials whose results can
not be explained by assuming that our intrinsic efficacies inferences are globally valid.
This indicates that there exist other reasons behind the geographical variance of BCG
efficacy additionally to blocking or masking, and that our estimations of the base
efficacies have to be constricted to the local context of Barreto’s trials.
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11.3 Influence of blocking and immunity waning on
novel vaccine’s impact
In the last section, we studied the case of BCG vaccine, and concluded that, in a likely
scenario, high levels of blocking are able to explain the variability observed for the
efficacy of BCG vaccine in the trials by Barreto et al. [195], with residual (or null)
levels of masking acting on the population.
When facing the problem of implementing a novel vaccine, the situation is different,
as protection due to BCG has to be considered as a masking-like background protection
acting on un-vaccinated people with the novel preventive drug. BCG is massively
applied in virtually all the countries that face minimum levels of TB burden, and so,
the efficacy and impact of any novel vaccine (substitutive or not) should be evaluated
in comparison to BCG performance. Taking this in mind, our main purpose in this
section will be that of offering a faithful description of two paradigmatic vaccines,
when compared to BCG: a BCG-substitutive vaccine applied on newborns and a BCG
booster applied on adolescents. Our intention is to use the model for vaccine efficacy
estimations used in the last section to estimate plausible age-dependent efficacy profiles
to introduce in our TB spreading model, developed in chapters 9 and 10, in order to
compare the impacts of each vaccine.
First, we conceive the efficacy evaluation of a novel prime vaccine applied on new-
borns of base efficacy eprime(t), when compared to newborn vaccination with BCG,
whose base efficacy we denote as eBCG(t). The argument of these functions is time
after vaccination. In other words, we are comparing two identical cohorts of type 2
(i.e. newborn vaccinated, see figure 11.1), in each of which we apply a different vaccine,
t years after vaccination. Since the vaccines we are modeling from chapter 9 on act
by reducing infection probability, in order to measure their efficacy we will work with
fractions of infected individuals. In this case, the relevant fractions will be:
I2,prime(t) = (1− eprime(t))x (11.16)
I2,BCG(t) = (1− eBCG(t))x (11.17)
and we will have that the measured efficacy of our novel vaccine as a function of
age e¯prime(t) is:
e¯prime(t) = 1− I2,prime(t)
I2,BCG(t)
=
eprime(t)− eBCG(t)
1− eBCG(t) (11.18)
Since, in this case, time after vaccination coincides with individuals’ age a, we have:
e¯prime(a) =
eprime(a)− eBCG(a)
1− eBCG(a) (11.19)
The case of booster vaccination on adolescents (i.e. at average age of 17.5 y.o.) is
subtler. First, we have to assure a proper map between the base efficacy of the newborn
vaccine eprime(t) and the corresponding base efficacy of the booster vaccine eboost(t) so as
11.3 — Influence of blocking and immunity waning on novel vaccine’s impact 
to guarantee that the two vaccines being compared are intrinsically identical. In order
to do so, first step is to calculate the corresponding fractions of infected individuals for
the booster case t years after second vaccination in a blocking-free scenario, taking into
account that, this time, we compare a cohort of type 4 (i.e. newborn first vaccination
and posterior booster, see figure 11.1) to a cohort of type 2 (newborn vaccination):
I4,BCG+boost(t) = (1− eBCG(t′))(1− eboost(t))x (11.20)
I2,BCG(t
′) = (1− eBCG(t′))x (11.21)
Where t′ is the time after BCG vaccination, which is t′ = t+ 17.5, so we have:
I4,BCG+boost(t) = (1− eBCG(t+ 17.5))(1− eboost(t))x (11.22)
I2,BCG(t+ 17.5) = (1− eBCG(t+ 17.5))x (11.23)
To assure that the prime vaccine (BCG substitutive) and the booster are identical,
we impose that, t years after the end of each vaccination setup, and in case we have no
blocking, both must protect the same fraction of individuals, which implies I2,prime(t) =
I4,BCG+boost(t):
(1− eBCG(t+ 17.5))(1− eboost(t))x = (1− eprime(t))x (11.24)
which allows us to express eboost(t) as a function of eprime(t) as follows:
eboost(t) =
e(t)prime − eBCG(t+ 17.5)
1− eBCG(t+ 17.5) (11.25)
At this point, we have that, in this blocking-free scenario, the novel prime vaccine,
and the combination of BCG and its new booster are able to protect the same fractions
of individuals from getting infected, when comparing at the same times after vaccina-
tion. This is a suitable basis for setting up the comparison between both vaccines, but,
unfortunately, such a couple of intrinsically identical vaccines (they could ideally be the
same one, if its application on both unvaccinated and BCG-immunized is safe) might
present different observed efficacies as a consequence of the age of the individuals being
vaccinated. As we saw in section 11.2.2 for the case of BCG, vaccine’s blocking may
act on the AFV booster. As a matter of fact, the effect of blocking has to be taken
into account when acting on the booster. In case the booster is affected by a certain
level of blocking b, we have:
I4,BCG+boost(t) = (1− eBCG(t+ 17.5))(1− (1− b)eboost(t))x (11.26)
I2,BCG(t+ 17.5) = (1− eBCG(t+ 17.5))x (11.27)
And now, we can calculate the observed efficacy for the booster vaccine e¯boost(t) as
follows:
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e¯boost(t) = 1− D4,BCG+boost(t)
D2,BCG(t+ 17.5)
= eboost(t)(1− b) (11.28)
And, substituting eboost(t) from eq. 11.25, we have:
e¯boost(t) =
eprime(t)− eBCG(t+ 17.5)
1− eBCG(t+ 17.5) (1− b) (11.29)
Finally, taking into account that the booster is applied when individuals are 17.5
y.o., we recover the following explicit age-dependency:
e¯boost(a) =
{
0 if a < 17.5
eprime(a−17.5)−eBCG(a)
1−eBCG(a) (1− b) if a ≥ 17.5
(11.30)
Equations 11.19 and 11.30 define the observed efficacies of two identically perfor-
mant vaccines, one of which is intended to substitute BCG, being applied on new-
borns, and the other one intended to boost BCG, being used on adolescents. The
differences between the observed efficacies –which are measured in counterposition to
BCG’s performance– arise as a consequence of the ages on which they are being applied,
more specifically, as a consequence of 1) the pattern of immunity waning over time of
both BCG and the novel vaccines (eBCG(t), eprime(t), and eboost(t) = f(eboost(t))) and
2) the differential effect introduced by blocking, which only acts on the booster as a
consequence of the older age of the individuals receiving it. In the following subsec-
tions we explore different scenarios that contemplate the effects on observed efficacy
and vaccine impacts of dealing with vaccines following different patterns of immunity
waning and/or subject to different levels of blocking.
11.3.1 Fast waning vaccines
As a first case scenario, let us suppose that both BCG ad the novel vaccines follow
the same temporal waning pattern identified in section 11.2.2 for BCG in Manaus and
Salvador. In section 11.2.2 we found: eBCG(4.5) = 0.6 and eBCG(15) = 0.4. As a first
approximation, we consider a linear age-dependence to get, for BCG:
eBCG(a) = max(0,−0.02 · a+ 0.69). (11.31)
When a stands for the individuals’ age, supposed they received BCG at birth.
Then, let us assume that the intrinsic efficacies of the novel vaccines are greater at
t = 0, but they wane at the same linear pace of BCG. For the prime vaccine, we have
eprime(a) = max(0,−0.02 · a + 0.94), when the independent term has been calculated
so as to make the vaccine have a 70% observed efficacy at the first age group a ∈ [0, 5].
In what regards eboost(a), we calculate it from eprime(a), following equation 11.25.
The intrinsic and observed efficacies for each vaccine are represented in figure 11.5,
panels A and B. In that figure, for the case of booster vaccines, three scenarios have been
explored: high blocking (i.e. b = 0.84, like BCG in Manaus), medium blocking (b = 0.4,
like BCG in Salvador) and no blocking. In turn, in panel C we observe the impact
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Figure 11.5: A. Intrinsic efficacies of different waning vaccines (BCG: black, novel prime
vaccine: orange, novel booster vaccine: purple) B. Observed efficacies of novel vaccines (or-
ange: prime, purple, violet and magenta: booster). Different levels of blocking reduce the
observed efficacy of booster vaccines, when applied on adolescents. C: forecasted impacts of
each vaccine, as predicted by our TB spreading model.
foreseen by our spreading model, in which,  parameters are assimilated to 1 minus
the observed efficacies e¯. At this point, it is worth mentioning that this assimilation
 = 1− e¯ makes sense because of that the non-immune branch of our spreading model is
assimilated to the regular population, so it includes BCG vaccinated individuals, who
virtually constitute the entire population in most high burden countries. This means
that our fitting procedure of the spreading model is embedding the BCG effects, and
so, the parameter  represents the outperformance of any novel vaccine with respect
to BCG, just as desired. Additionally, it is worth mentioning that, in this case, we
are describing immunity waning by a progressive decay in vaccine’s efficacy (i.e. an
increasing of ), and so, no recovery fluxes from V S to W classes are needed in the
spreading model (i.e. γ = 0). Of course, if we consider a vaccination strategy focused
on a traget age group ao, a hypothetical subsequent age-group a1 = ao + τ will only be
protected by the vaccine τ years after the vaccination campaign, which we set in 2020.
Many relevant observations can be noted from figure 11.5. First, after a careful
observation of the intrinsic efficacies (panel a), we see that, leaving apart the 15 years
shift among them, they are not perfectly identical, which would seem to be contradic-
tory with the premise of both vaccines being intrinsically identical. What is actually
happening is that, while the prime vaccine acts alone, the booster vaccine cooperates
with BCG in order to provide protection to the same fraction of the population (i.e.
to be identical, see equation 11.24), and therefore, so as to protect the same fraction
of people, its efficacy eboost must be lower than eprime.
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Additionally, even if prime and booster vaccines have similar intrinsic efficacies, if
no blocking is acting, the pattern of time waning for the observed efficacies (panel b)
is remarkably different. The reason, this case, is a consequence of the different protec-
tion levels provided by BCG when displacing 15 years in the horizontal axis. Indeed,
observed efficacies are different because these are calculated from the comparison pro-
vided against sole BCG, which is different in both cases because of the 15 years shift.
In this case, BCG efficacy decays with age, which supposes that it is more difficult to
overcome in the first age groups: this translates in higher observed efficacies for the
booster vaccine than for the prime when comparing age groups separated 15 years.
The final impact for each vaccine, in terms of the number of active TB cases pre-
vented up to 2050 in SEAR after the introduction of a vaccine in 2020 is represented
in panel C. As we see, when no blocking is present, an adolescent-focused booster vac-
cine will offer a larger impact than a prime vaccine on newborns. This is the result
of two concurrent factors. First, as we discussed in chapter 10, adolescents and young
adults are the main contributors to TB transmission, and so, it is of utmost impor-
tance to immunize them as fast as possible, something that is achieved by the AFV
booster. Additionally, BCG is more difficult to overcome for the youngest segments of
the population, which works in detriment to the NFV, again.
However, these effects, both advising the use of AFVs instead of NFVs, may be
deactivated by vaccine’s blocking. As we see in panel C, if the novel booster suffers
from similar levels of blocking to those found for BCG in the trials by Barreto, the
advantages mentioned before may be lost.
11.3.2 Novel persistent vaccines vs. fast waning BCG
In this case, we will explore a more optimistic scenario according to which the novel
vaccine is able to maintain its persistence during the entire lives of vaccinated indi-
viduals; while the same behavior of section 11.3.2 is reserved for BCG (eq. 11.31).
In this case, for the efficacy of new vaccines, we discard the linear terms that make
them time-dependent to recover constant values for all ages, to get eprime(a) = 0.91
and eboost(a) = 0.70 for all individuals regardless how old they are. The intrinsic and
observed efficacies for each vaccine are represented in figure 11.6, panels A and B,
whilst the projected impacts for each vaccine are represented in panel C.
As we see, forecasted impacts are now higher due to the increased vaccine efficacies
considered. Furthermore, the picture is very similar to that obtained in section 11.3.2,
with the difference that now, as there is no efficacy waning for the novel vaccines, these
attain an slightly improvement in the observed efficacy as BCG efficacy, to which they
are compared, wanes. In this case, the out-performance of the booster vaccine with
respect to the prime to be more modest than before: in this case, the impact by the
booster with no blocking is 2.44 times larger the impact generated by the prime vaccine;
while, if the vaccines show the same fast waning behavior of BCG, this coefficient is
3.5. This is due to the fact that, in this case, the prime vaccine preserves its entire
performance once it reaches the age segments more affected by the disease (adolescents
and young adults), on which BCG is not working any more: the advantage of the
11.3 — Influence of blocking and immunity waning on novel vaccine’s impact 
Figure 11.6: A. Intrinsic efficacies of different persistent vaccines (BCG: black (waning),
novel prime vaccine: orange, novel booster vaccine: purple) B. Observed efficacies of novel
vaccines (orange: prime, purple, violet and magenta: booster). Different levels of blocking
reduce the observed efficacy of booster vaccines, when applied on adolescents. C: forecasted
impacts of each vaccine, as predicted by our TB spreading model.
booster, now, is reduced to a consequence of immunizing faster these age-groups.
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11.4 Discussion
In this chapter we have explored the influence of sensitization to environmental my-
cobacteria and immunity waning to the observed efficacy of anti-TB vaccines. Cap-
italizing on the results from recent clinical trials conducted in Brazil [195], we have
quantified, through a simple mathematical model, the relevance of the principal mech-
anisms proposed, concluding that blocking of vaccine assimilation is the most likely
mechanism responsible for BCG reduced efficacy when applied on school-age individ-
uals, specially in lower latitudes.
Additionally, in chapter 10, we conducted impact comparisons between AFVs and
NFVs, when both of the them showed identical observed efficacies. On that basis, in
this chapter we have characterized the way in which two identical vaccines will present
different levels of observed efficacies when used on different age groups. The reason
for this is twofold. On the one hand, BCG background efficacy may be different in
different age groups, and its protection may not be equally easy to overcome at all ages.
Typically, BCG is considered to perform better on children, and losses its efficacy on
older age groups, which would derive in AFVs having more observed efficacy than NFVs.
On the contrary, AFVs may have to face vaccine blocking, an issue that is not expected
to happen for NFVs. All these aspects make even less obvious the debate between AFVs
and NFVs, as the result of the comparison between their observed efficacies will be the
outcome of a final tradeoff between the two opposite factors mentioned before. In
this chapter, we have developed a modeling platform for the quantitative evaluation of
vaccine’s impacts taking into account all these effects.
As a result, the major conclusions derived from our study are clear: first: a global
effort to reliably measure age-dependent patterns for the efficacy of BCG are urgently
needed, if novel vaccine impacts have to be undertaken, as the efficacy of them cru-
cially depends on the background levels of protection provided by BCG. Furthermore,
blocking effect, that solely affects to AFVs, may dramatically reduce their impacts,
eventually causing AFVs to lose their initial advantage derived from reaching faster
the most infectious age segments of the population. At this point, it is worth noticing
that the vaccine impact evaluations accomplished in this chapter constitute just some
relevant examples of how these effects may affect vaccines impacts, and other patterns
could be observed when testing and implementing novel vaccines. For example, also
the worst case in which time persistence of novel vaccines were lower than that of BCG
could apply, and, being the persistence of BCG itself a controversial matter, in some
areas, the fast-waning efficacy that we have used to describe BCG behavior may not
apply.
As a conclusion from this chapter, as we can see from the studies by Barreto and
Mangtani, the question of what are the causes for BCG efficacy variation among dif-
ferent parts of the world is probably complex enough so as not to admit a unique
answer. In this section we have studied masking and blocking effects, capitalizing on
the specifically designed trials by Barreto et al., concluding that blocking constitutes a
major effect impairing BCG performance when applied on grown individuals, instead of
masking, which is discarded as a plausible mechanism by our analysis. Notwithstand-
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ing that, the extrapolation to these results to other trials is not easy, as particularly the
intrinsic efficacies derived from the analysis of Barreto’s data are not totally compatible
with some of the outcomes of the trials meta-analyzed in [194]. As a conclusion, further
efforts and clinical trials have to be conducted in order to achieve a deep understand-
ing of the actual protective role currently played by BCG at different age segments in
the different parts of the world. Provided that any future novel vaccine’s performance
should be compared to that of BCG, that unarguably constitutes an unavoidable task
to accomplish if reliable impact estimations for novel anti-TB vaccines are intended, as
we have seen in this chapter.
 Age-dependent effects on vaccine efficacy: masking, blocking and efficacy waning
Part VI
Conclusions
Metáforas que apuntan hacia esa vaga, incitante dirección: el latigazo de la triple
carambola, la jugada del alfil que modifica las tensiones de todo el tablero.
Julio Cortázar.
Territorios, 1978.
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Chapter 12
Conclusions and prospects
Tuberculosis is an extraordinarily old companion of mankind. It was with us before we
were able to write, and it remains with us now, in the digital era [92]. The discovery
of its microbiological cause, by Robert Koch in 1882, constituted one of the most rel-
evant milestones of the young discipline of medical microbiology, whose revolutionary
paradigm have had a tremendous impact in public health, from Koch and Pasteur days
to the end of XXth century. Notwithstanding that, it is precisely the long endurance of
our relationship with MTB, the cause of most misconceptions about the disease, which
difficult the labour of both the researcher and the clinician. As Susan Sontag wrote
[431], when infectious diseases reach epidemic proportions before a proper description
of its nature is available, peoples hit by it provide an explanation for its causes and
enable it with complex, metaphoric meanings through non scientific narratives collec-
tively constructed. This commonly includes supernatural elements and a component
of judgement associated to punishable conducts, that contribute to the creation of
stigma. This has happened many times in History, from syphilis and TB to AIDS. Be-
yond the dramatic repercussions of the stigmatization of sick individuals, the collective
construction of these ideas of disease has a negative impact on the social perception of
risk associated with them, as they cease to constitute a threat of unknown reach to be
an issue that is somehow understood and to which the community gets accustomed.
In this sense, the ancient nature of TB might invite us to rely in the apparent de-
cline of the disease, and to think that current medical and epidemiological knowledge
about it should be complete by now. However, as we have seen along this Thesis, the
disease still remains a major cause of morbidity and death worldwide, and its com-
plexity, at different scales of description, poses strong limitations that hinders not just
our knowledge about the disease, but more importantly, our ability to fight it. In this
sense, for example, the incomplete description of human immune response against TB
hinders the task of finding precise immunological correlates for protection against in-
fection, which in turn makes harder the evaluation of novel vaccines. Simultaneously,
epidemiological studies and vaccine impact estimations are hindered by the complex
life cycle of the disease, and the difficulty of its surveillance, –specially in the countries
with a greater burden, which are those for which public health infrastructures are more
fragile [432]– makes uncertain any burden measure. These drawbacks evidence that
there is yet a long way to walk in TB research, at all scales from Biochemistry and cell
Biology to immunology and epidemiology, and, –even more remarkable– that further
developments in every scale will strongly influence each other. These observations,
along with the enormous societal implications associated to TB burden worldwide,
should be enough to motivate the idea, already developed by Young, Stark and Kirch-
ner [2], among others [433] of that comprehensive, multidisciplinary research efforts
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embracing all the disciplines mentioned around integrated approaches are needed to
achieve a deeper knowledge about this old companion of mankind, and, which is more
important, to maximize our chances of fighting, and ultimately eradicating it. This is
the spirit in which this thesis finds its context.
Along the chapters 3 to 11, we have exposed the results of the research conducted
in this thesis; in the following lines, we review the most relevant conclusions attained
after these studies, the research threads they open and, remarkably, how these threads
intertwine and how their simultaneous consideration around integrated approaches can
contribute to address unsolved questions in TB research.
12.1 Cell interactomes in MTB
In chapters 3 to 6 of this thesis we have focused on the characterization of a bibliography-
based TRN of MTB and on the study of the PPIN of the pathogen, and its adaptation
to disparate environmental conditions. Furthermore, we have studied the effects of data
incompleteness in the outcomes of different topological analysis conducted on TRNs,
and how networks based methods can be used to deal with the uncertainty that is
inherent to these and other complex directed networks.
The bibliographical revision presented in chapter 3 constituted, at the time the work
was published, the most complete dataset onMTB transcriptional regulation, reporting
more than three times the number of links than previous compilations [89]. This allowed
us to perform a detailed topological analysis of the system, identifying most connected
genes in the network and analyzing its overall topological properties, which resulted
similar, widely speaking, to those of analogous systems in other organisms.
Remarkably enough, even if the heterogeneous character of the network compiled
(which incorporates data of different quality and meanings) supposes a major limita-
tion, the sole integration of the information available around a single dataset shed light
about the roles played by each gene in the whole system. In this line, a network view
can help to contextualize the relevance of each regulator, and, something which is more
difficult to achieve otherwise, to identify genes whose expression has been reported to
be affected by a greater number of transcription factors. In this sense, while it will not
be surprising that PhoP appears as one of most prominent hubs in the network, it is
remarkable that two of the genes receiving a higher number of links –fadD26 and icl–,
have been identified to play central roles in controlling MTB virulence and persistence,
as we commented in chapter 2 (see figure 2.2). These genes show divergent expres-
sion in the attenuated strain MTBVAC, (icl is overexpressed and fadD26, as well as
PhoP, deleted) which has been associated directly with its attenuated, immunogenic
and persistent phenotype [129, 88, 186].
In the context of the topological analysis of the TRN of MTB, the analysis of motifs
statistics in the network brought some interesting results. On the one hand, the TRN
of MTB, in an first analysis, constituted an apparent exception to the classification
proposed by Alon and collaborators in [267]. In that work, authors identify four main
groups –or superfamilies– of complex networks according to their different contents in
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network motifs, each of which formed by similar systems. Among the four superfamilies,
two are formed by biological systems: a first group formed by TRNs of unicellular
organisms –which MTB “should” have joined– and another family formed by regulatory
networks of pluricellular organisms and synaptic networks, to which MTB seemed to
belong. According to the interpretation of this division provided by Alon et al. in [267],
the first family would be formed by “shallow” networks in which typical response times
associated to single interactions are similar to the response times of the whole system,
because of which they called it “rate-limited” network superfamily. By contrast, the
situation is the opposite for the systems in the second family of “not rate limited”
networks, in which systemic response times can be much longer than those of single
interactions. According these observations it would seem that the fact that MTB was
the first unicellular organism with a TSP more similar to those of the second family
could be a consequence of its particular lifestyle, very particularly to its ability to
survive within the host for long periods of time, which is a wrong conclusion as we
later show in chapter 5. In fact, what we show in that second phase of our research is
that it is the whole division of biological networks around two superfamilies of related
motifs profiles which is probably wrong. In chapter 5 we see how, by analyzing updated
versions of the TRNs of bacteria originally belonging to the family of rate limited
networks (B.subtilis and E.coli) we see how their TSPs now become compatible to
those of the non-rate-limited family. The cause of this phenomenon is methodological:
since the null model used in [267] to determine triads significances in real networks
consisted in random versions of the original systems preserving the number of in, out,
and bi-directional links of each node; in case there are no bi-directional links in a
real network, they will neither appear in the null-ensemble, which makes impossible
to define the Z-score for motifs containing bi-directional edges. In this sense, TSPs of
networks with no bi-directional links are affected by a lack of robustness against the
addition of even a reduced number of them. This was the case of some of the networks
analyzed in [267] as members of the first superfamily, that lacked bi-directional links in
the datasets used by Alon and collaborators in 2004, gaining some of them during the
following years as resulting from the progressive gain in data quality and completeness.
In chapter 5 we show how a simple update of the systems analyzed in [267], according
to the data publicly available on-line [314, 358] completely changed their TSPs, making
them switch from the “rate limited” family to the “not-rate limited” one, which actually
evidences that the division of biological networks of information processing around two
families is an artifactual consequence of data incompleteness.
Admittedly, the former result does neither offer an answer to the causes behind the
observed motif statistics in biological networks nor compromise the essential interpre-
tation of Alon and co-workers about it, which is related to the existence of evolutionary
pressures affecting networks’ topologies at the level of motifs, related to their dynami-
cal performance. In this sense, it has been hypothesized that the reason for which some
motifs are more selected than others in real networks is related to the benefits associ-
ated to the dynamics they drive. For example, feed-forward loops act, depending on
the signs and logical coupling of the links involved, as noise discriminators [261, 268] or
response-accelerator devices [269], both useful to drive cell adaptation to unpredictable,
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volatile environments. In order to indirectly test this hypothesis, we have analyzed the
TRNs of E.coli and MTB, looking for motifs presenting more divergent statistics in
both organisms. The results of our analysis show that E.coli shows a differential trend
towards forming four nodes FFL-related structures, which is coherent with a lifestyle
much more disparate and unpredictable than that of MTB. These “fine grain” obser-
vations would be compatible with the hypothesis of network motifs as a product of
evolutionary pressures, and may constitute a feasible methodological resource to pro-
vide further testing of it, if similar results were robustly found on a substantial number
of related systems (for example, groups of TRNs of intracellular parasites vs TRNS of
free-life organisms).
It is worth mentioning that the hypothesis of networks motifs being the product of
hidden evolutionary pressures have been largely discussed in the literature, and that
there exist relevant alternative hypothesis to explain non-trivial motifs profiles, such
as the existence of physical spaces on which networks are embedded [339], or the ef-
fect of systematic errors related to network’s inference process [434]. In chapter 5, we
test this last hypothesis in the precise context of TRNs, and the emergence of system-
atic correlations between deficient characterization of links and their topological local
profiles. The conclusion of our analysis is that lack of robust experimental evidence
of large fractions of the interactions in a gene network may cause Z-scores associated
to the significance of some motifs to increase, even if overall significance profiles (i.e.
the relative significance of each motif with respect to the others) remained remarkably
stable.
In chapter 5 we also analyzed the mesoscale of the TRN of MTB, and its com-
patibility with the functional characterization of genes at different resolution levels.
This way, we find how a greater correspondence between functional and topological
partitions is attained when all the information available on the system (i.e. links di-
rections and signs) is rendered available to the corresponding modularity optimization
algorithms, no matter the size of the scales explored. This result lies in the same line
that those recalled in previous paragraphs, and highlights the relevance of the quality
of the datasets on the outcomes of different kinds of topological analysis.
Taking that in mind, we moved our focus to the analysis of current network-based
approaches to distinguish spurious information in complex systems, a relevant topic
in the field. More precisely, being interested in their use on TRNs, we developed a
new method for finding missing and spurious links in directed networks, based on a
previous work by R.Guimerá and M. Sales-Pardo devoted to the analysis of undirected
systems [276]. Our model was compared to other methods currently available in the
literature for solving the same problem, showing a slightly better performance when
identifying randomly distributed errors, that may not justify the greater computational
costs associated to our approach. However, these higher computational costs appear
justified when the algorithms are used to detect systematic missing data, as those asso-
ciated to inherently incomplete datasets, as TRN s built up upon series of independent
experiments.
In this first half of the Thesis, devoted to the analysis of biological networks, we also
present, in chapter 4, a study of the PPIN ofMTB, and its transformations as a function
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of gene expression. The results of our analysis shed light about the mechanisms of
transcriptional adaptation that allow MTB to face different situations and stresses. On
the one hand, we have shown how networks associated to expression profiles measured
in different experiments can be analyzed through phylogenetic analysis to identify the
influence on their topologies of the experimental procedures, strains used and stimuli
types. This kind of analysis can help to discriminate among different experimental
protocols those causing a bacterial state more tightly resembling a desired phenotype,
something of relevance in a field in which lack of proper models of infection constitute
a crucial drawback. On the other hand, our methodology is used to study how the
PPIN adapts to some of the specific stresses that are thought to constitute the basis of
biological hostility of phagosomal environment: hypoxia, nutrient starvation, generic
oxidative stress, exposure to NO, key-ions deprivation and cell wall damage. Our
analysis evidences strong similarities in the PPIN of MTB in response of all these
stimuli, which suggests the existence of convergent regulatory pathways associated to
the specific adaptation of the bacteria to its host, whereby the pathogen deploy highly
similar responses to these stimuli, which appear highly correlated in vivo. This result
can be interpreted in the context of a series of works in which these kind of convergent
regulatory pathways are identified [227, 133].
Remarkably, network analysis allows the identification of a group of proteins that
systematically act as hubs under all stresses mentioned. These proteins constitute
six pairs of ESAT6-cfp10 analogous, whose central role in the PPIN under any of the
stresses mentioned suggests a deep biological implication. The fact that our method is
able to capture the central importance of the gene pair ESAT-6/cfp10 constitutes an
encouraging argument evidencing the need of systemic analysis of global cellular adap-
tation beyond standard transcriptional characterization. Nevertheless, our method
also predicts a comparable role for five additional gene pairs parents to ESAT-6/cfp10.
These proteins have not received a comparable attention, and their biological role is
assumed to be that of providing a source for antigenic diversity to the pathogen that
could help it to control host’ immune response [435, 436]. Summarizing, our results
suggest that the proteins mentioned could play a role comparable to their most rele-
vant cognates ESAT-6 and cfp10, as all of them are promoted to play equally relevant
roles in the PPIN under any stress. This suggests that these dimeric proteins could
play relevant roles as major antigens, as important as ESAT6-cfp10; an hypothesis that
deserves further exploration.
Admittedly, several aspects of this work require further testing. On the one hand,
the comparison between the consensus networks associated to different stresses must
be reproduced in other organisms so as to elucidate whether their convergent topolog-
ical profiles can be confidently related to its parasitic lifestyle or, instead, are found in
other kinds of bacteria thus pointing to the existence of broader mechanisms of conver-
gent stress sensing and adaptation valid regardless specific environmental adaptation
strategies (or other effects). On the other hand, although, in general terms, genes’ roles
within the multi-layer system of stress response are a product of both their topological
position in the original unweighted network and the gene expression profiles associated
to each condition, it remains pendent to show what of these factors are more impor-
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tant on defining, for example, the strengths and participation coefficients of each gene.
These two issues are being addressed in the context of an on-going research.
12.2 Epidemic models
In the second part of this Thesis, in chapters 7 to 11, we focus on the development of
epidemiological models to describe TB and other diseases sharing some of its principal
characteristics, as these are long latency periods of persistence and strong interactions
with other infections.
In this sense, in chapters 7 and 8, our aim was to extend the well stablished paradigm
of mathematical epidemiology on complex networks towards epidemiological scenarios
tightly related to TB. The complexity that characterizes the contact networks on top of
which infectious diseases spread, as well as its effects on the epidemic phenomena, con-
stitute matters extensively addressed in the literature. However, the puzzle can hardly
be considered complete, as, for example, the interplay between complex topologies and
disease persistence, or the effects of the co-existence of two (or more) interacting dis-
eases spreading through complex networks constitute topics only partly addressed in
the literature.
In this sense, in chapter 7, we present a mean-field model aimed at describing the
dynamics of a disease that, like TB, simultaneously presents primoinfection and long
latency periods; when spreading on both homogeneous and heterogeneous populations.
By doing so, we are able to derive, numerical and analytically, the expression for
epidemic thresholds, addressing the influence of the parameters related to disease’s
dynamics and that of those related to the demography. Doing so, we corroborate,
within the range of application of our HMF, that the epidemic threshold also depends
on the quotient 〈k〉/〈k2〉. In the context of this work we have addressed a series of novel
questions that arise from the interplay between network complexity and persistence, as
for example, how the degree distribution of the system can be reshaped by the effect
of the disease depending on how newborn individuals are incorporated to the system.
In turn, in chapter 8, we present a mathematical model for the description of the
simultaneous spreading of two interacting diseases on one population, through two
distinct complex networks of contacts. In our model, special attention is paid to the
description of the different mechanisms of interaction that can be observed between
two diseases, like variations in the infectiousness, recovery rate or susceptibility to the
disease. In this sense, by exhaustively considering all the possible interaction routes,
we have been able to identify overall conditions for “positive” or “negative” interactions
-disease enhancement or impairment, in terms of epidemic threshold shifts-, and to
foresee the possibility that one disease can enhance or impair the spreading of another
one as a function of its prevalence level. In addition, our description, simultaneously
valid for SIS and SIR models, show that epidemic thresholds differ for both models not
just as a consequence of dynamical correlations, (intrinsically disregarded in the HMF
formulation) but as an effect of disease-disease interactions. Additionally, our model
provide a description of epidemic thresholds within and outside equilibrium. That, as
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we show in Figure 8.8, implies an understanding of how the epidemic threshold for one
disease changes as the outbreak of a conjugate infection evolves. Such a dynamical
description of epidemic thresholds makes explicit the relevant influence of timing on
the critical properties of a system of interacting diseases. Finally, we have shown
how our approach, despite its simplicity, is able to reproduce, at least in a qualitative
way, real burden data corresponding to a well known system of interacting diseases:
the syndemics formed by HIV and TB, using data from the Republic of South Africa,
arguably one of the places in the world more dramatically affected by the concurrence of
both diseases. By performing a simple fitting procedure, our model is able to provide a
suitable reproduction of the time series of TB and HIV prevalence, from 1990 to 2010,
when the interaction between them is known to have constituted the main driving
effect responsible of the enhancement in TB burden rates. By doing this exercise,
more importantly than showing that our model is able to reproduce real data (which,
as we say, could hardly be considered surprising), it is to observe that, despite our
model is a strong simplification of actual natural histories of both TB and HIV, the
parameters yielding the best fit consistently reflect the interaction mechanisms whereby
HIV modifies TB spreading dynamics; including the enhancement of the susceptibility
to TB disease of HIV infected individuals [157] and the reduced TB transmission rates
of patients co-infected with HIV [146]. This indicates that collective fitting in epidemic
models of interacting diseases –an approach which has been demonstrated of usefulness
in other grounds [437]– may help us to discriminate between the actual mechanisms of
interaction between them.
Once we have explored the interplay between topological complexity of contact
networks and different dynamical aspects of the epidemic spreading (like persistence
or interactions between diseases), we specifically focused on TB spreading modeling in
chapters 9 to 11. In this part of the Thesis we analyzed the state of the art in TB
modeling and incorporated to the picture some new ingredients inspired from what was
learnt in previous chapters and, in general, from what is customarily being done in other
grounds of computational epidemiology. The aim is to test, at a quantitative level, the
influence of these new hypothesis on model outcomes, as well as the feasibility of their
incorporation to the models; with the final purpose in mind of increasing reliability of
current modeling platforms for the impact evaluation of novel epidemic interventions;
very remarkably preventive vaccines.
In this context, in chapter 9, we developed a data-driven model for the evaluation
of TB burden, based upon a series of works by C.Dye et al. Our model processes two
distinct sources of data. First, it uses demographical projections regarding populations’
age distributions provided by UN population division [23]. Additionally, incidence and
mortality rates are extracted from the WHO tuberculosis database [24]. The principal
conceptual novelties of our model are four: 1) the use of heterogeneous contact patterns
to drive disease transmission, 2) the explicit consideration of the coupling between
disease dynamics and demographic evolution, 3) the abandon of the hypothesis of
initial equilibrium and 4) The introduction of a fitting procedure (in chapter 10) that
is able to reproduce age-distributed burden levels.
Our motivations to introduce these ingredients on the already sophisticated models
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of TB spreading have to do with the current scientific context in the field. As we say,
the importance of being able to provide reliable impact evaluations for the novel TB
vaccines currently under development constitutes an strong reason advising the need of
revising current models, and to assure that all the quantitative data resources currently
on disposal are taken into account in model development. In this sense, as we have
discussed in the text, the age at which novel vaccines are intended to be administered
constitute a central question to address, and consequently, all possible age-dependencies
must be exhaustively considered in the models. This includes the different population
volumes at each age group (i.e. the demographic pyramids); the intrinsic variations of
dynamical parameters depending on age; the distinct social behaviors, and connectivity
profiles of the individuals as a function of age; the distribution of disease burden among
the different age groups, and, finally, the addressing of the age dependence of vaccine
efficacy, both for the case of BCG –that constitutes the background– and for the case
of the novel vaccines which we want to test.
The new modeling ingredients introduced in chapters 9 and 10 contribute to provide
a more consistent description of the mentioned age-dependencies, and, as we thoroughly
discuss, they exert relevant influences on the impact forecasts at a quantitative level.
Noteworthy, age-dependent contact patterns heterogeneities cause strong variations in
these impact estimations, which makes evident the need of measuring them as reliably
as possible. Contact matrices used in this work come from transnational surveys per-
formed in a series of european countries [12], and, in this sense, the results presented
in this Thesis should be considered an approximation, and these could vary if contact
patterns of some of the regions differ from those of Polymod project.
Our results confirm the common hypothesis of that adolescents may constitute an
optimal age-group to immunize in order to get faster, greater impacts up to 2050, for
several reasons. On the one hand, adolescents and young adults constitute both the
age groups affected by heavier levels of disease burden and the first segments for which
infectious forms of pulmonary TB constitute the dominant form to disease. In addition,
current BCG vaccine –even if subject to high uncertainty and variability– seems to
present a rapid efficacy waning as time from vaccination passes by [214, 203, 215]. Given
that the efficacy of novel vaccines is measured on the basis of a comparison to BCG,
the protection by the old vaccine is probably easier to overcome in adolescents than in
infants, if the waning of BCG vaccine is accepted as a general rule, something that is
not totally clear though [197, 198, 199, 194, 195]. Finally, when heterogeneous contact
patterns are introduced, the assortativity of these patterns makes more effective the
immunization of these age-groups when compared to vaccination campaign focused on
children, as disease transmission is being interrupted in the age groups that are, at the
same time, responsible for a higher number of cases and contagions. Despite all these
advantages of adolescent focused vaccination campaigns, these are, by definition, unable
to protect children beyond BCG does, leaving a permanent reservoir of population
at hand for the bacillus, something that could compromise the final goal of disease
eradication.
Because of that reason, the complementation of adolescent focused vaccination cam-
paigns with immunization of newborns should be an strategy to consider. Besides being
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the only conceptual way to guarantee the eventual protection of all the population (if
protection persistence is achieved), newborn immunization is, in certain aspects, safer
than vaccinating adolescents. The reason, as we discuss in chapter 11, is the existence
of prior sensitization to environmental mycobacteria that could compromise proper
vaccine performance if it is applied on grown individuals. As we show in this Thesis,
in case a novel vaccine applied on adolescents suffers of comparable levels of blocking
to those estimated for BCG, the advantages related to directly immunizing adolescents
could dissappear.
Furthermore, the discussion regarding the age of target populations in an optimized
immunization campaign is tightly related to the type of vaccines to consider, as, as we
have said in chapter 2, prime vaccines are initially intended to be applied on newborns
substituting BCG while boosters are designed to be used on BCG individuals, reme-
diating its immunity levels. In what regards BCG boosters, the negative results of
PhaseIIb trials of MVA85A on infants advise in favor to change trial design for future
vaccines to test them on adolescents, which hopefully will result in better protection
and impact in case the effects of prior exposition to mycobacterial (or other) antigens
are modest. Indeed, the interference of NTM on vaccine’s performance are more un-
likely for boosters because their biological mechanisms of dissemination throughout
the body and their immunogenic mechanisms are different from those of a live vaccine
like BCG, whose proper replication is thought to be blocked by the immune system
previously sensitized. Taken together, these reasons advise for testing booster vaccines
on adolescents as the safest strategy to follow in the context of vaccine development,
although, for the case of boosters based on viral vectors, presence of viral antibodies
in the individuals being vaccinated could also block vaccine assimilation in this case
[139].
The situation is more problematic for live attenuated vaccines, for which vaccine’s
blocking is arguably more probable. As we have seen in chapter 11, according the
analysis of the clinical trials recently conducted in Brazil by Barreto et al. [195], BCG
is subject to strong levels of blocking when applied on school age individuals. If a
novel live vaccine shares a similar behavior, its application on adolescents might result
into residual observed efficacies, at least in low latitudes (where are, in turn, some
of the countries with highest TB burden in the world). This is a likely scenario, not
just because we talk about live vaccines like BCG, but also because, if a novel live
vaccine is intended to be applied on adolescents, these will be previously immunized
with BCG, which in this case would act as a source of prior sensitization contributing
to vaccine blocking. Admittedly, the alternative strategy in this case is neither a
guarantee of success, as BCG, as we know, is harder to overcome in infants. The most
important property of a new TB vaccine, if it is intended to substitute BCG on infants,
is a longer persistence than the old vaccine, rather than a better initial performance,
and, for this reason, even a modest result for a novel vaccine could be interpreted
positively in that phase. This complex situation would advise, at least for the case
of live vaccines, to consider stratified trials conducted simultaneously in different age
groups, as in ref. [195], as well as to foresee, from the beginning of the development
process, further extensions of follow up periods from which protection waning patterns
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could be estimated as fast as possible.
This is unarguably an exigent wish list, taking into account the high costs associated
to the design of such clinical trials, and the difficulty to conduct them on high burden
settings. Nevertheless, live vaccines constitute a conceptual complementary approach
to boosters that shouldn’t be disregarded, as they might become the only alternative
to these in case the booster vaccines currently on the pipeline are not able to improve
the results of MVA85A on infants [213]. Last, but not least, we mustn’t forget that
boosters could enhance the protection induced by any novel live vaccine the same way
they are intended to enhance BCG.
In conclusion, the comparison between newborn and adolescents focused vaccina-
tion campaigns faced in this Thesis is subject to the precise compromise between the
temporal patterns of protection waning (both of the new vaccines and of BCG, whose
behavior is not fully understood yet), that advise for immunizing adolescents instead
of infants, and the existence of relevant levels of sensitization of individuals to environ-
mental mycobacterial agents that could be responsible of vaccine blocking, which may
act in the opposite direction. However, it is not clear how these effects could affect to
the different types of vaccines currently under development, and so, as a relevant part
of the development process, the need of clinical trials specifically designed to estimate
the impact of these phenomenologies on vaccine performance should be considered.
All that being said, beyond defining the age profile of target populations associated
to each possible vaccine candidate, the pipeline for the development of new TB vaccines
is committed to consider many other criteria to guarantee an adequate identification,
among all the candidates, of those showing more promising protective features, com-
patible with safety concerns. What makes more insidious the task, -i.e. the seek of
a safe candidate able to offer the greatest impact possible– is that the more time is
devoted to the task, the worse will be the result (see figure 12.2).
The implementation of novel vaccines and other epidemiological measures to reduce
tuberculosis burden at a global level is an urgent matter, and each year of delay is paid
with hundreds of thousands of lives.
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Figure 12.1: Effects of the delay in the time of application of a 70% efficacy vaccine. Left
column: newborn focused vaccine. Right: adolescents focused vaccine. (a,b): Incidence rates
after the application of vaccines in different moments from 2020 to 2035. (c,d): number of
TB cases prevented, until 2050, as a function of the year of vaccine implementation. (e,f):
Mortality rates after the application of vaccines in different moments from 2020 to 2035. (g,h)
number of TB deaths prevented until 2050 by vaccines applied in different years.
12.3 Prospects
In the precedent lines, we have summarized the principal conclusions reached after
the research completed around this Thesis, focused on different levels of description
of TB infection process; from bacterial cells to human populations. As we have seen
throughout this Thesis, the development of novel epidemiological tools against TB
constitute an urgent need to reduce the affection caused by the disease worldwide,
and, for that development to be possible, concurrent efforts must be undertaken from
genetics and cell Biology to immunology and epidemiology; which is particularly true
for the case of new preventive vaccines against TB. In this sense, the Thesis here
presented, beyond the specific results summarized in the preceding sections, supposes
a suitable springboard for the development of a deeper research program aimed at
assisting the development of novel vaccines from the perspective of complex systems
sciences.
In this sense, as we have discussed before, one of the most limiting caveats for TB
vaccine’s development is the lack of reliable immunological correlates of vaccine’s in-
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duced protection against disease that could be used to test vaccines before performing
large, expensive and long-lasting clinical trials. As we say, most used readouts for
addressing vaccine’s performance are MTB reduced intracellular replication or IFNγ
production by T-cells; which have been shown to constitute defective correlates of vac-
cine’s protection [212, 210, 186]. Noteworthy, transcriptional analysis constitutes one
of the most feasible approaches to the problem. In a recent work, Berry et al. found
a transcriptional footprint for active disease in TB patients [438], which constitutes
a promising result that suggests that transcriptional analysis and modeling may con-
stitute a fruitful way to discriminate between different host’s status relative to TB
infection. In order to explore this possibility, dynamical modeling of gene response to
phagocytosis –both of host and pathogen– constitute a fundamental task to undertake.
Admittedly, the TRN of MTB compiled in chapter 3 of this Thesis, –despite con-
stituting a valuable resource by itself, as we have shown in this Thesis–, may not con-
stitute a suitable basis for these modeling tasks. As we have already noted, the data
compilation underneath our TRN includes interactions reported under very disparate
conditions and through disparate experimental methods, which yields the appearance
in the network of links that are only present under specific environmental conditions
(particularly, links susceptible to be absent in the contexts mentioned before), links
reflecting indirect dynamical effects and even links with no dynamical consequences at
all. Similarly, even if the interactions in our network were reliable enough, the task
of inferring the way multiple inputs couple on a single target is hard to achieve from
such heterogeneous dataset. That would make any genome-wide dynamical model per-
formed on our network very uncertain, and thus, the seek of transcriptional correlates
of immunological states respect to TB infection will require the characterization of
specific regulatory networks, both of host and pathogen, based on specific datasets
compiled with that purpose.
A promising approach to achieve that goal is based on expression-quantitative trait
loci (eQTL) mapping methods, which have already been shown useful to identify genes
associated to susceptibility to TB [439]. EQTL are defined as single nucleotide poly-
morphisms (SNPs) significantly associated to variation in gene expression levels under a
given experimental setup, and their characterization relies on the simultaneous analysis
of genotypes and gene-expressions of extended series of different individuals, through
multi-variate Bayesian methods [440, 441]. Furthermore, the use of multi-variate data
from eQTL mapping to infer specific, highly reliable gene regulatory networks has
turned into a hot topic in the field [442, 443, 444, 445]. The combined use of eQTL
mapping and transcriptional modeling holds the promise of allowing us to go beyond
the simple characterization of genetic factors correlated to disease susceptibility by
addressing the dynamical pathways whereby the phenotypes related to TB disease are
regulated.
Characterization of gene diversity in the response to MTB infection has further
implications that hit directly the epidemiological part of the puzzle. Particularly, it
has been demonstrated that the global geographical distribution of human ethnic pro-
files and the diverse lineages of MTBC are strikingly correlated [175], which has been
related to the specific adaptation of the mentioned pathogenic clades to the ethnic
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groups present in different geographical areas [174]. The relevance of these facts in
the present time goes far beyond simple theoretical motivations. Instead, the dangers
associated to the introduction of vaccines conferring heterogeneous levels of protection
for different strains of a disease can not be overemphasized [177], as it could introduce
differential evolutive pressures among lineages that could have undesired consequences,
as it has occurred already in History, with other pathogens like Streptococcus pneumo-
niae, Haemophilus influenzae, Neisseria meningitides and Bordetella pertussis [446].
For example, a vaccine offering less protection against infection by asian lineages than
against others may have dramatic consequences, as it would cause an increase in the
incidence of drug resistant tuberculosis associated to the proliferation of Beijing strains;
which belongs to asian lineages and are known to be more prune to develop antibiotic
resistances.
For these aspects to be properly modeled and understood, a suitable meta-populations
model for TB spreading should be implemented; on top on which heterogeneous fit-
ness landscapes between MTB strains and human ethnic groups could be explored and
related to geographical location. In such a model mobility patterns are intended to
be driven by migratory fluxes over extended time periods, and other phenomenologies,
like antibiotic resistances and HIV interactions can and must be incorporated. Vaccine
impacts evaluations should be faced within this context, and the TB spreading model
developed in chapter 9 constitute a first step towards that goal.
Admittedly, the implementation of such modeling platform will necessarily depend
on data availability, which, especially in what regards the effects of genetic diversity
on TB spreading dynamics is still very limited. For this reason, once again, a deeper
knowledge of the genetic mechanisms yielding different levels of susceptibility to disease,
as well as how these are distributed among the populations of different countries, are
needed to provide reliable descriptions of multi-strain spreading dynamics for TB.
Once again, tuberculosis reveals its complexity at multiple scales, each of which
unavoidably attached to the rest. Once again, the advances made so far appear before
us as conjoined pieces of a greater puzzle, which are in turn a further source of error,
hesitation, dismay, and expectation to face in years of future work.
Chapter 13
Conclusiones y perspectivas
La tuberculosis es una vieja compañera del género humano. Estaba con nosotros antes
de que fuésemos capaces de escribir y permanece a nuestro lado hoy, en plena era digital
[92]. El descubrimiento de su origen microbiológico, por Robert Koch, en 1882, consti-
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tuyó uno de los más relevantes hitos de la microbiología médica, una joven disciplina
cuyo revolucionario paradigma estaba llamado a proporcionar un impacto excepcional
en la Historia de la Salud Pública, desde los días de Koch y Pasteur hasta el final del
siglo XX. No obstante, es precisamente lo dilatado de nuestra relación con el patógeno
la causa de una gran cantidad de malentendidos y falsas interpretaciones acerca de la
enfermedad que dificultan la tarea clínica e investigadora. Tal como escribió Susan
Sontag [431], cuando las enfermedades infecciosas alcanzan proporciones epidémicas
antes de que sus verdaderas causas sean comprendidas en profundidad, los pueblos
golpeados por ellas elaboran explicaciones sobre sus causas y las dotan de comple-
jos significados metafóricos a través de narrativas construidas colectivamente ajenas
a cualquier método científico. Comúnmente, esto incluye elementos sobrenaturales y
una cierta componente de juicio asociado a conductas punibles asociadas con la en-
fermedad que contribuyen a la creación de estigmas. Se trata de un proceso que ha
ocurrido innumerables veces en la Historia; desde la sífilis hasta la tuberculosis y el
VIH.
Más allá de la estigmatización del enfermo, la construcción colectiva de estas ideas
de enfermedad arrastra un impacto negativo sobre la percepción social del riesgo asoci-
ado a la propia patología, que pasa de constituir una amenaza de alcance desconocido
a un elemento familiar, conocido, al que la comunidad es capaz de acostumbrarse.
En este sentido, la antigua naturaleza de la tuberculosis parecería invitarnos a
creer en el aparente declive de la enfermedad, y a pensar que el corpus de conocimiento
médico y epidemiológico actual sobre esta vieja enfermedad debería estar completo ya.
Sin embargo, tal como hemos visto a lo largo de esta Tesis, la tisis todavía consti-
tuye una de las mayores causas de morbilidad y muerte a nivel mundial, y su com-
plejidad, en cualquiera de las escalas involucradas en el proceso de infección, impone
severas limitaciones que dificultan no sólo nuestro conocimiento sobre la patología sino
nuestra capacidad de combatirla. En este sentido, por ejemplo, nuestro incompleto
conocimiento de los mecanismos de respuesta inmune frente a la infección tuberculosa
dificulta la búsqueda de indicadores inmunológicos de protección ante la infección; lo
cual, a su vez, lastra enormemente el desarrollo y evaluación de nuevas vacunas. Del
mismo modo, la propia complejidad del ciclo de vida del bacilo dificulta la vigilancia
epidemiológica, especialmente en los países más azotados por la enfermedad –que son
precisamente aquellos con sistemas de salud pública más frágiles y vulnerables [432]–,
haciendo muy complicada cualquier evaluación de la afección de la TB a nivel pobla-
cional. En definitiva, todos estos problemas evidencian que todavía queda un largo
camino por recorrer en investigación sobre TB a todos los niveles, desde la Bioquímica
y Biología celular hasta la epidemiología; y lo que es más importante, que los avances
que se produzcan en cada uno de dichos campos influirán potentemente en los demás.
Estas observaciones, junto a las dramáticas implicaciones sociales que la TB arrastra
tras de sí deberían ser suficientes para motivar la idea –ya desarrollada por Young,
Stark and Kirschner [2], entre otros [433]– de que el desarrollo de nuevos enfoques mul-
tidisciplinares e integrados, abarcando el estudio de la enfermedad a todos los niveles
de forma coordinada, son necesarios si pretendemos alcanzar un conocimiento más pro-
fundo de este viejo compañero del hombre, y, lo que es más importante, si pretendemos
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maximizar nuestras oportunidades de erradicarlo. Este es el espíritu en el que esta
Tesis encuentra su contexto.
En los capítulos 3 a 11 de este texto hemos presentado los resultados de la investi-
gación llevada a cabo en esta Tesis; en las líneas siguientes repasaremos las principales
conclusiones alcanzadas a partir de estos estudios, las líneas de investigación que estos
abren y cómo éstas están llamadas a entrelazase alrededor de enfoques integrados para
la resolución de ciertos problemas abiertos en el campo.
13.1 Interactomas celulares en MTB
En los capítulos 3 a 6 e esta Tesis nos hemos centrado en la caracterización de la
red de regulación transcripcional de MTB y el estudio de su red de interacciones entre
proteínas. Además, hemos estudiado los efectos de la incompletitud y falta de fiabilidad
en los datos que constituyen las redes de transcripción a un nivel más general. Hemos
estudiado cómo estos problemas afectan determinados análisis topológicos de las redes
y hemos propuesto métodos para la identificación de errores en este tipo de redes y
otros sistemas descritos como redes dirigidas.
La revisión bibliográfica presentada en el capítulo 3 constituyó, en el momento de la
publicación de dicho trabajo, la compilación más completa sobre regulación transcrip-
cional en MTB, conteniendo tres veces más interacciones que cualquier dataset previo
[89]. Esto nos permitió llevar a cabo un análisis topológico detallado del sistema que
condujo a la identificación de los genes más conectados en la red y la medición de
las propiedades globales del sistema, que resultaron similares a las de redes análogas
pertenecientes a otros organismos.
Notablemente, y pese a que la heterogénea naturaleza de la información compilada,
que incluye datos de muy diferente naturaleza y significado, impone importantes lim-
itaciones, la simple integración de toda esta información alrededor de un único dataset
ha contribuido a arrojar luz acerca de los roles jugados por los distintos genes en la
red. En esta linea, integrar los datos y analizar el sistema como una red ha servido
de ayuda para contextualizar la importancia de cada regulador y, algo más difícil de
conseguir de otro modo, identificar genes cuya expresión queda afectada por un número
mayor de reguladores. En este sentido, aunque no resulta sorprendente que el regulador
PhoP aparezca como uno de los nodos más conectados del sistema, resulta interesante
comprobar que dos de los genes ecibiendo un número mayor de regulaciones –fadD26
y icl–, hayan sido identificados como factores claves en el control de la virulencia del
patógeno y su capacidad para persistir in vivo, tal cómo comentáramos en el capítulo 2
(ver figura 2.2). La modificación de la expresión de estos genes, de hecho, se encuentra
en la base del fenotipo atenuado de la vacuna MTBVAC [129, 88, 186], fadD26, (como
PhoP) se han eliminado, e icl aparece sobre-expresado a consecuencia de la ausencia
de PhoP.
En el contexto del análisis topológico de la red de transcripción de MTB, el estudio
estadístico de los motivos de red conllevó algunos resultados de interés. Por un lado, la
red transcripcional de MTB, tras un primer análisis, parecía constituir una excepción a
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la clasificación propuesta por Alon y colaboradores en [267]. En el mencionado trabajo,
los autores identifican cuatro grupos o superfamilias de redes en función de la presencia
de los diferentes motivos (ver figura 1.3) en las mismas, formadas por redes de similar
naturaleza. De entre los cuatro grupos, dos estarían formados por sistemas biológi-
cos: un primer grupo formado por redes de regulación transcripcional de organismos
unicelulares (en el cual MTB debería haberse integrado) y otro formado por redes de
regulación de organismos pluricelulares y redes sinápticas; al cual, sorprendentemente,
la red de transcripción de MTB parecía pertenecer. Según la intrepretación de esta
división propuesta en [267], la primera familia estaría compuesta por redes “superfi-
ciales”, de poca profundidad, donde el tiempo de respuesta del sistema completo es del
orden del de una simple interacción. Por el contrario, el segundo grupo lo formarían
redes más profundas para las cuales el tiempo de respuesta del sistema puede ser mucho
mayor que el de una sola interacción.
A la luz de esta interpretación, podría resultar tentador atribuir el hecho de que
los motivos de la red de transcripción de MTB presenten un perfil más compatible
con el segundo grupo de redes a razones evolutivas, relacionadas con su habilidad para
sobrevivir dentro del huésped durante largos periodos de tiempo, por ejemplo. Sin
embargo, tal como demostramos en el capítulo 5, la propia división de los sistemas
biológicos estudiados en dos familias diferentes constituye, muy probablemente, un
error de origen metodológico. En el capítulo 5, analizamos las versiones actualizadas
de algunas redes de transcripción de organismos que fueron ya estudiados en [267] como
miembros de la primera familia: particularmente B.subtilis y E.coli. Curiosamente, tras
actualizar los datasets 7 años después del análisis original, los motivos de red de estos
sistemas pasan, como MTB, a presentar perfiles compatibles con el segundo grupo. La
razón de esto es metodológica, y relacionada con la falta de enlaces bi-direccionales en
los datasets originales y la aparición de algunos de ellos tras el proceso de actualización,
del mismo modo que la red transcripcional de MTB presenta varios de estos feedback
loops. En el modelo propuesto en [267] para el análisis de motifs, las redes aleatorias
del null ensemble conservan el número de enlaces bi-direccionales del sistema original,
lo cual hace que, cuando se analiza una red sin tales elementos, el Z-score asociado
a motivos que contienen enlaces bi-direccionales no pueda ser definido. A causa de
esta situación, los perfiles de los motivos de red pertenecientes a las redes del primer
grupo en sus versiones antiguas –esencialmente carentes de enlaces bi-direccionales– se
diferenciaban de los del segundo grupo; una situación que se revierte al añadir siquiera
una reducida cantidad de enlaces bi-direccionales a consecuencia de la actualización de
las redes.
De cualquier modo, el estudio realizado no pretende ofrecer una respuesta a la
cuestión de porqué diferentes redes complejas presentan distintos tipos de motivos de
red en sus estructuras. Del mismo modo, no compromete la interpretación general
propuesta por Alon y colaboradores de acuerdo con la cual este fenómeno sería una
consecuencia de la presencia de presiones evolutiva favoreciendo la aparición de unos
motivos e impidiendo la de otros en función de sus características dinámicas. por ejem-
plo, los llamados feed-forward loops son estructuras capaces de actuar, dependiendo de
los signos de los enlaces que los componen y el modo en que éstos se acoplan, como
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discriminadores de ruido [261, 268] o como módulos aceleradores de respuesta [269],
lo cual los hace particularmente útiles en redes de regulación genética de organismos
adaptados a medios variados y difíciles de predecir. Con el objetivo de evaluar indirec-
tamente esta hipótesis, hemos analizado las redes transcripcionales de E.coli y MTB
en busca de motivos diferencialmente expresados en ambos sistemas (i.e. motivos que
aparecen más veces de lo esperado en una de las redes, y menos en la otra). Los re-
sultados de este análisis indican que E.coli presenta una tendencia mayor a presentar
estructuras relacionadas con el feed-forward loop, lo cual es coherente con el hecho
de que la bacteria es capaz de habitar en muy diversos medios, de modo mucho más
predecible que MTB, cuya estrategia evolutiva ha consistido en adaptarse muy especí-
ficamente a un estilo de vida parasítico. Estas observaciones resultan coherentes con
la hipótesis de que el contenido en motivos de una red específica obedece a presiones
evolutivas, aunque puedan interpretarse, como mucho, como un indicio parcial de su
existencia. La comparación de redes pertenecientes a organismos similares resulta una
metodología plausible para verificarla, si, por ejemplo, un mayor número de párasitos
intracelulares como MTB se comparan frente a un mayor número de organismos de
vida libre como E.coli, y los resultados resultan robustos.
No obstante, conviene anotar que la hipótesis evolutiva para explicar los contenidos
en motivos en redes dirigidas ha sido fuertemente cuestionada en la literatura. Ex-
isten, de hecho, relevantes interpretaciones alternativas de acuerdo a las cuales una
red puede presentar un contenido en motivos no trivial sin necesidad de ningún efecto
evolutivo. Tal es el caso de redes embebidas en espacios geométricos [339], o de redes
conteniendo errores sistemáticos [434]. En el capítulo 5 hemos puesto a prueba esta
última posibilidad en redes de transcripción, estudiando posibles correlaciones entre el
nivel de fiabilidad con el que un enlace es caracterizado y su entorno topológico local.
La conclusión de dicho análisis en que la caracterización defectuosa de algunos enlaces
es capaz de aumentar el valor absoluto del Z-score asociado a diferentes motivos, de-
jando aproximadamente invariante la significación estadística relativa de unos frente a
otros.
Por último, en el capítulo 5, también estudiamos la meso-escala de la red transcrip-
cional de MTB, y su relación con la caracterización funcional de los distintos genes que
la componen a diferentes niveles de resolución. En este punto hemos observado que el
análisis de modularidad de la red transcripcional muestra una mayor correspondencia
con la partición funcional cuando toda la información correspondiente a la dirección y
signo de las interacciones es tenida en cuenta por los algoritmos. Este resultado, una
vez más, resalta la influencia que la calidad y completitud de los datos ejerce sobre el
resultado del análisis topológico de redes complejas.
Considerando todo lo anterior, en el capítulo 6 nos centramos en el estudio de
distintos métodos para la estimación de la fiabilidad de los enlaces de una red, con el
ánimo de identificar enlaces falsos y perdidos. Específicamente, a partir de un trabajo
previo de R. Guimerá y M. Sales-Pardo [276], en el cual se propone un método útil
a tal efecto en redes no-dirigidas, desarrollamos un método análogo para efectuar la
misma labor en sistemas en los que, como las redes de transcripción, los enlaces tienen
dirección. Nuestro método, comparado con otros algoritmos disponibles en la literatura,
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ofrece un rendimiento ligeramente superior en la identificación de errores aleatorios;
una mejora de rendimiento que podría ser insuficiente para justificar los elevados costes
computacionales del método propuesto. La situación es probablemente distinta cuando
se trata de identificar enlaces perdidos en un dataset real, donde nuestro método se
muestra superior a cualquier otra alternativa.
Además de todo el trabajo anteriormente mencionado, en esta primera mitad de la
tesis dedicada al análisis de redes biológicas hemos también estudiado, en el capítulo 4,
la red de interacciones entre proteínas de MTB, y, más específicamente, como esta cam-
bia a resultas de los cambios en los perfiles de expresión genética con los que la bacteria
responde a diferentes estímulos externos. Por un lado, hemos estudiado, a través de un
análisis filogenético, de qué modo las principales características ambientales asociadas
a diferentes setups experimentales se reflejan en la topología de la red de proteínas del
bacilo. Este tipo de análisis podría ayudar a discriminar, entre diferentes modelos in
vitro, aquellos asociados a fenotipos más compatibles con un cierto estado de referencia,
ayudando en la mejora de los modelos de infección, un aspecto fundamental en TB. Por
otro lado, en este capítulo usamos la red de interacciones entre proteínas del bacilo para
estudiar su respuesta ante diferentes stresses fundamentales en el ambiente fagosómico:
hipoxia, escasez de nutrientes, estrés oxidativo genérico, exposición a NO, escasez de
iones como Fe++ y daño celular. Nuestro análisis evidencia una fuerte coherencia en la
red PPIN ante todos estos estímulos generadores de estrés, lo cual sugiere la existencia
de mecanismos evolutivos convergentes a partir de los cuales la bacteria responde de
manera muy similar a diferentes estímulos que aparecen altamente correlacionados in
vivo. Este resultado de puede interpretar en relación a una serie de trabajos en los
cuales este tipo de mecanismos de regulación convergentes son estudiados [227, 133].
Notablemente, este análisis nos ha permitido identificar una serie de proteínas que
ejercen el papel de hubs en respuesta a todos los estreses mencionados. Estas proteínas
constituyen seis pares de antígenos análogos a la pareja ESAT6-cfp10, cuyo rol central
y persistente en la red de interacciones entre proteínas en respuesta a estrés sugiere
una implicación biológica robusta. Más allá de que nuestro método destaque la propia
pareja de proteínas ESAT6-cfp10 entre dichos hubs globales, resulta llamativo que
sus análogos presenten un perfil similar en la red, puesto que, hasta ahora, es mucho
menos lo que se sabe sobre ellos, más allá de la hipótesis de que constituyen una fuente
de variedad antigénica que podría proporcionar al patógeno medios para mantener
bajo control la respuesta inmune del huésped [435, 436]. Nuestro análisis sugiere que
las proteínas identificadas en nuestro análisis podrían ejercer funciones biológicas tan
relevantes como el propio par ESAT6-cfp10, una hipótesis que sin duda merece ser
explorada en el futuro.
No obstante, diversos aspectos de este trabajo requieren de verificación adicional.
Por una parte, la interpretación de las redes de respuesta a estrés en MTB debería
someterse a comparación con otros organismos. El objetivo sería elucidar si la con-
vergencia observada en los perfiles topológicos de las redes asociadas con los distintos
estreses son una consecuencia de la adaptación del bacilo a un estilo de vida parasítico
o no. Por otra parte, en términos generales, nuestro método implica que los nodos con
mayor strength son aquellos que presentan una alta conectividad y, a la vez, tanto ellos
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como su entorno se encuentran sobre-expresados. Una parte relevante, sin embargo,
consiste en aislar el efecto de cada uno de los dos factores (i.e. topología y expre-
sión) sobre los resultados obtenidos. Estas dos cuestiones, entre otras, están siendo
investigadas actualmente.
13.2 Modelos epidemiológicos
En la segunda parte de la Tesis, en los capítulos 7 a 11, nos centramos en el desarrollo
de modelos epidemiológicos para describir la tuberculosis y otras enfermedades que
comparten con ella características como prolongados periodos de latencia e intensas
interacciones con otras infecciones.
En este sentido, en los capítulos 7 y 8, pretendemos extender el paradigma de
la epidemiología matemática en redes complejas hacia escenarios epidemiológicos es-
trechamente relacionados con la tuberculosis. La complejidad característica de las redes
de contactos sobre las cuales se propagan las enfermedades infecciosas y sus efectos so-
bre los fenómenos epidémicos constituyen una materia recurrentemente tratada en la
literatura científica. Sin embargo, el puzzle difícilmente puede considerarse resuelto
cuando ciertos factores clave no han sido todavía explorados, como la interacción entre
topologías complejas y la persistencia de la enfermedad, o los efectos de la coexistencia
de dos (o más) enfermedades relacionadas transmitiéndose a través de redes complejas.
En el capítulo 7, presentamos un modelo de campo medio para describir la dinámica
de una enfermedad que, al igual que la TB, presenta simultáneamente primo-infección
y periodos de latencia prolongados al transmitirse tanto en poblaciones homogéneas
como heterogéneas. Con ello logramos derivar, numérica y analíticamente, la expresión
para los umbrales epidémicos, señalando la influencia de los parámetros relacionados
con la dinámica de la enfermedad así como los relacionados con la demografía. De esta
manera podemos corroborar, dentro del ámbito de aplicación de nuestro HMF, que
el umbral epidémico depende del cociente 〈k〉/〈k2〉. En el contexto de este trabajo,
hemos identificado fenomenologías específicas que surgen de la interacción entre las
redes complejas y la persistencia, como por ejemplo el modo en que la distribución
de grado del sistema puede ser alterada por efecto de la enfermedad en función de la
forma en que los neonatos se incorporan al sistema.
Asimismo, en el capítulo 8, presentamos un modelo matemático para la descripción
de la propagación simultánea de dos enfermedades propagándose sobre una misma
población, a través de dos diferentes redes complejas de contactos, capaces de inter-
accionar entre sí. En nuestro modelo, prestamos especial atención a la descripción
de los distintos mecanismos de interacción que se pueden observar entre dos enfer-
medades, como variaciones en la probabilidad de propagación, tasa de recuperación o
susceptibilidad a la enfermedad. En este sentido, considerando exhaustivamente todas
las posibles vías de interacción, somos capaces de identificar las condiciones globales
necesarias para que se produzcan interacciones positivas o negativas - favorecimiento
u obstaculización de la enfermedad, en términos del desplazamiento de los umbrales
epidémicos-, previendo, por vez primera, la posibilidad de que una enfermedad pueda
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facilitar o dificultar la transmisión de otra en función de su nivel de prevalencia. Nues-
tra descripción, válida simultáneamente para los modelos SIS y SIR, muestra además
que los umbrales epidémicos difieren para ambos modelos, no sólo como consecuencia
de correlaciones dinámicas (no consideradas en nuestro campo medio heterogéneo) sino
por efecto de la interacción entre las enfermedades. Adicionalmente, nuestro modelo
ofrece una descripción de los umbrales epidémicos tanto dentro como fuera de equi-
librio. Esto, tal y como se muestra en la Figura refinteracting-lambda-2-c,supone ser
capaces de describir cómo el umbral epidémico de una enfermedad cambia mientras
evoluciona el brote epidémico de una infección conjugada, lo cual evidencia la im-
portancia del factor temporal en este tipo de problemas. Finalmente, hemos mostrado
cómo nuestro enfoque, a pesar de su simplicidad, es capaz de reproducir, al menos cuan-
titativamente, datos reales de prevalencia correspondientes a un sistema bien conocido
de enfermedades interactuantes: el sistema sindémico formado por el VIH y la TB,
utilizando datos procedentes de la República Sudafricana, sin duda uno de los lugares
más afectados por la concurrencia de las dos enfermedades. Llevando a cabo un pro-
cedimiento simple de ajuste, nuestro modelo puede proporcionar una fiel reproducción
de la serie temporal de la prevalencia de la TB y del VIH, desde el año 1900 hasta el
2000, periodo durante el cual la interacción entre las mismas ha constituido el prin-
cipal factor responsable de incremento de las tasas de prevalencia de TB. Haciendo
este ejercicio, más allá de mostrar que nuestro modelo es capaz de reproducir datos
reales (lo cual, como hemos comentado, difícilmente puede considerarse sorprendente),
podemos observar que, aunque nuestro modelo supone una simplificación significativa
de historias reales tanto de la TB como del VIH, los parámetros obtenidos en el ajuste
reflejan de forma consistente los mecanismos de interacción por los que el VIH modifica
la dinámica de propagación de la TB: tanto el incremento de la susceptibilidad a la TB
de los individuos afectados por VIH [157] como las reducidas tasas de transmisión de
TB de los pacientes co-infectados con VIH [146]. Esto indica que el ajuste colectivo en
modelos epidémicos de enfermedades interactuantes –un enfoque que ha mostrado su
utilidad en otros campos [437]- puede ayudarnos a discriminar entre los mecanismos
reales de interacción entre ellas.
Una vez explorada la relación entre la complejidad topológica de las redes de contac-
tos y diferentes aspectos dinámicos de la transmisión epidémica (como la persistencia o
la interacción entre enfermedades), nos centramos en la modelización de la propagación
de la TB en los capítulos 9 a 11. En esta parte de la Tesis analizamos el estado del
arte en modelización matemática de TB e incorporamos nuevos ingredientes basados
en lo aprendido en capítulos anteriores y, en general, de lo que está siendo utilizado
en otros campos de la epidemiología computacional. El objetivo es examinar, a nivel
cuantitativo, la influencia de estas nuevas hipótesis sobre los resultados de los mod-
elos, así como la posibilidad de incorporarlos a los mismos. El objetivo último es el
de incrementar la fiabilidad de las plataformas de modelado actuales para el caso de
la TB, y aplicar dichas mejoras en la evaluación del impacto de nuevas intervenciones
epidémicas, muy especialmente vacunas preventivas.
Así, en el capítulo 9, desarrollamos un modelo cuantitativo para la descripción de la
propagación de la TB, basado en una serie de trabajos de C. Dye y colaboradores. Nue-
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stro modelo procesa dos fuentes diferentes de datos. Por un lado, utiliza proyecciones
demográficas sobre distribuciones de edad de la población facilitadas por la división
de población de Naciones Unidas [23]. Adicionalmente, las tasas de incidencia y mor-
talidad se extraen de la base de datos de tuberculosis de la Organización Mundial de
la Salud [24]. Las principales novedades conceptuales de nuestro modelo son cuatro:
1) la utilización de patrones de contactos heterogéneos para simular la transmisión de
la enfermedad, 2) la consideración explícita del acoplamiento entre la dinámica de la
enfermedad y la evolución demográfica, 3) el abandono de la hipótesis de equilibrio
inicial y 4) la introducción de un procedimiento de ajuste distribuido por edades (en el
capítulo 10) capaz de reproducir niveles de incidencia por separado en cada grupo de
edad.
Nuestras motivaciones para introducir estos ingredientes en los ya de por sí sofisti-
cados modelos de propagación de TB tienen que ver con el contexto científico actual
en este campo. Tal y como hemos comentado, la capacidad de ofrecer evaluaciones de
impacto fiables para las nuevas vacunas de TB actualmente en desarrollo constituye
un objetivo lo suficientemente relevante para justificar la necesidad de refinar los mod-
elos actuales y de asegurar que todas las fuentes de datos actualmente disponibles son
tenidas en cuenta en el desarrollo de nuevos modelos. En este sentido, como ya se ha
señalado en el texto, la edad a la que las nuevas vacunas se dirigen supone una cuestión
central que debe atenderse, y en consecuencia, todas las posibles dependencias rela-
cionadas con la edad deben ser consideradas de forma exhaustiva en los modelos. Esto
incluye los diferentes volúmenes de población para cada grupo de edad (las pirámides
demográficas); las variaciones intrínsecas de parámetros dinámicos de la enfermedad;
los diferentes comportamientos sociales y perfiles de conectividad de los individuos;
la distribución de la afección de la enfermedad y, finalmente, la caracterización de la
efectividad de la vacuna; todos ellos factores fuertemente dependientes de la edad de
los individuos.
Los nuevos ingredientes introducidos en los modelos, en los capítulos 9 y 10 con-
tribuyen a proporcionar una descripción más consistente de las mencionadas dependen-
cias con la edad y, como hemos discutido en profundidad, ejercen influencias relevantes
sobre las previsiones de impacto a un nivel cuantitativo. Las heterogeneidades de los
patrones de de contacto dependientes de la edad causan fuertes variaciones en estas
estimaciones de impacto, lo que evidencia la necesidad de medirlas de la forma más fi-
able posible. Las matrices de contactos utilizadas en este trabajo provienen de sondeos
transnacionales realizados en varios países europeos [12] y, en este sentido, los resultados
presentados en esta Tesis deberían considerarse una aproximación, que podría variar
si los patrones de contacto de algunas de las regiones fueran medidos específicamente
y difirieran de aquéllos del proyecto Polymod.
Nuestros resultados confirman la hipótesis común de que los adolescentes podrían
constituir un grupo de edad óptimo de inmunización para conseguir mayores y más
rápidos impactos hasta el 2050 por varias razones. Por un lado, los adolescentes y
los adultos jóvenes son los grupos que sufren los más altos niveles de afección de la
enfermedad y los primeros segmentos para los cuales la TB pulmonar es la forma
dominante de la enfermedad. Además, la actual vacuna BCG, aún estando sujeta a
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una alta incertidumbre y variabilidad, parece presentar una rápida pérdida de eficacia
a medida que pasa el tiempo desde el momento de la vacunación [214, 203, 215]. Dado
que la eficacia de las nuevas vacunas se mide por comparación con la BCG, la protección
ofrecida por la antigua vacuna es probablemente más fácil de superar en adolescentes
que en niños, si el decaimiento de la vacuna BCG es aceptado como regla general,
algo que por otro lado no está totalmente claro [197, 198, 199, 194, 195]. Finalmente,
cuando se introducen patrones de contacto heterogéneos, la asortatividad de estos
patrones hace más efectiva la inmunización de estos grupos de edad, al compararla
con campañas de vacunación infantiles, ya que la transmisión de la enfermedad se
interrumpe más rápido en los grupos de edad que son, al mismo tiempo, responsables
de un mayor número de casos sufridos y de contagios causados. A pesar de todas las
ventajas de las campañas de vacunación para adolescentes, éstas son por definición
incapaces de proteger a los niños más de lo que lo hace la BCG, dejando una reserva
permanente de población al alcance del bacilo, algo que podría comprometer el objetivo
final de la erradicación de la enfermedad.
Por esta razón, la complementación de las campañas de vacunación destinadas a
la población adolescente con la inmunización de neonatos debería ser una estrategia
tomada en consideración. Además, siendo la única vía conceptual para garantizar la
eventual protección de toda la población (si se consiguiera la persistencia temporal de
la eficacia en las nuevas vacunas), la inmunización de los recién nacidos es, en deter-
minados aspectos, más segura que la vacunación de adolescentes. El motivo, como
se ha discutido en el capítulo 11, es la existencia de exposición previa a mycobac-
terias ambientales que podría comprometer el buen funcionamiento de la vacuna al
aplicarse en individuos adultos. Tal y como se muestra en esta Tesis, en caso de que
una nueva vacuna aplicada en adolescentes sufriera niveles comparables de bloqueo a
aquéllos estimados para la BCG, las ventajas relacionadas con la inmunización directa
de adolescentes podrían desaparecer.
Además, la discusión sobre la edad de la población a inmunizar en una campaña
de vacunación optimizada está estrechamente relacionada con el tipo de vacunas a
considerar, puesto que, tal y como se ha comentado en el capítulo 2, las vacunas
prime están inicialmente orientadas para su aplicación en recién nacidos en lugar de
la BCG, mientras que las vacunas booster están diseñadas para su uso en individuos
mayores, previamente vacunados con BCG, a fin de restaurar los niveles de inmunidad
de la vieja vacuna. En lo que respecta a las boosters, los resultados negativos de
los ensayos de fase IIb de MVA85A en niños aconsejan la prueba de futuras vacunas
en adolescentes, lo cual, con suerte, resultará en una mejor protección en caso de
que los efectos de la exposición previa a mycobacterias sean modestos. De hecho, la
interferencia de las mycobacterias ambientales en el funcionamiento de las vacunas es
menos probable para las boosters ya que sus mecanismos biológicos de diseminación a
través del cuerpo y sus mecanismos inmunogénicos son diferentes de los de una vacuna
viva como la BCG, cuya adecuada reproducción es bloqueada por el sistema inmunitario
a resultas de la exposición previa a antígenos mycobacterianos. Por todas estas razones
es recomendable evaluar las vacunas booster en adolescentes como la estrategia más
segura para continuar con el desarrollo de vacunas, aunque para el caso de boosters
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basadas en vectores víricos, la presencia de anticuerpos virales en los individuos a
vacunar podría también bloquear la asimilación de la vacuna [139]. Esta situación es
más problemática para vacunas vivas atenuadas, para las cuales el bloqueo de vacunas
es más probable. Tal y como hemos visto en el capítulo 11, de acuerdo con el análisis de
los ensayos clínicos recientemente realizados en Brasil por Barreto y colaboradores [195],
BCG sufriría intensos niveles de bloqueo cuando se aplica a individuos en edad escolar.
Si una nueva vacuna viva comparte un comportamiento similar, su aplicación sobre
adolescentes podría resultar en observadas eficacias residuales, al menos en latitudes
bajas (donde se encuentran, asimismo, algunos de los países con los mayores niveles de
TB en el mundo). Este es un escenario probable, no sólo porque nos referimos a vacunas
vivas como la BCG, sino porque además, si una nueva vacuna viva está dirigida a
una población adolescente, dicha población se encontrará previamente inmunizada con
BCG, lo cual en este caso actuaría como una fuente adicional de exposición antigénica
que contribuiría al bloqueo de la vacuna. Hay que admitir que la estrategia alternativa
en este caso no es garantía de éxito, ya que la BCG, como sabemos, es más difícil
de superar en niños. La propiedad más importante de una nueva vacuna de TB, si
pretende sustituir la BCG en niños, es una persistencia más prolongada que la de la
antigua vacuna más que un mejor funcionamiento inicial y, por esta razón, incluso un
modesto resultado para una vacuna nueva podría ser interpretado positivamente en
esta fase. Esta compleja situación haría conveniente, al menos para el caso de vacunas
vivas, considerar ensayos estratificados llevados a cabo simultáneamente en diferentes
grupos de edad, como en la referencia [195], así como prever, desde el principio del
proceso de desarrollo, ulteriores extensiones de los periodos de seguimiento a fin de que
los patrones temporales de decaímiento de la protección vacunal puedan ser estimados
tan pronto como sea posible. Sin duda alguna, ésta es una exigente lista de deseos,
teniendo en cuenta los altos costes asociados al diseño de dichos ensayos clínicos y
la dificultad de llevarlos a cabo en escenarios de alta incidencia de la enfermedad.
Sin embargo, las vacunas vivas constituyen un en enfoque conceptual complementario
a las boosters que no debería ser obviado, puesto que podrían convertirse en la única
alternativa a estas últimas en caso de que los booster actualmente en desarrollo no sean
capaces de mejorar los resultados de MVA85A en niños [213]. Por último y no por ello
menos importante, debemos recordar que las boosters podrían potenciar la protección
inducida por cualquier nueva vacuna viva de la misma forma que podrían hacerlo con
la BCG. En conclusión, la comparación entre las campañas de vacunación dirigidas
a recién nacidos y las orientadas a adolescentes afrontada en esta Tesis está sujeta
al compromiso preciso entre los patrones temporales del deterioro de la protección
(tanto de las nuevas vacunas como de la BCG, cuyo comportamiento no ha sido aún
completamente descifrado), que aconsejan la inmunización de adolescentes en lugar de
niños; y la existencia de niveles relevantes de exposición a agentes mycobacterianos en
la población, que podrían ser responsables del bloqueo de la vacuna, lo cual tendría el
efecto contrario. Sin embrago, no está claro cómo estos aspectos podrían afectar a los
distintos tipos de vacuna actualmente en proceso de desarrollo y por ello, como parte
relevante del proceso, la necesidad de ensayos clínicos específicamente diseñados para
estimar el impacto de estos factores debería tenerse en consideración.
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Figure 13.1: Efectos sobre el retraso en el tiempo de aplicación de una vacuna de un 70%
de eficacia. Columna izquierda: vacuna dirigida a neonatos. Derecha: vacuna dirigida a
adolescentes. (a,b): Las tasas de incidencia después de la aplicación de vacunas en momen-
tos diferentes desde 2020 a 2035. (c,d): número de casos evitados hasta 2050 por vacunas
introducidas en distintos momentos. (e,f): Tasas de mortalidad después de la aplicación de
vacunas en diferentes momentos desde 2020 a 2035. (g,h): Número de muertes evitadas hasta
2050 en función del momento de implementación de la vacuna.
Dicho todo esto, más allá de definir el perfil de edad de la población objetivo
asociada a cada posible vacuna candidata, el desarrollo de nuevas vacunas de TB
está comprometido a considerar muchos otros criterios para garantizar una adecuada
identificación de aquéllas que muestren características óptimas siendo compatibles con
criterios de seguridad. Lo que hace más insidiosa la tarea de buscar entre todos los
proyectos una vacuna segura capaz de ofercer el mayor impacto es que cuanto más
tiempo se dedique a la tarea peor será el resultado, tal como se evidencia en la figura
13.2. La implementación de nuevas vacunas para reducir llos niveles de Tb a escala
global es un asunto urgente y el precio por cada año de retraso son cientos de miles de
vidas.
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13.3 Perspectivas
En los párrafos precedentes hemos resumido las principales conclusiones alcanzadas tras
la investigación realizada para esta Tesis, centrada en diferentes niveles de descripción
del proceso de infección de la TB; desde las células de la bacteria hasta las poblaciones
humanas. Tal y como hemos visto a lo largo de este trabajo, el desarrollo de nuevas
herramientas epidemiológicas contra la TB se destaca como una necesidad urgente
para reducir la afección causada por la enfermedad en todo el planeta y, para que este
desarrollo sea posible, deben aunarse esfuerzos desde la genética y la Biología celular
a la inmunología y la epidemiología; lo que es particularmente cierto para el caso del
desarrollo de nuevas vacunas preventivas contra la TB. En este sentido, la Tesis aquí
presentada, más allá de los resultados específicos resumidos en las secciones anteriores,
supone un apropiado trampolín para el desarrollo de un programa de investigación
más profundo orientado a la asistencia para el desarrollo de nuevas vacunas desde
la perspectiva de la ciencia de sistemas complejos. Tal y como hemos comentado
anteriormente, una de las limitaciones principales en el desarrollo de vacunas para la
TB es la ausencia de indicadores inmunológicos fiables de protección contra la infección
a los que recurrir antes de pasar a realizar prolongados y costosos ensayos clínicos. Las
mediciones más usadas hoy en día como indicadores de la eficacia de una vacuna se
basan en la reducción de la replicación de la bacteria in vivo o en la producción de
IFNγ por células T; técnicas éstas capaces de ofrecer resultados sólo parcialmente
fiables [212, 210, 186].
En este contexto, el análisis transcripcional constituye uno de los enfoques más
prometedores para tratar de resolver este problema. En un trabajo reciente, Barry y
colaboradores han identificado una huella transcripcional específica capaz de distin-
guir pacientes con TB activa del resto [438], lo cual supone un espaldarazo a la idea de
usar análisis transcriptómico para discriminar entre diferentes estatus del huésped (por
ejemplo, inmune, susceptible, infectado o protegido por una vacuna) en relación con la
infección de TB. Para explorar esta posibilidad, el modelado dinámico de la respuesta
genética tras la fagocitosis –tanto del huésped como del patógeno– es una tarea fun-
damental a llevar a cabo. No obstante, la red de regulación transcripcional de MTB
compilada en el capítulo 3, aún constituyendo un valioso recurso por sí mismo, como se
ha mostrado en la Tesis-, puede no constituir una base apropiada para estas tareas de
modelización. Como ya hemos señalado, nuestra red incluye interacciones identificadas
bajo condiciones muy diferentes y a través de muy diversos métodos experimentales,
que causan la aparición en el sistema de enlaces presentes sólo bajo condiciones am-
bientales específicas, enlaces que reflejan efectos dinámicos indirectos e incluso enlaces
sin ningún tipo de consecuencia dinámica. Igualmente, incluso con interacciones lo
suficientemente robustas en nuestra red, inferir el modo en que múltiples inputs se
emparejan en un único objetivo es difícil de conseguir partiendo de datos tan heterogé-
neos. Así, la implementación de cualquier modelo dinámico sobre nuestra red resultaría
particularmente incierta y, por ello, la búsqueda de indicadores transcripcionales de es-
tados inmunológicos en relación a la infección de TB requerirá la caracterización de
redes reguladoras específicas, tanto para el portador como para el patógeno, basadas
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en bases de datos reunidas a tal propósito. Un enfoque prometedor para conseguir este
objetivo se basa en métodos de mapeado de expression-quantitative trait loci (eQTL)
, un método que ya se ha revelado útil para identificar genes asociados a susceptibili-
dad a la TB [439]. Los eQTL se definen como single nucleotid polymorphisms (SNPs)
significativamente asociados a la variación en niveles de expresión genética de un de-
terminado gen bajo unas condiciones experimentales dadas, y su caracterización se
apoya en el análisis simultáneo de genotipos y expresiones genéticas de un conjunto
de distintos individuos, a través de métodos Bayesianos [440, 441]. En esta línea, el
uso de conjuntos de datos multivariados de esta naturaleza para inferir redes regulado-
ras genéticas específicas y fiables se ha convertido en un tema de actualidad en este
ámbito [442, 443, 444, 445]. El uso combinado de mapeado eQLT y modelos transcrip-
cionales podría permitir ir más allá de la simple caracterización de factores genéticos
relacionados con la susceptibilidad a la enfermedad identificando las vías dinámicas
por las cuales los fenotipos asociados a la TB son regulados. La caracterización de la
diversidad genética en la respuesta a la infección de MTB tiene mayores implicaciones
que van a dar directamente con la parte epidemiológica del puzzle. Particularmente,
se ha demostrado que la distribución geográfica global de los perfiles étnicos humanos
y los diversos linajes en el MTBC están sorprendentemente relacionados [175], lo que
ha sido asociado con la adaptación específica de dichos linajes patogénicos a los grupos
étnicos presentes en diferentes áreas geográficas [174]. La relevancia de estos hechos va
mucho más allá de motivaciones teóricas, y tiene que ver con los peligros asociados a
la introducción de vacunas con niveles heterogéneos de protección contra los diferentes
linajes de MTB [177]. Si algo así sucediera, podría suponer la introducción de pre-
siones evolutivas diferenciales entre linajes, lo cual podría tener consecuencias graves,
como ha ocurrido anteriormente a lo largo de la Historia con otros patógeneos como
Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitides y Borde-
tella pertussis [446]. Por ejemplo, una vacuna que ofreciera menos protección contra la
familia de linajes asiáticos que podría tener consecuencias dramáticas causando un in-
cremento en la incidencia de tuberculosis resistente asociada a la proliferación de cepas
Beijing; pertenecientes a los linajes asiáticos y más proclives a desarrollar resistencia
a los antibióticos. Para que estos aspectos puedan ser modelados y comprendidos,
debería implementarse un modelo apropiado de meta-poblaciones para la TB; sobre el
cual estudiar los diferentes niveles de compatibilidad entre los grupos filogenéticos de
patógenos y huéspedes, y relacionarlos con su dispersión geográfica. En un modelo tal,
los patrones de movilidad serían dirigidos por flujos migratorios sobre periodos tem-
porales extensos, y otras fenomenologías, como la resistencia a los antibióticos y las
interacciones con el VIH podrán ser y serán incorporadas. Idealmente, las evaluaciones
de impacto de las vacunas deberían ser afrontadas dentro de este contexto, para lo
cual el desarrollo del modelo de propagación de la TB que se presenta en esta Tesis
en el capítulo 9 constituye un primer paso. No obstante, la implementación de una
plataforma de modelado tal dependerá necesariamente de la disponibilidad de datos;
todavía muy limitada especialmente en lo que respecta a los efectos de la diversidad
genética sobre la dinámica de propagación de la TB. Por este motivo, una vez más, se
hace necesario un conocimiento de los mecanismos genéticos que conllevan diferentes
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niveles de susceptibilidad a la enfermedad, así como una descripción de su distribución
en las poblaciones de diferentes países, para poder ofrecer descripciones robustas de la
dinámica de propagación de la TB, cuando este tipo de cuestiones se tienen en con-
sideración. Una vez más, la tuberculosis revela su complejidad en múltiples escalas,
cada una de ellas inevitablemente asociada a las demás. Los avances realizados hasta
ahora aparecen ante nosotros como piezas entrelazadas de un puzzle mayor, que son
asimismo una fuente de error, de duda, de desazón y de espera a afrontar en futuros
años de trabajo.
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